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Abstract 
 Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated 
steroids to yield biologically active desulfated steroids and is currently being examined as a 
target for therapeutic intervention for the treatment of breast and other steroid-dependent 
cancers.  A series of 17-arylsulfonamides of 17-aminoestra-1,3,5(10)-trien-3-ol were prepared 
and evaluated as inhibitors of STS.  Introducing n-alkyl groups into the 4´-position of the 17-
benzenesulfonamide derivative resulted in an increase in potency with the n-butyl derivative 
exhibiting the best potency with an IC50 of 26 nM.  A further increase in carbon units (to n-
pentyl) resulted in a decrease in potency.  Branching of the 4´-n-propyl group resulted in a 
decrease in potency while branching of the 4´-n-butyl group (to a tert-butyl group) resulted in a 
slight increase in potency (IC50 = 18 nM).  Studies with 17-benzenesulfonamides substituted at 
the 3´- and 4´-positions with small electron donating and electron withdrawing groups revealed 
the 3´-bromo and 3´-trifluoromethyl derivatives to be excellent inhibitors with IC50‘s of 30 and 
23 nM respectively.  The 17-2´-naphthalenesulfonamide was also an excellent inhibitor (IC50 = 
20 nM) while the 17-4´-phenylbenzenesulfonamide derivative was the most potent inhibitor 
with an IC50 of 9 nM.  Kinetic studies with 3´-bromo derivative revealed it to be a                  
non-competitive inhibitor and so these types of inhibitors might be capable of binding at the 
active site and also at a secondary site outside the active site.  The amide analogs of some of 
these compounds were found not to be as potent inhibitors as the sulfonamides.  Introducing a 
nitro group or fluorine atom into the 4-position of the 17-arylsulfonamide inhibitors resulted in 
an increase in potency.  Some of these compounds are the most potent reversible STS inhibitors 
ever reported with apparent Ki‘s as low as 1 nM.  3-O-Sulfation of these compounds did not 
significantly alter their potency.  It is not known if 3-O-sulfated derivatives were acting as 
iv 
 
inhibitors or reversible suicide inhibitors.  Docking studies were performed on selected inhibitors 
to gain insight into how they might interact with STS.   
Selected 17-arylsulfonamide inhibitors were sent to the NCI (USA) for in vitro 
screening with a panel of 60 human tumor cell lines (NCI-60 panel).  Almost all of the 
compounds exhibited GI50‘s in the 1 to 10 M range with all 60 cell lines and so were only 
moderately potent in terms of their ability to inhibit the growth.  None of the compounds stood 
out in terms of their ability to inhibit the growth of any breast cancer, prostate cancer or any 
other cancer cell line studied.   
The thiadiazolidinedione group was proposed as a sulfate mimic for obtaining STS 
inhibitors.  A new approach to the synthesis of 3-aminoestrone was achieved as part of an 
attempt to prepare the thiadiazolidinedione target.  3-O-Sulfamoylation of one of the 17-
arylsulfonamide inhibitors was attempted using a variety of reaction conditions but was 
unsuccessful.  
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Chapter 1 – Steroid Sulfatase: Function, Localization, Structure, Mechanism, 
and Inhibitors 
1 Introduction  
1.1 Sulfatases 
Sulfatases are esterases that catalyze sulfate ester hydrolysis of physiological substrates 
with diverse structure ranging from macromolecules such as sulfated proteoglycans to relatively 
small ones such as estrogen sulfate.
1
 Seventeen sulfatases have been characterized in humans, 
with the majority functioning optimally at acidic pH (4-5) and are lysosomal enzymes (Table 
1.1).
1,2
  They are involved in numerous biological processes such as mediating signalling 
between cells and the activation of soluble sulfated steroids.
3
 
Table 1.1.  Known human sulfatases. 
Sulfatase Name Abbreviation Location Natural Substrate Ref. 
Aryl sulfatase A ARSA Lysosome Cerebroside sulfate 4 
Aryl sulfatase B ARSB Lysosome Dermatan sulfate 5 
Aryl sulfatase C (Steroid sulfatase) ARSC (STS) ER Steroid sulfates 4 
Aryl sulfatase D ARSD ER Unknown 6 
Aryl sulfatase E ARSE Golgi App. Unknown 6 
Aryl sulfatase F ARSF ER Unknown 7 
Aryl sulfatase G ARSG ER Unknown 8 
Aryl sulfatase H ARSH Unknown Unknown 9 
Aryl sulfatase I ARSI Unknown Unknown 9 
Aryl sulfatase J ARSJ Unknown Unknown 9 
Aryl sulfatase K ARSK Lysosomal Glycosaminoglycans 10 
Galactosamine (N-acetyl)-6-sulfatase GALNS Lysosome Keratin and Chondroitin sulfate 11 
Glucosamine (N-acetyl)-6-sulfatase G6S Lysosome Heparan and Keratan sulfate 12 
N-sulfoglucosamine sulfohydroloase SGSH Lysosome Heparan sulfate 13 
Iduronate-2-sulfatase IDS Lysosome Dermatan and Heparan sulfate 14 
2 
 
Endo sulfatase 1 Sulf 1 ECM Heparan sulfate 15 
Endo sulfatase 2 Sulf 2 ECM Heparan sulfate 15 
 
Shortly after the discovery of the sulfatases it was found that their activity could be 
measured using small aromatic sulfated substrates like p-nitrophenol sulfate (pNPS, compound 
1.1, Fig. 1.1) and/ or 4-methylumbelliferyl sulfate (4-MUS, compound 1.2, Fig. 1.1).  For this 
reason human sulfatases have been historically classified as arylsulfatases (ARSs).
3
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Fig. 1.1.  Common aromatic sulfated substrates for sulfatases 
Subsequent studies on the sulfatases showed that they share common structural features 
such as their significant sequence homology over their entire length especially in the N-terminal 
region, in addition to having a similar size ranging from 500 to 800 amino acid residues. 
Moreover, they were found to be extensively glycosylated and have highly similar active sites 
which undergo a unique post-translational modification process.
16
 
1.2 Steroid sulfatase (STS) 
1.2.1 STS Substrates and Physiological function 
Steroid sulfatase catalyzes the desulfation of steroidal sulfates to give unconjugated 
steroids (Fig. 1.2).  Sulfated steroidal substrates are biosynthesized via the action of a 
sulfotransferase (SULT) using 3‘-phosphoadenosine-5‘-phosphosulfate (PAPS) as the sulfate 
donor. The best characterized steroidal substrates of STS are estrone sulfate (E1S), estradiol 
sulfate (E2S), dehydroepiandrosterone sulfate (DHEAS), pregnenolone sulfate (PREGS) and 
cholesterol sulfate (CS) (Fig. 1.2).
17
  STS functions optimally between pH 7-8, and as all the 
3 
 
ARSs, STS can also act upon simple aryl sulfates such as pNPS and MUS although the Km‘s for 
these substrates are more than 100 times higher than the Km‘s of the natural steroidal substrates 
(0.6-2 M).17  
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Fig. 1.2.  The reaction catalyzed by STS.  The best characterized steroidal STS substrates are 
shown.
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Sulfated steroids are unable to bind to steroid hormone receptors and are biologically 
inactive until removal of the sulfate group by STS.  It has been proposed that the role of sulfated 
steroids is as a storage reservoir of water soluble and transportable steroids and so act as a source 
of biologically active steroid hormones when activated by STS.  This is supported by the finding 
that circulating plasma concentrations of the sulfated steroids such as E1S, and DHEAS are 
significantly higher than those of their non-sulfated counterparts, E1 and DHEA.
18
 Additionally, 
the half-life of E1S and DHEAS in plasma is about 10-12 hours, which is considerably longer 
than the 30-40 minutes half-life of E1 and DHEA.
19
  
4 
 
Immunohistochemical and biochemical localization assays of STS showed that it is an 
integral membrane protein tightly bound with the membrane of the endoplasmic reticulum of 
tissues of the reproductive system such as the endometrium, ovary, prostate, testis, and placenta.  
It is also found in the skin, brain, breast, bone, and blood.  One of the richest sources of STS is 
the placental microsomal fraction.
20-22
 
STS has a pseudoautosomal gene which is located on the distal short arm of X-
chromosome at band Xp22.3, and consisting of 10 exons and spans 146 kb, with intron sizes 
ranging from 102 bp up to 35 kb. The cDNA for STS encodes a protein of 583 amino acid 
residues, with 4 glycosylation sites of which at least two are used (Asn 47 and Asn 259).
20-22
 
1.2.2 STS: Post Translation Modification, Structure and Catalytic Mechanism 
All sulfatases undergo a unique posttranslational modification in which an active site 
cysteine or serine (prokaryotes only) is oxidized by an enzyme, called the formyl generating 
enzyme (FGE), to give C-formylglycine (FGly; 2-amino-3-oxopropionic acid) (Fig. 1.3).23 The 
discovery of this unique post-translational modification occurring was important in 
understanding the catalytic mechanism of this class of enzymes.
23
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hydrate  
Fig. 1.3.  The post-translational modification in eukaryotes that gives -formylglycine (FGly) 
and the subsequent hydration of FGly. 
 
This modified cysteine residue is highly conserved across the evolution of all human 
sulfatases. A lysosomal storage disease called multiple sulfatase deficiency (MSD) is 
5 
 
characterized by catalytically inactive sulfatases.  Sulfatases derived from MSD cells were found 
not to have undergone the post-translational modification as a result of a mutation in a gene or 
genes encoding the FGE.
16,23-25
 
The X-ray crystal structure of STS was resolved to 2.60 Ǻ by Ghosh and coworkers in 
2003.  The topology of the overall fold of STS shows that the tertiary structure consists of two 
domains; a globular polar domain and a two transmembrane (TM) helices protruding on one side 
of the nearly spherical polar domain imparting the overall molecule a ―mushroom-like‖ shape, as 
shown in Fig 1.4.
26,27
 
The polar globular domain (55  60  70 Ǻ) consists of two subdomains. Subdomain 1 
(SD1) winds around a central 11-stranded mixed -sheets (strands 1, 2, 4-11, and 17) flanked by 
13 -helical turns (helices 1-7, and 10-15). Inside SD1, the catalytic residue, FGly75 was found 
covalently bound to a sulfate group and a metal ion closely located near FGly75 was interpreted 
to be Ca
+2
. The other subdomain, subdomain 2 (SD2) winds around a 4-stranded anti-parallel -
sheets (strands 13-16), flanked by -helix 16, and packs against the turn and loop regions of the 
-sheets of SD1.26,27 
Even though the STS globular polar domain resembles ARSA and ARSB in shape, size, 
and folding, some of its loop regions (loop 4 and 5, and between 9 and 13), which 
approach the lipid bilayer and are proposed to associate with the membrane, have 4 to 7 residue 
peptide insertions which are not found in the structures of ARSA and ARSB. These insertions 
were found to be critical for anchoring its catalytic domain to the membrane surface.
26,27
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Fig. 1.4.  A stereographic ribbon diagram of the STS crystal structure showing the secondary and 
tertiary structures. Sheets are drawn in green, and helices are in pink; Sub-Domains 1 and 2 (SD1 
and SD2), Transmembrane domain (TM), Membrane-Associated Loops (MAL).
27
 
 
A close look inside the STS crystal structure showed that the active site is located near 
the membrane surface of a cavity in the ‗‗gill‘‘ of the polar globular domain.  Interestingly, the 
crucial catalytic residue, FGly75 was found as a sulfated hydrate form as shown in Fig. 1.5.
26,27
 
This is in contrast to ARSA whose crystal structure revealed a non-sulfated hydrate.
28
 Although 
it is not known if the FGly75 hydrate is sulfated in STS‘s resting state in solution it is believed 
that this is not the case based upon the proposed mechanism (Fig.1.6).
27
  It is believed that the 
enzyme crystalizes more efficiently when the hydrate in STS is sulfated with the sulfate coming 
from the crystallization buffer. The Ca
+2
 ion is found at the center of the catalytic site near the 
sulfated FGly75 residue, and is fixed there by a H-bonding interactions with oxygen atoms of 
various amino acid residues; Asp35, Asp36, Asp342, Gln343, and FGS75, with a distance 
ranging between 2.2 and 2.8Å.
27
  Additionally, it was found that both Lys134 and Lys368 have 
TM 
MAL 
SD2 
SD1 
7 
 
their positively charged amino group within contact distances (2.7-3.1 Å) of the sulfate oxygen 
atoms of FGS75, and in the same way another two sulfate oxygen atoms were found within a co-
ordination distances of Ca
+2
 ion (2.6-2.7 Å).
27
  
 
Fig. 1.5.  Active site catalytic residues in STS and the coordination of Ca
+2
.
26,27
  Nitrogens are in 
blue, oxygens are in red and the sulfur atom is in yellow. 
 
Von Figura and coworkers proposed a general mechanism for ARSs based on kinetic 
studies and the crystal structures of ARSs (Fig. 1.6).
3,26,29,30
  The first step of the mechanism 
involves the activation of one of the oxygen atoms on the FGly75 hydrate by an aspartate residue 
acting as a general base.  The oxygen performs a nucleophilic attack on the sulphur atom of the 
substrate, which consequently releases the desulfated product as well as forming a sulfated 
hydrate intermediate.
29,30
  A histidine residue acting as a general acid aids the displacement of 
the desulfated product.  The sulfated hydrate then undergoes a general-base catalyzed 
elimination reaction to release inorganic sulfate and forming formylglycine, which is then 
rehydrated to regenerate the initial formylglycine hydrate (Fig.1.6).
29,30
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Fig. 1.6.  A schematic diagram showing steps involved in the proposed reaction mechanism of 
steroid sulfatase.
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1.2.3 STS and Breast Cancer 
The vast majority of research on STS inhibitors has been directed toward the 
development of drugs for treating estrogen receptor-positive (ER+) hormone-dependent breast 
cancer. This type of breast cancer occurs most frequently in post-menopausal women which is 
paradoxical as ovarian production of estrogen, which is the main, though not only source of 
estrogens has stopped.
17
 Instead of local production of estrogens in tumors, it has been 
hypothesized that tumor growth is stimulated in part by estrogens derived from their sulfated 
precursors which are produced in peripheral tissues (Fig. 1.7). These soluble sulfated precursors 
are transported into the cancer cells by specific membrane transporters where they are then 
desulfated by STS.  
Several lines of evidence suggest that STS plays an important role in the progression of 
steroid-dependent breast cancer.
31
 The production of E1 from estrone sulfate (E1S) in breast 
cancer tissue is approximately 10 times greater than from androstenedione, which is converted to 
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E1 by aromatase (Fig. 1.7).
32
 90% of Adiol in post-menopausal women originates from DHEAS 
via desulfation of DHEAS by STS to give DHEA which is converted into Adiol by the 
dehydrogenase. There is approximately 50–200 times greater STS activity than aromatase 
activity in malignant breast tissues. Sulfatase activity in breast cancer cells is higher than that of 
normal breast cells.
33
 Finally, STS expression in breast tissue is significantly higher than in 
normal tissue and STS expression is now used as a prognostic factor in human breast 
carcinoma.
34
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Fig. 1.7.  The origin of estrogenic steroids in postmenopausal women with hormone-dependent 
breast cancer. 
 
It is worth mentioning that there is little known in the literature about the control of STS 
expression, however both TNF and IL-6 were found to up-regulate STS activity in MCF-7 
breast cancer cells. Additionally, E2 was found to up-regulate STS expression through the 
10 
 
increased binding of the ER to estrogen responsive elements (EREs) located in the promoter 
regions of STS gene. Taken together, these findings could be used as strong evidence for the up-
regulation of STS activity in hormone-dependent cancer, thus STS became a target for drug 
design.
35,36
  
1.3 Current Therapies for Treating Hormone-Dependent Breast Cancer 
Estrogenic steroids supporting the growth and development of hormone-dependent breast 
cancer represent the most common type of hormone-dependent malignancy. In postmenopausal 
HR+ breast cancer, therapies that block either the synthesis or action of estrogen are now 
established as first-line treatments for most postmenopausal women with estrogen receptor 
positive (ER+) breast cancer.  Tamoxifen, (Fig. 1.8), is the first-generation selective estrogen 
receptor modulator (SERM), which has been the endocrine therapy of choice till the past 5 years 
or so. It is reported that tamoxifen has helped more than 400,000 women survive breast cancer; 
however, vaginal bleeding, thromboembolism, endometrial cancer, and therapeutic resistance 
were its long-term side-effects.
37
  Consequently, looking for alternative therapeutic agents was 
very crucial. Aromatase inhibitors (AIs) and selective estrogen receptor down-regulators 
(SERDs) were used as alternative therapies for tamoxifen; AIs prevent estrogen synthesis by 
inhibiting the aromatase enzyme converting androgens to estrogen, whereas SERDs act by 
down-regulating ER expression.
37,38
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Fig. 1.8. Structure of Tamoxifen 
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Estrogen depletion achieved from the use of AIs in treating HDBC in ER postmenopausal 
early breast cancer has turned out to be in general a more effective way of treatment in 
comparison to blocking ER by SERMs.  The most notable AIs are the third generation AI‘s; 
letrozole and anastrozole (Fig. 1.9), which have proven to be effective in the treatment of breast 
cancer and having greater benefits of reducing the risk of occurrence of contralateral breast 
cancer than tamoxifen.
37,38
 Unfortunately, AIs share common side effects affecting both muscles 
and bones, and so tamoxifen is still used as a standard therapy or as an alternative to AI‘s. 
Moreover, many of breast cancer patients experience relapse of their breast cancer after 
treatment with AI‘s especially those with metastatic ER+ breast cancer.37,38  
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Fig. 1.9.  Aromatase inhibitors letrozole and anastrozole 
The 3
rd
 generation non-steroidal AIs, fulvestrant and exemestane (Fig. 1.10), are 
currently used as second- or third-line endocrine therapies in selected patients with metastatic 
breast cancer (MBC) based on the studies that suggested dependency of tumors on estrogens 
following progression on the first-line and even second-line endocrine therapies.
37,38
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Fig. 1.10.  Structures of Fulvestrant and Exemestrane 
One of these major drawbacks of using AIs and SERD in treatment of different types of 
HDBC is the development of cross-resistance, thus new non-cross-resistant therapies are 
urgently needed to give patients with HDBC an alternative treatment option to prolong the time 
period without the use of the chemotherapy option. STS-inhibition represents such a novel 
approach which can be used to block the synthesis of a variety of steroids that have the potential 
to stimulate growth of HDBC.
38
 
1.4 STS Inhibitors 
 STS inhibitors have been traditionally divided into two classes: steroidal and non-
steroidal.  These two classes have been divided into two subclasses: sulfamate and non-
sulfamate-based. 
1.4.1. Non-sulfamate Steroid-based Inhibitors 
1.4.1.1 Early studies and Substrate Analogs 
Initial reports on STS inhibitors, which appeared in the late 1960‘s and early 1970‘s, 
focussed on examining unconjugated steroids, both natural and synthetic, as potential STS 
inhibitors.
39-43
 The ultimate objective of these studies was not the development of anticancer 
agents but rather to elucidate steroidal regulatory mechanisms and determine whether inhibition 
of STS by endogenous steroids could provide a mechanism for regulation of estrogen production 
13 
 
during human pregnancy.
 
 Crude preparations of STS (such as human placental or testicular 
homogenates) were used for the majority of these studies.  None of the compounds studied 
proved to be potent STS inhibitors.  Nevertheless, these studies revealed that inhibitory activity 
of these compounds is favored by planar 5- or 5- structures unsubstituted except for oxygen 
functions at C-3 and C-20.
39-43
   
Synthetic steroids such as danazol, and several progestins (Fig. 1.11), such as 
promegestone, tibolone, and medroxyprogesterone acetate, norelgestromin, and nomegestrol 
acetate, have been tested as potential STS inhibitors by incubating intact breast cancer cells with 
labeled E1S and the formation of E1 and E2 determined.
44-47
 In these assays, the formation of E1 
or E2 was reduced by varying degrees, however whether this was due to direct inhibition of STS 
was sometimes not ascertained.  In cases where direct STS inhibition was determined (using 
purified enzyme or cell homogenates), the extent of inhibition was nil to moderate.  This work 
has been reviewed and the reader is referred to these articles for a more in-depth discussion of 
these studies.
44-47
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Fig. 1.11.  Progestins that have been tested as potential STS inhibitors. 
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Efforts to develop STS inhibitors into drugs did not really begin in earnest until the early 
1990‘s.  Many of the studies from this time period centered upon finding substrate analogs in 
which the labile sulfate group was replaced with a sulfate mimic (Table 1.2).  It was these studies 
which led to the discovery of estrone-3-O-sulfamate (EMATE, compound 1.36 in Table 1.2), a 
highly potent, irreversible STS inhibitor which is now the prototypical STS inhibitor and used as 
a standard when evaluating the in vitro potency of other STS inhibitors.  As can be seen from 
Table 1.2, with the exception of EMATE, little success has been obtained using this approach to 
STS inhibitors as most of these compounds have proven to be moderate to weak reversible 
inhibitors.  However, a few of these mimics are worthy of note.  The methylthiophosphonate 
group (compound 1.3) was one of the first sulfate mimics to be examined in detail.
48
 It is a 
moderate, reversible, competitive STS inhibitor in both breast tumours and placental 
microsomes.  The sulfur atom is not essential to activity as the oxygen analog was only 50% less 
potent.  The Sp diastereomer is more potent than the Rp diastereomer. The 
methylthiophosphonate analogs of other natural substrates of STS such as DHEA-, cholesterol-, 
and pregnenolone-3-methylthiophosphonate were also reasonably good inhibitors with Ki‘s 
ranging from 1.4-6.2 M in placental microsomes and inhibited STS activity in MCF-7 breast 
cancer cells by 31-85% at 1 M.  The N,N-dimethylated analog of EMATE (compound 1.38) 
was a good reversible inhibitor though still considerably less potent than EMATE.
57
  
Formylation of E1 gave an irreversible inhibitor (compound 1.35) though less potent than 
EMATE.  This compound is labile and so is not suitable for as a lead for further drug 
development.
56
  Surprisingly, a boronic acid group turned out to be a good sulfate mimic with 
compound 1.47 being a competitive inhibitor and exhibiting one of the lowest Ki‘s for all 
15 
 
substrate-based, reversible inhibitors bearing a sulfate mimic studied so far, though once again 
this compound was still considerably less potent than EMATE.
63
   
Table 1.2.  Substrate analogs of E1S in which the labile sulfate group is replaced with a sulfate 
mimic. 
R
O
 
 
Compound 
 
R 
% Inhibition, Ki 
or IC50 (M) 
 
Assay 
 
Ref. 
1.3 -OPSCH3 
43 (IC50) 
15 (Ki) 
Placental microsomes 
Placental microsomes 
48 
48 
1.14 -OPO3
-2
 
0.3 (Ki) 
0.17-52 (Ki) 
Purified STS 
Partially purified STS 
49 
50 
1.15 -OPO2F 14 (Ki) Partially purified STS 50 
1.16 -SO3
-
 
40% at 300 M 
40 (Ki) 
Placental microsomes 
Purified STS 
51 
52 
 
1.17 
-SO2Cl 
92% at 300 M 
65% at 60 M 
28 (Ki) 
Placental microsomes 
Placental microsomes 
Purified STS 
51 
51 
52 
1.18 -SO2F 
44% at 300 M 
35 (Ki) 
Placental microsomes 
Purified STS 
51 
52 
1.19 -SO2NH2 
45% at 300 M 
35 (Ki) 
Placental microsomes 
Purified STS 
51 
52 
1.20 -SO2CH3 
36% at 300 M 
130 (Ki) 
Placental microsomes 
Purified STS 
51 
52 
1.21 -SH 10% at 10 M Placental microsomes 53 
1.22 -SSO2NH2 12% at 50 M Placental microsomes 54 
1.23 -SSO2N(CH3)2 0% at 100 M Placental microsomes 54 
1.24 -SCON(CH3)2 4% at 50 M Placental microsomes 54 
1.25 -NHSO2NH2 53% at 50 M Placental microsomes 54 
1.26 -NHSO2CF3 10.2 (IC50) Placental microsomes 55 
1.27 -N(SO2CF3)2 14.6 (IC50) Placental microsomes 55 
1.28 -NHCOCF3 8.7 (IC50) Placental microsomes 55 
1.29 -NHCONH2 12.9 (IC50) Placental microsomes 55 
1.30 -NH2 15% at 10 M Placental microsomes 53 
1.31 -OCONH2 >50 M (IC50) Purified STS 56 
1.32 -OCSNH2 >50 M (IC50) Purified STS 56 
1.33 -OCN >50 M (IC50) Purified STS 56 
1.34 -OCOCH3 >50 M (IC50) Purified STS 56 
1.35 -OCHO 0.42 (IC50) Purified STS 56 
1.36 
-OSO2NH2 
(EMATE) 
0.004 (IC50) 
0.056 (IC50) 
0.67 (Ki) 
Placental microsomes 
Purified STS 
Placental microsomes 
57 
58 
59 
1.37 -OSO2NHCH3 87% at 1 M Intact MCF-7 cells 57 
1.38 -OSO2NH(CH3)2 79% at 0.1 M Intact MCF-7 cells 57 
1.39 -OSO2CH3 
28% at 10 M 
23 (Ki) 
Intact MCF-7 cells 
Purified STS 
60 
50 
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1.40 -OSO2C6H4CH3 30% at 0.1 M Intact MCF-7 cells 60 
1.41 -CH2SO3H 
140 (Ki) 
600 (Ki) 
Purified STS 
Purified STS 
50 
62 
1.42 -CF2SO3H 57 (Ki) Purified STS 61 
1.43 -CH2SO2NH2 350 (Ki) Purified STS 62 
1.44 -CF2SO2NH2 82 (Ki) Purified STS 62 
1.45 -CH2tetrazole 72 (Ki) Purified STS 61 
1.46 -CF2tetrazole 16 (Ki) Purified STS 61 
1.47 -B(OH)2 2.8 (Ki) Purified STS 63 
 
Sulfated compounds like 2-(hydroxyphenyl) indole series have been examined as STS 
inhibitors, and one of which, compound 1.48 (Fig. 1.12), inhibited STS activity with an IC50 of 
80 M).64  
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Fig. 1.12.  Structure of 2-(hydroxyphenyl) indole sulfate 1.48.
64
 
1.4.1.2 Estradiol-based inhibitors 
The Poirier group has examined a wide variety of 17α-substituted E2 derivatives of 
general structure 1.49 (Fig. 1.13) as STS inhibitors.
65-69
 Many of these compounds proved to be 
highly potent reversible inhibitors of STS using JEG-3 cells as the source of STS.  The potency 
of these compounds increased with the length of the alkyl substituent up to 8 carbon units 
whereas longer substituents led to a decrease in potency.  Those bearing benzyl groups were 
found to be particularly good STS inhibitors with the most potent ones being 3´-bromobenzyl 
and 4´-t-butylbenzyl analogs (1.51 and 1.52, IC50‘s = 24 and 28 nM respectively).  Compound 
1.52 was found to be 7.5-fold less potent than EMATE using HEK-293 cells overexpressing 
17 
 
STS.  The Poirier group performed an in-depth QSAR study on the benzylic derivatives and this 
led to the identification of compound 1.53 as a highly potent inhibitor (IC50 = 21 nM).
68,69
   
1.49,  R = various alkyl, Bn or Ph substituted
1.50,  R = Bn
1.51,  R = CH2(m-Br)Ph
1.52,  R = CH2 (p-t-Bu)Ph
1.53,  R = CH2(p-(o-CF3)-Ph)-Ph
1.54,  R = cyclohexylmethyl
1.55,  R = CH2C6F5
OH
R
HO
 
Fig. 1.13.  17α-benzyl E2 based inhibitors of STS. 
Poirier and coworkers suggested that the high potency of these compounds is a result of 
the hydrophobic benzyl groups extending down into the tunnel that exists between the two 
hydrophobic alpha helices which are responsible for insertion of STS into the membrane of the 
endoplasmic reticulum.  For compounds having a t-butyl, trifluoromethyl, or benzyloxy groups 
at the meta or para positions of the benzyl group, potency of the m-disubstituted benzyl 
derivatives is lower than both the single-substituted meta or para derivatives.  The only 
exceptions were the derivatives substituted with bromine, a smaller substituent than the above 
mentioned groups, which had roughly the same potency.  These results are consistent with the 
hydrophobic tunnel in STS being narrow and deep. These workers suggested that there may be a 
 interaction between the 17-benzyl groups and three phenylalanines in the tunnel.  
However, the cyclohexylmethyl and pentafluorobenzyl derivatives, 1.54 and 1.55, had similar 
potencies to the benzyl derivative 1.50, suggesting that aromaticity is not necessary for high 
potency and that the interaction between the inhibitors and residues in the hydrophobic tunnel is 
not of the - type.69 
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The benzyl pharmacophore was also examined in the context of 17- and 20-substituted 
androstane and pregnane derivatives 1.56-1.62 (Fig. 1.14).
70
 In general, lower potencies were 
found for the compounds of these series compared to the estrane derivative 1.50 (Fig. 1.14) with 
the exceptions of compounds 1.56 (3) which was approximately equipotent to 1.50 when 
assayed using JEG-3 cell homogenates.
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Fig. 1.14.  17- and 20-Substituted androstane and pregnane derivatives as inhibitors of STS. 
17-Alkan and alkyn amide derivatives of E2 (compounds 1.63) have also been 
examined as STS inhibitors using STS from homogenated JEG-3 cells.
71
 The most potent 
inhibitor (1.63, X = (CH2)2, R
1
 = Me, n = 7) had an IC50 of 80 nM. No estrogenic activity was 
observed for this compound at 30 nM in estrogen-sensitive ZR-75-1 cells (Fig. 1.15).
71
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          R = CH3 or (CH2)7CH3
          n = 3, 5, or 7
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Fig. 1.15.  17-Alkan (or alkyn) amide derivatives of E2 as STS inhibitors. 
 The Taylor group has reported that 17-benzyl E2 (compound 1.50, Fig. 1.13) is a 
noncompetitive inhibitor of purified STS using MUS as substrate.  Compound 1.50 had a Ki of 
230 nM and Ki of 420 nM respectively (Ki is the dissociation constant for the inhibitor with 
the ES complex).
63
 Interestingly, the boronic acid E2 derivative 1.64 (Fig. 1.16) was also a 
noncompetitive inhibitor with an almost identical affinity for STS.  This is in contrast to 
aforementioned boronic acid inhibitor 1.47 (Table 1.2) which was a competitive inhibitor and 
was 20-fold more potent an STS inhibitor than estrone.
63
 These studies suggest that there is an 
alternative binding site for the 17-substituted inhibitors.  This prompted Poirier and coworkers 
to examine E2 dimers (compounds 1.65 and 1.66, Fig. 1.16), which could potentially occupy 
both binding sites, as STS inhibitors.
72
 The best inhibitors were the C17-C17 dimers with an 
alkene or alkane spacer of four carbons and these compounds exhibited inhibitory potencies 
similar to compound 1.37 (56-62% inhibition at 1 M) in an assay with homogenated HEK-293 
cells overexpressing STS.
72
 
20 
 
1.65,  X = (CH2)n or CH2CH=CHCH2,
          C17-C17 or C-16-C16
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Fig. 1.16.  A boronic acid and E2 dimers as STS inhibitors. 
1.4.1.3 E1S-based Suicide Inhibitors (SIs) 
 The Taylor group has examined 2- and 4- mono- or difluoromethyl derivatives of E1S 
(compounds 1.67-1.70, Fig. 1.17) as inhibitors of purified STS.
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Fig. 1.17.  2- and 4- mono- or difluoromethyl derivatives of E1 (1.67-1.70) and 4-formyl-17-
benzyl E2 (1.71). 
 
These compounds were designed to act as suicide inhibitors of STS by producing a 
reactive quinone methide in the active site which would then react with an active site nucleophile 
thus irreversibly inactivating STS (Fig. 1.18).
73
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Fig. 1.18.  Anticipated mechanism of inhibition of STS with compounds 1.69 and 1.70.  
Compounds 1.67 and 1.68 were expected to inhibit by a similar mechanism. 
 
The monofluoromethyl derivatives, 1.67 and 1.69, were found to act as suicide inhibitors 
presumably by the mechanism outlined in Fig. 1.18.  Interestingly, the 2-difluoromethyl 
derivative 1.68 was found to be a substrate but not an inhibitor while the 4-difluoromethyl 
derivative 1.70 exhibited time and concentration dependent inhibition.  Detailed kinetic studies 
with 1.70 and STS suggested that this compound inactivates STS by multiple pathways.  One 
route involves the process outlined in Fig. 1.19.  The other route involves dissociation of the 
initial hydrolysis product from the active site where it undergoes decomposition to the quinone 
methide and subsequent reaction with water to give 4-formyl estrone (4-FE1).  4-FE1 then enters 
the active site and acts as an almost irreversible STS inhibitor (Fig. 1.19).  Kinetic studies with 
purified STS and authentic, chemically synthesized 4-FE1 revealed 4-FE1 to be a time- and 
concentration-dependent inhibitor with a KI of 1.5 M and a kinact of 0.13 min
-1
 and a kinact/KI = 1 
x 10
5
 M
-1
 min
-1
.  Interestingly, 2-formyl estrone, the ultimate product of the reaction of the 2-
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difluoromethyl derivative, 1.68, with STS, was found to not be a time- and concentration-
dependent STS inhibitor up to a concentration of 10 M.73     
 
STS
OH
OH
OS
O
O
O
F
O
F
O
O
S
O
O
O
H
HO
F
O
F
-HF
1.70
H
+
O
O
F
HO
F
O
F
release 
from active site
H2O
HO
O
O H
4-formyl estrone
enter STS active
inhibiton of STS
 
 
Fig. 1.19.  Mechanism of inhibition of STS with compound 1.70.  The product of the reaction of 
STS with 1.70, 4-formylestrone (4-FE1) enters the active site and inhibits STS in a time- and 
concentration-dependent manner. 
 
These results prompted the Taylor group to examine the 4-formyl-17-benzyl E2 (1.71, 
Fig. 1.17) as an STS inhibitor.
74
  Compound 1.71 turned out to be a potent time and conc-
dependent STS inhibitor with a KI of 85 nM and a Kinact of 0.021 min
-1
 (kinact/KI of 2.3 x 10
5
 M
-
1
min
-1
) with purified STS preparations.
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1.4.2 Steroidal Sulfamate-based STS Inhibitors 
1.4.2.1 Estrone-3-O-Sulfamate (EMATE) 
A breakthrough in the development of STS inhibitors was reported in 1994 when Potter 
and coworkers reported that the sulfamate analog of estrone sulfate (E1S), estrone-3-O-sulfamate 
(EMATE, 1.36, Table 1.2, Fig. 1.20), was a potent, irreversible, dose and time-dependent 
inhibitor of STS.
57,59
 Cleavage of the S-O bond was found to occur indicating that EMATE is a 
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suicide inhibitor of STS.  EMATE exhibited an IC50 and KI of 100 nM and 670 nM respectively 
using a placental microsome preparation of STS.
59
 In intact MCF-7 cells EMATE exhibited 99% 
inhibition of STS at 100 nM and almost completely abolishes STS activity in rat tissues.
75
 
Unfortunately, EMATE is estrogenic and so is not a suitable candidate for further drug 
development.
76
 Nevertheless, the discovery of EMATE spawned a plethora of work on 
sulfamate-based STS inhibitors.   
O
H2NO2SO
1.36 (EMATE)  
Fig. 1.20.  Estrone-O-sulfamate (EMATE). 
Early SAR studies on EMATE and other steroidal sulfamate-based inhibitors revealed the 
following: 
(a) N-Alkylation of the sulfamate functionality in EMATE generally resulted in a significant 
decrease in activity.
57,59
 Although good activity was obtained with the N,N-dimethyl 
derivative (Table 1.2, compound 1.38) this compound was still considerably less potent 
than EMATE and, like other N-alkylated derivatives, was a reversible inhibitor.
57,59
 N-
acylation also resulted in a significant decrease in activity and a change in the mode of 
inhibition from irreversible to reversible. The N-acetyl analog of EMATE was reported to 
irreversibly inhibit STS although less efficiently than EMATE.
77
 However, it was later 
demonstrated that this compound hydrolyzes to EMATE under the assay conditions and 
that its inhibitory activity as well as its supposed irreversible inhibition directly correlates 
with the amount of EMATE formed.
44
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(b) Replacing the bridging oxygen of the sulfamate group in EMATE with a sulfur, nitrogen, 
methylene or difluoromethylene (Table 1.2, compounds 1.22, 1.25, 1.43 and 1.44) moiety 
results in a considerable loss of potency and the mode of inhibition changes from 
irreversible to reversible.
54,62
 
(c) Sulfamate derivatives of steroids having non-aromatic A-rings such as 
dehydroepiandrosterone (DHEA), cholesterol, pregnenolone, androsterone and 
epiandrosterone, are poor reversible inhibitors revealing that an aromatic A-ring is 
essential to potent activity.
58,78
 This was somewhat surprising as STS accepts aromatic A-
ring substrates (i.e. estrone sulfate) and non-aromatic A-ring substrates (i.e. cholesterol 
sulfate and DHEA sulfate).  Examining a series of phenylsulfamates substituted at the 3- 
and 4-positions with various electron donating and electron withdrawing groups as STS 
inhibitors, it was shown that the inhibition of STS by these compounds depended upon the 
pKa of the leaving group (phenol portion of the substrate):  the lower the pKa of the leaving 
group the lower the IC50 of the inhibitor.
79
 Although rates of inactivation and a detailed 
kinetic study was not performed with these compounds and STS the results suggest that the 
lack of activity of the sulfamate derivatives of steroids having non-aromatic A-rings may 
be due in part to the poor leaving group ability of these steroids.  Overall, the above studies 
suggest that the mechanism by which sulfamate-based inhibitors inhibit STS may be 
different from the mechanism by which STS hydrolyses its natural substrates. 
Many modifications to the steroid skeleton of EMATE have been made.  The main 
impetus behind such modifications has been the development of compounds with potencies 
similar to or greater than EMATE but with no estrogenic effects.  The vast majority of these 
modifications have been on the A- and D-rings. 
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1.4.2.2 Modification of A-ring of EMATE 
In 1998, the effect of modifying the 2- and/or 4-position of EMATE by either a small 
electron-donating or electron-withdrawing groups was examined by Purohit and co-workers. 
(Fig. 1.21, compounds 1.72a). They found that placing an allyl group at the 4-position of 
EMATE, compounds 1.72b resulted in derivatives more potent inhibitors than their propyl 
analogues. However both of these classes of compounds were less potent than EMATE. On the 
other hand, nitro analogues were potent STS inhibitors than EMATE, especially those having the 
nitro group at 4-position of EMATE ring (5-fold more active than EMATE). Some of these new 
derivatives were non-estrogenic or having estrogenic activity less than EMATE.
80
  
H2NO2SO
O
R1
R2
1.72a; R1 and/or R2= H, OCH3, NO2, n-Pr
1.72b; R1 and/or R2= H, allyl  
Fig. 1.21.  A-ring-modified EMATES 
2-Methoxyestradiol (Fig. 1.22, 1.73a, 2-MeOE2) is a natural metabolite of E2 but with a 
poor affinity for the ER. It is also an experimental drug candidate (under trade name of 
Panzem).
81
  It induces apoptosis in some cancer cell lines and is undergoing clinical trials for 
treating breast cancer and ovarian cancer.  This provided the impetus for the study of 2-
methoxyestrone-3-O-sulfamate (2-MeOEMATE, compound 1.73c) which was found to be 
equipotent to EMATE in inhibiting STS activity in placental microsomal preparation (IC50 = 30 
nM), with the advantage of being non-estrogenic.
82,83 
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X
R1
R2
1.73a, 2-MeOE2; R1= OH, R2= OMe, X= CH(OH)()
1.73b, 2-MeOE1; R1= OH, R2= OMe, X= C=O
1.73c, 2-MeOEMATE; R1= OSO2NH2, R2= OMe, X= C=O  
Fig. 1.22.  Structures of 2-MeOE1, 2-MeOE2 and 2-MeOEMATE. 
The 2-difluoromethylestrone 3-O-sulfamate, compound 1.74 (Fig. 1.23) was found by 
Reed and co-workers to be a highly potent irreversible STS inhibitor with an IC50 of 100 pM in a 
placental microsomes preparation, which was 90-fold lower than EMATE in the same assay.
84
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Fig. 1.23.  Structure of 1.74. 
1.4.2.3 Modification of the D-ring of EMATE 
Modification of the B- and/or C-rings of EMATE has not been widely pursued possibly 
because modification of these two rings is more challenging from a synthetic point-of-view than 
modification of the A and D-rings.  Most D-ring modifications were done to afford new classes 
of STS inhibitors and to supress the estrogenic side effects of the parent compounds. 
Numerous D-ring modified EMATE derivatives have been prepared with the most 
common involving modification at the 17-position.  Modification at this position not only 
provides a means of increasing potency but also as means of decreasing the estrogenicity of the 
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released steroidal portion upon inhibition as it has been shown that the estrogenicity of E1 and 
E2 can be abolished or significantly reduced by introducing substituents at this position.   
Li et al. reported that 17-(N-alkylcarbamoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (1.75, 
Fig. 1.24) and 17-(N-alkanoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (1.76, Fig. 1.24) inhibited 
STS in intact MDA-MB-231 cells.
85
 At 10 nM, the level of inhibition for all of them was similar 
to or exceeded that of EMATE. Some of these compounds (n = 5) exhibited IC50‘s as low as 0.5 
nM and were not found to be estrogenic as determined by measuring the growth of estrogen-
dependent MCF-7 human breast cancer cells at a concentration of 1 M. Later Li et al. reported 
in a series of patents other 17-(N-alkylcarbamoyl)-estra-1,3,5(10)-triene-3-O-sulfamates (1.77) 
and the inverse amides are good inhibitors of STS with IC50 values ranging from the mid to low 
nanomolar using STS from CHO cells and E1S as substrate.
86-88
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Fig. 1.24.  17-(N-alkylcarbamoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (1.75 and 1.77)  and 
17-(N-alkanoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (1.76). 
 
The Li and Ishida groups have examined the bis-isopropyl derivative in more detail (1.77, 
R
1
 = R
2
 = i-Pr, also known as KW-2581, Fig.1. 24).
89,90
 KW-2581, which exhibited an IC50 of 
4.0 nM with crude human STS from transfected CHO cells and using MUS as substrate, was 
found to be non-estrogenic and inhibited tumour growth in a nitrosylmethylurea-induced rat 
mammary tumor model and a mouse xenograft model.  It was also demonstrated that KW-2581 
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could inhibit the ability of AdiolS (see Fig. 1.7) to stimulate the in vivo growth of MCF-7 breast 
cancer cells overexpressing STS.  
Several groups have examined 17-benzyl derivatives of E2-3-O-sulfamate as well as 
other D-ring-benzylated steroidal sulfamates as STS inhibitors (Fig. 1.25).  These compounds 
were based upon the observation by Poirier and coworkers that E2 derivatives bearing an -
benzylic group at the 17-position are potent STS inhibitors mentioned earlier.
65-69
 
Poirier and coworkers examined compounds 1.78 and 1.79 (Fig. 1.25) as STS inhibitors 
in a homogenate of human embryonic kidney (HEK) cells transiently transfected with an STS 
expression vector and JEG-3 cells respectively.
66
 Compounds 1.78 and 1.79 were 5- and 14-fold 
more potent than EMATE respectively for the transformation of DHEAS to DHEA.  Compound 
1.79 was examined in more detail and found to inhibit STS in a time and concentration-
dependent manner. The same workers reported that 1.78 (IC50 = 85 nM) was 4-fold less potent 
than EMATE (IC50 = 20 nM) but considerably more potent than the corresponding non-
sulfamoylated derivative 1.50 (Fig. 1.13) (IC50 = 6100 nM) in a placental microsomes assay 
using E1S as substrate.  The antiproliferative activity for 1.78 was modest (10 M gave 50% 
inhibition of basal MCF-7 cell growth in the absence of estrogen precursor E1S).  Moreover, it 
was noted that the sulfamate group was not necessary for antiproliferative activity for 1.78 as the 
non-sulfamoylated analog 1.50 exhibited slightly superior antiproliferative activity.   
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Fig. 1.25.  17-Benzyl derivatives of E2-3-O-sulfamate (1.78-1.80), 3-O-sulfamate derivatives 
of C19 and C21 steroids bearing t-butylbenzyl or benzyl groups (1.82 and 1.82) and 2-
substituted-17-benzyl-E2-3-O-sulfamates (1.83).  
 
Nippon Organon reported in a patent that compounds of this type (compounds 1.80, Fig 1.26) 
inhibited STS with IC50 values ranging from 30-160 nM and were more potent than EMATE 
under the same assay conditions (400 nM).
91
 
The Poirier group has also examined 3-O-sulfamate derivatives of C19 and C21 steroids 
bearing a t-butylbenzyl or a benzyl group as steroid sulfatase inhibitors (1.81 and 1.82, Fig. 1.25) 
using crude STS obtained from HEK 293 homogenates and E1S as substrate.
58
 No significant 
inhibition was found at a concentration of 3 M when only a sulfamate group was added.  With 
only a t-butylbenzyl or a benzyl group but no sulfamate group, good inhibition was obtained for 
pregn-5-ene series (IC50‘s 60-360 nM) but not the androst-5-ene series (IC50‘s > 1 µM).  
Addition of a sulfamate moiety to the t-butylbenzyl or benzyl-bearing compounds resulted in 
modest increases (1 to 2-fold) in potency when using E1S as substrate though more significant 
increases in potency were found when using DHEAS as substrate (up to 7.5-fold increase in 
potency).  3-Sulfamoyloxy-17-t-butylbenzyl-5-androsten-17-ol (1.81, R1 = OH, R2 = 4-(t-
Bu)-Bn) was the most potent compound with IC50 values of 46 and 14 nM; respectively for the 
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transformations of E1S to E1 and DHEAS to DHEA.  However, in contrast to 17-t-butylbenzyl-
EMATE (1.79), this compound did not induce any proliferative effect on estrogen sensitive ZR-
75-1 cells nor on androgen-sensitive Shionogi cells up to the highest concentration tested (1 
M).   
Potter and coworkers have examined 2-substituted-17-benzyl-E2-3-O-sulfamates 
(compounds 1.83, Fig 1.25) as STS inhibitors.  2-MeO-17-benzyl EMATE analogues (1.83, R1 
= OMe, R
2
 = H or t-Bu, IC50‘s = 430 and 4300 nM respectively) were much less potent STS 
inhibitors than 2-MeOEMATE or EMATE in a placental microsome assay using E1S as 
substrate and did not exhibit antiproliferative activity at 10 µM in an MCF-7 assay.
92
 This is in 
contrast to a report where Poirier and coworkers found that the same 2-MeO-17-benzyl 
EMATE analogues (1.83, R
1
 = OMe, R
2
 = H or t-Bu) were found to be more potent (IC50‘s of 
0.024 and 0.040 nM for the R
2
 = H and R
2
 =t-Bu derivatives respectively) than EMATE when 
assayed using STS obtained from HEK 293 homogenates and E1S as substrate.
93
  Poirier and co-
workers verified the activity of 2-MeO-17-benzyl EMATE (1.83, R1 = OMe, R2 = H) in an 
animal model and found this inhibitor to block stimulation induced by E1S on the uterine weight 
of OVX mice.
93
  Surprisingly, Potter and coworkers found that the 17-benzyl derivative of 2-
MeSEMATE (1.83, R
1
 = SMe, R
2
 = H) was a 3-fold more potent STS inhibitor than 2-
MeSEMATE (IC50s of 44 and 120 nM, respectively) in a placental microsomes assay and did 
exhibit some antiproliferative activity at 10 M in the MCF-7 assay.92 It is not yet clear why this 
effect is not seen with the 17-benzyl derivatives of EMATE and 2-MeOEMATE under these 
conditions.   
In addition to the benzylated derivatives discussed above, a variety of other C-17-
modified steroidal sulfamates have been examined as STS inhibitors (Fig. 1.26).  Potter and 
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coworkers have evaluated the antiproliferative activity of an array of 17-oxime derivatives of 2-
MeOEMATE (compounds 1.84, Fig. 1.26) in MCF-7 cells.
92
 With the exception of the 
NCH2C6F5 derivative, these compounds displayed equal or superior antiproliferative activity 
compared to 2-MeOEMATE and 2-EtEMATE (GI50 = 2.2 and 0.92 M respectively).  The 
sulfamoyl group was found to be necessary for good antiproliferative activity.   
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Fig. 1.26.  17-Oximo and 17-imino derivatives of 2-MeOEMATE (1.84), 3,17-O,O-bis-
sulfamates (1.85 and 1.86) and estra-1,3,5(10)-triene-3-O-sulfamates bearing cyano (1.87) 
heterocyclic (1.88) and piperidinyl substituents (1.89) at C17. 
 
The STS inhibitory and antiproliferative activity of 3,17-O,O-bis-sulfamates 
(E2bisMATEs, compounds 1.85, Fig. 1.26) have been reported.
94,95
 3,17-O,O-bis-sulfamates 
bearing unsubstituted sulfamate groups (SO2NH2) at the 3- and 17-positions with or without a 
methoxy group at the 2-position were excellent irreversible STS inhibitors (IC50 18-39 nM) and 
were much more effective than the corresponding 17-O-monosulfamate derivatives when 
assayed using placental microsomes and E1S as substrate.  Bis-sulfamates bearing a methoxy or 
ethyl group at the 2-position exhibited potent antiproliferative activity with DU145, MDA-MB-
231, and MCF7 cells and with mean graph midpoint values of 18-87 nM in the NCI 60-cell-line 
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panel. The 2-Et derivative dosed P.O. caused growth inhibition in a nude mouse xenograft tumor 
model. 
A more extensive study of bis-sulfamoylated as well as 3-sulfamoyl-17-carbamate 
derivatives was carried out (compounds 1.86, Fig. 1.26).
96
 Evaluation against human cancer cell 
lines (DU145, MDA-MB-231, and MCF-7) revealed the 2-methyl (DU145 GI50 = 0.38 M) and 
2-ethyl derivatives to be the most active novel bis-sulfamates (DU145 GI50 = 0.21 M), while 
the 2-ethyl-17-carbamate derivative (GI50 = 0.22 M) proved most active of its series. Larger C-
2 substituents were deleterious to activity for both series. 
17-Cyanated 2-substituted estra-1,3,5(10)-trienes (compounds 1.87, Fig. 1.26) have been 
examined as STS inhibitors and as antiproliferative agents.
97
 2-Methoxy-17-cyanomethyl-E2, 
but not the related 2-ethyl derivative, and the related 3-O-sulfamates displayed potent 
antiproliferative effects against human cancer cells in vitro (with MCF-7 cells, GI50 = 300, 60 
and 70 nM, respectively).  The 3-O-sulfamate of 2-methoxy-17-cyanomethyl-E2 showed good 
activity in an athymic nude mouse MDA-MB-231 human breast cancer xenograft model when 
administered orally. 
The anti-proliferative activities of a series of 2-substituted estra-1,3,5(10)-triene-3-O-
sulfamates bearing heterocyclic substituents (oxazole, tetrazole, triazole) tethered to C-17 
(compounds 1.88, Fig. 1.26) has been reported.
98
 In vitro evaluation of these molecules revealed 
that high anti-proliferative activity in breast and prostate cancer cells lines (GI50 of 340–850 nM 
with (DU145, MDA-MB-231 and MCF-7) could be retained when the heterocyclic substituent 
possesses H-bond acceptor properties. A good correlation was found between the calculated 
electron density of the heterocyclic ring and anti-proliferative activity. 
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Poirier and coworkers used a solid phase approach to synthesize a series of N-derivatized 
17-piperazinomethyl estradiol derivatives (compounds 1.89, Fig. 1.26) which were 
subsequently evaluated for STS inhibitory activity using homogenized HEK 293 cells 
overexpressing STS and E1S as substrate.
99
 Many of the compounds were more potent than 
EMATE.  Those bearing a hydrophobic amino acid and carboxylic acid substituents were the 
most effective inhibitors with the most potent being as effective as 17-t-butylbenzyl estradiol 3-
O-sulfamate mentioned previously (1.79, Fig. 1.25).  The corresponding non-sulfamoylated 
compounds were considerably less potent.  The estrogenicity and antiproliferative ability of these 
compounds was not reported.  
Peters et al have reported the evaluation of a large array of steroidal cyclic sulfamates 
bearing a wide variety of substituents at the 17-position as inhibitors of STS (compounds 1.90, 
Fig. 1.27).  These compounds exhibited IC50‘s in the low to high nM range in MCF-7 cells with 
compound 1.91 (Fig. 1.27) being the most potent (IC50 = 9 nM).  Compound 1.91 was reported 
to be active in a breast cancer xenograft model in vivo.
100
 The mode of inhibition (reversible or 
irreversible) of these compounds was not reported.  Compounds 1.92 and 1.93 (Fig. 1.27) were 
also found to be good inhibitors with IC50 of 44 and 15 nM respectively.  These results are in 
contrast to Woo et al. recent report that the five-membered cyclic sulfamates 1.94 and 1.95 (Fig. 
1.27) are not inhibitors of STS up to concentrations of 10 M when evaluated in a placental 
microsomes preparation of STS and in MCF-7 cells.
101
 Interestingly, Hanson et al. reported that 
the non-steroidal cyclic sulfamates, 1.96 and 1.97 (Fig. 1.27), are irreversible, time and 
concentration dependent inhibitors of the aryl sulfatase from Pseudomonas aeruginosa; 
unfortunately, these compounds were not examined as STS inhibitors.
102
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Fig. 1.27. Cyclic sulfamates. 
The 17-deoxy analog of EMATE (1.98, NOMATE, Fig. 1.28) inhibited activity in MCF-
7 cells by 97% at 10 nM, similar to the inhibition achieved with EMATE.
101,103
 In contrast, the 
17-deoxy analogue of 2-MeOEMATE (1.99, Fig. 1.28) and the related 2-ethyl and 2-
methylsulfanyl compounds (1.100 and 101, Fig. 1.28) showed significantly reduced inhibition of 
MCF-7 proliferation.
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H2NO2SO
R
1.98,   R = H
1.99,   R = OMe
1.100, R = SMe
1.101, R = Et  
Fig. 1.28.  17-Deoxy analogs of EMATE and 2-substituted EMATE 
There are only a handful of examples where analogs of EMATE have been developed 
that have been modified on the D-ring at positions other than or in addition to the 17-position or 
on the B or C rings.  Poirier and coworkers have reported the solid phase synthesis of a library of 
16-aminopropyl estradiol derivatives (1.102, Fig. 1.29), which were subsequently evaluated for 
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STS inhibitory activity using homogenized HEK 293 cells overexpressing STS and E1S as 
substrate.
105
 Several library members containing hydrophobic amino acids or substituents were 
more potent inhibitors than EMATE.  The estrogenicity and antiproliferative ability of these 
compounds was not reported.   
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Fig. 1.29. 16-Aminopropyl estradiol derivatives of E2EMATE, (1.102), SR 16517 (1.103) and 
SR 16137 (1.104), 6-substituted EMATE derivatives (1.105), cyclic amide (1.106), cyclic ester 
(1.107), and imide derivatives (1.108-1.110). 
 
The Peters and Lykkesfeldt groups have reported compound 1.103 (Fig. 1.29), known as 
SR 16157, as a dual-action STS inhibitor and antiestrogen.
105
 This compound is the sulfamate of 
the known antiestrogen 1.104 (Fig. 1.29).  Upon inhibition of STS by 1.103, the antiestrogen 
1.104 would be produced and interact with the ER thus providing a dual mode of action.  
Compound 1.103 exhibited an IC50 of 100 nM when assayed using an MCF-7 extract and E1S as 
substrate.  Compound 1.103 was found to bind poorly to the ER yet it was 10-fold more potent 
than 1.104 in inhibiting the growth of MCF-7 cells. 
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6-Me- and 6-phenyl-substituted EMATE (compounds 1.105, Fig. 1.29) have been 
examined as STS inhibitors using placental microsomes preparations of STS and E1S as 
substrate.
106
 These compounds were found to be much poorer inhibitors of STS than EMATE. 
Potter and coworkers reported in a patent that cyclic amide 1.106 (Fig. 1.29) exhibited 
91% inhibition of STS activity at 100 nM in MCF-7 cells.
107
 In an independent patent, Koizumi 
et al. reported that the analogous ester 1.107 (Fig. 1.29) exhibited 97% and 78% inhibition at 10 
nM and 1 nM respectively.
108
 Both 1.106 and 1.107 blocked liver STS activity in rats at an oral 
dose of 2mg/kg/day over 5 days and both were found to be nonestrogenic. 
In a somewhat different approach to D-ring modification, Potter and coworkers described 
a series of imide derivatives of type 1.108 (Fig. 1.29) as STS inhibitors.
109-112
 Several of these 
compounds (R = Me, n-Pr, Bn and (3-pyridyl)methyl, IC50‘s 1-12 nM) were more potent than 
EMATE (IC50 = 18 nM) using STS in placental microsomes and E1S as substrate.  The two most 
potent derivatives, the n-propyl and (3-pyridyl)methyl compounds (IC50‘s = 1 nM) were found to 
almost completely inhibit rat liver STS in vivo and to be devoid of estrogenic activity in the 
uterine weight gain assay.  The propyl derivative, (compound 1.109, known as STX213, Fig. 29) 
was shown to reduce circulating E2 levels by >90% and arrest tumor progression stimulated by 
E2S in a MCF-7 xenograft breast cancer model.  In this regard, STX213 was found to be 
superior to STX64 (compound 1.111, also known as 667-COUMATE and by the generic name 
Irosustat, Fig. 1.29) a non-steroidal STS inhibitor discovered in the 1990‘s that has been 
undergoing evaluation in clinical trials (see section 1.5)  It also had an improved duration of 
activity in vivo compared to STX64.  To improve the pharmacokinetic profile of STX213, the n-
propyl group was replaced with a 3,3,3-trifluoropropyl group (compound 1.110, STX1938, Fig. 
1.29).  This resulted in a 5-fold improvement in in vitro activity using intact JEG-3 cells as the 
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source of STS.  This compound completely inhibited the rat liver STS after a single dose of 0.5 
mg/kg, and exhibited a significantly longer duration of action over the n-propyl derivative. The 
improved pharmacokinetic properties were attributed to an increase in metabolic stability and 
lipophilicity.
109-112
 
1.4.3 Non-Steroidal Sulfamate-based STS Inhibitors 
1.4.3.1 Monocyclic Aryl Sulfamates 
Shortly after the discovery of EMATE in 1994,
57
 the sulfamate group became a clickable 
target for medicinal chemists who were looking for designing potent inhibitors of STS that did 
not have the estrogenic effects of EMATE.  One of these approaches is to attach the sulfamate to 
a substituted aryl ring. The first such derivatives consisted of a sulfamoylated benzene ring 
substituted with small electron withdrawing groups (compounds 1.112, Fig. 1.30). These 
compounds were far less potent STS inhibitors than EMATE.
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1.112, R= 3- or 4-NO2, CN, F, Br, Cl
X
R
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1.113, X = -O- or -C=O or -COO
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R
 
Fig. 1.30.  Simple aryl sulfamates as STS inhibitors. 
Attaching alkyl or aryl chains to the sulfamoylated benzene ring by a carbonyl, ether, or 
ester functional group was another approach examined in designing such type of inhibitors 
(compounds 1.113). Even though the new modifications enhanced the potency of such type of 
inhibitors compared to 1.112 they still considerably less potent than EMATE.
113-115
 
Another approach involved the attachment of another aromatic ring, with or without a 
spacer, to the sulfamoylated benzene ring (compounds 1.114 and 1.115, Fig. 1.31).
  
Interestingly, 
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the benzophenone sulfamates showed moderate inhibitory activity against STS, while the 
reduced analog, the benzyl phenyl sulfamate, was lacking any activity up to 100 µM.
116
 
Moreover, Ahmed et al. in 2002 also reported another analog series of EMATE, the biphenyl 
series, compounds 1.115, and the 2',4'-dicyano derivative (TZS-8478, compound 1.116), was 
among the most potent inhibitors in vitro, in addition of being non-estrogenic.
117,118
 Interestingly, 
it was found that daily administration of compound 1.116 (0.5 mg/kg/day) caused a marked 
suppression of the growth of breast tumors in rats stimulated by E1.  Moreover, 1.116 completely 
inhibited STS activity in uterus and liver tumours in rats and reduced plasma concentrations of 
both E1 and E2.
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Fig. 1.31.  Biphenyl and benzophenone sulfamates as STS inhibitors. 
In 2002, Ciobanu and Poirier reported a new series of inhibitors, compounds 1.117 (Fig. 
1.32), which has some of the structural features of the previously reported potent STS inhibitor 
compound 1.79 (Fig. 1.25). In this class of compounds both the C18-Me and the hydrocarbon 
skeleton (rings B, C, and D), were replaced with an alkyl chain. Even though, compounds 1.117 
were slightly less active than their steroidal analogues.  Structural features required for STS 
inhibition by this class of compounds showed that the presence of six carbon atoms in the side 
chain is the optimal length mimic for the B, C and D steroid rings, between C6 and C17.
  
The 
undecanol derivative showed the highest inhibitory potency of this class of compounds with an 
IC50 value of 0.4 nM (2-fold more potent than EMATE).
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Fig. 1.32.  Compounds 1.117.   
A series of 2-phenylindole sulfamates, compounds 1.118 (Fig. 1.33), with lipophilic side 
chains at either position 1 or 5 of the indole ring, were reported to be moderate to strong 
inhibitors of STS in MDA-MB-231 breast cancer cells (IC50‘s = 0.002-1 µM). Submicromolar 
concentrations of compounds 1.118 reduced proliferation of ER (+) MCF-7 breast cancer 
cells.
121
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1.118, R1 = alkyl; R2 = OH or OSO2NH2;
          R3 = H or Me; R4 = H, CN, CO-
         -NH(alkyl); R5 = H or OSO2NH2  
Fig. 1.33.  2-phenylindole sulfamates as STS inhibitors. 
It has been proposed that dual aromatase/sulfatase (DASIs) inhibitors should provide a 
more effective endocrine therapy.  Recently, a series of sulfamoylated derivatives, compounds 
1.119b, of the aromatase inhibitor YM511, compound 1.119a, have been examined as DASIs 
and were found to strongly inhibit STS and aromatase in JEG-3 cells with IC50 values ranging 
from 20 to 227 nM and from 0.82 to 100 nM, respectively (Fig. 1.34).
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Fig. 1.34. Triazole-based DASIs. 
Later on, Woo and coworkers examined the effect of placing the sulfamate group at the 
meta position (1.119b) instead of the para one as in the previous series (1.119a).  They found a 
marked improvement in the inhibitory activity on the aromatase enzyme, especially with 
derivatives bearing a fluorine ortho to the sulfamate group, which indicates that such motif is a 
good building block for a preparation of a potent DASI.
123
 In 2008, the same group examined 
another approach by placing a different linker between the aryl sulfamate motif and the triazole-
benzonitrile scaffold (compounds 1.120, Fig. 1.34).  They found that nearly all derivatives show 
improved in vitro aromatase inhibition but with a marked decrease in STS inhibition.
124
  
In 2010, Woo and coworkers published an article about joining their previously designed 
triazole-based DASIs into known biphenyl STS inhibitors. Their approach furnished a series of 
potent DASIs (compounds 1.121), with some of them, at 1 mg/kg po, able to significantly reduce 
plasma E2 levels and strongly inhibit STS activity in the liver in rats.  Moreover, these novel 
DASIs were found to be non-estrogenic.
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1.4.3.2 Bicyclic and Polycyclic Aryl Sulfamates 
There are numerous studies concerning sulfamate-based inhibitors in which the sulfamate 
group has been attached to a scaffold that mimics the A and B rings of EMATE.  Such scaffolds 
include naphthalenes, indanones, tetralones, 7-hydroxycoumarins, 4-(thio)chromenones, 
41 
 
benzoxazoles, and benzofurans.
58,126,127
 To date, the most important is the coumarin scaffold.  
COUMATE, compound 1.122 (Fig. 1.35), is the corresponding sulfamate of 4-MUS.  This 
compound inhibits STS in the micromolar range and is non-estrogenic in vivo.  SAR studies 
showed that the optimal position for the sulfamate group, in terms of STS inhibition, is at C7.  
Moreover, the inclusion of alkyl substituents in C3 or C4 enhances STS inhibition.
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O OH2NO2SO
1.122 (COUMATE)  
Fig. 1.35. Structure of COUMATE 
Sterix Ltd, in the year 2000, reported one of the most potent irreversible STS inhibitors; 
667COUMATE (compound 1.111, STX-64 or Irusostat) which is a carbocyclic ring derivative of 
COUMATE as shown in Fig. 1.29. STX-64 efficiently inhibited STS in placental microsomal 
preparations (IC50 of 8 nM), without showing any estrogenic side effects. STX-64 is the first STS 
inhibitor to enter phase I clinical studies for treatment of HDBC.
128,129 
  
Interestingly, the benzocoumarin sulfamate 1.123, which is structurally closely related to 
STX-64, (Fig. 1.36), was found to be 3-times less active than EMATE against purified STS (IC50 
= 166 nM, vs. 56 nM for EMATE).
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Fig. 1.36.  Benzocoumarin (1.123) and coumestane derivatives (1.124).  
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The same research group tested another approach in designing STS inhibitors, by 
preparing coumestane derivatives (Fig. 1.36, compounds 1.124). These derivatives exhibited 
quite divergent activity against STS, with highest potency achieved when R1 is H and R2 is equal 
to OSO2NH2 (IC50 = 280 nM, versus 18.5 µM when the R groups are inverted), and it was 
explained that the first regioisomer has much better resemblance to the steroid skeleton than the 
other isomer when the sulfamate groups were superimposed with that of EMATE.
128
 
In 2002, Novartis examined a series of the 4-(thio)chromenone sulfamates, compounds 
1.125 (Fig. 1.37), as STS inhibitors. Notably, this class demonstrated high inhibitory potency 
when both the sulfamate group and the side chain were placed in a diagonally opposite positions 
(i.e., 2,6- and 3,7-substitution pattern).  The best inhibitory potency was achieved when fully 
branched, bulky aliphatic side chains were used in combination with the 4-thiochromenone 
scaffold. Compounds 1.125 were irreversible STS inhibitors with a biphasic time course of 
inactivation.
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1.125, X= O, or S; R= (cyclo)alkyl,
           or 1-adamantyl  
Fig. 1.37.  Chromenone sulfamate STS inhibitors 
Researchers at Novartis also published a number of articles about the use of 
sulfamoylated benzoxazoles and their sulfur analogs (compounds 1.126) as inhibitors of STS 
(Fig. 1.38) as STS inhibitors. They preferred to use highly bulky substituents in their design in 
contrast to the previous chromenone series (Fig.1.37), in addition to substituting the bicyclic core 
with an adamantyl or an adamantylmethyl group. These structural modifications gave derivatives 
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with moderate inhibitory activity. However, switching from the saturated adamantylmethyl 
residue to the unsaturated adamantylidienemethyl residue, compound 1.127, resulted in a 
derivative which is as efficient as EMATE in enzyme inactivation and was non-estrogenic in 
vitro.  In a proof-of-concept study using rat models compound 1.127 was found to be able to 
inhibit STS activity in skin after both oral and topical administration.  This provided support for 
STS inhibitors as potential therapeutics for treating acne.
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           R3 = (un)substituted alkyl  
Fig. 1.38.  Sulfamoylated benzoxazoles as STS inhibitors 
In 2002, a series of sulfamoyloxy-substituted 2-phenylindoles, compounds 1.128, were 
synthesized by a German group who were attempting to design STS inhibitors with no agonistic 
activity on the ER (Fig. 1.39). This series of compounds were found to be able to suppress STS 
gene expression in stably-transfected MCF-7/2a breast cancer cells via their enzyme inhibitory 
activity (IC50 values in the submicromolar range).
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R1
R3
R4
R2
1.128,  R1 = Et, (CH2)5CONC4H8, (CH2)6NC4H8,
           or (CH2)10SO2C5H10; R2 = H, OH, or OSO2NH2;
           R3 = R4 = H, CN, OH, COOMe  
Fig. 1.39.  Sulfamoyloxy-substituted 2-phenylindoles as STS inhibitors. 
1.4.4. Non-Steroidal, Non-Sulfamate-based STS Inhibitors 
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Nussbaumer and his co-workers at Novartis used high-throughput screening to find novel 
STS inhibitors (Fig. 1.40). These studies yielded the nortropinyl-arylsulfonylurea derivatives 
(compounds 1.129) as moderate to a strong reversible inhibitors of purified STS using MUS as 
substrate (IC50 ranging from 84 nM to 100 µM).
134,135
  The same group extended their SAR 
studies by modifying both the phenylacetyl side chain and nortropine groups. These 
modifications lead to the N-(Boc-piperidine-4-carbonyl)benzenesulfonamides (compounds 
1.130), which exhibited improved cellular potency, with the best inhibitory potency reported for 
compound 1.131 (IC50 of 270 nM using STS over-expressed in CHO-cells, Fig.1.40). 
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Fig. 1.40.  Nortropinyl-arylsulfonylurea and N-(Boc-piperidine-4-carbonyl)benzenesulfonamides 
as STS inhibitors. 
 
The Novartis group, on the basis of their previous studies on chromenone sulfamates 
(Fig. 1.37), extended these investigations to using sulfamate replacements. They discovered that 
2-(1-adamantyl)-4-(thio)chromenone-6-carboxylic acids (Fig. 1.41, compounds 1.132) are good 
reversible inhibitors of purified STS with the best Ki value for the 4-chromenone-6-carboxylic 
acid derivative (Ki = 0.50 µM ).
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1.132,  X = O or S; R = COOH, CH2OH, CHO, COOMe, 
           CONH2, CN, C(O)CH2OH, CH2COOH, C(O)COOH  
Fig. 1.41.  2-(1-adamantyl)-4-(thio)chromenone-6-carboxylic acids as STS inhibitors. 
In 2004, Novartis reported novel STS inhibitors having a N-sulfonylaminothiazole 
scaffold (Fig. 1.42, compounds 1.133), but unfortunately, such compounds were much less 
potent inhibitors of purified STS than EMATE.
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            or alkoxycarbonyl  
Fig. 1.42.  N-sulfonylaminothiazoles as STS inhibitors. 
In 2002, Jütten et al. examined 32 thiosemicarbazone and N-acyl-hydrazone derivatives 
of madurahydroxylactone (Fig. 1.43, compounds 1.134) as inhibitors of STS using E1S as 
substrate and the placental microsome fraction as a source of crude STS.  Their IC50 values 
ranged from 0.35 to >100 µM, with a non-competitive mode of inhibition of STS.
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Fig. 1.43.  Thiosemicarbazone and N-acyl-hydrazone derivatives of madurahydroxylactone as 
STS inhibitors. 
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In 2006 the Taylor group incorporated the boronic acid group into the chromenone and 
coumarin scaffolds (Fig. 1.44, compound 1.135 and 1.135). However, these two compounds 
were moderate reversible inhibitors of purified STS (IC50 = 86 and 171 µM, respectively).
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Fig. 1.44.  Boronic acids as STS inhibitors. 
 
1.5 Clinical Studies with STS Inhibitors 
The only STS inhibitor to have entered clinical trials is Irosustat or STX64 (compound 
1.111, Fig. 1.29).
139-141
 The results of these trials are mixed; in a phase I clinical trial with 
postmenopausal women having HDBC, Irosustat to a great extent abolished STS activity in the 
peripheral blood lymphocytes and tumour tissue; however, reductions in serum E1 and E2 
concentrations were still moderate.  Nevertheless, five out of 14 patients (previously treated with 
AIs), showed evidence of stable disease.  Interestingly, the concentration of androstenedione was 
reduced by 86%, which suggests that androstenedione is mainly derived from the peripheral 
conversion of DHEAS and not by direct secretion from the adrenal cortex.  This supports the 
supposition that STS inhibitors may prove to be very effective in treating androgen-dependent 
cancers such as prostate cancer.   
In a phase II endometrial cancer (EC) open-label trial, 17 out of 36 patients taking 
Irosustat (STX64) for 6 months showed more stable disease than did megestrol acetate (MA), a 
drug commonly administered to patients with advanced EC (only 12 out of 37 patients showed 
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stable disease). However, Irosustat did not show the desired effects on progression-free survival 
(PFS); for Irosustat the median PFS for 16 out of 36 patients ranged from 9 to 34 weeks, while 
for MA it was 16-63 weeks in 32 out of 37 patients. Hence development is now more directed to 
potential use of Irosustat as a combination therapy with AIs. 
The somewhat promising results obtained in the initial breast cancer trial with STX64 
and the potential of STS inhibitors as drugs for treating other HDCs, such as prostate and 
endometrial cancer, as well as non-oncological disorders, such as skin disorders, provides the 
impetus for the future development and study of new/better STS inhibitors.
142,143
   
1.6 Thesis Objectives and Overview 
The global objective of this thesis is to develop new classes of potent STS inhibitors. It is 
hoped that such inhibitors could be used as drugs or as lead structures for the development of 
therapeutics for treating hormone-dependent cancers (HDC).   
We prefer to examine our inhibitors with purified enzyme as opposed to using crude 
enzyme preparations (i.e. placental microsome preparations), since this will enable us to more 
accurately obtain kinetic parameters and ascertain the mode of inhibition (competitive, 
noncompetitive, tight-binding, or irreversible).  Hence, in Chapter 2, we briefly discuss the 
purification of STS from human placenta, which is one of the richest sources of STS.   
In Chapter 3 we describe a new class of potent, reversible non-competitive STS 
inhibitors based on the steroidal scaffold bearing a sulfonamide group at the 17-position. 
Molecular modelling studies were performed on selected compounds to provide information on 
where and how they interact with STS.   
In Chapter 4, we describe the most potent reversible STS inhibitors described to date.  
These compounds are analogs of our STS sulfonamide inhibitors described in Chapter 3 in that 
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they have a small electron-withdrawing group at the 2- and/or 4-positions.  Some of these 
inhibitors, as well as some described in Chapter 3, were sent to the National Cancer Institute 
(Bethesda, Maryland, USA) where they were examined for their in vitro anti-proliferative 
activity against the NCI 60-cancer cell line screen. 
In Chapter 5, initial efforts to introduce a sulfamate group into the 3-position of our 
sulfonamide-based inhibitors were done.  We also describe our preliminary efforts to prepare an 
E1S analog in which the sulfate group is replaced with a 1,2,5-thiadiazolidin-3-one-1,1-dioxide 
ring.  It is anticipated that this group will act as a novel hydrolytically stable sulfate mimic and 
will be useful in developing STS inhibitors.   
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Chapter 2 - Purification of Steroid Sulfatase 
2.1. Introduction 
2.1.1 Why Purify STS? 
The vast majority of inhibitor studies on STS that have been reported have used impure 
STS either in the form of the microsomal fraction from human placenta or as cell lysates or 
homogenates from CHO, HEK-293, or JEG-3 cells expressing STS.
70,77,122,144-146
  This makes 
performing detailed kinetic studies on the inhibitors challenging as contaminating enzymes can 
affect the results if using a general sulfatase substrate such as 4-MUS in the enzyme assays or 
time consuming if using radiolabelled substrates such as Tritiated E1S.  Regardless of substrate, 
reproducibility can also be challenging when using impure enzyme.   
The Taylor group performs their inhibition studies with purified STS since we believe 
that this provides more accurate and reproducible results.  To our knowledge, with the exception 
of the Novartis group in Austria, the Taylor group is the only group that currently uses purified 
STS for their inhibition studies. STS is usually purified from human placenta.  It does not 
express well in bacteria.
147
 Although a report by Sterix Ltd. has appeared in which recombinant 
STS was overexpressed as a hexa-histidine tagged fusion protein in 293-EBNA cells (human, 
embryonic kidney cells expressing Epstein Barr virus nuclear antigen-1)
148
 most researchers 
working with pure STS, such as ourselves and the Novartis group, still purify STS from human 
placenta mainly for reasons of ease and/or economy.  
There are several published purifications of STS mainly from human placenta.
30,149,150 
 In 
all of these instances, the purification requires many columns, the yield is usually very low and 
the purity sometimes suspect.  The purification that is used in the Taylor group was, in part, 
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developed by researchers at Novartis (never published by Novartis) and has since been modified 
and improved upon in the Taylor group.  It makes use of an immunoaffinity column to purify 
STS from human placenta and is vastly superior to other published procedures in terms of time, 
purity, yield, and specific activity.   
2.2. Objectives   
The objective of the work described in this chapter is to purify STS using a procedure 
developed by researchers at Novartis and modified in the Taylor group.
151
 
2.3. Results and Discussion  
2.3.1. Placental Purification of STS 
The extraction protocol of STS from human placenta was based on extraction procedures 
provided by Hernandez-Guzman et al.
152
 Briefly, a number of homogenization and extraction 
steps of the placental tissue to obtain microsomal fraction were initially performed.  This 
involved homogenization of the placental tissues in a 50 mM tris-HCl, pH 7, 0.25 M sucrose, pH 
7.4 followed by centrifugation at 20,000  g at 0oC. The pellet was resuspended in the same 
buffer and centrifuged again.  The pellet was suspended in an extraction buffer consisting of 20 
mM tris-HCl, pH 7.4, and 0.3% v/v Triton X-100.  This was subjected to ultracentrifugation at 
100,000  g and the supernatant was saved.  This pellet was resuspended in the extraction buffer 
and the centrifugation repeated.  The pellet was discarded and the two supernatants combined to 
give the solubilized microsomal fraction of the placenta in which STS resides. 
Shankaran et al. reported that partial purification of STS can be achieved using an anion 
exchange column (DEAE, DiEthylAminoEthyl cellulose).  A salt gradient is used to elute STS 
whose isoelecterical point (pI) is 6.9.  This procedure has been widely used in many STS 
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purifications.  Before we applied our material to a DEAE column it was necessary to dialyze the 
microsomal fraction into 20 mM tris-HCl, pH 7.4 but containing only 0.1% v/v Triton X-100 
since high concentrations of Triton X-100 will not allow the STS protein to adhere to DEAE.  
After dialysis the solubilized microsomal fractions were applied to a DEAE column and STS was 
eluted with a salt gradient as shown in Fig.2.1. 
 
Fig. 2.1.  Elution profile of STS activity by DEAE chromatography 
 
Fractions from the DEAE column were assayed for STS activity using 4-
methylumbelliferyl sulfate (4-MUS), a substrate that is widely used to assay STS and other 
sulfatases.
153
 In this assay, the production of a fluorescent species called 4-methylumbelliferone 
(4-MU) is monitored using a fluorescence reading plate reader (Fig. 2.2).  4-MU is not highly 
fluorescent at ext = 360 nm, however; when it is deprotonated it gives a highly fluorescent 
species with em = 460 nm. Although the pKa of 4-MU is 7.8, there is still enough of the 
fluorescent anion present at pH 7.0 such that the reaction can be easily followed continuously.
153
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Fig. 2.2.  The fluorogenic assay of STS using 4-MUS.  
Fractions from the DEAE column containing sulfatase activity were pooled and then 
dialyzed into 20 mM Hepes buffer, pH 7.4, 1% v/v Triton X-100.  These pooled fractions were 
applied to an immunoaffinity column consisting of anti-STS monoclonal antibodies covalently 
linked to Sepharose 4B.  The column was washed with the same buffer and then 20 mM Hepes 
buffer containing, 100 mM NaCl, 0.1% v/v Triton X-100 at pH 7.4, and then STS was eluted 
with 50 mM citric acid, pH 2.7, 140 mM NaCl, 0.1% v/v Triton X-100 (fractions 49 to 53),  as 
shown in Fig.2.3.  Fractions containing STS activity were immediately pooled and then 
immediately neutralized by dialysis into 20 mM Tris, pH 7.4, 0.1% v/v Triton X-100 (STS 
storage buffer). 
 
Fig. 2.3.  Elution profile of STS activity from the anti-STS immunoaffinity column.  The 
application of 50 mM citric acid, pH 2.7, 140 mM NaCl, 0.1% v/v Triton X-100 began after the 
column had been washed with 40 mL of 0 mM Hepes buffer containing, 100 mM NaCl, 0.1% 
v/v Triton X-100 at pH 7.4. 
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2.3.2 Evaluation of the Protein Concentration, Specific Activity and Molecular Weight of 
STS  
 
Shankaran et al. and Vaccaro et al. have reported the purification of STS from human 
placenta by protocols different for the one reported here and both required four to five 
chromatographic steps after extraction from placenta.  Their specific activities were 0.2 nmol 4-
MU produced/mg/min in 0.25 M tris-HCl, pH 7.3 at 37
o
C (Shankaran et al),
154
 and 70 nmol 4-
MU produced/mg/min in 0.02 M tris, pH 6.8, pH 7.0 (Vaccaro et al).
155
 It appears that the 
specific activity of the protein purified in our lab is much higher than that of Shankaran et al., 
and Vaccaro et al, as seen in Table 2.1. The advantage of the method we used is that it employs a 
fewer number of chromatographic steps than those employed by both Shankaran and Vaccaro et 
al‘s.   
Table 2.1.  STS protein concentration and 
specific activity from three separate 
purifications. 
Purification 
Protein Conc. 
(mg/mL) 
Specific Activity 
(µmol/mg/min) 
1
st
 0.175 0.33 
2
nd
 0.339 0.38 
3
rd
 0.256 0.41 
 
SDS-PAGE of our purified STS (Fig. 2.4) indicated a high degree of purity.  The shadow 
bands that are present on our SDS-PAGE have also been reported by others and are attributed to 
N-glycosylation of STS.
52,152  
It has been reported in the literature that STS has a wide range of 
molecular weights for its monomeric form with values ranging from 63-78 kDa.
149,150,155,156 
 The 
molecular mass of the major band detected by the SDS-PAGE as shown in Fig. 2.4 is 
approximately 68 kDa and 63 kDa for deglycosylated form, which is in a good agreement with 
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the results reported by Hernandez-Guzman et al., who reported a molecular mass of 65 kDa 
based on SDS-PAGE and whose placental extraction method we followed.
152
  
 
 
 
 
 
 
Fig. 2.4.  SDS-PAGE of the purified STS. The gel was stained in Fermentas PageBlue
TM
 Protein 
staining solution. lane 1 (protein Ladder), lane 2 (deglycosylated STS), lanes 3, 4, 5, and 6 
(native STS at different concentrations). 
 
There used to be conflicting evidence in the literature concerning the functional oligomer 
of STS, which had been reported as either trimeric,
155
 tetrameric,
149
 or hexameric,
156
 according to 
SDS-PAGE. In fact these faint shadow bands were used later to grow diffraction-quality crystals 
to elucidate the first X-ray crystal structure of STS.
152 
However, with the publication of the 
crystal structure in 2003,
30
 there is now an agreement that the protein is a monomer and the 
previous reports of multimeric forms were caused by variations in detergent solubilization.
154,155  
2.4. Conclusions  
The purification of STS is an important initial step for our inhibition studies as it allows 
for accurate kinetic analysis of our STS inhibitors.  In the Taylor lab, we have developed a 
reliable method for the purification of STS from human placenta which yields the enzyme in 
very high purity and specific activity. This method represents an efficient adaptation of an 
established ion exchange chromatography method paired with an immunoaffinity column to 
1 2 3 4 5 6 
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yield a large quantity of highly purified enzyme, essential for the detailed inhibitor studies we are 
performing. 
2.5 Experimental 
2.5.1 Materials  
Biochemical reagents and buffers were obtained from Sigma-Aldrich® Chemicals Co. 
(St. Louis, Missouri, USA) unless stated otherwise. DEAE cellulose (DE-52) was obtained from 
Whatman
®
 (Maidstone, UK). The STS Immunoaffinity column was prepared by Vanessa 
Ahmed, a previous PhD student in the Taylor group, by coupling an anti-STS monoclonal 
antibody, obtained as a gift from Novartis Austria GmbH, to a CNBr-activated Sepharose 4B 
obtained from Pharmacia (Sweden) at a density of 10 mg/ml resin. The procedure for 
purification of STS by immunoaffinity chromatography was provided by Dr. Andreas Billich at 
Novartis Austria GmbH. Protease inhibitor cocktail was obtained from Sigma-Aldrich
®
 
Chemicals Co. DC Protein Assay kit for Bradford protein determination was obtained from Bio-
Rad Laboratories (Richmond, California). A gel electrophoresis silver-staining kit was obtained 
from InvitrogenTM (Carlsbad, California). Gel electrophoresis PageBlueTM Protein Staining 
Solution was obtained from Fermentas Life Science (Vilnius, Lithuania). Fluorometric assays 
were performed using a SpectraMax Gemini XS plate reader equipped with SOFTmax
®
 Pro 
Version 3.1.1 software from Molecular Devices (Sunnyvale, California). Human placenta was 
obtained from Credit Valley Hospital, Mississauga, Ontario, shortly after birth, and immediately 
frozen at -80 
o
C until purification, for no longer than two weeks.  
2.5.2 Methods  
2.5.2.1 Activity Assay  
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Steroid sulfatase (STS) activity was assayed by the addition of 20 µL of sample to 180 
µL of 0.1 M tris, pH 7.0, containing 200 µM 4-MUS, in a 96-well black microtiter plate 
(Corning), similar to the method reported by Roy, A. B. in 1971.
153
 Production of fluorescent 
product (4-MU) was monitored for 10 minutes at an excitation  of 360 nm and an emission  of 
460 nm, using a fluorescence plate reader (Gemini XS, Molecular Devices, Sunnyvale, CA). 
Enzyme activity was monitored in terms of relative fluorescence units per second 
(RFUs/Second) using a data acquisition software package, Softmax Pro 3.1.1. 
2.5.2.2 Homogenization and Chromatography  
Full-term human placenta was defrosted slowly at room temperature and a 200 g sample 
(excluding umbilical cord and surrounding membranes) was homogenized using a Brinkman 
polytron in 50 mM Tris HCl pH 7.5, 0.25 M sucrose, and 1g of protease inhibitor cocktail 
(Sigma-Aldrich
®
).  The homogenate (400 mL) was centrifuged (20,000  g, 30 min., 4o C), and 
the supernatant was discarded. The pellet was resuspended in the same buffer (300 mL) used in 
the homogenization and subjected to an additional centrifugation (20,000  g, 30 min., 4oC). The 
supernatant was discarded and the pellet was resuspended in an extraction buffer of 20 mM Tris 
HCl pH 7.4, 0.3% v/v Triton X-100 (300 mL) and subjected to ultracentrifugation (100,000  g, 
70 min., 4
o
C).  After centrifugation the supernatant was saved while the pellet was resuspended 
in the same extraction buffer (200 mL) and subjected to a second ultracentrifugation (100,000  
g, 70 min., 4
o
C). The resulting supernatant was pooled with that of the first ultracentrifugation 
and the pellet was discarded. This microsomal fraction (400 mL) was dialyzed into 20 mM tris 
HCl, pH 7.4, 0.1% v/v Triton X-100 (4 L  3) and then subjected to a DEAE column (250 mL of 
DE-52, Whatman
TM
) according to the procedure of Hernandez-Guzman et al.
30
 After the 
dialysate was applied, the column was washed with 5 column volumes of 20 mM tris HCl, pH 
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7.4, 0.1% v/v Triton X-100, and eluted with a linear gradient of 10 column volumes of increasing 
NaCl concentration of up to 1 M.  The pooled fractions containing STS (250 mL) were dialyzed 
into 20 mM Hepes buffer, pH 7.4, 1% v/v Triton X-100 (2 L  3). To obtain pure STS, dialyzed 
fractions from the DEAE column were applied to a anti-STS immunoaffinity column (2.5 mL) 
that had been pre-equilibrated with 10 column volumes of the dialysis buffer based on a method 
provided to us by Novartis. The immunoaffinity column was prepared by coupling a purified 
monoclonal antibody raised against STS to a CNBr-activated Sepharose 4B at a concentration of 
10 mg antibody per mL of resin according to the manufacturer‘s instructions (Pharmacia). The 
column was washed with 5 column volumes of the same buffer and then 10 column volumes of 
20 mM Hepes, pH 7.4, 100 mM NaCl, 0.1% v/v Triton X-100 and then eluted with 10 column 
volumes of 50 mM citric acid, pH 2.7, 140 mM NaCl, 0.1% v/v Triton X-100. Fractions 
containing STS activity were immediately pooled and were neutralized by dialysis into 20 mM 
Tris, pH 7.4, 0.1% v/v Triton X-100 (STS storage buffer). The dialysed enzyme was then divided 
into aliquots of 40 µL each and flash frozen in N2 (l) and stored at -80
o
C until use. The purified 
STS homogeneity was > 95% as judged by 10% SDS-PAGE (stained with PageBlue
TM
 Protein 
Staining Solution, Fermentas Life Science).  
2.5.2.3 Protein concentration determination 
The protein concentration was determined according to DC Biorad Laboratories 
(Richmond, CA) protein concentration determination kit instructions using bovine serum 
albumin (BSA) as a standard. This colorimetric assay is for the determination of protein 
concentration following solubilization with a detergent such as Triton X-100. The assay is based 
on the reaction of protein with an alkaline copper tartrate solution and Folin reagent.
157
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Chapter 3 – 17-Arylsulfonamides of 17-Aminoestra-1,3,5(10)-trien-3-ol as 
Highly Potent Inhibitors of Steroid Sulfatase. 
 
3.1. Introduction 
 Although the vast majority of STS inhibitors are irreversible sulfamate-based inhibitors 
(see chapter 1), we decided to focus our efforts on developing reversible, non-sulfamate 
inhibitors.  There are several reasons for this.  First, although hundreds of aryl sulfamates have 
been examined as STS inhibitors over the previous 18 years, only one, STX64 (see chapter 1, 
section 1.5), has made it to phase I clinical trials and with mixed results.  Second, many aryl 
sulfamates, such as STX64 and EMATE, are very potent inhibitors of carbonic anhydrases 
(CAs).
158
  Although binding to CAs protected STX64 against first pass metabolism,
159
 the 
potential for side effects as a result of potent CA inhibition with this and other aryl sulfamate-
based STS inhibitors is an issue for concern.  Binding to CAs would also be expected to affect 
bioavailability.   
 As noted in Chapter 1, not many reversible inhibitors of STS have been developed.  
Perhaps the most notable are the E2 derivatives developed by Poirier and coworkers (compounds 
of type 1.49, see Chapter 1, section 1.4.1.2, Fig. 1.13).  Some of these compounds, such as 1.51 
and 1.52, exhibited IC50‘s as low as 24-28 nM when assayed using HEK-293 cells 
overexpressing STS and E1S as substrate.  We decided to use these E2 derivatives as lead 
compounds for STS inhibitor development.  However, there were some issues with these 
compounds.  In our previous studies with these types of compounds (compound 1.50)
63
 we noted 
that they were very hydrophobic and so very poorly soluble in water (the log P coefficient has 
not been reported for these compounds).  This made them difficult to assay in aqueous solution.  
Moreover, compounds of such hydrophobicity can sometimes be difficult to develop into drugs 
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due to their poor solubility, partitioning into cellular membranes and accumulation in adipose 
tissue.  Finally, the synthesis of these compounds involved reacting estrone with a considerable 
excess of a Grignard reagent (sometimes 8-fold excess) and, even with this excessive amount of 
Grignard reagent, the yields were often very low.  This made them inefficient and expensive to 
prepare.  We decided to modify these compounds by introducing a different linker between 
appended aryl group and the carbon at the 17-position.  This led us to design compounds such as 
sulfonates of type 3.1 and sulfonamides of type 3.2 as potential STS inhibitors (Fig. 3.1).  It is 
expected that such compounds would be less hydrophobic than compounds of type 1.49.  
Moreover, their synthesis would simply involve reacting 3-OH-protected E2 or the 17-amino 
analog of E2 with sulfonyl chlorides. Since a large number of sulfonyl chlorides are 
commercially available a large number of potential inhibitors could be made relatively quickly. 
Finally as far as the sulfonamides 3.2 are concerned, the sulfonamide group is very chemically 
and metabolically stable and is one of the most important pharmacophores in medicinal 
chemistry and numerous bioactive agents bear this functionality.  
HO
X
H
S
O
O
3.1, X = O
3.2, X = NH
R
 
Fig. 3.1.  General structure of proposed STS inhibitors. 
3.2. Objectives 
These objectives of the work presented in this chapter were to synthesize a series of 
compounds of type 3.1 or 3.2 and evaluate these compounds, both in terms of potency and 
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modality of inhibition, as in vitro STS inhibitors using purified STS. 
3.3. Results and Discussion 
3.3.1 Studies with model sulfonates and sulfonamides 
To determine which series of compounds (sulfonate or sulfonamide) that we would focus 
our efforts on we initiated these studies by synthesizing model sulfonates 3.3 and 3.4 and the 
analogous model sulfonamides 3.5 and 3.6 and then examined them as STS inhibitors (Fig. 3.2). 
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3.6, R = CH3
R
 
Fig. 3.2.  Model sulfonates and sulfonamides. 
Compound 3.4 was reported before in a US patent in 1958.
160
 It was prepared from 3-
acetoxy derivative of E2 according to Scheme 3.1.  Unfortunately, they did not report any details 
including percent yield or spectral data.
160
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3.4  
Scheme 3.1.  Literature synthesis of compound 3.4. 
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We decided to prepare compounds 3.3 and 3.4 from E1 using the route shown in Scheme 
3.2.  Alkylation of E1 by benzyl bromide in presence of potassium carbonate and acetone as a 
solvent afforded compound 3.7 in a 91% yield.
161
 Reduction of the keto group in 3.3 using by 
NaBH4 afforded the alcohol, 3.8, in a 74% yield.
162
 Reaction of 3.4 with a slightly excess of 
benzene sulfonyl chloride or tosyl chloride in anhydrous pyridine at room temperature for 18 h 
afforded the desired sulfonates 3.9a and 3.9b as white solids in 68 and 63% yield respectively.  
Finally, removal of the benzyl protecting group in 3.9a and 3.9b using H2 and Pd(OH)2 afforded 
the target compounds 3.3 and 3.4 in 69 and 71 % yield respectively.  
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HO
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O
O
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1.2 eq. BnBr, 1.5 eq. K2CO3
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1. 2 eq. NaBH4, EtOH/
THF(5/1), 0
o
C, 1h, HCl
0.8 eq. Pd(OH)2, MeOH/
EtOAc (1:1), HOAc, H2, O/N
E1 3.7 (91%)
3.8 (74%) 3.9a; R = H (63%)
3.9b; R = CH3 (68%)
1.1 eq. ArSO2Cl, Py, 
0
o
C, 1h; then rt, O/N
3.3; R = H (69%)
3.4; R = CH3 (71%)  
Scheme 3.2.  Synthesis of 17-Sulfonate derivatives of E1 
The analogous sulfonamide compounds 3.5 and 3.6 were prepared according to Scheme 
3.3.  Reductive amination of E1 using benzylamine and sodium triacetoxyborohydride (STAB-
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H) gave compound 3.10 in a 93% yield after recrystallization from MeOH.  Removal of the 
benzyl protecting group by hydrogenolysis with H2 and Pd(OH)2 gave amine 3.11 in good 
yield.
163
  The appropriate sulfonyl chloride was then added dropwise as a solution in  DCM via a 
syringe pump over 30 min to a solution of amine 3.11 in pyridine at 0 
o
C which gave 
sulfonamides 3.5 and 3.6 in good yield.  By adding the sulfonyl chloride slowly we were able to 
minimize the amount of the disubstituted product which could happen from the presence of the 
unprotected phenolic 3-OH group.  
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Scheme 3.3.  Synthesis of the 17β-Sulfonamides 3.5 and 3.6. 
The IC50‘s of compounds 3.3-3.6 were determined using purified STS in tris-HCl buffer 
at pH 7.0 containing 5% DMSO, 0.01% Triton X-100 with 200 µM 4-MUS as a substrate (Km of 
4-MUS).  The results are given in Table 3.1.  All four compounds were relatively good inhibitors 
of STS.  The difference in inhibitory potency between the sulfonates and sulfonamides was 
relatively small. The best inhibitor of the series was the tosyl sulfonamide 3.6 with an IC50 of 
207 nM which was about 30% lower than the IC50 of the analogous sulfonate 3.4.
164
  Although 
the difference in potency was relatively small between these sulfonates and sulfonamides we 
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decided to focus our future efforts on preparing and evaluating the sulfonamide series as these 
compounds were more readily prepared than the sulfonates and would be expected to be more 
stable than sulfonates. 
Table 3.1.  IC50‘s of compounds 
3.3-3.6.
164
 
Compound IC50 (nM)
a
 
3.3 benzenesulfoante 301 
3.4 tosylsulfonate 293 
3.5 benzenesulfamide 343 
3.6 tosylamide 207 
a 
Errors are within    5% 
In Poirier‘s E2-based inhibitors (compounds 1.49, Figure 1.13) the bulky benzyl group at 
the 17-position had the -configuration.  This is the inverse configuration of the compounds in 
Table 3.1.  So before proceeding any further we decided to prepare the -isomer of sulfonamides 
3.5 and 3.6 and determine if the stereochemistry at the 17-position had a significant impact on 
inhibitory potency. 
In 1998, Lemini et al. reported, albeit in low yield, the synthesis of the 17α-amino 
derivative of E1, compound 3.15, via the route outlined in Scheme 3.4.
165
  We decided to take a 
similar approach (Scheme 3.5) except starting from compound 3.9b (Scheme 3.2) which we had 
made previously and had retained a small quantity from our synthesis of sulfonate 3.4.  Reacting 
3.9b with 11 equivalent of NaN3 in DMF at 80 
o
C resulted in almost no consumption of 3.9b.  
Adding another 5 equivalents of NaN3 and increasing the temperature to 90
o
C and reacting for 7 
days also did not result in much consumption of 3.9b.  However, using HMPA as solvent and 11 
eq. NaN3 and heating for 6 days the desired azide 3.16 was obtained in a 71% yield. 
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Scheme 3.4.   Lemini‘s procedure for preparing the 17α-amino derivative of E1 (3.15). 
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Scheme 3.5.  Initial route to compound 3.15. 
Reduction of compound 3.16 by hydrogenation over 10% Pd/C for 2 days gave a 1:1 
mixture of our target compound and another compound with a molecular weight that was 14 
mass units (MW 285) greater than X (MW 271) as determined by +EI-MS.  It is possible that 
this impurity is ketoxime derivative 3.17.  Since LiAlH4 is one of the best reagents for the 
reducing oximes to the corresponding amines,
166
 we took this mixture and heated it under reflux 
with LiAlH4 in THF for 6 hours.  We noticed that the intensity of the peak at 285 decreased 
65 
 
while our target‘s peak increased in intensity suggesting to us that the impurity is indeed the 
ketoxime.  Unfortunately, after these manipulations we had only a very small amount of impure 
3.15 and that for our studies we needed to make more which meant that we would have to make 
more of the starting material 3.9b.  Although it looked like our route to 3.15 was promising in 
that it might produce 3.15 in a higher yield than Lemini‘s route it was longer than the one used 
by Lemini as the synthesis of 3.9b requires three steps while the synthesis of 3.12 in Lemini‘s 
procedure only requires one.  So we decided to pursue Lemini‘s route to 3.15.   We managed to 
obtain similar yields for most of the intermediate compounds (Scheme 3.6).  Lemini and 
coworkers reported that the 17α (quasi-axial) hydrogen in 3.11 (17-amino isomer) appears 
further upfield than the corresponding 17β (quasi-equatorial) hydrogen in 3.15 (17-amino 
isomer).  These signals exhibit also different splitting patterns; the 17α-hydrogen in 3.11 appears 
as a triplet, indicating couplings with both hydrogens at position 16, whereas the 17β-hydrogen 
in the isomeric 17α-isomer is coupled only with the 16β-H and so appears as a doublet.  This is 
consistent with what we found with these two compounds.  We also noted that the C-18 methyl 
group is further downfield in the 17α-isomer than the C18- methyl group in the 17β isomer.165-168 
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E2 3.12 (72%)
3.13 (78%)  3.15 (23%)
3.18,  R = H (47%)
3.19,  R = CH3 (58%)  
Scheme 3.6.  Our synthesis of compound 3.15 using Lemini‘s route and the formation of 
sulfonamides 3.18 and 3.19. 
 
With sufficient quantities of 3.15 in hand we then subjected it to tosyl chloride or 
benzenesulfonyl chloride in pyridine which gave sulfonamides 3.18 and 3.19 in reasonable yields 
(Scheme 3.6).  The IC50‘s of compounds 3.18 and 3.19 were determined to be 921 nM and 341 
nM respectively which is greater than that of their corresponding -isomers (3.5 and 3.6). 
3.3.2. Inhibition of STS with 17β-arylsulfonamides. 
In the light of these results we decided to focus on the preparation and evaluation of a 
collection of the 17β-sulfonamides.  We initially focused on preparing arylsulfonamides 
substituted at the 4´-position with alkyl groups since Poirier had previously demonstrated that 
17-benzylE2 derivatives of type 1.49 bearing certain alkyl groups at the 4´-position of the 
benzyl moiety are potent STS inhibitors.
69
 These sulfonamides were readily prepared using the 
same approach for the synthesis of 3.5 and 3.6 (reaction of 3.11 with the appropriate sulfonyl 
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chloride as shown in Scheme 3.3).  The yields for these reactions are given in Table 3.2.  The 
yields were not optimized. The IC50‘s of these compounds are shown in Table 3.3.
164
   
Table 3.2.  Yields of compounds 3.20-3.27. 
HO
N
H
H
S
O
O
R
 
 
compound R % yield 
3.20 Benzyl 26 
3.21 4´-methylbenzyl 38 
3.22 4´-chlorobenzyl 27 
3.23 4´-n-propylbenzene 27 
3.24 4´-n-butylbenzene 56 
3.25 4´-n-pentylbenzene 21 
3.26 4´-isopropylbenzene 43 
3.27 4´-tert-butylbenzene 53 
 
The unsubstituted benzyl derivative, compound 3.20, exhibited a potency that was very 
close to its phenyl analog 3.5 (IC50 = 364 nM for 3.20, 343 nM for 3.5).  Substituting the benzyl 
ring with hydrophobic groups such as CH3 (electron donating) (3.21) or Cl (electron 
withdrawing) (3.22) resulted in an increase in potency compared to 3.20 but were poorer 
inhibitors than tosyl derivative 3.6.  Increasing the length of the n-alkyl group at the 4´-position 
in the benzenesulfonamide moiety from one (methyl, compound 3.6) to four carbons (n-butyl 
derivative 3.24) resulted in a significant increase in binding affinity with the n-butyl derivative 
3.24 being a potent inhibitor with an IC50 of 26 nM.  However, a decrease in affinity occurred 
when a fifth carbon unit was present (n-pentyl derivative 3.25).  Branching of the n-propyl group 
proved to be slightly detrimental to binding affinity (isopropyl derivative 3.26) while the tert-
butyl derivative 3.27 proved to be more potent than the n-butyl derivative with an IC50 of 18 
68 
 
nM.
164
  It is worthy of note that among Poirier‘s 17-benzylE2 inhibitors the 4‘-tert-butyl 
derivative (1.52, Fig. 1.13) exhibited an IC50 (28 nM) that is remarkably similar to 3.27 
suggesting that the sulfonamides studied here bind in a similar manner to the 17-benzylE2 
inhibitors.
69,164
 
Table 3.3.  Inhibition of STS with 4‘-alkyl 
sulfonamide derivatives
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HO
N
H
H
S
O
O
R
 
 
compound R IC50 (nM)
a
 
3.5 Benzene 343 
3.20 Benzyl 364 
3.21 4´-methylbenzyl 261 
3.22 4´-chlorobenzyl 291 
3.6 4´-methylbenzene 207 
3.23 4´-n-propylbenzene 44 
3.24 4´-n-butylbenzene 26 
3.25 4´-n-pentylbenzene 51 
3.26 4´-isopropylbenzene 62 
3.27 4´-tert-butylbenzene 18 
a
Errors are within ± 5%. 
 
 Since it has been demonstrated that among Poirier‘s 17-benzylE2 derivatives certain 
groups/atoms (i.e. Br, compound 1.51, Fig. 1.13) at the 3´-position significantly enhanced 
potency, the next series of compounds we prepared, using the usual procedure, were 
sulfonamides bearing small electron donating and electron withdrawing groups at the 3´-positon.  
The yields of these compounds are given in Table 3.4.  No attempt was made to optimize the 
yields.  The IC50‘s of these compounds are shown in Table 3.5.   
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Table 3.4.  Yields of compounds 3.28-3.36. 
HN
HO
S
O
O R
 
Compound R % yield 
3.28 Br 82 
3.29 Cl 73 
3.30 F 65 
3.31 NO2 49 
3.32 CN 53 
3.33 CF3 48 
3.34 OCF3 31 
3.35 CH3 43 
3.36 OCH3 70 
 
Among the halobenzene derivatives (3.28-3.30), the 3'-Br derivative, compound 3.28, 
was the most potent having an IC50 of 25 nM.  Br, Cl and F are electron withdrawing with 
similar m values though Br is the most hydrophobic of the three (largest positive  value) 
suggesting that hydrophobicity is important at this position.
169,170
  The methyl derivative 3.35 is 
2.5-fold less potent than the Br derivative.  The methyl group is less hydrophobic than Br and 
more electron donating.  One the other hand, the CF3 derivative, 3.33, was almost equipotent to 
the Br derivative.  This compound is considerable more electron withdrawing than Br.  The 
potency of the CF3 derivative might not be due to the CF3 group electron withdrawing ability as 
the introduction of polar and strongly electron withdrawing groups (at least by resonance) such 
as nitro and cyano groups (compounds 3.31 and 3.32) at this position are less potent than the CF3 
derivative.  The CF3 group has almost an almost identical  value (same hydrophobicity) as a Br 
atom suggesting again that the presence of a hydrophobic group at the 3‘-position may be 
important.  We should also point out that the fluorines in 3.33 are also capable of acting as an H-
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bond acceptor which may also contribute to the potency of 3.33.  The OCF3 derivative, 3.34, was 
3-fold less potent than the Br and CF3 derivatives.  The OCF3 group is slightly more hydrophobic 
than the Br or CF3 groups and less electron withdrawing than the CF3 group but more electron 
withdrawing than the Br group.  Hence it is possible that the effect of the CF3 group in 3.33 may 
in part be due to H-bonding interactions with the fluorines and that this effect is not as 
pronounced with the OCF3 group. On the other hand the difference may be due to the larger size 
of the OCF3 group.  The electron donating OCH3 derivative was the least potent of all of the 3‘-
derivatives studied suggesting that strongly electron donating groups at this position are 
detrimental to binding and also its greater size may also be a factor.  The Br derivatives 3.28 was 
almost the most potent of all of the compounds studied in Table 3.5.  The 3‘-Br derivative was 
also among the most potent of Poirier‘s 17-benzylE2 inhibitors again suggesting that our 
sulfonamide inhibitors and the 17-benzylE2 inhibitors bind to STS in a similar manner.69   
Table 3.5. Inhibition of STS with 3'-
substituted benzene sulfonamide 
derivatives 3.28-3.36.
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HN
HO
S
O
O R
 
Compound R IC50 (nM)
a
 
3.28 Br 25 
3.29 Cl 67 
3.30 F 112 
3.31 NO2 90 
3.32 CN 137 
3.33 CF3 23 
3.34 OCF3 74 
3.35 CH3 65 
3.36 OCH3 192 
a 
Error‘s are within    5% 
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A more detailed kinetic study was performed with compound 3.28 to determine the mode 
of inhibition of this class of compounds.  It turns out that this compound exhibits a                 
non-competitive mode of inhibition with a Ki of 23 nM and an αKi of 108 nM (Ki being the 
dissociation constant for the inhibitor with the enzyme-substrate complex) (Figure 3.3).  The fact 
that compound 3.8 is a non-competitive inhibitor of STS suggests that the inhibitor may also 
bind at a site besides the active site.  Our previous studies with one of Poirier‘s compounds, 
compound 1.50 (Fig. 1.13), revealed that it too was a non-competitive inhibitor again supporting 
the supposition that our sulfonamides and Poirier‘s 17-benzylE2 inhibitors may bind in a 
similar manner.
69
 
 
Fig. 3.3.  Lineweaver-Burk plot of compound 3.28 (See Fig. A.21 and A.22 for the re-plot of this 
data that was used to determine both Ki and αKi.
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Several 4'-halo analogs, 3.28-3.30, as well as the 4‘-methyl, 4‘-CF3 and 4‘-acetyl analogs 
3.40-3.42, were synthesized (see Table 3.6 for yields) and examined as STS inhibitors.  Although 
the analogous 3'-substituted derivatives were highly potent (Table 3.5, IC50‘s ranging from 23 
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nM to 192 nM), the 4'-substituted halo-analogs were dramatically less active, as seen in Table 
3.7.   Moving the bromine atom and trifluoromethyl group from the 3'-position to the 4‘-position, 
as in compounds 3.37 and 3.40; resulted in a significant decrease in their inhibitory activity 
(IC50‘s of 492 nM and 503 nM, respectively).  Poirier‘s noted a similar phenomenon with the 
17-benzylE2 inhibitors in that that the meta-substituted Br derivative was considerably more 
potent than either its ortho or para analogs.
68
 
Table 3.6.  Yields of 4´-derivatives 3.37-3.42 
Compound R % yield 
3.37 Br 78 
3.38 Cl 69 
3.39 F 61 
3.40 CF3 34 
3.41 CH3 33 
3.42 COCH3 53 
 
Table 3.7. Inhibition of STS with 
4'-substituted benzene sulfonamide 
derivatives 3.37-3.42.
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HN
HO
S
O
O
R
 
Compound R IC50 (nM)
a
 
3.37 Br 190 
3.38 Cl 271 
3.39 F 479 
3.40 CF3 74 
3.41 CH3 207 
3.42 COCH3 204 
a 
Error‘s are within  5% 
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Moving the bromine atom and trifluoromethyl group to the 2'-position, as in compounds 
3.43 and 3.44 (Fig. 3.4), resulted in a significant decrease in their inhibitory activity (IC50‘s of 
492 nM and 503 nM, respectively) compared to their 3‘ and 4‘ analogs. 
HO
HN
H
S
O
Br
O
3.43
HO
HN
H
S
O
O
CF3
3.44  
Fig. 3.4.  Ortho-substituted analogs 3.43 and 3.44. 
Finally, we prepared and examined bicyclic and biaryl sulfonamides as STS inhibitors 
3.45-3.51.  These were prepared in the usual manner and the yields are given in Table 3.8.  The  
Table 3.8.  Yields of 4´-derivatives 3.45-3.51 
Compound R % yield 
3.45  
O O
 
56 
3.46 
 
25 
3.47  
N  
63 
3.48  
O
 
38 
3.49  
 
31 
3.50  
O
 
23 
74 
 
3.51 
O  
18 
 
benzophenonesulfonyl chlorides (3.53 and 3.55) that used to prepare sulfonamides 3.50 and 3.51 
were not commercially available and had to be prepared.  This was readily achieved using the 
literature procedures outlined in Schemes 3.7 and 3.8.
171,172
   
ClO2S
OSO3K
COOH
SO2Cl
COCl
SOCl2, DMF
reflux, 4 h
C6H6, AlCl3
DCE, rt, 24 h
3.52 (100%) 3.53 (78%)3.50  
Scheme 3.7.   Preparation of sulfonyl chloride 3.53 
SO2Cl
COCl
ClO2S
O
C6H6, AlCl3
DCE, rt, 24 h
3.55 (83%)3.54  
Scheme 3.8.   Preparation of sulfonyl chloride 3.55 
Two of the bicyclic and biaryl sulfonamides, the naphthyl and biphenyl derivatives 3.43 
and 3.49, proved to be highly potent inhibitors (Table 3.9), and were even more potent than the 
4‘-t-butyl (3.27), 3‘-Br (3.28) and 3‘-CF3 (3.33) derivatives.  Placing an oxygen or carbonyl 
spacer between the two phenyl rings in 3.49 (compounds 3.48, 3.50 and 3.51) resulted in a 
decrease in potency.  The dramatically lower potency of benzophenone derivatives was 
particularly surprising as the acetophenone derivative (3.42 in Table 3.7) is considerably more 
potent.   
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Table 3.9.  Inhibition of STS with bicyclic and biaryl sulfonamides 3.45-
3.51.
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HN
HO
S R
O
O
 
 
Compound R IC50 (nM)
a
 
3.45 (Coumarin-6-yl) 
O O
 
185 
3.46 (Naphthalen-2-yl) 
 
20 
3.47 (5'-(Dimethylamino)- 
naphthalen-2-yl (Dansyl )) 
N  
113 
3.48 (4'-Phenoxybenzen-1-yl) 
O
 
39 
3.49 (4'-Phenylbenzen-4-yl (Biphenyl)) 
 
9 
3.50 (4'-Benzoylbenzen-4-yl) 
O
 
1300 
3.51 (3'-Benzoylbenzen-4-yl) 
O  
900 
a Error‘s in IC50 are within    5% 
3.3.3 Studies with 17β-Amides of E1 
An obvious avenue for further extending our studies was to see if the sulfonamide group 
could be replaced with an amide which is considered to a sulfonamide biosteres (or vice versa).  
This could be important as it would be possible to test dozens of such amides as many acid 
chlorides are readily available.  To determine this we prepared model amide 3.56 (Fig. 3.5).  This 
compound was almost equipotent to the sulfonamide analog (with an IC50 value of 219 nM) and 
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so we decided to examine two other amides bearing a 3‘-Br (3.57) or 3‘-CF3 (3.58) group on the 
aryl ring. 
HO
HN
H
C
O
CH3
Compound 3.56  
Fig. 3.5.  Model amide 3.56. 
The synthesis of amides 3.57 and 3.58 is given in Scheme 3.9.  We found that reaction of 
3.11 with one equiv of the appropriate acid chlorides gave a mixture of the two mono- and 
disubstituted products which were surprisingly difficult to separate by column.  To get around 
this problem we reacted 3.11 with an excess of the acid chloride to get mainly disubstituted 
products 3.59 and 3.60 which was easily purified.  These compounds were then subjected to 
K2CO3 in MeOH which resulted in exclusive hydrolysis of the ester group to give the desired 
compounds 3.57 and 3.58 in reasonable yields. 
Much to our surprise, inhibition studies with compound 3.57 and 3.58 and STS revealed 
that these two amides were far less potent than their sulfonamide analogs:  compound 3.57 was 
10-times less potent (IC50 of 308 nM) than its sulfonamide analog, 3.28, while compound 3.58 
(IC50 of 705 nM) was 31-times less potent than its sulfonamide analog, 3.33.   On the basis of 
these finding we decided to abandon pursuing the amide-based inhibitors.  
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NH2
ArCOCl, Py.,
0oC, rt, O/N
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HN
R
R
O
O
K2CO3, MeOH,
rt, 3 h
HO
HN
R
O
3.57; R = Br (67%)
3.58; R = CF3 (74%)
3.59; R = Br (71%)
3.60; R = CF3 (57%)
3.11
 
Scheme 3.9  Synthesis of 17β-amides, compounds 3.57 and 3.58. 
3.3.4 X-ray Crystallography of Compound 3.33 
The X-ray crystal structure of one of our best inhibitors, the 3´-CF3 derivative 3.33 was 
obtained.  A colorless plate crystal of 3.33 with approximate dimension of 0.25 × 0.08 × 0.02 
mm was used for data collection. An ORTEP plot of the asymmetric unit of 3.33 is shown in 
Figure 3.6.  All four rings and the key features of the steroid are clearly visible. The asymmetric 
unit is seen to consist of two molecules of 3.33.  All C-C bond lengths were in the range 1.340-
1.566 Å, the C-O bond lengths were between 1.358 and 1.40 Å, all S-O bond lengths were in the 
range 1.421-1.441 Å, and the C-N bond lengths were in the range 1.466-1.473 Å.  
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Fig. 3.6.  ORTEP plot of the asymmetric unit in the X-ray crystal structure of sulfonamide 3.33 
(thermal ellipsoids are shown at the 30% probability level). 
 
As shown in Fig. 3.7 molecules of 3.33 interact via a network of intermolecular hydrogen 
bonds viewed along the b axis. In particular, the proton NH of the sulfonamide group (H1BA) 
interacts with oxygen atom (O2A) of the sulfonamide SO2NH group in a proximate molecule, 
whereas the other oxygen atom (O1A) interacts with the proton of the 3-hydroxyl group 
(H3AA).  
 
Fig. 3.7.  Portion of extended structure present in 3.33 showing the network of intermolecular 
hydrogen bonding viewed along the b axis. 
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3.3.5 Molecular Modelling Studies  
The finding that some of our sulfonamide inhibitors, such as the 4´-tert-butyl (3.27) and 
3‘-bromobenzene (3.28) derivatives, exhibit IC50‘s that are remarkably close to the analogous 
17-benzylE2 inhibitors reported by Poirier and coworkers suggests that these two classes of 
compounds may be binding in a similar fashion.  This is somewhat surprising since the 17-
sulfonamide link between the aryl moieties and C-17 in the inhibitors described here is 
structurally, electronically and spatially ( versus ) very different from the 17-CH2 unit in the 
17-benzylestradiol inhibitors and lacks a 17-OH group. Moreover, the two sets of compounds 
were assayed under different conditions (the IC50‘s of 17-benzyl estradiol inhibitors were 
determined using homogenates of JEG-3 cells in Tris-acetate buffer, 10% glycerol, pH 7.0 and 
[
3
H]E1S as substrate
69
 while our work was done with pure STS in Tris buffer, pH 7.0, 0.01% 
TritonX-100, and 5 % DMSO using 4-MUS as substrate).  However, some differences in IC50‘s 
between the two sets of compounds do exist.  For examples, the 4´-biphenyl derivative 3.49 (IC50 
= 9 nM) and naphthyl derivative 3.46 (IC50 = 20 nM) are 4-6-fold more potent than 17-4´-
phenylbenzylestradiol (Fig. 3.8, 3.61, IC50 of 35 nM) and the 17-naphth-2´-ylmethylestradiol 
(Fig. 3.8, 3.62, IC50 = 120 nM).
68,69
 The 3´-trifluoromethylbenzenesulfonamide derivative 3.33 
(IC50 = 23 nM) is almost six-fold more potent than 17-3´-trifluoromethylbenzylestradiol (Fig. 
3.8, 3.63, IC50 = 126 nM).
68,69
  
HO
3.61
HO
HO
HO
HO
3.63
HO
CF3
3.62  
Fig. 3.8  17-benzylE2 derivatives 3.61-3.63. 
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As discussed in Chapter 1, the X-ray crystal structure of STS has been reported by Ghosh 
and coworkers.
26,27 
 Over the last ten years the Ghosh group has attempted to obtain the X-ray 
crystal structure of STS complexed with inhibitors developed in the Taylor group and other 
groups.  Unfortunately this has not been successful.  Consequently we have turned to molecular 
modeling to learn more about how our sulfonamide inhibitors might interact with STS.  
However, without an x-ray crystal structure of one of our inhibitors bound to STS to guide these 
studies, assumptions must be made about how these compounds interact with STS to initiate the 
modeling studies.  Under our assay conditions, sulfonamide inhibitor 3.28 and 17-benzylE2 
inhibitor 1.50 exhibit mixed inhibition and so these types of inhibitors may be capable of binding 
at the active site and also at a secondary site outside the active site (possibly in the hydrophobic 
channel between the two alpha helices as mentioned earlier).  Since we do not know exactly 
where a possible secondary site might be, we focussed our modeling efforts on inhibitor-active 
site interactions.  We had to assume a particular mode of binding in the active site to initiate 
these studies so we made the assumption that these compounds are capable of binding in the 
active site in a manner similar to what has been proposed for sulfamate-based inhibitors:
112
 with 
the 3-OH on the A-ring occupying space that is in the proximity (facing) of the FGly75 hydrate.  
Selected inhibitors were docked into the crystal structure of STS (PDB ID: 1P49) after 
conversion of the sulfated Fgly75 hydrate to an Fgly75 hydrate, using the LibDock docking 
algorithm (see experimental 3.5.4 for details). 
The docking results for the sulfonamide, 3.6 and its sulfonate analog 3.4 are shown in 
Fig. 3.9.  In common with compounds 3.6, 3.4, and the rest of the compounds in the sulfonamide 
series studied in this section; the nonpolar rings B, C, and D of the steroid skeleton including the 
C18 methyl group were oriented in the centre of the active site and underwent non-polar 
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interaction with side chains of the hydrophobic pocket formed by Leu74, Arg98, Thr99, Val101, 
Leu103, Val177, phe178, Thr180, Gly181, Thr484, His485, Val486, phe488, and phe553 with a 
distance less than 5 Å. For reasons of clarity, not all of these hydrophobic interactions are 
indicated in Fig. 3.9 and subsequent docking figures.  For both compounds, the bulky aromatic 
group at the 17-position was oriented closer to what is considered to be the entrance to the active 
site, and the aromatic A ring was oriented in the polar catalytic site at the apex comprised of 
FGly75, His290, and Lys368.  For these two compounds and all other sulfonamide inhibitors 
studied in this section, the 3-OH is involved in an H-bond with the FGly75 hydrate. 
 
 
Fig. 3.9.  The binding mode of compounds 3.6 (left) and 3.4 (right) with STS (green dotted lines 
indicate hydrogen bonding interactions, violet dotted lines indicate hydrophobic interactions; H-
atoms were removed to increase clarity). 
 
The N-H of the sulfonamide group in 3.6 is involved in an H-bond with the carbonyl 
oxygen of Phe178 and there is a hydrophobic interaction between the C-18 methyl group and the 
side chain of val177.  No interactions between the sulfonate group and STS were evident.  This 
may have been compensated somewhat by a hydrophobic interaction between the aromatic side 
chain of Phe178 and the aromatic group of the aryl sulfonate.  
We then performed modeling studies on compound 3.19, the -isomer of compound 3.6.  
These two compounds exhibited slightly different affinities for STS (IC50 = 207 nM for 
compound 3.6, IC50 = 341 nM for compound 3.19).  The change in stereochemistry from the  to 
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the  configuration at the 17-position caused the NH of SO2NH group to move away from 
Phe178 and the hydrophobic interactions between its C-18 methyl and Val177 were lost.   The 
aryl group was bent away active site entrance (Fig. 3.10).  Nevertheless, the N-H of the 
sulfonamide group in 3.19 was able to form a H-bond with the carbonyl oxygen of Arg98.  A 
hydrophobic interaction with the Arg98 side chain and the aryl group of the sulfonamide moiety 
in 3.19 was also evident as was a Pi-alkyl interaction between his aliphatic skeleton and His 485. 
            
Fig. 3.10. The binding mode of compounds 3.19 (left) and 3.6 (right) with STS. 
 
From our results in § 3.3.2, we noticed that inclusion of alkyl chain at the 4´-position  of 
our sulfonamide inhibitors caused a marked increase in potency till the chain length approaches 4 
carbon atoms length (i.e. the n-pentyl derivative 3.25) and then activity starts to decrease.  The 
alkyl chain of the n-pentyl derivative 3.25 starts to bend away from the active site entrance (Fig. 
3.11).  The n-pentyl tail interacts through a network of hydrophobic and pi-alkyl interactions 
with Trp550, Phe553, and Leu554, while the n-butyl tail was having hydrophobic interactions 
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with Phe104 and Leu554.  It is not clear from these studies as to why the n-pentyl derivative is a 
poorer inhibitor than the butyl derivative. 
  
Fig. 3.11.  The binding mode of compounds 3.24 (red) and 3.25 (green) with STS in its full 
shape (left Fig.) and zoomed active site (right Fig.) 
 
We also investigated the binding interactions of one of our most potent inhibitors, the 3‘-
CF3 sulfonamide (3.33, IC50 = 24 nM) and the corresponding compound reported by the Poirier 
group, (3.63 in Fig. 3.8, IC50 = 126 nM),
68
 as shown in Fig. 3.12. 
   
Fig. 3.12.  The binding mode of compounds 3.33 (left) and 3.63 (right) with STS (green dotted 
lines indicate H-bonding interactions; light violet indicate non-polar interactions; H-atoms are 
removed to increase clarity). 
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The 3-OH in both compounds is involved in H-bond interactions with FGly75 (length ~ 3 
Å).  The N-H of the sulfonamide group in 3.33 was again involved in an H-bond with the 
carbonyl of Phe178 as was the 17-OH group in 3.63 (2.9 and 3.3 Å, respectively).  One of the 
oxygens of the sulfonamide group in 3.33 was involved in an H-bond with the N-H of Gly181.  
Two of the fluorines of the CF3 group of the sulfonamide were involved in H-bonding 
interactions with the side chains of Arg98 and Tyr 493 and these interactions were not evident in 
3.63.  Moreover, multiple hydrophobic Pi-alkyl interactions with Leu74, Arg98, and Val177, 
however; the ones for the sulfonamide 3.33 were shorter than those of 3.63. 
We noted that the trifluoromethoxy derivative, 3.34, was 3-fold less potent than 3.33.   
Docking 3.34 into the STS active revealed that the oxygen spacer of the CF3O group caused a 
marked change in the orientation of the arylsulfonamide group which resulted in the loss of the 
H-bond interaction with Gly181 and the pi-alkyl hydrophobic interaction with as shown in Fig. 
3.13. 
 
 
 
Fig. 3.13. The binding mode of compounds 3.33 (light brown) and 3.34 (yellow) with STS 
(green dotted lines indicate H-bonding interactions; H-atoms are removed to increase clarity).  
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One of the more dramatic changes in potency was when the sulfonamide group in 3.33 
was replaced with an amide group (compound 3.58):  compound 3.58 was 31-times less potent 
than its sulfonamide analog, 3.33.  Docking of 3.58 into the STS active site revealed that it 
bound to STS in a very different manner than 3.33 (Fig. 3.14).  One of the most significant 
changes compared to all of the compounds docked and mentioned above was the loss of the H-
bond interaction between the 3-OH group and the catalytically crucial FGly75 residue.  
Moreover, the H-bonding interactions between the CF3 group in 3.33 and STS are not evident in 
3.58.  The carbonyl of the amide group in 3.58 is involved in H-bonding interactions with the 
side chain of Arg98 (3.19 and 3.2 A) but this does not seem to be sufficient to compensate for 
the loss of the key interactions that were evident in 3.33.   
 
Fig. 3.14.  The binding mode of compound 3.58 with STS (green dotted lines indicate H-bonding 
interactions, light violet dotted lines indicate hydrophobic interactions; H-atoms are removed to 
increase clarity). 
 
3.4 Conclusions and Future Work 
 We have prepared and examined a library of 17β-arylsulfonamides of type 3.2 as STS 
inhibitors.  Some of these compounds; such as the 4'-t-butyl derivative (3.27), 3'-Br derivative 
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(3.28), 3'-CF3 derivative (3.33), 2'-naphthyl derivative (3.46), and the 4'-biphenyl derivative 
(3.49), are among the most potent reversible STS inhibitors reported to date.  Kinetic studies 
with compound 3.28 revealed it to be a non-competitive inhibitor and so these types of inhibitors 
might be capable of binding at the active site and also at a secondary site outside the active site, 
possibly in the hydrophobic channel between the two alpha helices as mentioned earlier.  The 
amide analogs of some of these compounds (3.57 and 3.58) were found not to be as potent 
inhibitors as the sulfonamides.  Modeling studies provided some information as to how certain 
inhibitors might interact with STS.  In Chapter 4 we describe how a simple modification of these 
sulfonamide inhibitors resulted in the development of the most potent reversible inhibitors of 
STS reported to date.  
3.5 Experimental 
3.5.1 General 
 All starting materials and reagents were obtained from Aldrich Chemical Company.  
THF was distilled from sodium-benzophenone, Pyridine was distilled from KOH pellets. DCE 
was dried by standing over activated type 4A molecular sieves. CH2Cl2 was distilled from 
calcium hydride under nitrogen.  Silica gel chromatography was performed using silica gel (60Å, 
230-400 mesh) obtained from Silicycle (Laval, Quebec, Canada). 
1
H, 
13
C, and 
19
F NMR spectra 
were recorded on a Bruker Avance 300 spectrometer.  For NMR spectra obtained using CDCl3 as 
the solvent, chemical shifts () for 1H NMR spectra are reported relative to internal Me4Si ( 0.0 
ppm), chemical shifts for 
13
C spectra are relative to the residual solvent peak (77.0 ppm, central 
peak), and chemical shifts for 
19
F NMR are relative to a CFCl3 ( 0.0 ppm) external standard.  
Low-resolution (LRMS) and high-resolution (HRMS) electron impact (EI) and electrospray 
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ionization (ESI) mass spectra were obtained on a JEOL HX110 double focusing mass 
spectrometer. Electrospray (ESI) mass spectra were obtained with a Waters/Micromass QTOF 
Ultima Global mass spectrometer. Melting points were determined on a Fisher-Johns melting 
point apparatus and are uncorrected.  
3.5.2 Syntheses 
HO
O S
OO
3.3  
17β-Benzenesulfonyloxy-estra-1,3,5(10)-trien-3-ol (3.3). To a solution of compound 
3.9a (150 mg, 0.30 mmol) in a methanol/ethyl acetate (1:1, 10 mL) and a catalytic amount of 
acetic acid (150 µL) was added 20% Pd(OH)2 (0.8 eq, 0.24 mmol).  The mixture was stirred 
under H2 gas for 16 h then filtered and concentrated.  Purification of the residue by flash 
chromatography (ethyl acetate/hexane, 1:4) giving compound 3.3 as a white solid (85 mg, 69%). 
Mp 193-195 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.90 (dd, J = 7.1 and 1.4 Hz, 2H, ArH), 7.65-
7.51 (m, 3H, ArH), 7.07 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.3 and 2.5 Hz, 1H, H-2), 6.51 (d, 
J = 2.4 Hz, 1H, H-4), 4.60 (s, 1H, ArOH), 4.35 (t, J = 7.8 Hz, 1H, H-17), 2.76 (m, 2H), 2.20-1.96 
(m, 3H), 1.82-1.63 (m, 4H), 1.44-1.23 (m, 4H), 1.13-1.08 (m, 2H), 0.81 (s, 3H, CH3, H-18);
 13
C 
NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 138.0 (C-SO2O-), 137.2 (C-5), 133.5 (CHAr), 132.1 (C-
10), 129.1 (2CHAr), 127.8 (2CHAr), 126.3 (CHAr), 115.2 (CHAr), 112.7 (CHAr), 90.1 (C-17), 49.0 
(CH), 43.6 (CH), 43.3 (CH2), 38.4 (CH), 36.0 (CH2), 29.4 (CH2), 27.7 (CH2), 27.0 (CH2), 25.9 
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(CH2), 23.0 (CH2), 11.7 (CH3, C-18) ); LRMS (ESI
-
) m/z (%)  411 (M-H, 100); HRMS (ESI
-
) 
calcd for C24H27O4S (M-H)
-
 411.1641; found 411.1641. 
HO
O S
OO
CH3
3.4  
17β-Toluenesulfonyloxy-estra-1,3,5(10)-trien-3-ol (3.4). To a solution of compound 
3.9b (150 mg, 0.29 mmol) in a methanol/ethyl acetate (1:1, 10 mL) and a catalytic amount of 
acetic acid (150 µL) was added Pd(OH)2 (0.8 eq., 0.23 mmol).  The mixture was stirred under H2 
gas for 16 h then filtered and concentrated.  Purification of the residue by flash chromatography 
(ethyl acetate/hexane, 1:9) afforded compound 3.4 as a white solid (88 mg, 71%). Mp 185-186 
o
C (lit. 186-187
o
C)
160
; 
1
H NMR (CDCl3, 300 MHz) δ 7.78 (dd, J = 6.6 and 1.7 Hz, 2H, ArH), 
7.33 (d, J = 6.6 Hz, 2H, ArH), 7.08 (d, J = 8.5 Hz, 1H, H-1), 6.59 (dd, J = 8.4 and 2.7 Hz, 1H, H-
2), 6.52 (d, J = 2.7 Hz, 1H, H-4), 4.59 (s, 1H, Ar-OH), 4.33 (q, J = 7.7 Hz, 1H, H-17), 2.76 (m, 
2H), 2.43 (s, 3H, OSO2C6H4-CH3), 2.09-1.95 (m, 3H), 1.78-1.67 (m, 4H), 1.41-1.33 (m, 4H), 
1.14-1.09 (m, 2H), 0.81 (s, 3H, CH3, H-18). 
O
O
Bn
3.7  
 3-Benzyloxyestrone (3.7). Potassium carbonate (511 mg, 3.70 mmol) was added to a 
stirred solution of E1 (500 mg, 1.85 mmol) in anhydrous acetone (25 mL), and the resulting 
suspension was stirred for 1 hour. Benzyl bromide (348 mg, 2.2 mmol) was added and the 
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mixture was refluxed for 4 hours. The mixture was poured into ice/water then extracted with 
ethyl acetate.  The combined extracts were washed with water then dried by Na2SO4, and 
concentrated under vacuum. The resulting pale yellow crude solid was recrystallized from 
ethanol to yield compound 3.7 as white crystals (606 mg, 91%). Mp 132-133 
o
C (lit 132-134 
o
C)
161
;
1
H NMR (CDCl3, 300 MHz) δ 7.42-7.29 (m 5H, C6H5), 7.18 (d, J = 8.6 Hz, 1H, H-1), 6.77 
(d, J = 8.5 Hz, 1H, H-2), 6.72 (br-s, 1H, H-4), 5.02 (s, 2H, C6H5CH2), 2.87 (d, J = 5.3 Hz, 2H), 
2.53-2.35 (m, 2H), 2.24-1.88 (m, 4H), 1.63-1.41 (m, 7H), 0.89 (s, 3H, CH3, H-18). 
O
HO
Bn
H
3.8  
3-Benzyloxyestra-1,3,5(10)-trien-17β-ol (3.8). To a solution of compound 3.3 (500 mg, 
1.38 mmol) in EtOH/THF (20 mL, 5:1) at 0
o
C was added NaBH4 (103 mg, 2.77 mmol). The 
resulting mixture was stirred for 1 h at 0
o
C then the reaction was quenched with 1 M HCl. After 
extraction with ethyl acetate, the combined extracts were washed with water, brine, dried with 
Na2SO4, and finally concentrated under vacuum. Purification of the residue by flash 
chromatography (ethyl acetate/hexane, 1:4) gave compound 3.8 as a white solid (372 mg, 74%). 
Mp 62-63 
o
C (lit 61-63 
o
C);
173
 
1
H NMR (CDCl3, 300 MHz) δ 7.44-7.31 (m 5H, C6H5), 7.21 (d, J 
= 8.6 Hz, 1H, H-1), 6.78 (d, J = 8.5 Hz, 1H, H-2), 6.73 (brs, 1H, H-4), 5.03 (s, 2H, C6H5CH2), 
3.72 (t, J = 7.8 Hz, 1H, H-17), 2.84 (m, 2H), 2.33-2.09 (m, 3H), 1.97-1.87 (m, 2H), 1.17-1.69 
(m, 2H), 1.51-1.14 (m, 7H), 0.78 (s, 3H, CH3, H-18). 
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O
O S
OO
3.9a  
3-Benzyloxy-17β-benzenesulfonyl-estra-1,3,5(10)-trien-17β-ol (3.9a). To a stirred 
solution of compound 3.8 (200 mg, 0.55 mmol) in anhydrous pyridine (5 mL) at 0
o
C was added 
benzenesulfonyl chloride (106 mg, 0.60 mmol). The solution was stirred at room temperature for 
overnight, and then pyridine was azeotropically removed with toluene under vacuum. The 
residue was dissolved in ethyl acetate, then washed with 2 N HCl, water and brine then dried 
with Na2SO4, and concentrated. The residue was purified by flash chromatography (ethyl 
acetate/hexane, 3:7), to give 3.9a as a white solid (175 mg, 63%). Mp 98-99
o
C; 
1
H NMR 
(CDCl3, 300 MHz)  7.92 (d, J = 6.9 Hz, 2H, ArH), 7.63-7.51 (m, 3H, ArH), 7.39-7.25 (m, 5H, 
ArH), 7.13 (d, J = 8.3 Hz, 1H, H-1), 6.76-6.68 (m, 2H, H-2 and H-4), 5.00 (brs, 2H, C6H5CH2O-
), 4.34 (d, J = 8.2 Hz, 1H, H-17), 2.81 (brs, 2H, H-6), 2.22-1.97 (m, 3H), 1.83-1.72 (m, 4H), 
1.42-1.05 (m, 6H), 0.82 (s, 3H, H-18). 
13
C NMR (CDCl3, 75 MHz) δ 156.8 (C-3), 137.8 (C-
SO2O-), 137.3 (C-5), 133.5 (CHAr), 132.4 (C-10), 129.1 (2CHAr), 128.5 (2CHAr), 127.8 (2CHAr), 
127.4 (2CHAr), 126.3 (CHAr), 114.8 (CHAr), 112.3 (CHAr), 90.1 (C-17), 69.9 (CH2), 49.0 (CH), 
43.7 (CH), 43.3 (CH2), 38.4 (CH), 36.0 (CH2), 29.6 (CH2), 27.7 (CH2), 27.0 (CH2), 25.9 (CH2), 
23.0 (CH2), 11.7 (CH3, C-18) ); LRMS (ESI
+
) m/z (%)  503 (M+H, 100), 345 (40); HRMS (ESI
+
) 
calcd for C31H35O4S (M+H)
+
 503.2256; found 503.2245. 
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O
O S
CH3
OO
3.9b  
3-Benzyloxy-17β-toluenesulfonyl-estra-1,3,5(10)-trien-17β-ol (3.9b). To a stirred 
solution of compound 3.8 (200 mg, 0.55 mmol) in anhydrous pyridine (5 mL) at 0
o
C was added 
toluene-4-suflonylchloride (115 mg, 0.60 mmol). The solution was stirred at room temperature 
for overnight, and then pyridine was azeotropically removed with toluene under vacuum. The 
residue was dissolved in ethyl acetate, then washed with 2 N HCl, water and brine then dried 
with Na2SO4, and concentrated. The residue was purified by flash chromatography (ethyl 
acetate/hexane, 3:7), to give 3.9b as a white solid (194 mg, 68%). Mp 115-117 
o
C (lit 115-117 
o
C); 
1
H NMR (CDCl3, 300 MHz)  7.80 (d, J = 7.8 Hz, 2H, ArH), 7.42-7.32 (m, 7H, ArH), 7.15 
(d, J = 8.5 Hz, 1H, H-1), 6.76 (d, J = 8.4 Hz, 1H, H-2), 6.70 (brs, 1H, H-4), 5.01 (s, 2H, 
C6H5CH2O-), 4.35 (t, J = 8.1 Hz, 1H, H-17), 2.81 (m, 2H), 2.45 (s, 3H, -OSO2C6H4CH3), 2.24-
2.10 (m, 2H), 1.99-1.92 (m, 1H), 1.85-1.61 (m, 4H), 1.43-1.26 (m, 4H), 1.16-1.08 (m, 2H), 0.83 
(s, 3H, CH3, H-18).  
HO
HN
H
3.10  
17β-Benzylamino-1,3,5(10)-estratrien-3-ol (3.10).163 Estrone, E1 (0.5 g, 1.85 mmol), 
and benzylamine (0.8 mL, 4 eq.) were mixed in 1,2-dichloroethane and THF mixture (1:1, 15 
mL), and then treated with sodium triacetoxyborohydride (1 g, 2.5 eq.) and AcOH (0.5 mL, 4 
92 
 
eq.). The mixture was stirred at rt under a argon atmosphere for 48 h, then it was quenched by 
adding saturated solution of NaHCO3, and the product was then extracted with EtOAc, washed 
with water (4), brine (1), then dried with Na2SO4, filtered and concentrated. The residue was 
then crystallized from methanol, giving white shiny crystals (92.6%): Mp 260-261
o
C. 
1
H NMR 
(CDCl3, 300 MHz), δ 7.34-7.20 (m, 5H, C6H5), 7.12 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 2.5 
and 8.4 Hz, 1H, H-2), 6.51 (d, J = 2.5 Hz, 1H, H-4), 3.83 (AB system, overlapping dd, J = 13.4 
Hz, 2H, C6H5CH2), 2.87-2.76 (m, 2H), 2.65 (t, J = 8.4 Hz, 1H, NH), 2.26-1.99 (m, 5H), 1.86-
1.80 (m, 1H), 1.72-1.64 (m, 1H), 1.46-1.15 (m, 8H), 0.77 (s, 3H, CH3, C-18). 
HO
H2N
H
3.11  
17β-Amino-1,3,5(10)-estratrien-3-ol (3.11).163 To a solution of compound 3.10 (0.7 g, 
1.9 mmol), in a methanol/ethyl acetate (6 mL, 1:1) mixture, was stirred with Pd(OH)2 (0.8 eq.) in 
presence of catalytic amount of acetic acid (100 µL) under H2 gas overnight. After that, it was 
filtered, concentrated under vacuum and flash chromatography (10% MeOH/1% aq. NH4OH/ 
89% CHCl3), yielding 3.11 as a white solid (88%): Mp 232-33
o
C (lit. 235-37). 
1
H NMR (CDCl3, 
300 MHz), δ 7.11 (d, J = 8.3 Hz, 1H, H-1), 6.59 (dd, J = 2.7 and 8.4 Hz, 1H, H-2), 6.52 (d, J = 
2.6 Hz, 1H, H-4), 2.82-2.40 (m, 6H), 2.31-2.25 (m, 1H), 2.20-2.03 (m, 2H), 1.87-1.81 (m, 2H), 
1.71-1.65 (m, 1H), 1.51-1.15 (m, 7H), 0.67 (s, 3H, CH3, C-18).  
TsO
TsO
H
3.12  
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3,17β-bis(Toluene-4-sulfonyloxy)-1,3,5(10)-estratriene (3.12).165 To a stirred solution 
of E2 (350 mg, 0.52 mmol) in pyridine (5 ml) at room temperature, was added toluene-4-sulonyl 
chloride (217 mg, 1.13 mmol), and stirring was continued overnight. Pyridine was azeotropically 
removed with toluene under vacuum (2  5 ml), residue dissolved in ethyl acetate, washed with 
water, brine, and finally concentrated and dried with Na2SO4. The residue was purified by flash 
chromatography (ethyl acetate/hexane, 1:9) to give 3.12 as a white solid (537 mg, 72%). Mp: 
155-156
o
C (lit. 153-156); 
1
H NMR (CDCl3, 300 MHz) δ 7.76 (d, J = 8.2 Hz, 2H, ArH), 7.69 (d, J 
= 8.2 Hz, 1H, ArH), 7.30 (t, J = 7.6 Hz, 4H, ArH), 7.05 (d, J = 8.6 Hz, 1H, H-1), 6.71 (d, J = 2.2 
Hz, 1H, H-4), 6.62 (dd, J = 2.2 and 8.5 Hz 1H, H-2), 4.32 (t, J = 8.6 Hz, 1H, H-17), 2.73 (m, 2H, 
H-6), 2.42 (s, 6H, SO2C6H4CH3), 2.15 (m, 2H), 1.93 (m, 1H), 1.79-1.62 (m, 4H), 1.42-1.25 (m, 
4H), 1.15-1.05 (m, 2H), 0.79 (s, 3H, H-18). 
TsO
H
N3
3.13  
17α-Azido-3-(toluene-4-sulfonyloxy)-1,3,5(10)-estratriene (3.13).165 To a stirred 
solution of 3.12 (500 mg, 0.87 mmol) in HMPA (10 mL), sodium azide (671 mg, 10.3 mmol) 
was added. Stirring was continued at 60-70
o
C for 5 d, then reaction was poured on ice-water 
bath, precipitate filtered, dissolved in ethyl acetate, washed with water, brine, dried with Na2SO4, 
and finally concentrated under vacuum. The residue was purified by flash chromatography 
(CH3OH/CHCl3, 1:5) to yield compound 3.13 as a white solid (600 mg, 78%). Mp: 94-95
o
C (lit. 
93-95); 
1
H NMR (CDCl3, 300 MHz) δ 7.71 (d, J = 8.0 Hz, 2H, ArH), 7.30 (d, J = 7.7 Hz, 2H, 
ArH), 7.13 (d, J = 8.4 Hz, 1H, ArH), 6.72 (brs, 1H, H-4), 6.63 (d, J = 8.2 Hz, 1H, H-2), 3.56 (d, 
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J = 6.0 Hz, 1H, H-17), 2.76 (m, 2H, H-6), 2.43 (s, 3H, SO2C6H4CH3), 2.30-2.19 (m, 3H), 1.83-
1.63 (m, 5H), 1.47-1.24 (m, 5H), 0.75 (s, 3H, H-18).  
HO
HO
H
E2  
Estratrien-1,3,5(10)-3,17β-diol (E2). To a solution of E1 (500 mg, 1.85 mmol) in 
EtOH/THF (150 mL, 2:1, heated to make a solution then cooled) at 0
o
C was added NaBH4 (84 
mg, 2.20 mmol, 1.2 equiv). The reaction was stirred 1 h at 0
o
C. The solvent was removed under 
vacuum and the residue was acidified with 1 N HCl and extracted with ethyl acetate. The 
combined extracts were washed with H2O and brine then dried (Na2SO4), filtered and 
concentrated. The residue was purified by flash chromatography (ethyl acetate/hexane, 3:7) to 
give E2 as a white solid (370 mg, 74%). Mp: 185-186
o
C (lit. 184-187);
174
 
1
H NMR (CDCl3, 300 
MHz) δ 7.13 (d, J = 8.4 Hz, 1H, H-1), 6.60 (dd, J = 2.4 and 8.3 Hz, 1H, H-2), 6.54 (brs, 1H, H-
4), 4.60 (brs, 1H, ArOH), 3.71 (t, J = 8.2 Hz, 1H, H-17), 2.81 (m, 2H, H-6), 2.25 (m, 1H), 2.12 
(m, 2H), 1.91 (m, 2H), 1.67 (m, 1H), 1.55-1.16 (m, 8H), 0.76 (s, 3H, H-18). 
HO
H
NH2
3.15  
17α-Amino-1,3,5(10)-estratrien-3-ol (3.15).165 To a stirred solution of 3.13 (500 mg, 
1.11 mmol) in THF (10 mL), LiAlH4 (1 g, 26.5 mmol) was added and stirring was continued for 
24 h at room temperature. The reaction was quenched carefully with water (10 mL), and then 
acidified by HCl (10%, 10-12 mL) to pH of 1. The aqueous layer was then basified with NaOH 
95 
 
(10%, 15 mL), and extracted with ethyl acetate, washed with water, brine, dried with Na2SO4, 
and finally concentrated under vacuum. The residue was purified by flash chromatography 
(CH3OH/CHCl3, 1:5 then 1:1) to afford 3.15 as white solid (105 mg, 23%). Mp: 223-224
o
C (lit. 
226-227); 
1
H NMR (DMSO-d6, 300 MHz) δ 8.93 (brs, 1H, ArOH), 7.01 (d, J = 8.4 Hz, 1H, H-1), 
6.46 (dd, J = 2.3 and 8.4 Hz, 1H, H-2), 6.39 (brs, 1H, H-4), 3.28 (s, 2H, NH2 overlapping DMSO 
water), 2.80 (d, J = 6.9 Hz, 1H, H-17), 2.66 (m, 2H, H-6), 2.22 (m, 1H), 2.01 (m, 2H), 1.79-1.49 
(m, 4H), 1.42-1.02 (m, 8H), 0.75 (s, 3H, H-18). 
O
H
N3
3.16  
17α-Azido-3-Benzyloxy-1,3,5(10)-estratriene (3.16). To a stirred solution of 3.9b (250 
mg, 0.48 mmol) in HMPA (10 mL), sodium azide (500 mg, 7.7 mmol) was added. Stirring was 
continued at 90
o
C for 2 d, then reaction was poured on ice-water bath, precipitate filtered, 
dissolved in ethyl acetate, washed with water, brine, dried with Na2SO4, and finally concentrated 
under vacuum. The residue was purified by flash chromatography (CH3OH/CHCl3, 1:5) to yield 
compound 3.16 as a white solid (133 mg, 71%). Mp: 77-78 
o
C (lit. 78-79
o
C);
165
 
1
H NMR 
(CDCl3, 300 MHz) δ 7.43-7.28 (m, 5H, C6H5CH2O-), 7.20 (d, J = 8.6 Hz, 1H, H-1), 6.77 (d, J = 
8.5 Hz, 1H, H-2), 6.71 (brs, 1H, H-4), 5.02 (brs, 2H, C6H5CH2O-), 3.58 (d, J = 6.5 Hz, 1H, H-
17), 2.83 (m, 2H, H-6), 2.37-2.33 (m, 1H), 2.24-2.19 (m, 2H), 1.90-1.70 (m, 5H), 1.54-1.23 (m, 
6H), 0.77 (s, 3H, H-18). 
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HO
H
NH
SO
O
3.18  
17α-Benzenesulfonamide-1,3,5(10)-estratrien-3-ol (3.18). To a stirred solution of 3.15 
(100 mg, 0.37 mmol) in pyridine (2 mL) under Argon atmosphere, benzenesulfonyl chloride 
(71.5 mg, 0.40 mmol) in DCM (1 mL) was added portion-wise via a syringe pump at 0
o
C. After 
complete addition of the benzenesulfonyl chloride, the reaction was left stirred overnight at room 
temperature, then pyridine was azeotropically removed under vacuum with toluene, and the 
residue was dissolved in ethyl acetate, washed with water, brine, and dried with Na2SO4, then 
filtered, and concentrated. The residue was purified by flash chromatography (ethyl 
acetate/hexane, 3:7) to afford 3.18 as white solid (71 mg, 47%). Mp: 118-119 
o
C; 
1
H NMR 
(CDCl3, 300 MHz) δ 7.87 (d, J = 7.7 Hz, 2H, ArH), 7.58-7.47 (m, 3H, ArH), 7.08 (d, J = 8.4 Hz, 
1H, H-1), 6.58 (dd, J = 2.4 and 8.4 Hz, 1H, H-2), 6.52 (brs, 1H, H-4), 4.49 (s, 1H, ArOH), 4.38 
(d, J = 9.2 Hz, 1H, NH), 3.17 (d, J = 8.6 Hz, 1H, H-17), 2.80 (d, J = 6.9 Hz, 1H, H-17), 2.76 (m, 
2H, H-6), 2.22-2.07 (m, 2H), 1.85-1.58 (m, 5H), 1.38-1.10 (m, 7H), 0.68 (s, 3H, H-18).
 13
C NMR 
(CDCl3, 75 MHz), δ 153.3 (C-3), 141.1 (C-SO2NH-), 138.1 (C-5), 132.5 (CHAr), 132.4 (C-6), 
129.0 (2CHAr), 127.1 (2CHAr), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.4 (C-17), 51.1 (C-14), 
43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.5 (2CH2 overlapping), 27.1 (CH2), 26.0 
(CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%)  412 (M+H, 100), 325 (20); HRMS 
(ESI
+
) calcd for C24H30NO3S (M+H)
+
 412.19409; found 412.19379. 
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HO
H
NH
SO
O
CH3
3.19  
17α-Toluenesulfonamide-1,3,5(10)-estratrien-3-ol (3.19). To a stirred solution of 3.15 
(100 mg, 0.37 mmol) in pyridine (2 mL) under Argon atmosphere, toluene-4-sulfonyl chloride 
(78 mg, 0.40 mmol) in DCM (1 mL) was added portion-wise via a syringe pump at 0
o
C. After 
complete addition of the benzenesulfonyl chloride, the reaction was left stirred overnight at room 
temperature, then pyridine was azeotropically removed under vacuum with toluene, and the 
residue was dissolved in ethyl acetate, washed with water, brine, and dried with Na2SO4, then 
filtered, and concentrated under vacuum. Purification was achieved using flash chromatography 
(ethyl acetate/hexane, 1:9) which provided 3.19 as a white solid (88mg, 56%). Mp 131-132
 o
C; 
1
H NMR (CDCl3, 300 MHz), δ 7.72 (d, J = 8.2 Hz, 2H, ArH-a), 7.28 (d, J = 8.0 Hz, 2H, ArH-b), 
7.10 (d, J = 8.4 Hz, 1H, H-1), 6.64 (dd, J = 8.4 and 2.7 Hz, 1H, H-2), 6.53 (d, J = 2.5 Hz, 1H, H-
4), 5.03 (br-s, 1H, Ar-OH), 4. 50 (d,  J = 9.1 Hz, 1H, NH), 3.29 (t, J = 8.3 Hz, 1H, H-17), 2.75 
(br-s, 2H, H-6), 2.41 (s, 3H, C6H4CH3), 2.25-2.20 (m, 1H), 2.08-2.03 (m, 1H), 1.79-1.58 (m, 
3H), 1.51 (m, 1H), 1.41-1.05 (m, 8H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 
153.3 (C-3), 143.1 (CH3-C6H4SO2NH-), 138.3 (C-SO2NH-), 138.0 (C-5), 132.4 (C-6), 129.0 
(2ArCH), 126.9 (2ArCH), 126.5 (C-1), 115.2 (C-4), 112.8 (C-2), 63.5 (C-17), 49.6 (C-14), 44.9 
(CH2), 43.2 (C-13), 39.0 (CH), 32.7 (CH2), 31.2 (CH2), 29.6 (CH2), 27.8 (CH2), 26.0 (CH2), 24.0 
(CH2), 21.5 (CH3-C6H4-SO2NH-), 18.2 (CH3, C-18); LRMS (ESI
+
) m/z (%)  426 (M+H, 22), 255 
(100); HRMS (ESI
+
) calcd for C25H32NO3S (M+H)
+
 426.2103; found 426.2104. 
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General procedure for synthesis of sulfonamides of17-aminoestra-1,3,5(10)-trien-3-
ol (3.11). 
 
To a stirred solution of 17β-amino-1,3,5(10)-estratrien-3-ol, compound  3.11 (0.38 
mmol), in dry pyridine (3 mL) at 0
o
C was added a solution of the sulfonyl chlorides (0.40 mmol) 
in dichloromethane (1 mL) via a syringe pump for 30 min. After addition, the reaction was 
stirred for 16 h at room temperature, then pyridine was azeotropically removed with toluene 
under vacuum, the residue was dissolved in ethyl acetate, washed with water and brine then dried 
(Na2SO4), filtered, and concentrated under vacuum.
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O
3.5  
17β-Benzenesulfonamide-1,3,5(10)-estratrien-3-ol (3.5). Purification was achieved 
using flash chromatography (ethyl acetate/hexane, 2:8) which provided compound 3.5 as a white 
solid (67%). Mp 234-235 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.88 (d, J = 8.1 Hz, 2H, H-a & a` ), 
7.58-7.47 (m, 3H, H-b, b` & c), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.59 (d, J = 8.4 Hz, 1H, H-2), 6.52 
(s, 1H, H-4), 4.60 (s, 1H, Ar-OH), 4.48 (d, J = 9.2 Hz, 1H, NH), 3.15 (q, J = 8.9 Hz, 1H, H-17), 
2.75 (br-s, 2H), 2.21-2.16 (m, 2H), 1.88-1.60 (m, 4H), 1.42-1.07 (m, 7H), 0.68 (s, 3H, CH3, H-
18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 141.1 (C-SO2NH-), 138.1 (C-5), 132.5 (CHAr), 
132.4 (C-6), 129.0 (2CHAr), 127.1 (2CHAr), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.4 (C-17), 
51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.5 (2CH2 overlapping), 27.1 
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(CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%)  412 (M+H, 100), 255 
(18); HRMS (ESI
+
) calcd for C24H30NO3S (M+H)
+
 412.1946; found 412.1950. 
HO
HN
H
S
O
O
CH3
3.6  
17β-(4´-Methylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol, (3.6). Purification was 
done by flash chromatography (methanol/chloroform, 1:9), yielding (33%) of compound 3.6 as a 
white solid: Mp 179-180
o
C. 
1
H NMR (CDCl3, 300 MHz), δ 7.75 (d, J = 8.2 Hz, 2H, H-a), 7.28 
(d, J = 8.0 Hz, 2H, H-b), 7.08 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.3 and 2.7 Hz, 1H, H-2), 
6.52 (d, J = 2.6 Hz, 1H, H-4), 4.73 (br-s, 1H, Ar-OH), 4. 50 (d,  J = 9.2 Hz, 1H, NH), 3.13 (q, J = 
8.9 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.41 (s, 3H, C6H4-CH3), 2.23-2.10 (m, 2H), 1.83-1.71 (m, 
3H), 1.62-1.60 (m, 1H), 1.39-1.08 (m, 7H), 0.68 (s, 3H, CH3, H-18);
 13
C NMR (CDCl3, 75 MHz)  
δ 153.3 (C-3), 140.9 (C-SO2NH-), 139.1 (C-CH3), 138 (C-5), 133.2 (ArCH), 132.4 (C-6), 129.0 
(2Ar-CH‘s-b), 127.1 (2Ar-CH‘s-a), 115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.7 
(CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.5 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 21.3 
(Ar-CH3), 11.8 (CH3, C-18); LRMS (EI) m/z (%) 425 (M
+
, 100), 270 (60), 253 (25), 213 (20); 
HRMS (EI) calcd for C25H31NO3S  425.2025; found 425.2031. 
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3.20  
17β-Benzylsulfonamide-1,3,5(10)-estratrien-3-ol (3.20). Purification was achieved 
using flash chromatography (methanol/chloroform, 1:9) which provided 3.20 as a white solid 
(26%). Mp 202-203
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.40-7.35 (m, 5H, ArH‘s), 7.11 (d, J = 8.4 
Hz, 1H, H-1), 6.60 (dd, J = 8.4 and 2.6 Hz, 1H, H-2), 6.53 (d, J = 2.5 Hz, 1H, H-4), 4.79 (br-s, 
1H, Ar-OH), 4.23 (AB system, 2H, J = 13.9 and 13.9 Hz, 2H, Ar-CH2), 4.09 (d, J = 9.2 Hz, 1H, 
NH), 3.23 (q, J = 8.4 Hz, 1H, H-17), 2.77 (br-s, 2H), 2.28-2.09 (m, 3H), 1.94-1.68 (m, 3H), 1.42-
1.18 (m, 7H), 0.65 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 138.1 (C-5), 
132.4 (C-6), 130.7 (2Ar-CH), 129.4, 128.7 (2Ar-CH), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 
63.8 (C-17), 59.7 (ArCH2SO2NH), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.9 (CH), 36.5 (CH2), 
29.9 (CH2), 29.5 (CH2), 27.1 (CH2), 26.1 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (EI) m/z 
(%) 425 (M
+
, 100), 270 (35), 213, 91; HRMS (EI) calcd for C25H31NO3S  425.2025; found 
425.2018. 
HN
HO
S
O
O
CH3
3.21  
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17β-(4´-Methylbenzylsulfonamide-1,3,5(10)-estratrien-3-ol (3.21). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:9) which provided 3.21 as a white 
solid (38%). Mp 140-141 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.27 (d, J = 7.9 Hz, 2H, ArH-a), 
7.17 (d, J = 7.9 Hz, 2H, ArH-b), 7.11 (d, J = 8.4 Hz, 1H, H-1), 6.60 (dd, J = 8.4 and 2.5 Hz, 1H, 
H-2), 6.53 (d, J = 2.2 Hz, 1H, H-4), 4.66 (br-s, 1H, Ar-OH), 4.18 (AB system, 2H, J = 13.9 and 
13.9 Hz, 2H, Ar-CH2), 3.99 (d, J = 9.2 Hz, 1H, NH),  3.27 (q, J = 8.9 Hz, 1H, H-17), 2.78 (br-s, 
2H), 2.34 (s, 3H, Ar-CH3), 2.30-2.25 (m, 1H), 2.15-2.10 (m, 2H), 1.95-1.69 (m, 3H), 1.43-1.13 
(m, 7H), 0.65 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 138.6, 138.1 (C-5), 
132.4 (C-6), 130.6 (2Ar-CH), 129.4 (2Ar-CH), 126.5 (C-1), 126.4, 115.2 (C-4), 112.7 (C-2), 
63.8 (C-17), 59.3 (CH2SO2NH), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.9 (CH), 36.5 (CH2), 
30.0 (CH2), 29.5 (CH2), 27.1 (CH2), 26.1 (CH2), 23.1 (CH2), 21.2 (Ar-CH3), 11.8 (CH3, C-18); 
LRMS (ESI
+
) m/z (%) 440 (M+H, 31), 377 (28), 376 (100), 270 (28); HRMS (ESI
+
) calcd for 
C26H34NO3S (M+H)
+
 440.2259; found 440.2265. 
HN
HO
S
O
O
Cl
3.22  
17β-(4´-Chlorobenzylsulfonamide-1,3,5(10)-estratrien-3-ol (3.22). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:4) which provided 3.22 as a white 
solid (27%). Mp 178-179 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.34 (m, 4H, ArH), 7.12 (d, J = 8.3 
Hz, 1H, H-1), 6.60 (dd, J = 2.5 and 8.3 Hz, 1H, H-2), 6.53 (brs, 1H, H-4), 4.50 (brs, 1H, ArOH), 
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4.19 (AB system, 2H, J = 13.9 and 13.9 Hz, 2H, Ar-CH2), 3.98 (d, J = 9.4 Hz, 1H, NH),  3.26 (q, 
J = 8.8 Hz, 1H, H-17), 2.78 (brs, 2H), 2.31-2.26 (m, 1H), 2.17-2.06 (m, 2H), 1.94-1.68 (m, 3H), 
1.48-1.15 (m, 7H), 0.67 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 138.1 
(C-5), 134.9 (C-Cl), 132.4 (C-6), 132.0 (2 CHAr), 128.9 (2 CHAr), 127.9 (CH), 126.5 (C-1), 115.2 
(C-4), 112.7 (C-2), 63.8 (C-17), 59.0 (CH2SO2NH), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.9 
(CH), 36.5 (CH2), 30.0 (CH2), 29.5 (CH2), 27.1 (CH2), 26.1 (CH2), 23.1 (CH2), 11.8 (CH3, C-
18); LRMS (ESI
+
) m/z (%) 460 (M+H, 35), 396 (100); HRMS (ESI
+
) calcd for C25H31NO3SCl 
(M+H)
+
 460.1713; found 460.1708. 
HN
HO
S
O
O
3.23  
17β-(4´-n-Propylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.23). Purification 
was achieved using flash chromatography (methanol/chloroform, 1:9) which provided compound 
3.23 as a white solid (27%). Mp 217-218 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.76 (d, J = 8.1 Hz, 
2H, ArH-a), 7.27 (d, J = 8.1 Hz, 2H, ArH-b), 7.08 (d, J = 8.4 Hz, 1H, H-1), 6.58 (d, J = 8.4 Hz, 
1H, H-2), 6.52 (br-s, 1H, H-4), 4.59 (br-s, 1H, Ar-OH), 4.39 (d,  J = 9.2 Hz, 1H, NH), 3.15 (q, J 
= 8.7 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.64 (t, J = 7.6 Hz, 2H, CH2-CH2-CH3), 2.20-2.07 (m, 2H), 
1.89-1.61 (m, 6H), 1.42-1.06 (m, 7H), 0.92 (t, J = 7.3 Hz, 3H, CH2-CH2-CH3), 0.68 (s, 3H, CH3, 
H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 147.9 (C-propyl), 138.3 (C-SO2NH-), 138.0 
(C-5), 132.4 (C-6), 129.0 (2Ar-CH‘s-b), 127.1 (2Ar-CH‘s-a), 126.5 (C-1), 115.2 (C-4), 112.7 (C-
2), 63.3 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 37.8 (CH2-CH2-CH3), 36.3 
(CH2), 29.5 (2CH2), 27.1 (CH2), 26.0 (CH2), 24.2 (CH2-CH2-CH3), 23.1 (CH2), 13.6 (CH2-CH2-
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CH3), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 454 (M+H, 72), 256 (20), 255 (100); HRMS 
(ESI
+
) calcd for C27H36NO3S (M+H)
+
 454.2416; found 454.2410.  
HN
HO
S
O
O
3.24  
17β-(4'-n-Butylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.24). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:9) which provided compound 
3.24 as a white solid (56%). Mp 221-222 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.76 (d, J = 8.3 Hz, 
2H, ArH-a), 7.28 (d, J = 8.3 Hz, 2H, ArH-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.3 and 
2.6 Hz, 1H, H-2), 6.52 (d, J = 2.6 Hz, 1H, H-4), 4.50 (br-s, 1H, Ar-OH), 4.32 (d,  J = 9.2 Hz, 1H, 
NH), 3.15 (q, J = 8.9 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.67 (t, J = 7.5 Hz, 2H, CH2-CH2-CH2-
CH3), 2.20-2.11 (m, 2H), 1.83-1.58 (m, 6H), 1.37-1.10 (m, 9H), 0.92 (t, J = 7.3 Hz, 3H, CH2-
CH2-CH2-CH3), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 148.1 (C-
Butyl), 138.3 (C-SO2NH-), 138.1 (C-5), 132.5 (C-6), 129.0 (2Ar-CH‘s-b), 127.1 (2Ar-CH‘s-a), 
126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 
(CH), 36.3 (CH2), 35.5 (CH2- CH2-CH2-CH3), 33.2 (CH2-CH2-CH2-CH3), 29.5 (2CH2), 27.1 
(CH2), 26.0 (CH2), 23.1 (CH2), 22.2 (CH2-CH2-CH2-CH3), 13.9 (CH2-CH2-CH2-CH3), 11.8 
(CH3, C-18); LRMS (ESI
+
) m/z (%) 468 (M+H, 100), 255 (74), 219 (29), 152 (31); HRMS 
(ESI
+
) calcd for C28H38NO3S (M+H)
+
 468.2572; found 468.2559.  
104 
 
HN
HO
S
O
O
3.25  
17β-(4'-n-Pentylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.25). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:4), which provided compound 
3.25 as a white solid (21%). Mp 168-169 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.76 (d, J = 7.8 Hz, 
2H, ArH-a), 7.28 (d, J = 8.0 Hz, 2H, ArH-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.2 and 
2.2 Hz, 1H, H-2), 6.52 (br-s, 1H, H-4), 4.50 (br-s, 1H, Ar-OH), 4.35 (d,  J = 9.2 Hz, 1H, NH), 
3.15 (q, J = 8.7 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.66 (t, J = 7.4 Hz, 2H, CH2-CH2- CH2-CH2-
CH3), 2.21-2.11 (m, 2H), 1.85-1.80 (m, 2H), 1.77-1.59 (m, 4H), 1.38-1.09 (m, 11H), 0.87 (t, J = 
6.3 Hz, 3H, CH2-CH2- CH2-CH2-CH3), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 
153.3 (C-3), 148.2 (C-pentyl), 138.3 (C-SO2NH-), 138.1 (C-5), 132.5 (C-6), 129.0 (2Ar-CH‘s-b), 
127.1 (2Ar-CH‘s-a), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.7 (CH), 
42.9 (C-13), 38.8 (CH), 36.3 (CH2), 35.8 (CH2-CH2-CH2-CH2-CH3), 31.3 (CH2-CH2- CH2-CH2-
CH3), 30.7 (CH2-CH2- CH2-CH2-CH3), 29.5 (2CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 22.4 
(CH2-CH2-CH2-CH2-CH3), 13.9 (CH2-CH2-CH2-CH2-CH3), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z 
(%) 482 (M+H, 100), 255 (80); HRMS (ESI
+
) calcd for C29H40NO3S (M+H)
+
 482.2729; found 
482.2721. 
HN
HO
S
O
O
3.26  
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17β-(4'-i-Propylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.26). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:9) which provided 3.26 as a white 
solid (43%). Mp 206-207 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.78 (d, J = 8.4 Hz, 2H, ArH-a), 
7.33 (d, J = 8.3 Hz, 2H, ArH-b), 7.08 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.4 and 2.7 Hz, 1H, 
H-2), 6.52 (d, J = 2.6 Hz, 1H, H-4), 4.61 (br-s, 1H, Ar-OH), 4.42 (d,  J = 9.2 Hz, 1H, NH), 3.15 
(q, J = 8.8 Hz, 1H, H-17), 3.01-2.92 (m, 1H), 2.76 (br-s, 2H), 2.20-2.11 (m, 2H), 1.82-1.61 (m, 
4H), 1.38-1.10 (m overlapping d of –CH(CH3)2 with J = 7.0 Hz, 13H), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz)  δ 154.0 (C-isopropyl), 153.3 (C-3), 138.4 (C-SO2NH-), 138.1 (C-
5), 132.4 (C-6), 127.1 (4Ar-CH‘s-b & a overlapping), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.3 
(C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 34.1 (CH(CH3)2), 29.5 
(2CH2), 27.1 (CH2), 26.0 (CH2), 23.7 (2CH3, CH(CH3)2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS 
(EI) m/z (%) 453 (M
+
, 100), 270 (90), 253 (30); HRMS (ESI
+
) calcd for C27H36NO3S (M+H)
+
 
454.2416; found 454.2403.  
HN
HO
S
O
O
3.27  
17β-(4´-t-Butylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.27). Purification was 
achieved by flash chromatography (methanol/chloroform, 1:9) which provided 3.27 as a white 
solid (53%). Mp 218-219 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.78 (d, J = 8.4 Hz, 2H, ArH-a), 
7.48 (d, J = 8.5 Hz, 2H, ArH-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.3 and 2.5 Hz, 1H, 
H-2), 6.52 (d, J = 2.5 Hz, 1H, H-4), 4.56 (br-s, 1H, Ar-OH), 4.32 (d,  J = 9.2 Hz, 1H, NH), 3.15 
(q, J = 8.7 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.15-2.03 (m, 2H), 1.86-1.61 (m, 4H), 1.39-1.11 (m, 
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16H), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) 156.3 (C-t-butyl), 153.3 (C-3), 
148.1 (C-t-butyl), 138.1 (C-SO2NH-), 138.0 (C-5), 132.5 (C-6), 126.9 (2Ar-CH‘s-b), 126.5 (C-
1), 125.9 (2Ar-CH‘s-a), 115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-
13), 38.8 (CH), 36.3 (CH2), 35.1 (C(CH3)3), 31.1 (C(CH3)3), 29.5 (2CH2), 27.1 (CH2), 26.0 
(CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (EI) m/z (%) 467 (M
+
, 91), 270 (100), 253 (32); 
HRMS (ESI
+
) calcd for C28H38NO3S (M+H)
+
 468.2572; found 468.2566. 
HN
HO
S
O
O Br
3.28  
17β-(3'-Bromobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.28). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided compound 3.28 
as a white solid (82%).  Mp 182-183 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.03 (dd overlapping, J 
= 1.7 and 1.6 Hz, 1H, H-d), 7.80 (d, J = 7.9 Hz, 1H, H-a), 7.67 (dd, J = 7.7 and 6.9 Hz, 1H, H-c), 
7.37 (dd, J = 7.9 and 7.9 Hz, 1H, H-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.60 (dd, J = 8.3 and 2.6 
Hz, 1H, H-2), 6.52 (d, J = 2.5 Hz, 1H, H-4), 4.76 (s, 1H, Ar-OH), 4.63 (d, J = 9.4 Hz, 1H, NH), 
3.17 (q, J = 8.8 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.23-2.12 (m, 2H), 1.84-1.65 (m, 4H), 1.39-1.13 
(m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 143 (C-SO2NH-), 
138 (C-5), 135.5 (C-c ), 132.3 (C-6), 130.5 (C-b), 130 (C-d), 126.5 (C-1), 125.5 (C-a), 122.9 (C-
Br), 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 
(CH2), 29.5 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
-
) m/z (%) 
491 (M+2, 27), 490 (M-H+2, 98), 489 (M
+
, 28), 488 (M-H, 97), 255 (100), HRMS (ESI
-
) calcd 
for C24H27BrNO3S (M-H)
-
 488.0895; found 488.0908. 
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3.29  
17β-(3'-Chlorobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.29). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided 3.29 as a white 
solid (73%). Mp 186-187 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.87 (dd overlapping, J = 1.8 and 
1.7 Hz, 1H, H-d), 7.75 (ddd, J = 7.7, 1.6, and 1.2 Hz, 1H, H-a), 7.53 (dddd, J = 8.02, 2.0, 1.9, 
and 1.2 Hz, 1H, H-c), 7.43 (dd overlapping, J = 7.9 and 7.9 Hz, 1H, H-b), 7.09 (d, J = 8.4 Hz, 
1H, H-1), 6.59 (dd, J = 8.4 and 2.7 Hz, 1H, H-2), 6.52 (d, J = 2.6 Hz, 1H, H-4), 4.53 (s, 1H, Ar-
OH), 4.50 (d, , J = 9.5 Hz, 1H, NH), 3.18 (q, J = 8.9 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.24-2.12 
(m, 2H), 1.85-1.69 (m, 4H), 1.40-1.13 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 
MHz) δ 153.3 (C-3), 142.9 (C-SO2NH-), 138 (C-5), 135.1 (C-6), 132.6 (C-c), 132.3 (C-Cl), 
130.3 (C-b), 127.2 (C-d), 126.5 (C-1), 125.1 (C-a), 115.2 (C-4), 112.6 (C-2), 63.5 (C-17), 51 (C-
14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 
(CH2), 11.8 (CH3, C-18); LRMS (EI) m/z (%) 447 (M+2, 40), 445 (M
+
, 100), 270 (43), 253 (25), 
213 (30), HRMS (EI) calcd for C24H28ClNO3S  445.1478; found 445.1474. 
HN
HO
S
O
O F
3.30  
17β-(3'-Fluorobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.30). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 3:7) which provided 3.30 as a white 
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solid (65%). Mp 182-183 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.67 (d, J = 7.8 Hz, 1H, H-a), 7.58 
(d, J = 8.2 Hz, 1H, H-d), 7.48 (m, 1H, H-b), 7.26 (m, overlapped with CDCl3, 1H, H-c), 7.09 (d, 
J = 8.4 Hz, 1H, H-1), 6.59 (dd, J = 8.4 and 2.5 Hz, 1H, H-2), 6.52 (d, J = 2.3 Hz, 1H, H-4), 4.60 
(s, 1H, Ar-OH), 4.56 (d, , J = 9.3 Hz, 1H, NH), 3.18 (q, J = 8.8 Hz, 1H, H-17), 2.76 (br-s, 2H), 
2.22-2.12 (m, 2H), 1.88-1.63 (m, 4H), 1.39-1.12 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR 
(CDCl3, 75 MHz) δ 162.3 (d,  J = 250 Hz, C-F), 153.3 (C-3), 143.2 (d,  J = 6.6 Hz, C-SO2NH-), 
138 (C-5), 132.3 (C-6), 130.8 (d, J = 7.6 Hz, C-b), 126.5 (C-1), 122.7 (d, J = 3.3 Hz, C-a), 119.6 
(d, J = 21.0 Hz, C-c), 115.2 (C-4), 114.4 (d, J = 24.1 Hz, C-d), 112.7 (C-2), 63.5 (C-17), 51 (C-
14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 
(CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ -109; LRMS (EI) m/z (%) 429 (M
+
, 
100), 270 (25), 213 (22); HRMS (EI) calcd for C24H28FNO3S  429.1774; found 429.1782. 
HN
HO
S
O
O NO2
3.31  
17β-(3'-Nitrobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.31). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 3:2) which provided 3.31 as a 
yellow solid (49%). Mp 200-201 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.72 (br-s, 1H, H-d), 8.41 
(m, 1H, H-c), 8.20 (m, 1H, H-a), 7.72 (m, 1H, H-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 
8.3 and 2.4 Hz, 1H, H-2), 6.52 (br-s, 1H, H-4), 4.53 (d, , J = 9.5 Hz, 1H, NH), 4.45 (s, 1H, Ar-
OH), 3.25 (q, J = 8.6 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.24-2.13 (m, 2H), 1.92-1.66 (m, 4H), 1.40-
1.14 (m, 7H), 0.71 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 148.2 (C-
NO2), 143.5 (C-SO2NH-), 138 (C-5), 132.5 (ArCH), 132.2 (C-6), 130.4 (ArCH), 127 (ArCH), 
109 
 
126.5 (C-1), 122.3 (ArCH), 115.2 (C-4), 112.7 (C-2), 63.6 (C-17), 51 (C-14), 43.7 (CH), 43 (C-
13), 38.7 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 11.9 (CH3, C-18); 
LRMS (EI) m/z (%) 456 (M
+
, 100), 270 (18), 213 (20); HRMS (ESI
+
) calcd for C24H29N2O5S  
(M+H)
+
 457.1797; found 457.1807. 
HN
HO
S
O
O CN
3.32  
17β-(3'-Cyanobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.32). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 2:3) which provided 3.32 as a white 
solid (53%). Mp 127-128 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.16 (s, 1H, H-a), 8.10 (d, J = 7.9 
Hz, 1H, H-d), 7.84 (d, J = 7.8 Hz, 1H, H-c), 7.64 (dd, J = 7.7 and 7.9 Hz, 1H, H-b), 7.09 (d, J = 
8.4 Hz, 1H, H-1), 6.59 (dd, J = 8.4 and 2.5 Hz, 1H, H-2), 6.53 (br-s, 1H, H-4), 4.48-4.46 (s and d 
overlapping, 2H, Ar-OH and NH), 3.20 (q, J = 8.9 Hz, 1H, H-17), 2.77 (br-s, 2H), 2.25-2.13 (m, 
2H), 1.89-1.79 (m, 2H), 1.70-1.66 (m, 2H), 1.40-1.09 (m, 7H), 0.70 (s, 3H, CH3, H-18); 
13
C 
NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 143 (C-SO2NH-), 138 (C-5), 135.6 (C-d), 132.2 (C-6), 
130.9 (CHAr), 130.6 (CHAr), 130.1 (CHAr), 126.4 (C-1), 117.1 (CN), 115.2 (C-4), 113.6 (C-CN), 
112.7 (C-2), 63.5 (C-17), 51 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.6 (CH2), 
29.6 (CH2), 27 (CH2), 26 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (EI) m/z (%) 436 (M
+
, 
100), 253 (15), 213 (22); HRMS (EI) calcd for C25H28 N2O3S 436.1821; found 436.1811. 
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HN
HO
S
O
O CF3
3.33  
17β-(3´-Trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.33). 
Purification was achieved using flash chromatography (ethyl acetate/hexane, 1:4) which 
provided 3.33 as a white solid (48%). Mp 196-197 
o
C; 
1
H NMR (CDCl3, 300 MHz), δ 8.14 (br-s, 
1H, ArH), 8.07 (d, J = 7.9 Hz, 1H, ArH), 7.82 (d, J = 7.8 Hz, 1H, ArH), 7.65 (dd overlapping, J 
= 7.8 and 7.8 Hz, 1H, H-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.59 (dd, J = 8.3 and 2.5 Hz, 1H, H-2), 
6.52 (d, J = 2.5 Hz, 1H, H-4), 4.47 (s overlapping d, J = 8.8 Hz, 2H, Ar-OH and NH), 3.21 (q, J 
= 8.8 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.22-2.12 (m, 2H), 1.86-1.65 (m, 4H), 1.39-1.12 (m, 7H), 
0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 142.5 (C-SO2NH-), 138.0 
(C-5), 132.3 (C-6), 131.7 (q, J = 33.2 Hz C-CF3), 130.2 (d, J =1.0 Hz, Ar-CH), 129.8 (Ar-CH), 
129.1 (q, J = 3.7 Hz, , Ar-CH), 126.5 (C-1), 124.1 (q, J = 3.9 Hz, Ar-CH), 123.2 (q, J = 271.3 
Hz, -CF3), 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51.0 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 
(CH), 36.3 (CH2), 29.4 (2CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); 
19
F NMR 
(CDCl3, 282 MHz), δ -62.8; LRMS (EI) m/z (%) 479 (M
+
, 100), 270 (21), 213 (22); HRMS (EI) 
calcd for C25H28F3NO3S  479.1742; found 479.1732.  
HN
HO
S
O
O OCF3
3.34  
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17β-(3'-Trifluoromethoxybenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.34). 
Purification was achieved using flash chromatography (ethyl acetate/hexane, 1:1) which 
provided 3.34 as a white solid (31%). Mp 152-153 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.84 (d, J 
= 7.8 Hz, 1H, H-a), 7.75 (br-s, 1H, ArH), 7.55 (dd overlapped, J = 8.0 and 7.9 Hz, 1H, H-b), 
7.41 (d, J = 8.1 Hz, 1H, ArH), 7.07 (d, J = 8.4 Hz, 1H, H-1), 6.59 (d, J = 8.4 Hz, 1H, H-2), 6.53 
(br-s, 1H, H-4), 4.98 (s, 1H, Ar-OH), 4.92 (d, J = 9.3 Hz, 1H, NH), 3.18 (q, J = 8.9 Hz, 1H, H-
17), 2.75 (br-s, 2H), 2.20-2.06 (m, 2H), 1.89-1.69 (m, 2H), 1.68-1.59 (m, 2H), 1.42-1.07 (m, 
7H), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 149.3 (q, J = 2.0 Hz, 
C-OCF3), 143.3 (C-SO2NH-), 138.0 (C-5), 132.3 (C-6), 130.7 (ArCH), 126.5 (C-1), 120.3 (q, J = 
275.2 Hz, OCF3), 125.3 (ArCH), 124.9 (ArCH), 119.7 (d, J = 0.8 Hz, ArCH), 115.2 (C-4), 112.7 
(C-2), 63.5 (C-17), 51.0 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (CH2), 29.3 
(CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz) δ -
57.6; LRMS (ESI
+
) m/z (%) 496 (M+H, 32), 255 (41); HRMS (ESI
+
) calcd for C25H29F3NO4S 
(M+H)
+
 496.1769; found 496.1758. 
HN
HO
S
O
O CH3
3.35  
17β-(3'-Methylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.35). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided 3.35 as a white 
solid (43%). Mp 202-203 
o
C; 
1
H NMR (CDCl3, 300 MHz)  δ 7.67 (pseudo t, 2H, ArH), 7.36 
(pseudo q, 2H, ArH), 7.09 (d, J = 8.5 Hz, 1H, H-1), 6.59 (dd, J = 8.4 and 2.7 Hz, 1H, H-2), 6.51 
(d, J = 2.5 Hz, 1H, H-4), 4.47 (s, 1H, Ar-OH), 4.34 (d, J = 9.3 Hz, 1H, NH), 3.16 (q, J = 8.7 Hz, 
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1H, H-17), 2.76 (br-s, 2H), 2.4 (s, 3H, Ar-CH3), 2.23-2.11 (m, 2H), 1.82-1.72 (m, 4H), 1.35-1.12 
(m, 7H), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz)  δ 153.3 (C-3), 140.9 (C-SO2NH-
), 139.1 (C-CH3), 138 (C-5), 133.2 (ArCH), 132.4 (C-6), 128.8 (ArCH), 127.4 (ArCH), 126.5 (C-
1), 124.1 (ArCH), 115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 
38.8 (CH), 36.3 (CH2), 29.5 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 21.3 (Ar-CH3), 11.8 
(CH3, C-18); LRMS (EI) m/z (%) 425 (M
+
, 100), 270 (60), 253 (25), 213 (20); HRMS (EI) calcd 
for C25H31NO3S  425.2025; found 425.2035. 
HN
HO
S
O
O OCH3
3.36  
17β-(3'-Methoxybenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.36). Purification 
was achieved using flash chromatography (ethyl acetate/hexane, 2:3) which provided 3.36 as a 
white solid (70%). Mp 198-199 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.43 (pseudo q, 3H, ArH), 
7.09 (pseudo d, 2H, ArH overlapping H-1), 6.58 (d, J = 8.3 Hz, 1H, H-2), 6.52 (s, 1H, H-4), 4.49 
(s, 1H, Ar-OH), 4.39 (d, J = 9.1 Hz, 1H, NH), 3.85 (s, 3H, ArOCH3), 3.16 (pseudo q, 1H, H-17), 
2.76 (br-s, 2H), 2.23-2.11 (m, 2H), 1.91-1.62 (m, 4H), 1.43-1.14 (m, 7H), 0.69 (s, 3H, CH3, H-
18); 
13
C NMR (CDCl3, 75 MHz) δ 159.8 (C-OCH3), 153.3 (C-3), 142.3 (C-SO2NH-), 138.1 (C-
5), 132.4 (C-6), 130 (ArCH), 126.5 (C-1), 119.2 (ArCH), 118.8 (ArCH), 115.2 (C-4), 112.7 (C-
2), 111.8 (C-d), 63.4 (C-17), 55.6 (OCH3), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 
(CH2), 29.5 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (EI) m/z (%) 
441 (M
+
, 100), 270 (70), 253 (26), 213 (20); HRMS (EI) calcd for C25H31NO4S  441.1974; found 
441.1979. 
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HN
HO
S
O
O
Br
3.37  
17β-(4'-Bromobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.37). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided 3.37 as a white 
solid (78%). Mp 115-116 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.74 (d, J = 8.7 Hz, 2H, ArH-a), 
7.64 (d, J = 8.7 Hz, 2H, ArH-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (dd, J = 8.5 and 2.5 Hz, 1H, 
H-2), 6.52 (d, J = 2.5 Hz, 1H, H-4), 4.54 (br-s, 1H, Ar-OH), 4.42 (d,  J = 9.4 Hz, 1H, NH), 3.15 
(q, J = 8.7 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.24-2.08 (m, 2H), 1.88-1.60 (m, 4H), 1.40-1.12 (m, 
7H), 0.68 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 140.2 (C-SO2NH-), 
138.1 (C-5), 132.3 (C-6), 132.2 (2Ar-CH‘s), 128.6 (2Ar-CH‘s), 127.4 (C-Br), 126.5 (C-1), 115.2 
(C-4), 112.7 (C-2), 63.4 (C-17), 51.1 (C-14), 43.7 (CH), 43.0 (C-13), 38.8 (CH), 36.3 (CH2), 
29.5 (CH2), 29.4 (CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) 
m/z (%) 492 (M+H+2, 75), 490 (M+H, 72), 256 (20), 255 (100); HRMS (ESI
+
) calcd for 
C24H29BrNO3S (M+H)
+
 490.1052; found 490.1046. 
HN
HO
S
O
O
Cl
3.38  
17β-(4'-Chlorobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.38). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided 3.38 as a white 
solid (69%). Mp 124-125 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.82 (d, J = 8.4 Hz, 2H, ArH-a), 
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7.45 (d, J = 8.4 Hz, 2H, ArH-b), 7.07 (d, J = 8.5 Hz, 1H, H-1), 6.60 (d, J = 8.4 Hz, 1H, H-2), 
6.53 (br-s, 1H, H-4), 5.29 (br-s, 1H, Ar-OH), 4.98 (d,  J = 9.2 Hz, 1H, NH), 3.13 (q, J = 8.6 Hz, 
1H, H-17), 2.74 (br-s, 2H), 2.21-2.05 (m, 2H), 1.87-1.60 (m, 4H), 1.42-1.07 (m, 7H), 0.67 (s, 3H, 
CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 139.7 (C-SO2NH-), 138.9 (C-Cl), 138.0 
(C-5), 132.3 (C-6), 129.3 (2Ar-CH‘s-b), 128.5 (2Ar-CH‘s-a), 126.5 (C-1), 115.2 (C-4), 112.7 (C-
2), 63.4 (C-17), 51.1 (C-14), 43.7 (CH), 43.0 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 
(CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 448 (M+H+2, 38), 447 
(M+2, 30), 446 (M+H, 100), 255 (18), 239 (38); HRMS (ESI
+
) calcd for C24H29ClNO3S (M+H)
+
 
446.1557; found 446.1542. 
HN
HO
S
O
O
F
3.39  
17β-(4'-Fluorobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.39). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 3:7) which provided 3.39 as a white 
solid (61%). Mp 140-141 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.89 (m, 2H, ArH-a), 7.16 (dd 
overlapping, J = 8.5 and 8.5 Hz, 2H, ArH-b), 7.08 (d, J = 8.4 Hz, 1H, H-1), 6.59 (dd, J = 8.4 and 
2.5 Hz, 1H, H-2), 6.53 (d, J = 2.5 Hz, 1H, H-4), 4.89 (br-s, 1H, Ar-OH), 4.71 (d,  J = 9.2 Hz, 1H, 
NH), 3.13 (q, J = 8.8 Hz, 1H, H-17), 2.75 (br-s, 2H), 2.22-2.10 (m, 2H), 1.85-1.61 (m, 4H), 1.38-
1.09 (m, 7H), 0.68 (s, 3H, CH3, H-18);  
13
C NMR (CDCl3, 75 MHz) δ 166.6-163.3 (d, J = 253.0 
Hz, C-F), 153.4 (C-3), 138.0 (C-5), 137.2 (d, J = 3.2 Hz, C-SO2NH-), 132.3 (C-6), 129.7 (d, J = 
9.9 Hz, 2Ar-CH‘s-a), 126.5 (C-1), 116.1 (d,  J = 22.4 Hz, 2Ar-CH‘s-b), 115.2 (C-4), 112.7 (C-2), 
63.4 (C-17), 51.1 (C-14), 43.7 (CH), 43.0 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 
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(CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz) δ -105; LRMS 
(ESI
+
) m/z (%) 430 (M+H, 100), 255 (13), 223 (15); HRMS (ESI
+
) calcd for C24H29FNO3S 
(M+H)
+
 430.1852; found 430.1847. 
HN
HO
S
O
O
CF3
3.40  
17β-(4'-Trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.40). Purification 
was achieved using flash chromatography (ethyl acetate/hexane, 1:1) which provided 3.40 as a 
white solid (34%). Mp 138-139 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.00 (d, J = 8.1 Hz, 2H, ArH-
a), 7.76 (d, J = 8.0 Hz, 2H, ArH-b), 7.09 (d, J = 8.4 Hz, 1H, H-1), 6.58 (d, J = 8.8 Hz, 1H, H-2), 
6.53 (br-s, 1H, H-4), 4.51 (pseudo d, 2H, Ar-OH and NH), 3.20 (q, J = 8.6 Hz, 1H, H-17), 2.77 
(br-s, 2H), 2.23-2.09 (m, 2H), 1.92-1.61 (m, 4H), 1.44-1.10 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.4 (C-3), 144.8 (d, J = 1.2 Hz, C-SO2NH-), 138.0 (C-5), 134.2 
(d, J = 33.0 Hz, C-CF3), 132.3 (C-6), 127.5 (2Ar-CH‘s-a), 126.5 (C-1), 126.2 (q,  J = 3.7 Hz, 
2Ar-CH‘s-b), 123.0 (q, J = 271.2 Hz, CF3), 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51.1 (C-14), 
43.7 (CH), 43.0 (C-13), 38.8 (CH), 36.3 (CH2), 29.4 (2CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 
11.8 (CH3, C-18);
 19
F NMR (CDCl3, 282 MHz) δ -62.5; LRMS (ESI
+
) m/z (%) 480 (M+H, 43), 
256 (19), 255 (100); HRMS (ESI
+
) calcd for C25H29F3NO3S (M+H)
+
 480.1820; found 480.1813.  
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HO
S
O
O
O
3.41  
17β-(4'-Acetylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.41). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:9) which provided 3.41 as a white 
solid (53%). Mp 118-119 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.05 (d, J = 8.5 Hz, 2H, ArH), 7.97 
(d, J = 8.2 Hz, 2H, ArH), 7.08 (d, J = 8.5 Hz, 1H, H-1), 6.59 (dd, J = 2.6 and 8.4 Hz, 1H, H-2), 
6.52 (d, J = 2.4 Hz, 1H, H-4), 4.59 (brs, 1H, ArOH), 4.53 (d,  J = 9.4 Hz, 1H, NH), 3.19 (q, J = 
8.7 Hz, 1H, H-17), 2.76 (m, 2H), 2.64 (s, 3H, -COCH3), 2.23-2.11 (m, 2H), 1.86-1.62 (m, 4H), 
1.39-1.12 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 196.8 (CO), 153.3 (C-
3), 145.2 (C-COCH3), 139.3 (C-SO2NH-), 138.0 (C-5), 132.3 (C-6), 128.9 (2 CHAr), 127.3 (2 
CHAr), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 
38.8 (CH), 36.3 (CH2), 29.5 (2 CH2), 27.1 (CH2), 26.9 (CH3), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, 
C-18); LRMS (ESI
+
) m/z (%) 454 (M+H, 40), 255 (100); HRMS (ESI
+
) calcd for C26H32NO4S 
(M+H)
+
 454.2052; found 454.2050. 
HN
HO
S
O
O
Br
3.42  
17β-(2´-Bromobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.42). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:4) which provided 3.42 as a white 
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solid (67%): Mp 225-226 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.14 (dd, J = 8.9 and 1.3 Hz 1H, H-
a), 7.72 (d, J = 7.4 Hz, 1H, H-d), 7.42 (m, 2H, H-c & b), 7.07 (d, J = 8.4 Hz, 1H, H-1), 6.58 (d, J 
= 8.3 Hz, 1H, H-2), 6.52 (br-s, 1H, H-4), 5.06 (d,  J = 8.9 Hz, 1H, NH), 4.64 (s, 1H, Ar-OH), 
3.12 (q, J = 8.8 Hz, 1H, H-17), 2.75 (br-s, 2H), 2.20-2.05 (m, 2H), 1.80-1.58 (m, 6H), 1.39-0.82 
(m, 6H), 0.74 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 139.9 (C-SO2NH-), 
138.0 (C-5), 134.9 (Ar-CH), 133.5 (Ar-CH), 132.3 (C-6), 131.4 (Ar-CH), 127.8 (Ar-CH), 126.5 
(C-1), 119.9 (C-Br), 115.2 (C-4), 112.7 (C-2), 63.7 (C-17), 51 (C-14), 43.7 (CH), 43.0 (C-13), 
38.7 (CH), 36.2 (CH2), 29.4 (CH2), 28.7 (CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 11.9 (CH3, C-
18); LRMS (ESI
+
) m/z (%)  492 (M+H+2, 28), 491 (M+2, 9), 490 (M+H, 28), 256 (20), 255 
(100); HRMS (ESI
+
) calcd for C24H29BrNO3S (M+H)
+
 490.1052; found 490.1053. 
HN
HO
S
O
O
F3C
3.43  
17β-(2´-Trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.43). 
Purification was achieved using flash chromatography (ethyl acetate/hexane, 3:7) which 
provided 3.43 as a white solid (51%). Mp 244-245 
o
C; 
1
H NMR (CDCl3, 300 MHz), δ 8.27-8.25 
(m, 1H, ArH), 7.89-7.86 (m, 1H, ArH), 7.72-7.69 (m,2H, ArH), 7.09 (d, J = 8.5 Hz, 1H, H-1), 
6.59 (d, J = 8.2 Hz, 1H, H-2), 6.53 (brs, 1H, H-4), 4.60 (d, J = 8.8 Hz, 1H, NH), 4.53 (s, 1H, 
ArOH), 3.21 (q, J = 9.4 Hz, 1H, H-17), 2.76 (m, 2H), 2.21-2.08 (m, 2H), 1.81-1.63 (m, 4H), 
1.43-1.05 (m, 8H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 139.8 
(C-SO2NH-), 138.0 (C-5 and C-6), 132.3 (d, J = 2.5 Hz, CHAr),  131.6 (CHAr), 128.4 (q, J = 32.5 
Hz, C-CF3), 124.8 (q, J = 272.2 Hz, C-CF3), 115.2 (C-4), 112.7 (C-2), 63.6 (C-17), 51.0 (C-14), 
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43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.2 (2CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 
11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ  -58.2; LRMS (ESI
+
) m/z (%) 480 (M+H, 40), 
255 (100); HRMS (ESI
+
) calcd for C25H29F3NO3S  480.1820; found 480.1823. 
HN
HO
S
O
O
O
O
3.44  
17β-(Coumarin-6-yl)sulfonamide-1,3,5(10)-estratrien-3-ol (3.44). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:4) which provided 3.44 as a white 
solid (56%). Mp 178-179 
o
C; 
1
H NMR (CDCl3, 300 MHz), δ 8.06 (d, J = 1.5 Hz, 1H, ArH), 8.00 
(dd, J = 1.8 and 8.2 Hz, 1H, ArH), 7.73 (d, J = 8.6 Hz, 1H, ArH), 7.42 (d, J = 8.6 Hz, 1H, ArH), 
7.06 (d, J = 8.4 Hz, 1H, H-1), 6.61-6.51 (m, 2H, H-2 and H-4), 5.09 (brs, 1H, ArOH), 4.80 (brs, 
1H, NH), 3.17 (q, J = 8.8 Hz, 1H, H-17), 2.75 (m, 2H), 2.21-2.06 (m, 2H), 1.86-1.59 (m, 4H), 
1.43-1.07 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 159.3 (C(O)O), 156.2, 
153.3 (C-3), 142.4 (CHAr), 138.0 (C-5), 137.6, 132.2 (C-6), 130.0 (CHAr), , 127.4 (CHAr), 126.5 
(C-1), 118.7, 118.4, 117.9, 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 
(C-13), 38.8 (CH), 36.4 (CH2), 29.5 (2CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-
18); LRMS (ESI
+
) m/z (%) 480 (M+H, 100), 256 (20), 255 (50); HRMS (ESI
+
) calcd for 
C27H30NO5S (M+H)
+
 480.1845; found 480.1820. 
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S
O
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3.45  
17β-Naphthalen-2-ylsulfonamide-1,3,5(10)-estratrien-3-ol (3.45). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 2:3) which provided 3.45 as a white 
solid (25%). Mp 136-137 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.45 (br-s, 1H, ArH), 7.96-7.82 (m, 
4H, ArH‘s), 7.66-7.57 (m, 2H, ArH), 7.06 (d, J = 8.3 Hz, 1H, H-1), 6.58 (d, J = 8.4 Hz, 1H, H-
2), 6.51 (br-s, 1H, H-4), 4.54 (s overlapping d, J = 8.8 Hz, 2H, Ar-OH and NH), 3.20 (q, J = 8.6 
Hz, 1H, H-17), 2.74 (br-s, 2H), 2.18-2.02 (m, 2H), 1.83-1.73 (m, 2H), 1.60-1.55 (pseudo d, 1H), 
1.41-1.12 (m, 7H), 0.70 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 138.1 
(C-5), 137.8, 134.7, 132.5 (C-6), 132.1, 129.4, 129.2, 128.7, 128.3, 127.9, 127.5, 126.5 (C-1), 
122.4, 115.1 (C-4), 112.6 (C-2), 63.4 (C-17), 51.1 (C-14), 43.7 (CH), 42.9 (C-13), 38.8 (CH), 
36.3 (CH2), 29.5 (2CH2), 27.1 (CH2), 26 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z 
(%) 462 (M+H, 100), 256 (20), 255 (97); HRMS (ESI
+
) calcd for C28H32NO3S (M+H)
+
 
462.2103; found 462.2102. 
HN
HO
S
O
O
N
3.46  
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17β-(5'-Dimethylamino)naphthalen-2-ylsulfonamide-1,3,5(10)-estratrien-3-ol (3.46). 
Purification was achieved using flash chromatography (ethyl acetate/hexane, 2:7) which 
provided 3.46 as a white solid (63%). Mp 206-207 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.52 (d, J 
= 8.5 Hz, 1H, ArH), 8.30-8.26 (m, 2H, ArH), 7.58-7.48 (m, 2H, ArH), 7.17 (d, J = 7.5 Hz, 
1H,ArH), 7.01 (d, J = 8.5 Hz, 1H, H-1), 6.56 (dd, J = 2.6 and 8.4 Hz, 1H, H-2), 6.49 (d, J = 2.5 
Hz, 1H, H-4), 4.91 (s 1H, ArOH), 4.68 (d, J = 9.3 Hz, 1H, NH), 3.09 (q, J = 8.6 Hz, 1H, H-17), 
2.88 (s, 6H, -N(CH3)2), 2.70 (m, 2H), 2.07-1.98 (m, 2H), 1.74-1.47 (m, 4H), 1.40-1.36 (m, 1H), 
1.30-1.01 (m, 6H), 0.92-0.84 (m, 1H), 0.61 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 
153.4 (C-3), 151.9 (C-N(CH3)2), 138.0 (C-5), 135.6 (C-SO2NH), 132.3 (C-6), 130.3, 129.7 (2 C), 
129.6, 128.3, 126.4 (C-1), 123.2, 118.8, 115.1 (2 CHAr), 112.6 (C-2), 63.5 (C-17), 51.0 (C-14), 
45.4 (2 CH3, -N(CH3)2), 43.7 (CH), 42.8 (C-13), 38.7 (CH), 36.0 (CH2), 29.3 (2 CH2), 27.1 
(CH2), 26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 505 (M+H, 100); 
HRMS (ESI
+
) calcd for C30H37N2O3S (M+H)
+
 505.2525; found 505.2518.  
HN
HO
S
O
O
O
3.47  
17β-(4'-Phenoxybenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.47). Purification 
was achieved using flash chromatography (methanol/chloroform, 2:3) which provided 3.47 as a 
white solid (38%). Mp 184-185 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.81 (d, J = 8.5 Hz, 2H, ArH-
a), 7.39 (dd overlapping, J = 7.7 and 7.7 Hz, 2H, ArH-b`), 7.18 (d, J = 7.1 Hz, 1H, Ar-H-c`), 
7.06 (d overlapping dd, J = 8.4 Hz, 8.2 and 8.6 Hz respectively, 5H, H-1 and 4 Ar-H-a` & b), 
6.58 (d, J = 8.5 Hz, 1H, H-2), 6.52 (br-s, 1H, H-4), 4.49 (br-s, 1H, Ar-OH), 4.35 (d, J = 9.3 Hz, 
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1H, NH), 3.15 (q, J = 8.7 Hz, 1H, H-17), 2.76 (br-s, 2H), 2.23-2.09 (m, 2H), 1.90-1.61 (m, 2H), 
1.40-1.09 (m, 7H), 0.69 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 161.3 (C-Phenyl), 
155.3 (O-C-Phenyl), 153.3 (C-3), 138.1 (C-5), , 134.8 (C-SO2NH-), 132.4 (C-6), 130.1 (2Ar-CH-
b`), 129.3 (2Ar-CH-a), 126.5 (C-1), 124.8 (Ar-CH-c`), 120.1 (2Ar-CH-b), 117.7 (2Ar-CH-a`), 
115.2 (C-4), 112.7 (C-2), 63.3 (C-17), 51.1 (C-14), 43.8 (CH), 42.9 (C-13), 38.8 (CH), 36.3 
(CH2), 29.5 (2CH2 overlapping), 27.1 (CH2), 26.1 (CH2), 23.2 (CH2), 11.8 (CH3, C-18); LRMS 
(ESI
+
) m/z (%) 504 (M+H, 100), 256 (15), 255 (75); HRMS (ESI
+
) calcd for C30H34NO4S 
(M+H)
+
  504.2209; found 504.2207. 
HN
HO
S
O
O
3.48  
17β-(4'-Phenylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.48). Purification was 
achieved using flash chromatography (methanol/chloroform, 1:4) which provided 3.48 as a white 
solid (31%). Mp 223-224 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.92 (d, J = 8.4 Hz, 2H, ArH-a), 
7.70 (d, J = 8.3 Hz, 2H, ArH-b), 7.62 (pseudo t, 2H, Ar-H-a`), 7.50-7.38 (m, 3H, Ar-H-b` and 
c`), 7.09 (d, J = 8.3 Hz, 1H, H-1), 6.58 (dd, J = 8.4 and 2.4 Hz, 1H, H-2), 6.52 (br-s, 1H, H-4), 
4.45 (br-s, 1H, Ar-OH), 4.40 (d, J = 9.3 Hz, 1H, NH), 3.20 (q, J = 8.5 Hz, 1H, H-17), 2.76 (br-s, 
2H), 2.23-2.12 (m, 2H), 1.91-1.63 (m, 2H), 1.40-1.12 (m, 7H), 0.70 (s, 3H, CH3, H-18); 
13
C 
NMR (CDCl3, 75 MHz) δ 153.3 (C-3), 145.4 (C-phenyl), 139.7 (C-SO2NH-), 139.3 (C-C-
phenyl), 138.1 (C-5), 132.5 (C-6), 129.0 (2Ar-CH‘s), 128.5 (Ar-CH-c`), 127.6 (4Ar-CH‘s 
overlapping), 127.3 (2Ar-CH‘s), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.4 (C-17), 51.1 (C-14), 
43.7 (CH), 42.9 (C-13), 38.8 (CH), 36.3 (CH2), 29.5 (2CH2 overlapping), 27.1 (CH2), 26.0 
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(CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 488 (M+H, 17), 391 (47), 323 (40), 
219 (100), 173 (48); HRMS (ESI
+
) calcd for C30H34NO3S (M+H)
+
 488.2259; found 488.2262.  
HN
HO
S
O
O O
3.49  
17β-(4'-Benzoylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.49). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 1:9) which provided 3.49 as a white 
solid (65 mg, 23%). Mp 145-147 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.99 (d, J = 8.5 Hz, 2H, 
ArH), 7.87 (d, J = 8.3 Hz, 2H, ArH), 7.78 (d, J = 7.4 Hz, 2H, ArH), 7.65-7.60 (m, 1H), 7.52-7.47 
(m, 1H), 7.07 (d, J = 8.5 Hz, 1H, H-1), 6.60 (dd, J = 2.3 and 8.3 Hz, 1H, H-2), 6.53 (brs, 1H, H-
4), 5.12 (brs, 1H, ArOH), 4.81 (d,  J = 9.2 Hz, 1H, NH), 3.21 (q, J = 8.7 Hz, 1H, H-17), 2.75 (m, 
2H), 2.22-2.03 (m, 2H), 1.89-1.60 (m, 5H), 1.39-1.09 (m, 8H), 0.70 (s, 3H, CH3, H-18); 
13
C 
NMR (CDCl3, 75 MHz) δ 195.5 (CO), 153.5 (C-3), 144.5 (C-COC6H5), 141.0 (C-SO2NH-), 
138.0 (C-5), 136.6 (C-6), 133.3 (CHAr), 132.2, 130.4 (2 CHAr), 130.1 (2 CHAr), 128.6 (2 CHAr), 
127.0 (2 CHAr), 126.5 (C-1), 115.2 (C-4), 112.7 (C-2), 63.5 (C-17), 51.1 (C-14), 43.7 (CH), 43.0 
(C-13), 38.8 (CH), 36.4 (CH2), 29.5 (2 CH2), 27.1 (CH2), 26.0 (CH2), 23.1 (CH2), 11.9 (CH3, C-
18); LRMS (ESI
+
) m/z (%) 516 (M+H, 100); HRMS (ESI
+
) calcd for C31H34NO4S (M+H)
+
 
516.22031; found 516.22007.  
HN
HO
S
O O O
3.50  
123 
 
17β-(3'-Benzoylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (3.50). Purification was 
achieved using flash chromatography (ethyl acetate/hexane, 3:7) which provided 3.50 as a white 
solid (20 mg, 18%). Mp 177-179 
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.27 (brs, 1H, ArH), 8.09 (d, 
J = 7.7 Hz, 1H, ArH), 7.97 (d, J = 7.6 Hz, 1H, ArH), 7.77 (d, J = 7.7 Hz, 2H, ArH), 7.66-7.60 
(m, 2H), 7.52-7.47 (m, 2H), 7.08 (d, J = 8.5 Hz, 1H, H-1), 6.58 (d, J = 8.2 Hz, 1H, H-2), 6.52 
(brs, 1H, H-4), 4.68 (brs, 1H, ArOH), 4.54 (d,  J = 9.5 Hz, 1H, NH), 3.19 (q, J = 8.3 Hz, 1H, H-
17), 2.76 (m, 2H), 2.22-2.11 (m, 2H), 1.91-1.59 (m, 5H), 1.42-1.09 (m, 8H), 0.69 (s, 3H, CH3, H-
18); 
13
C NMR (CDCl3, 75 MHz) δ 195.1 (CO), 153.5 (C-3), 141.8 (C-COC6H5), 138.5 (C-
SO2NH-), 138.0 (C-5), 136.5 (C-6), 133.5 (CHAr), 133.2 (CHAr), 132.2, 130.4 (CHAr), 130.1 (2 
CHAr), 129.3 (CHAr), 128.6 (2 CHAr), 128.3 (CHAr), 126.4 (C-1), 115.3 (C-4), 112.7 (C-2), 63.5 
(C-17), 51.1 (C-14), 43.7 (CH), 43.0 (C-13), 38.8 (CH), 36.4 (CH2), 29.5 (2 CH2), 27.1 (CH2), 
26.0 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 516 (M+H, 60), 371 (100); 
HRMS (ESI
+
) calcd for C31H34NO4S (M+H)
+
 516.22031; found 516.22043. 
SO2Cl
COCl
3.52  
4'-Chlorosulfonylbenzoyl chloride (3.52).
171
 A suspension of 4-sulfobenzoic acid 
potassium salt, compound 3.51 (2.0 g, 8.2 mmol) and thionyl chloride (20 mL) in DMF (two 
drop), was refluxed for 4 h., after that, the precipitate formed was filtered out, and filtrate was 
azeotropically evaporated with toluene, and formed precipitate was filtered and washed three 
times toluene to afford the acid chloride 3.52 as white solid (1.8 g, 100%). Mp 53-55
o
C (lit. 53-
57);
 1
H NMR (CDCl3, 300 MHz) δ 8.15 (d, J = 8.1 Hz, 2H, ArH), 7.96 (d, J = 8.1 Hz, 2H, ArH). 
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ClO2S
O
3.53  
4'-Benzoylbenzenesulfonyl chloride (3.53).
172
 To a solution of 3.52 (1.4 g, 5.85 mmol) 
in 1,2-DCE (40 mL), was added benzene (1.0 mL, 12 mmol) and AlCl3 (1.66 g, 12.5 mmol) at 
room temperature. The stirring was continued for 24 h, after that, it was quenched by ice-water 
mixture, and the organic layer was evaporated under vacuum, to afford pale yellow oil, which 
was crystallized from hexane to afford 3.53 as white crystals (1.3 g, 78%). Mp 85-87
o
C (lit. 88-
90); 
1
H NMR (CDCl3, 300 MHz) δ 8.15 (d, J = 8.1 Hz, 2H, ArH), 7.96 (d, J = 8.1 Hz, 2H, ArH), 
7.78 (d, J = 7.7 Hz, 2H, ArH), 7.67-7.62 (m, 1H), 7.54-7.49 (m, 2H). 
ClO2S
O
3.55  
3'-Benzoylbenzenesulfonyl chloride (3.55).
172
 To a solution of 3.54 (140 mg, 0.6 mmol) 
in 1,2-DCE (5 mL), was added benzene (0.1 mL, 1.2 mmol) and AlCl3 (0.16 mg, 1.2 mmol) at 
room temperature. The stirring was continued for 24 h, after that, it was quenched by ice-water 
mixture, and the organic layer was evaporated under vacuum, to afford 3.55 in an 83% yield as 
pale yellow oil, which is used without further purification. 
1
H NMR (CDCl3, 300 MHz) δ 9.41 
(brs, 2H, ArH), 9.16-8.93 (m, 4H, ArH), 8.54-8.45 (m, 3H, ArH). 
Br
COCl
3.58  
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3'-Bromobenzoyl chloride (3.58). 3-Bromobenzoic acid, compound 3.57 (1 g, 5 mmol) 
in toluene (20 mL) was heated under reflux together with thionyl chloride (10 mL) for 6 h, 
cooled and solvent removed under reduced pressure. The residue was dried azeotropically with 
toluene (2 x 15mL) to give 3.58 as pale yellow oil (1.1 g, 100%).  
1
H NMR (CDCl3, 300 MHz),  
8.65 (brs, 1H, ArH), 8.56 (d, J = 7.8 Hz, 1H, ArH), 7.89 (brs, 1H, ArH), 7.77 (d, J = 8.0 Hz, 1H, 
ArH). 
O
HN
Br
O
O
Br
3.59  
17-(3'-Bromo)benzamido-estra-1,3,5(10)-trien-3-yl-(3'-bromo)benzoate (3.59). To a 
stirred solution of 17β-amino-1,3,5(10)-estratrien-3-ol, compound 3.11 (150 mg, 0.55 mmol) in 
dry pyridine (3 mL) at 0 
o
C was added the 3'-bromobenzoyl chloride, compound 3.58 (241 mg, 
1.10 mmol). The reaction was stirred overnight at room temperature, then pyridine was 
azeotropically removed with toluene under vacuum, and the residue was dissolved in chloroform, 
washed with water, dil. HCl, water, NaHCO3, water, and finally brine then dried (Na2SO4), and 
concentrated. Purification was achieved using flash chromatography (ethyl acetate/hexane, 1:9) 
which provided 3.59 as a white solid (250 mg, 71%). Mp 143–144 oC; 1H NMR (CDCl3, 300 
MHz),  8.30 (brs, 1H, ArH), 8.09 (d, J = 7.8 Hz, 1H, ArH), 7.87 (brs, 1H, ArH), 7.73 (d, J = 8.0 
Hz, 1H, ArH), 7.66 (d, J = 7.8 Hz, 1H, ArH), 7.60 (d, J = 8.1 Hz, 1H, ArH), 7.38–7.26 (m, 3H, 
ArH), 6.92 (d overlapping brs, J = 8.9 Hz, 2H, H-2 and H-4, respectively), 5.96 (d, J = 8.9 Hz, 
1H, NH), 4.18 (q, J = 8.9 Hz, 1H, H-17), 2.88 (m, 2H), 2.34-2.20 (m, 3H), 1.91–1.83 (m, 3H), 
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1.60-1.23 (m, 7H), 0.83 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz)  166.0 (C(O)NH), 
164.1 (C(O)O), 148.5 (C-3), 138.3 (C-5), 138.2 (C-6), 136.9 (C-C(O)NH-),136.3 (CHAr), 134.3 
(CHAr), 133.0 (CHAr), 131.6 (C-C(O)O-), 130.6 (3 CHAr), 128.7 (CHAr), 126.6 (CHAr), 125.4 
(CHAr), 122.7 (C), 122.6 (C), 121.4 (C-4), 118.5 (C-2), 59.4 (C-17), 51.7 (C-14), 44.0 (C-13), 
43.8 (CH), 38.6 (CH), 37.0 (CH2), 29.5 (CH2), 28.7 (CH2), 27.1 (CH2), 26.1 (CH2), 23.4 (CH2), 
12.2 (CH3, C-18); LRMS (ESI
+
) m/z (%) 636 (M+H, 38), 622 (100%); HRMS (ESI
+
) calcd for 
C32H32NO3Br2 (M+H)
+
 636.0749; found 636.0760.  
O
HN
CF3
O
O
F3C
3.60  
17-(3'-Trifluoromethyl)benzamido-estra-1,3,5(10)-trien-3-yl-(3'-trifluoromethyl)- 
benzoate (3.60). To a stirred solution of 17-amino-1,3,5(10)-estratrien-3-ol, compound 3.11 (150 
mg, 0.55 mmol) in dry pyridine (3 mL) at 0 
o
C was added the 3-trifluoromethylbenzoyl chloride 
(230 mg, 1.10 mmol). The reaction was stirred overnight at room temperature. The pyridine was 
azeotropically removed with toluene under vacuum, the residue was dissolved in chloroform, 
washed with water, dil. HCl, water, NaHCO3, water, and finally brine then dried (Na2SO4), and 
concentrated. Purification was achieved using flash chromatography (ethyl acetate/ hexane, 3:7) 
which provided 3.60 as a white solid (194 mg, 57%). Mp 118–119 oC; 1H NMR (CDCl3, 300 
MHz),  8.43 (s, 1H, ArH), 8.35 (d, J = 8.1 Hz, 1H, ArH), 8.00 (s, 1H, ArH), 7.93 (d, J = 7.7 Hz, 
1H, ArH), 7.87 (d, J = 7.4 Hz, 1H, ArH), 7.74 (d, J = 7.6 Hz, 1H, ArH), 7.66–7.54 (m, 2H, ArH), 
7.33 (d, J = 8.7 Hz, 1H, H-1), 6.94 (d overlapping brs, J = 8.9 Hz, 2H, H-2 and H-4, 
respectively), 5.97 (d, J = 8.7 Hz, 1H, NH), 4.22 (q, J = 8.9 Hz, 1H, H-17), 2.89 (m, 2H), 2.33-
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2.26 (m, 3H), 1.94-1.82 (m, 3H), 1.63-1.40 (m, 7H), 0.83 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 
75 MHz)  166.1 (C(O)NH), 164.2 (C(O)O), 148.4 (C-3), 138.3 (2 C, C-5 and C-6), 135.8 (C-
C(O)NH-),133.3 (CHAr), 131.6 (q, J = 33 Hz, 2 C, C-CF3), 130.6 (C-C(O)O-), 130.1 (CHAr), 
130.0 (d, J = 3.5 Hz, CHAr), 129.2 (d, J = 3.4 Hz, 2 CHAr), 127.9 (d, J = 3.5 Hz, CHAr), 126.9 (d, 
J = 3.7 Hz, CHAr), 126.6 (C-1), 123.8 (q, J = 3.7 Hz, CHAr), 123.6 (q, J = 270.9 Hz, 2 C, C-CF3), 
121.4 (C-4), 118.5 (C-2), 59.5 (C-17), 51.7 (C-14), 44.0 (C-13), 43.8 (CH), 38.6 (CH), 37.0 
(CH2), 29.5 (CH2), 28.7 (CH2), 27.1 (CH2), 26.1 (CH2), 23.4 (CH2), 12.2 (CH3, C-18); 
19
F NMR 
(CDCl3, 282 MHz)  -62.5 (2 CF3 overlapping); LRMS (ESI
+
) m/z (%) 616 (M+H, 100); HRMS 
(ESI
+
) calcd for C34H32F6NO3 (M+H)
+
 616.2286; found 616.2296.  
HO
HN
Br
O
3.61  
17-(3'-Bromo)benzamido-estra-1,3,5(10)-trien-3-ol (3.61). To a stirred solution of 
3.59 (100 mg, 0.15 mmol) in methanol (10 mL), was added a solution of K2CO3 (21 mg, 0.15 
mmol) in H2O (100 µL). The resultant solution was stirred for 3 h, then diluted with water, 
neutralized with dil. HCl, and extracted with chloroform. The extract was then washed with 
water, brine, dried with Na2SO4, and concentred. Purification was achieved using flash 
chromatography (ethyl acetate/hexane, 1:9) which provided 3.61 as a white solid (48 mg, 67%). 
Mp 166-167
o
C; 
1
H NMR (CDCl3, 300 MHz),  7.86 (t, J = 1.7 Hz, 1H, ArH), 7.67-7.58 (m, 2H, 
ArH), 7.28 (m, 1H, ArH), 7.11 (d, J = 8.4, 1H, ArH), 7.12 (d, J = 8.3 Hz, 1H, H-1), 6.61 (dd, J = 
2.7 and 8.3 Hz, 1H, H-2), 6.55 (d, J = 2.6 Hz, 1H, H-4), 5.94 (d, J = 9.0 Hz, 1H, NH), 5.00 (brs, 
1H, OH), 4.15 (q, J = 8.8 Hz, 1H, H-17), 2.80 (m, 2H), 2.30-2.19 (m, 3H), 1.88-1.83 (m, 3H), 
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1.56-1.23 (m, 7H), 0.79 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz)  166.1 (C(O)NH), 
153.5 (C-3), 138.1 (C-5), 136.9 (C-C(O)NH), 134.3 (CHAr), 132.4 (C-6), 130.0 (2 CHAr), 126.5 
(CHAr), 125.4 (CHAr), 122.7 (C), 115.3 (C-4), 112.7 (C-2), 59.5 (C-17), 51.6 (C-14), 43.8 (C-13), 
43.7 (CH), 38.9 (CH), 37.0 (CH2), 29.6 (CH2), 28.8 (CH2), 27.3 (CH2), 26.2 (CH2), 23.4 (CH2), 
12.3 (CH3, C-18); LRMS (ESI
+
) m/z (%) 454 (M+H, 100); HRMS (ESI
+
) calcd for C25H29NO2Br 
(M+H)
+
 454.1382; found 454.1370. 
HO
HN
CF3
O
3.62  
17-(3'-Trifluoromethyl)benzamido-estra-1,3,5(10)-trien-3-ol (3.62). To a stirred 
solution of 3.60 (120 mg, 0.27 mmol) in methanol (15 mL), was added a solution of K2CO3 (35 
mg, 0.25 mmol) in H2O (120 µL). The resultant solution was stirred for 3 h, then diluted with 
water, neutralized with dil. HCl, and extracted with chloroform. The extract was then washed 
with water, brine, dried with Na2SO4, and concentred. Purification was achieved using flash 
chromatography (ethyl acetate/hexane, 3:7) which provided 3.62 as a white solid (123 mg, 74%). 
Mp 135-136
o
C; 
1
H NMR (CDCl3, 300 MHz),  7.99 (s, 1H, ArH), 7.92 (d, J = 7.7 Hz, 1H, ArH), 
7.74 (d, J = 7.8 Hz, 1H, ArH), 7.56 (dd overlapping, J = 7.7 and 7.8 Hz, 1H, ArH), 7.12 (d, J = 
8.3 Hz, 1H, H-1), 6.61 (d, J = 8.3 Hz, 1H, H-2), 6.56 (brs, 1H, H-4), 6.01 (d, J = 8.7 Hz, 1H, 
NH), 5.07 (brs, 1H, OH), 4.19 (q, J = 9.0 Hz, 1H, H-17), 2.80 (m, 2H), 2.29-2.21 (m, 3H), 1.89-
1.85 (m, 3H), 1.58-1.39 (m, 7H), 0.81 (s, 3H, CH3, H-18); 
13
C NMR (CDCl3, 75 MHz)  166.1 
(C(O)NH), 153.3 (C-3), 138.1 (C-5), 135.7 (C-C(O)NH-), 132.4 (C-6), 131.0 (d, J = 32.5 Hz, C-
CF3), 130.0 (d, J = 1.3 Hz, CHAr), 129.2 (d, J = 2.4 Hz, CHAr), 127.9 (q, J = 3.7 Hz, CHAr), 126.5 
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(C-1), 123.8 (q, J = 3.8 Hz, CHAr), 123.7 (q, J = 271.0 Hz, C-CF3), 115.3 (C-4), 112.7 (C-2), 
59.5 (C-17), 51.6 (C-14), 43.8 (C-13), 43.7 (CH), 38.9 (CH), 37.0 (CH2), 29.6 (CH2), 28.8 
(CH2), 27.3 (CH2), 26.2 (CH2), 23.4 (CH2), 12.3 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz)  -
62.9; LRMS (ESI
+
) m/z (%) 444 (M+H, 100); HRMS (ESI
+
) calcd for C26H29F3NO2 (M+H)
+
 
444.2150; found 444.2135. 
3.5.3 Inhibition Studies  
3.5.3.1 General 
STS was purified as previously described in Chapter 2. All buffers and assay reagents 
were purchased form Sigma Aldrich (Milwaukee, WI, USA). All fluorescent measurements were 
carried out on a SpectraMax GeminiXS
®
 fluorimeter (Molecular Devices, Sunnyvale, CA, USA) 
at 24 
o
C in 96-well black microtiter plates from Corning (Corning, MA, USA). All 
determinations were carried out in quadruplicate. 
3.5.3.2 Determination of IC50s 
An inhibitor stock solution in DMSO/0.1 M Tris-HCl, pH 7.0 (1:1), 20 L weas added to 
the wells of a 96-well microtiter plate containing 140 µL of 0.1 M Tris, pH 7.0. After that, 20 µL 
of a 2.0 mM MUS stock solution in 0.1 M Tris–HCl, pH 7.0, was added. The assay was initiated 
by adding 20 µL STS (100 nM stock solution in 20 mM Tris–HCl, pH 7.4, 0.1% Triton X-100). 
The final concentration of inhibitor ranged from 5 nM to 5 µM. The final concentration of 4-
MUS was 200 µM. The reactions was followed were followed by detection of fluorescent 
product, 4-methylumbelliferone (excitation 360 nm, emission, 460 nm), over 10 min at 24
o
C. 
Each reaction was performed in quadruplicate. Additional controls were performed in an 
identical manner but did not contain STS. Eleven concentrations of inhibitor bracketing the IC50 
value were used for each compound. The initial rates of enzyme activity in relative fluorescence 
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units per second (RFU/s) were used to determine the IC50. The ratio of the initial rate in the 
presence of inhibitor (Vi) to that in the absence of inhibitor (Vo) was calculated and plotted as a 
semi-log curve in Grafit (Erithacus Software, Surrey, U.K.), from which the IC50 value was 
calculated based on the following equation: Vi = Vo/[1 + ([I]/IC50)S] + B, where: Vi is the initial 
rate of reaction at an inhibitor concentration of [I]; Vo is the velocity in the absence of inhibitor; 
B is background and s is the slope factor (see Appendix A for IC50 plots). 
3.5.3.3 Determination of Ki and αKi values for compound 3.28.  
20 L of a MUS stock solution in 0.1 M Tris-HCl of pH 7.0 was added to the wells of a 
96-well microtiter plate containing 140 L 0.1 M Tris-HCl buffer of the same pH such that the 
total volume was 160 µL. To the wells was added 20 µL of a stock solution of inhibitor in 50% 
DMSO, (for a control, 20 µL of 50% DMSO was added instead). The assay was initiated by the 
addition of 20 µL STS (100 nM stock solution in 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100). 
To detect non-enzymatic hydrolysis of the substrate 20 µL of 20 mM Tris-HCl, pH 7.4, 0.1% 
Triton X-100 was added instead. The final volume of the assay was 200 µL. The final 
concentration of buffer was 184 mM Tris-HCl, 0.01% Triton X-100, and 5% DMSO. The final 
enzyme concentration was 10 nM.  
For studies with compound 3.28 at pH 7.0, the final concentration of MUS was 83.3–500 
µM, the final concentration of inhibitor was 1-3 times IC50. The reactions were followed by 
detection of fluorescent product, 4-methylumbelliferone (excitation 360 nm, emission, 460 nm), 
over 10 min at 24
o
C. Each reaction was performed in quadruplicate. Additional controls were 
performed in an identical manner but did not contain STS. Initial rates (v) were determined by 
taking the slopes of plots of the change in relative fluorescence units with time. These data were 
plotted as Lineweaver–Burk graphs and Ki and Ki values were calculated from re-plots of the 
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slopes or intercepts of the Lineweaver–Burk graphs according to the equations for mixed and 
competitive inhibition (see Appendix A for re-plots of these data). 
3.5.4 Molecular Modeling (Docking) Experiments 
Docking experiments were performed using Discovery Studio Client v2.5.0.9164 (2005-
09), Accelrys Software Inc. running on a HP xw4600 workstation (Processor x86 family 6 model 
23 stepping 10 Genuine Intel 2999 ~ MHz). The coordinates for the X-ray crystal structure of 
human steroid sulfatase enzyme were obtained from RCSB Protein Data Bank (PDB file: 1P49). 
The ligand molecules were constructed using the Build Fragment tool and energy minimized for 
1000 iterations reaching a convergence of 0.01 kcal/mol Å. The steroid sulfatase enzyme was 
prepared for docking experiments first by deleting water molecules and then by using the prepare 
protein tool in Discovery studio. The formylglycine (FGly75), present in the catalytic site was 
modified to the gem-diol using the build fragment tools. Subsequently, the enzyme was energy 
minimized by steepest descent method for 10,000 steps reaching a convergence of 0.1 kcal/mol 
Å and further by conjugate gradient method for 10,000 steps reaching a convergence of 0.01 
kcal/mol Å. The binding site of the enzyme was defined by generating a 10 Å radius sphere, after 
selecting using the amino acid Thr99. The test compounds were docked in the active site of 
steroid sulfatase enzyme using the Libdock command under the receptor-ligand protocol in 
Discovery Studio using the CHARMM force field. The quality of ligand-enzyme complex 
obtained was evaluated using the Libdock scoring function (kcal/mol) and by considering 
various intermolecular polar and nonpolar interactions between the ligand and the enzyme. 
3.5.5 X-ray Crystallography of Compound 3.33. 
Crystal data: C25H28F3NO3S, MW = 479.54, Monoclinic; a = 9.611 (3) Å, b = 13.461 (4) 
Å, c = 17.786 (6) Å, β = 96.239 (18)o, V = 2287.5 (12) A3; space group P21, Z = 4, Dc = 1.392 g 
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cm
-3; μ (Mo Kα) = 0.19 mm-1, F(000) = 1008. Crystallographic measurements were made at 200 
K on a Bruker Kappa APEX II diffractometer in the range 3.0
o
 < θ < 26.0o.Data (6503 
reflections) were corrected for absorption using intensity measurements (SADABS). 
The structure was solved by direct methods and refined using the Flack parameter 
measurement.
175
 Tables of geometric data, indicating bond angels, are available in Appendix C 
(for X-ray crystal data). 
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Chapter 4 – Steroid Sulfatase Inhibitors: A-Ring Modification of 17-
arylsulfonamide E1 Derivatives. 
 
4.1. Introduction 
The Taylor Group has shown that the affinity of estrogens for STS can be increased by 
introducing certain groups at the 4-position of the A-ring.
63,73,74
  For example, E1 was found to 
be a reversible non-competitive inhibitor of STS with IC50 of 51 µM, however; introducing a 
small electron-withdrawing group or atom, such as a F, Br, CN, and NO2 group at the 4-position 
of the A-ring of E2 or E1 (compounds 4.1, Fig. 4.1), resulted in reversible inhibitors with IC50‘s  
in the 2-7 micromolar range.  The 4-nitroE1 derivative proved to be the most potent of this series 
with an IC50 of 2.4 µM.
74
 The reason for this increase in potency is not known though studies 
showed that it was not due to the decrease in pKa of the 3-OH group (there was no correlation 
between the pKa of the steroid and IC50). 
X
HO
R
           4.1
R = F, Br, CN, NO2
X = CHOH (), C=O
HO
O
CHO
4-FE1
HO
OH
CHO
1.71
 
Fig. 4.1.  Structures of compounds 4.1, 4-FE1 and 1.71. 
Additionally, as mentioned before in Chapter 1 (see section 1.4.1.3), the Taylor group 
reported that 4-formyl estrone (4-FE1) acts as an almost irreversible inhibitor of STS, with a KI 
of 1.5 µM.
73 
 This finding prompted Taylor group to examine 4-formyl-17α-benzyl E2, 
compound 1.71 (see section 1.4.1.3), as an STS inhibitor.  This compound turned out to be a 
potent concentration and time-dependent STS inhibitor with a KI of 85 nM and a kinact of 0.021 
min
-1
 (kinact/KI of 2.3 × 10
5
 M
-1
 min
-1
).
74
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4.2. Objectives 
In Chapter 3 we developed some highly potent inhibitors of STS (of type 3.2, Fig. 3.1) 
with one of these inhibitors, compound 3.49 (Fig. 4.2), exhibiting an IC50 as low as 9 nM.  Based 
upon our previous results on the inhibition of STS with 4-substituted estrogens mentioned in 
section 4.1 we reasoned that the potency of compounds of type 3.2 could be further increased by 
introducing a small group or atom, such as NO2, F, Br, or CHO, at C-4.  The objective of the 
work described in this chapter is to synthesize such compounds and determine if this 
modification does indeed increase the potency of the parent molecules.  
HN
HO
S
O
O
3.49
HN
HO
S R
O
O
3.2, R = aryl  
Fig. 4.2.  General structure of 17-arylsulfonamide E1 derivatives 3.2 and the structure of 
compound 3.49. 
 
4.3. Results and Discussion 
4.3.1 Studies with 4-fluoro-17-E2 (compound 4.2) 
Previous to our work on compounds of type 4.1, Yong Liu, a former graduate student in 
the Taylor group and Prof. Scott D. Taylor had prepared 4-fluoro-17-benzylE2 (4.2, Fig. 4.3).74 
The purpose of making this compound was to determine if the introduction of a fluorine at the 4-
position of compound 1.50 would enhance its potency as an STS inhibitor.  We (Y. Mostafa) 
found that its IC50 was 40 nM, which is approximately six-fold lower than that of its parent 
compound 1.18a.
74
  Moreover, compound 4.2 exhibited mixed-type inhibition (Fig. 4.4) with Ki 
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of 40 nM and an Ki of 90 nM, which was the same inhibition mode shown by both E1 and its 
parent compound 1.50.  So the introduction of the fluorine atom at the 4-position improved the 
potency of its non-fluorinated derivative without affecting its mode of inhibition.
74
  These results 
provided further impetus to pursue compounds of type 4.1.  
 
HO
F
OH
                    4.2
noncompetitive STS inhibitor
Ki = 40 nM, Ki = 90 nM
HO
OH
                     1.50
noncompetitive STS inhibitor
Ki = 230 nM, Ki = 420 nM  
Fig. 4.3.  STS inhibitors 1.50 and 4.2.
74
   
 
Fig. 4.4.  Lineweaver-Burk plot of compound 4.2 ( 0 nM  10 nM  20 nM 40 nM ) [See 
Appendix B for the re-plot of this data that was used to determine both Ki and αKi].
74   
 
 
4.3.2. 2- and 4-Nitro-17-arylsulfonamide E1 derivatives as STS inhibitors. 
These studies were initiated by preparing the sulfonamide derivatives bearing a NO2 
group at 2- and/or 4-position.  Upon examining the literature about different methods for 
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nitration of the A-ring of estrogens we concluded that direct nitration of arylsulfonamides of type 
3.2 would not be a suitable approach to these compounds since nitration will most likely occur 
not only occur at 2- and/or 4-position but also occur on the aromatic ring of the arylsulfonamide 
moiety. So we decided to prepare 2- and 4-nitroE1 first and then convert these into the desired 
sulfonamides. 
Nitration of the A-ring of estrogens always results in the formation of a mixture of the 2- 
and 4-NO2 isomers and the 2,4-dinitro compound with the major product being the 2-NO2 isomer 
for steric reasons.
176-179
  The yields of the individual isomers are usually quite low especially for 
the 4-isomer.  One of these reports described the synthesis of 4-NO2E1 (4.3) and 2-NO2E1 (4.4) 
in low yields (isolated) but in almost equimolar amounts using HNO3/NaNO2/glacial AcOH 
(Scheme 4.1).
176
 Although the amount of NaNO2 was unspecified, we attempted this reaction 
using a cat. amount of NaNO2.  We obtained a 1:1 mixture of 4.3 and 4.4 plus other side 
products.  Several attempts to separate and purify the 2- and 4-isomers by flash or gravity 
column chromatography were unsuccessful.  However, recrystallization from hot glacial acetic 
acid gave pure 4.3 in a 12% yield as yellow crystals. 
 
HO
O
R2
R1
HO
O
glacial AcOH, 90 oC, then
HNO3/NaNO2/H2O, 50
oC
then ON
 4.3; R1 = H, R2 = NO2 (28%)
 4.4; R1 = NO2, R2 = H (29%)
E1
 
Scheme 4.1.  Nitration of E1 using a HNO3/NaNO2/glacial AcOH mixture.
176
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Due to the low yields of the above procedure we decided to try another older procedure 
which uses conc. HNO3 alone without use of NaNO2 again in glacial AcOH but at 70-75 
o
C 
(Scheme 4.2).
179
 During the reaction we noticed the formation of a yellow precipitate.   After 
stirring overnight (O/N) the mixture was filtered (while still hot) and the precipitate was washed 
with hot glacial AcOH.  The precipitate turned out to be pure 4-NO2E1, 4.3 (20% yield).  The 
filtrate, after work-up, afforded the 2-NO2 isomer, 4.4, in a 23% yield.   This was easily 
performed on a multigram scale.  This represents a significant improvement in the synthesis and 
isolation of these compounds.   
O
R1
HO
R2
HO
O
glacial  AcOH,
conc. HNO3 ,
70-75oC, O/N
4.3; R1= H, R2= NO2 (20%)
4.4; R1= NO2, R2= H (23%)
 
Scheme 4.2.  Nitration of E1 using conc. HNO3 in glacial AcOH at 70-75
o
C.
179
 
 
With the nitrated E1 isomers in hand, we then subjected these to the same reductive 
amination procedure that we used for the preparation of 17β-aminoE1 (compound 3.11, see 
chapter 3, section 3.3.1) except that instead of doing the reductive amination with benzyl amine 
we used allylamine since the nitro groups would not survive the removal of the benzyl group by 
hydrogenolysis (Scheme 4.3).  The reductive amination proceeded well with compounds 4.5 and 
4.6 being obtained in good yields.  Pd-catalyzed removal of the allyl group was achieved in 
reasonable to good yields using N,N'-dimethylbarbituric acid (NDMBA) as a carbon nucleophile 
scavenger for the allyl group.  The resulting 2- or 4-NO2-17β-amine derivatives of E1, 
compounds 4.7 and 4.8, were reacted with sulfonyl chlorides using the same general method we 
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reported in section 3.3.1 to give the desired nitrate sulfonamides 4.9-4.16.  The yields for the 
final step (not optimized) are shown in Table 4.1.  
 
HO
HN
R2
R1
HO
NH2
R2
R1
HO
HN
R2
R1
S
OO
R3
HO
O
R2
R1 3.9 eq. AllylNH2,
THF, 2.5 eq.STABH,
rt, 2 d
0.02 eq. Pd(PPh3)4, 
3.0 eq. NDMBA,
DCM, 35
o
C, 1 h
4.5; R1= H, R2= NO2 (63%)
4.6; R1= NO2, R2= H (73%)
4.7; R1= H, R2= NO2 (47%)
4.8; R1= NO2, R2= H (71%)
1.1 eq. ArSO2Cl, Pyridine,
DCM, 0
o
C, then rt ON
4.3; R1= H, R2= NO2 
4.4; R1= NO2, R2= H
Compounds 4.9-4.16
 
Scheme 4.3.  Synthesis of nitro sulfonamides 4.9-4.16. 
 
Table 4.1.  Yields of nitrated sulfonamides 4.9-
4.16. 
HO
HN
R2
R1
S
OO
R3
 
Compound R1 R2 R3 Yield (%) 
4.9 H NO2 3'-Br 48 
4.10 H NO2 3'-CF3 53 
4.11 H NO2 4'-t-Bu 40 
4.12 H NO2 4'-Phenyl 27 
4.13 NO2 H 3'-Br 66 
4.14 NO2 H 3'-CF3 67 
4.15 NO2 H 4'-t-Bu 26 
4.16 NO2 H 4'-Phenyl 43 
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Table4.2.  IC50‘s of nitrated sulfonamides 4.9-
4.16 and their non-nitrated analogs (3.27, 3.28, 
3.33, and 3.49) 
HO
HN
R2
R1
S
OO
R3
 
Compound R1 R2 R3 IC50 (nM)
a
 
3.28 H H 3'-Br 25 
3.33 H H 3'-CF3 23 
3.27 H H 4'-t-Bu 18 
3.49 H H 4'-Phenyl 9 
4.9 H NO2 3'-Br 12 
4.10 H NO2 3'-CF3 11 
4.11 H NO2 4'-t-Bu 8
b
 
4.12 H NO2 4'-Phenyl 1
b
 
4.13 NO2 H 3'-Br 50 
4.14 NO2 H 3'-CF3 67 
4.15 NO2 H 4'-t-Bu 81 
4.16 NO2 H 4'-Phenyl 33 
 a Errors are within ±5%; 
b 
Apparent Ki 
The IC50‘s or apparent Ki‘s (Ki
app
) for compounds 4.9-4.16 and their A-ring unsubstituted 
analogs (3.27, 3.28, 3.33, and 3.49) are shown in Table 4.2.  Introduction of a nitro group at the 
2-position resulted in a marked decrease in potency while substitution of a nitro group at the 4-
position resulted in an increase in potency.  To the best of our knowledge, these 4-substituted 
derivatives are the most potent reversible inhibitors ever reported for STS. 
Some of the inhibition data presented in Table 4.2 are given as IC50‘s while some are 
given as apparent Ki‘s (Ki
app
). The reason for this has to do with the potency of some of the 
inhibitors.  When one determines the IC50 of an inhibitor the concentration of the inhibitor ([I]) 
required to achieve 50% inhibition (IC50) is usually far in excess of the enzyme concentration 
since most inhibitors do not exhibit IC50‘s that are below the concentration of enzyme used in the 
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assay.  So the amount of inhibitor sequestered in formation of the enzyme-inhibitor complex is a 
small fraction of the total concentration of inhibitor.  Therefore, the amount of free inhibitor 
([I]F) is approximately the same as the total concentration of inhibitor ([I]T).  However, with a 
tight binding inhibitor (TBI), which is an inhibitor with a Ki is in the low nM region or lower 
which is usually less than the total concentration of enzyme ([E]T), then [I]F ≠ [I]T and the 
equilibrium assumptions used to derive the classic equations used for calculating Ki no longer 
hold.
180
   
The relationship between IC50 and the apparent Ki (for a competitive inhibitor Ki
app
 = 
Ki(1  + [S]/Km) while for a non-competitive inhibitor Ki
app
 = Ki(Km  + [S])/Km/KiE  + [S]/KiES) is 
shown in Eqn. 4.1.   
IC50 = Ki
app
  +  ½[E]T  (Eqn. 4.1) 
From this eqn. we can see that: 
(1)  When Ki
app
 >> [E]T then IC50 is approximately equal to Ki
app
 
(2)  When Ki
app
 = [E]T then IC50 is approximately equal to Ki
app
  +  ½[E]T 
(3) When Ki
app
 << [E]T then IC50 = ½[E]T   
Eqn. 4.1 shows that if one determines the IC50‘s of a series TBIs (when Ki
app
 << [E]T) 
then the results can be misleading as the IC50‘s for all of the TBI‘s will be the same (equal to half 
the concentration of the enzyme used in the assay).   Whether or not a compound is a TBI can be 
ascertained by the dependence of its IC50 on enzyme concentration.  If the inhibitor is not tight 
binding then there is no dependence of IC50 on [E]T.  If the inhibitor is a TBI then IC50 depends 
upon [E]T and a plot of IC50 vs. [E]T should be a straight line with the Y-intercept equal to 
Ki
app
.
180
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In our standard STS assay the concentration of STS was 10 nM and so we suspected that 
some of the compounds we examined in Table 4.2 might be TBIs and, therefore, their IC50‘s 
should depend on [E]T.  We examined the effect of enzyme concentration on the IC50‘s for two 
of the best inhibitors in Table 4.2, the 4'-t-butyl compound 4.11, and 4'-biphenyl compound 4.12.  
The IC50‘s of both of these inhibitors showed a dependence on enzyme concentration (see Figs 
4.5 and 4.6).  Their Ki
app‘s were obtained from the Y-intercept of these plots.  
 
 
Fig. 4.5.  A plot of IC50‘s for compound 4.11 as a function of [E]T. 
 
Figure 4.6.  A plot of IC50‘s for compound 4.12 as a function of [E]T.   
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It is interesting that we noticed that in the 
1
H-NMR of all 2-nitro arylsulfonamide 
derivatives, compounds 4.13-4.16; their phenolic 3-OH proton was strongly downfield shifted (δ 
= 10.4 ppm), while the one for 4-nitro arylsulfonamides, compounds 4.9-4.12, was less 
downfield shifted (δ = 9.4 ppm), suggesting the presence of a stronger interaction between the 2-
NO2 group and 3-OH in all the 2-nitro arylsulfonamides, than for 4-nitro derivatives.   How the 
nitro group interacts with the 3-OH may somehow affect the potency of these compounds.  
4.3.3 2- and 4-Bromo-17-arylsulfonamide E1 derivatives as STS inhibitors. 
For the 2- and 4-bromo series we focussed our efforts on just the 2- and 4-bromo 3‘-
trifluoromethylbenzensulfonamide derivatives.  We first prepared 2- and 4-bromoestrone first 
rather than trying to brominate our sulfonamide inhibitors to avoid brominating the aromatic ring 
of the arylsulfonamide group.  Bromination of the A-ring of an estrogen using common 
electrophilic brominating agents such as Br2/FeBr3 or NBS always results in the formation of a 
mixture of 2- and 4- bromoestrogen, with the 2-isomer as the major product, and are very 
challenging to separate.
181,182
  However, in 1968 Utne et al reported that if N-bromoacetamide 
(NBA) is used as the brominating agent with EtOH as solvent then 4-bromoestradiol (4-BrE2) 
could be obtained in reasonable yield (25-40%).
183
  This unusual selectivity for the 4-position for 
an electrophilic aromatic substitution (SEAr) is unprecedented for any other SEAr reaction on an 
estrogen and no explanation for this has been presented.  We decided to attempt the synthesis of 
4-BrE1 using this procedure. The brominating agent, NBA, was prepared according to a 
literature procedure from acetamide and bromine in the presence of KOH.  This afforded NBA in 
a 39% yield after recrystallization from hexane (Scheme 4.4).
184
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H2N CH3
O
N
H
CH3
O
BrBr2, KOH, 0 to 5
o
C, 
2-3h, recyst. Hexane
NBA (39%)  
Scheme 4.4.  Preparation of NBA from acetamide and bromine.
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The bromination of E1was achieved using equivalent amounts of E1 and NBA in ethanol 
with stirring at rt for 24 h (Scheme 4.5).
183
  The crude product was recrystallized from ethanol to 
afford 4-BrE1 (4.17) in an 89% yield as white crystalline plates.  
O
HO
NBA, EtOH
stirring, rt, 24 h
HO
O
Br
4.17 (4-Br E1, 89%)
E1
 
Scheme 4.5.  Bromination of E1 using NBA to give 4-BrE1 (4.17) in high yield. 
Selective bromination at the 2-position was not as easy as bromination at the 4-position. 
We tried two different methods; the first one involved the use of Br2 in presence of a catalytic 
amount of powdered Fe
o
 and glacial AcOH as a solvent, but we obtained a mixture of 2-, 4-, and 
2,4-diBrE1.
182
  We tried to purify the two isomers by chromatography but we failed because they 
had very similar Rf‘s. The other method was a 3-step reaction scheme, but was reported to 
exhibit high selectivity and produce the 2-Br derivative in high yield (Scheme 4.6).
185
  This 
method involved regioselective thallation of the A-ring of acetylated E1 (4.18) with thallic 
trifluoroacetate, Tl(OCOCF3)3, in trifluoroacetic acid  (TFA), and subsequent displacement of 
the thallium moiety with bromide anion to afford the 3-acetyl-2-bromo derivative, 4.19.  
Deprotection of the 3-OH gave 2-BrE1 (4.20) in good yield. 
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AcO
O
AcO
O
Br
HO
O
Br
O
HO
1- Tl(CF3OCO)3, TFA, (0-5
oC), 24 h
2- Dioxane, CuBr2, reflux 3 h
MeOH, K2CO3
reflux 3 h
4.18 (89 %)
4.19 (73%) 4.20 (91%)
E1
Ac2O, Pyridine 
Reflux, 2 hr
 
 
Scheme 4.6.  Synthesis of 2-BrE1 (4.20). 
 
2- and 4-BrE1 were subjected to our usual reductive amination conditions using 
benzylamine and STAB-H to give compounds 4.21 and 4.22 in good yield (Scheme 4.7).  
However, during the subsequent hydrogenolysis step the debrominated amine, compound 3.11, 
rather than the brominated ones, compounds 4.25, and 4.26, was formed (Scheme 4.7).  
Numazawa et al., reported that hydrodebromination of 2-, 4-mono- and/or 2,4-di-bromo 
estrogens is possible during catalytic hydrogenation using Pd over charcoal if there is acidic 
impurities in the reaction media.
186
 So we decided to use allylamine instead of benzylamine in 
the reductive amination.  The corresponding allyl-protected amines (4.23 and 4.24) were 
obtained in better than a 70% yield for each compound.  Deprotection of the amine using the Pd-
catalyzed deallylation method gave the desired amines, (4.25 and 4.26) in low to reasonable 
yields.   
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HO
O
R1
R2
BnNH2, AcOH
HO
NHBn
R1
R2
HO
NHAllyl
R1
R2
HO
NH2
HO
HN
R2
S
O
O
CF3
R1
HO
NH2
R1
R2
X
STABH, O/N
H2, Pd/C (10%)
MeOH, O/N
4.17; R1 = H, R2 = Br
4.20; R1 = Br, R2 = H
4.21; R1 = H, R2 = Br (81%)
4.22; R1 = Br, R2 = H (88%)
AcOH, STABH,
rt, O/N
4.23; R1 = H, R2 = Br (78%)
4.24; R1 = Br, R2 = H (71%)
4.25; R1 = H, R2 = Br (63%)
4.26; R1 = Br, R2 = H (21%)
AllylNH2,
DCE/THF,
ArSO2Cl, Pyrdine
0 oC, then rt, O/N
4.27; R1 = H, R2 = Br (48%)
4.28; R1 = Br, R2 = H (33%)
H2, Pd/C (10%)
MeOH, O/N
3.11
Pd(Ph3P)4 , NDMBA, 
DCM/THF, 35 oC
 
Scheme 4.7.  Synthesis of bromosulfonamides, 4.27 and 4.28. 
Compounds 4.27 and 4.28 were less potent than their non-brominated parent 
sulfonamide, compound 3.33 with their IC50‘s equal to 95 nM and 49 nM respectively (c.f. 23 
nM for compound 3.33).  This was somewhat unexpected, especially with the 4-bromo 
derivative, 4.28, because the Taylor group had previously demonstrated that placing a Br at the 
4-position of E1 enhanced its inhibitor potency of STS.
74
  It appears that 4.27 and 4.28 interact 
with STS in a different manner from 2- or 4-BrE1.   The 4-NO2 derivative, 4.10, is 4-fold more 
potent than the 4-Br derivative 4.28.  It is unlikely this difference is due to sterics as the Br atom 
is smaller than a NO2 group (smaller A value).  The greater electron withdrawing ability of the 
nitro group may be important here and also the nitro group can act as an H-bond acceptor while 
the Br atom cannot and this might be important for binding. 
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4.3.4 A 4-fluoro-17-arylsulfonamide E1 derivative as an STS inhibitor. 
Our approach to the synthesis of compounds of type 4.1 with a fluorine at the 4-position 
was to prepare 4-fluoroestrone (4-FlE1, 4.30) and then proceed with the introduction of the 
sulfonamide group in the usual manner.  Yong Liu in the Taylor group prepared 4-FlE1 by 
electrophilic fluorination of the tert-butyl derivative 4.29 with N-fluoropyridinium triflate 
(NFPT)
187
 followed by removal of the tert-butyl protecting group (Scheme 4.8).  Although this 
gave the desired compound the yield was very low, the purification was very challenging and 
NFPT is very expensive.  So we decided to look into alternative approaches to 4-FlE1.   
O
HO
O
F
HO
4.29
1.  NFPT, TCE
     135 
o
C, 14h
     glass bomb
4.30 (27%)
2.  MeNO2, AlCl3, 
    DCM reflux 24h
 
Scheme 4.8.  Liu‘s synthesis of 4-FlE1. 
4-FlE1 and similar compounds have been prepared in a variety of ways.  The 3-O-methyl 
ether of 4-FlE1 has been prepared in low yield by thermal decomposition of estrone 3-O-methyl 
ether 4-diazonium fluoroborate.
188
 4FlE1 has been prepared via oxidation of 4-F-19-
nortesterone,
189 
this is a multi-step procedure requiring expensive starting materials. (4)  
Electrophilic fluorination of E1 or E2 using Selectfluor
TM
 in ionic liquids like 1-butyl-3-
methylimidazolium tetrafluoroborate (bmim-BF4),
190
 or using N-fluoropyridinium triflate 
(NFPT) in chlorinated solvents like trichloroethane (TCE) has been used to prepare 4-FlE1 or 4-
FlE2 albeit in low yields..  These procedures gave mixtures of the 2- and 4-isomers with the 2-
isomer as the major product by far and the isomers were very challenging to separate.   
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Our first approach is shown in Scheme 4.9. The idea was to introduce the fluorine 
regioselectively by metal halogen exchange as this has been used previously to prepare aryl 
fluorides.
191
 Compound 4.29 was prepared in 93 % yield using t-BuOH and boron trifluoride 
diethyl etherate (BF3.OEt2).
192,193
  Bromination at the 4-position with NBA in EtOH gave 
compound 4.31 in good yield.  The ketone in 4.31 was protected as a ketal using ethylene glycol 
and p-toluene sulfonic acid (PTSA) and a Dean-Stark trap to give 4.32 in a moderate yield.  The 
point from this last protection step was to avoid fluorination at the 16-position. However, 
attempts to protect the 3-OH group with a benzyl group turned out to be challenging.  We were 
only able to obtain very small amounts of the desired compound 4.33 using XS BnBr in the 
presence of a base such as K2CO3 or NaH.  Attempts to introduce the benzyl group into 4.29 
were also unsuccessful.  We think that this is due to steric hindrance by the bulky t-butyl group 
at the 2-position. 
O
HO
O
HO
O
HO
Br
O
HO
Br
O
O
BnO
Br
O
O
BnO
F
O
O
HO
F
BF3(OEt)2, t-BuOH
DCM, stirring 2 h
NBA, EtOH
stirring 24 h
HOC2H4OH, C6H5CH3, 
PTSA
Dean-Stark, reflux 6 h
BnBr, K2CO3, Acetone
stirring 24, then reflux 6 hr
4.33 (5%)
4.29 (93%) 4.31 (81%)
4.32 (51%)
n-BuLi, NFSI Deprotection
E1
4.30  
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Scheme 4.9.  First attempted route to 4.30.  
We also attempted to introduce the 2-methoxyethoxymethyl (MEM) protecting group 
into compound 4.32, but unfortunately, this also did not work (Scheme 4.10).  
O
HO
Br
O
O
MEMO
Br
O
XMEMCl, NaH, DMFstirring 48 hr
4.32  
Scheme 4.10.  Attempted MEM-protection of compound 4.32. 
Since the introduction of the t-butyl group first into E1 prevented subsequent protection 
of the 3-OH we changed the order of protection (Scheme 4.11).  The 3-OH was protected with 
the MOM group (methoxymethyl) using MOMCl in presence of N,N-diisopropyl ethylamine 
(DIPEA, Hunig‘s base) to afford compound 4.34 in a 67% yield.  However, reaction of 4.34 with 
NBA in EtOH resulted in complete loss of the MOM group.  So instead we reacted 4-BrE1 
(4.17) with MOMCl in presence of either Hunig‘s base or t-BuOK base to give the desired 
compound 4.35 in reasonable yield with t-BuOK.  The 17-keto group was then reduced and then 
methylated to give compound 4.37.  We reasoned that it should be possible to introduce the 
fluorine into the 4-position without protection of the 3-position.  However, attempts to introduce 
the fluorine via metal halogen exchange followed by reaction with N-fluorobenzenesulfonimide 
were unsuccessful.  
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O
HO
O
HO
Br
O
MOMO
O
HO
O
MOMO
Br
OMe
MOMO
Br
OMe
MOMO
F
OH
MOMO
Br
X
X
MOMCl, Hunig's base, 
THF, stirrring at 0
o
C, 
then rt, then 
reflux 24 h
NBA, EtOH
stirring 24 h
4.34 (67%)
NaBH4, MeOH,
stirring at 0
o
C, 1 h
MeI, t-BuOK, DMF, 
stirring 0
o
C, then
rt for 24 h (46%)
MeI, NaH, THF, 
stirring 0
o
C, then
rt for 24 h (8%)
MOMCl, t-BuOK, DMF 
stirrring at 0
o
C, then 1h rt 
(65%)
4.36 (99%)
NFSI, THF, 
n-BuLi, -78
o
C
MOMCl, Hunig's base, THF, 
stirrring at 0
o
C, then rt, then 
reflux 24 h (48%)
NBA, EtOH
stirring 24 h
E1
4.17 (78%) 4.35
E1
4.37  4.38  
Scheme 4.11.  Attempted synthesis of 4.38. 
Our alternative strategy was to try fluorinating the 4-position of protected E1 using F-
TEDA-BF4 (Selectfluor
TM
) as a fluorinating agent in 1-butyl-3-methylimidazolium 
tetrafluoroborate (bmim-BF4), an ionic liquid (Scheme 4.12) since it has been reported that 
phenols undergo aromatic electrophilic fluorination very readily in this ionic liquid using 
Selectfluor.
190
 First we protected the ketone at the 17-position of 4.29 as a ketal to give 4.39 then 
subjected 4.39 to Selectfluor
TM
 in bmim BF4.  After 1 hour a major spot on the TLC was evident 
running slower than the starting material spot, and this increased in intensity over 24 h.  Upon 
workup we found that the fluorination did not happen but loss of the ketal occurred.  So, we 
reduced the ketone group of compound 4.29 using NaBH4, and subjecting the resulting alcohol 
4.41 to Selectfluor
TM
 in bmim BF4 but no reaction occurred.   
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O
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HO
OH
HO
F
O
HO
O
X
O
HO
X
HOC2H4OH, 
C6H5CH3, 
PTSA
Dean-Stark, 
reflux 6 h
stirring at 
0oC, 2 h
Selectflur, 
Ionic Liquid, 
MeOH, 
Stirring to 24 h
Selectfluor, 
Ionic Liquid, 
MeOH, 
Stirring to 24 h
 4.29 4.39 (47%)
NaBH4, 
EtOH/THF
 4.41(97%)
4.40 (%)
4.42  
Scheme 4.12.  Attempted synthesis of compounds 4.40 and 4.42. 
The approach used by Liu to prepare 4.30 (Scheme 4.7) was based upon a journal article 
published in 1990 which used NFPT to prepare 2- and 4-fluoroestrone (Scheme 4.13).
185
  The 
procedure involves refluxing E1 and NFPT in 1,1,2-trichloroethane (TCE) for 24 h.  This gives a 
mixture of the 2- and 4-fluoro products which were not separated until after acylation by flash 
chromatography followed by fractional recrystallization of the co-eluted isomers.  The yield was 
53% for 2-F-E1 acetate and 20% for 4-F-E1 acetate.  We followed their approach exactly but 
were unable to separate the two isomers.   
O
HO
O
HO
F
O
AcO
F
NFPT, TCE
reflux 24 h
Ac2O, Pyridine
reflux 2 h
E1  
Scheme 4.13.  Attempted synthesis of synthesis of 2- and 4-fluoroestrone using NFPT. 
Finally, we resorted back to the procedure developed by Liu.  The fluorination of 4.29 
followed by removal of the t-butyl group gave 4.30 in a 6 % yield for the two steps (Scheme 
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4.14).  We thought that perhaps the fluorination reaction might proceed better on 2-t-butylE2 
(4.41) than on 2-t-butylE1 (4.29) since a possible side reaction was fluorination  to the carbonyl 
at C-16 of 4.29 but this yield was equally poor with 4.41 (Scheme 4.14).  Reductive amination of 
4.30 with BnNH2 and STABH gave benzyl protected 17β-amine derivative, compound 4.46 in 
61% yield.  Hydrogenolysis of 4.46 gave the desired 17β-amino derivative, 4.47 together with 
another unknown compound which we could not remove.  Reacting impure 4.47 with excess of 
3'-CF3-benzenesulfonyl chloride gave pure 4.48 (7% yield over 2 steps).  Methanolysis of the 
sulfonate ester moiety in 4.48 with methanolic K2CO3 afforded our desired final 4-
fluorosulfonamide derivative, compound 4.59, in a 62% yield.   
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F3C
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HO
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4.29
NaBH4, EtOH,
stirring at 0oC
NFPT, TCE,
reflux 24 h
4.44 (14%)4.43 (98%)
K2CO3, MeOH,
60oC, 2 hr
H2, 13 wt%Pd/C (10%), 
MeOH/EtOH (1:1), 12 h
NFPT, TCE
BnNH2, AcOH, DCE/
THF, STABH, rt 2 d
3'-CF3C6H4SO2Cl,
pyridine/DCM, 0oC to 
rt, ON
Glass bomb, 
130oC, 15h
4.45 (16%)
MeNO2, AlCl3, 
DCM reflux 24h
4.30 (40%)
4.46 (61%) 4.47 (impure)
4.48 (31mg) 4.49 (62%)
 
Scheme 4.14.  Synthesis of 4.49. 
The IC50 of 4.49 was found to be dependent upon the concentration of enzyme indicating 
that this compound was a TBI (Fig. 4.7).  From this data an apparent Ki of 2.5 nM was obtained.  
So introduction of a fluorine at the 4 position of inhibitor 3.33 resulted in an increase in potency 
by almost 10-fold.  The F atom has a m value similar to that of Br (0.34 and 0.39 respectively) 
and a p value that is less than Br (0.06 vs. 0.23).  So it looks like electron-withdrawing ability is 
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not important here.  The ability of the F atom to act as an H-bond acceptor may be important for 
binding. 
 
Figure 4.7.  A plot of the IC50‘s for compound 4.49 as a function of [E]T. 
4.3.5 Inhibition studies with a 4-formyl 17-arylsulfonamide derivative of E1 
As we mentioned in § 1.4.1.3 and § 4.1, 4-formyl estrone (4-FE1) and the 4-formyl-17α-
benzyl E2, compound 1.71, were concentration and time-dependent inhibitors of STS.
73,74
   The 
mechanism by which these compounds inhibit STS is still unknown.  It is known that most 
aldehyde-based enzyme inhibitors function by forming Schiff bases (imine-formation) with 
residues such as lysine and arginine.
194
  This has been demonstrated by reducing the imine 
adducts to stable amines with borohydride followed by proteolytic digest of the inactivated 
enzyme and then sequencing of the modified peptides.  It is very possible that 4-FE1 and 1.71 
inhibit STS by forming relatively stable Schiff bases with active site residues such as Lys134, 
Lys368 and Arg79. 
If the 17-arylsulfonamide inhibitors reported here bind in manner similar to the 17α-
benzylE2 inhibitors (of type 1.49) reported by Poirier then one would expect that introducing a 
formyl group to the 4-position of the 17-arylsulfonamide inhibitors would yield time- and 
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concentration-dependent STS inhibitors. To determine if this is indeed the case compound 4.50 
(Fig. 4.8) was prepared (by Prof. Scott D. Taylor) and then examined as an STS inhibitor (by Y. 
Mostafa). Compound 4.50 is derived from one of our most potent inhibitors (compound 3.33, 
IC50 = 23 nM) and so we anticipate that if 4.50 is capable of forming a covalent adduct with STS 
then it should prove to be a very potent time- and concentration-dependent inhibitor of STS.   
HN S
HO
O
O
CHO
F3C
4.50
 
Fig. 4.8.  Proposed inhibitors 4.50. 
We examined 4.50 for time- and concentration-dependent inhibition of STS by 
incubating it with STS at pH 7.0 in 100 mM tris buffer containing 0.01% Triton X-100, and 
aliquots were withdrawn at various time intervals and diluted 50-fold into a solution of a high 
concentration (4 M, 20  Km) of 4-MUS in the same buffer and STS activity was determined by 
following the production of 4-MU by fluorometry.  The results were somewhat puzzling (Fig. 
4.9).  There was no inhibition up to 200 nM inhibitor.  At 250 nM inhibitor we see 55% loss of 
activity after 10 minutes and as the concentration of inhibitor increased greater loss of activity 
after 10 minutes was observed but no real further loss of activity occurred after 10 minutes.  It is 
possible that 4.50 is a very potent reversible inhibitor and MUS is able to compete for active site 
binding as the concentration of inhibitor decreases (i.e. 4 M MUS is able to completely displace 
the inhibitor when its concentration is 200 nM or less but not when the concentration of inhibitor 
is greater than 200 nM.   In any case, the kinetics of inhibition seen with 4.50 are very different 
from those seen with 1.71 where loss of activity was linear over the entire time course of the 
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experiment which suggests that the formyl groups in compound 1.71 and compound 4.50 interact 
with the enzyme differently.   
We also examined whether STS activity could be restored by dialysis after it had been 
incubated with 1 M 4.50 for 1 h.  After extensive dialysis (1012-fold dilution over a 24-hour 
period) we were able to restore 70% of STS activity.  This is in contrast to 1.71 where only 14% 
of the activity could be restored.  Nevertheless, if 4.50 was a reversible inhibitor like its non-
formylated analog 3.33, then all activity should have been restored and so it appears that 4.50 
may indeed be capable of forming some kind of covalent (though reversible) adduct with STS.  
More detailed studies will have to be performed to ascertain this such as looking at the time-
dependence of inhibition over the first 10 minutes of the reaction. 
 
Fig. 4.9.  Concentration-dependent inhibition of STS by compound 4.50.  
 
4.3.6 Inhibition studies with 3-O sulfated 17-arylsulfonamide derivative of E1 
Although P values have not been determined for the 17-benzylE2 inhibitors developed 
by Poirier or for the inhibitors described here, it is likely that our sulfonamide-based inhibitors 
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are more hydrophilic than their 17-benzylE2 counterparts.  Nevertheless, our sulfonamide 
inhibitors are still quite hydrophobic.  We reasoned that introduction of a polar group at the 3-
OH would increase the hydrophilicity of these compounds.  This could readily be accomplished 
by sulfation of the 3-OH.  Such compounds could turn out to be inhibitors of STS or they could 
be substrates for STS and so act as prodrugs (in this case they would be acting as reversible 
suicide inhibitors).  Although the cell permeability of our inhibitors may be compromised by 
sulfation, there is evidence that E1S is transported into cells and such transporters might be 
capable of transporting other sulfated steroids or steroid derivatives into cells.
31
 
To determine if 3-OH sulfation affects the potency of our sulfonamide inhibitors, Jason 
Tao (a former undergraduate student in the Taylor group) prepared four sulfated sulfonamides 
(compounds 4.51-4.54, Table 4.3) which were examined as STS inhibitors (by Y. Mostafa).  
Surprisingly, the introduction of the sulfate group did not significantly affect the potency of these 
compounds in that three of these sulfated derivatives exhibited potencies comparable to their 
non-sulfated counterparts.  The exception was the biphenyl derivative, compound 4.54, which 
was more potent than its parent compound.  This was not due to an increase in solubility: all of 
the inhibitors described in this thesis were soluble under our assay conditions. The IC50 of 4.54 
was dependent upon enzyme concentration and a Ki
app
 was obtained from a plot of IC50 vs. 
enzyme concentration (Fig. 4.10). 
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Table 4.3.  Inhibition studies with 
sulfated sulfonamides 4.51-4.54 
HN S
OO
O
R
S
O
O
O  
Compound R IC50 (nM)
a
 
4.51 3'-Br 18 
4.52 3'-CF3 22 
4.53 4'-t-Butyl 19 
4.54 4'-Phenyl 4
b
 
a 
Errors in IC50‘s are within ±5%;       
b 
Apparent Ki. 
 
We do not know if these sulfated inhibitors are substrates for STS and therefore acting as 
reversible suicide STS inhibitors.  This is difficult to ascertain since the products of such a 
reaction are very potent STS inhibitors themselves.  One would expect that if they are substrates 
then STS would only be capable of only one or two turnovers before being completely or 
significantly inhibited by the product.  This makes it very difficult to determine if these 
compounds are substrates as the amount of product formed will be very small (app. equal to the 
concentration of enzyme used in the assay).  Mass spectrometry might be the best method for 
detecting any products formed from the reaction of STS with these sulfated inhibitors though 
quantification of product would be challenging. 
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Figure 4.10.  A plot of IC50‘s for compound 4.54 as a function of [E]T. 
4.3.7 Molecular Modelling Studies 
Modelling studies were performed to gain some insight into possible modes of binding of 
some of the new inhibitors described above.  We started by examining the effect of placing the 
NO2 group at the 4-position (as in compound 4.10 and 4.4, Fig. 4.11).  Compounds 4.10 and 4.4 
share common hydrophobic alkyl or mixed pi-alkyl interactions with Val486, His485, and Val 
171.  The sulfonamide group in compound 4.10 as with most of our sulfonamide inhibitors is 
involved in H-bond interactions with Phe178 and Gly181 (2.8 and 2.4 Ǻ, respectively), as shown 
in Fig. 4.11.  In contrast to inhibitor 3.33 (see Fig. 3.14), which lacks a 4-NO2 group as is less 
potent than 4.10, the CF3-group in 4.10 lost its H-bond interactions with both Arg98 and Tyr493.  
However, the introduction of the nitro group at the 4-position resulted in the formation of an 
electrostatic charge attractive interaction with the side chain nitrogen of Lys 368.  There is also a 
very strong H-bond interaction between the 3-OH and one of the hydroxyl groups of FGly75 
(2.0Ǻ).  These additional interactions may account for the greater potency of 4.10 compared to 
3.33.  
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Fig. 4.11. The binding mode of 4.10 (left) and 4.4 (right) with STS (green dotted lines indicate 
H-bonding interactions, violet dotted lines indicate hydrophobic interactions, and orange dotted 
lines indicate electrostatic charge interactions; some of H-atoms were removed to increase 
clarity). 
 
The introduction of a bromine at the 4-position in 3.33 resulted in a decrease in potency 
(compound 4.27).  Upon examining the docking poses for 4.27 and 4.17 we found that both of 
them share the same interactions with the FGly75 hydrate (H-bonding), and the hydrophobic 
interactions with Lys368, Val486, His485, Val177, Leu74, Val101 (as shown in Fig. 4.12), 
however; the 17-sulfonamide scaffold of 4.29 added new bonding: two H-bonding interactions 
(one between NH of the SO2NH and oxygen atom of Val177, and another one between one of 
the oxygen atoms of SO2NH group and a H of Phe178) and three hydrophobic pi-alkyl or pi-
cation interactions (as seen in Fig. 4.12). The bromine is involved in a hydrophobic pi-alkyl 
interaction (4.49 Å).  Inhibitor 3.33 (Fig. 3.14) is involved in similar interactions between 3-OH 
and sulfonamide group NH and the amino acid residues FGgly75 and Phe178, respectively.  
However, the introduction of the bromine atom at 4-position caused a marked shift in the 
position of the whole molecule within active site compared to 3.33 as shown in Fig. 4.12.  This 
shift resulted in losing all the H-bond interactions between the CF3-group and Tyr493 and 
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Thr484 and the loss of an H-bond between one of oxygens of the sulfonamide group with the N-
H of Gly181 that were found in 3.33.   We think that the loss of such interactions could be one of 
the factors responsible for the lower potency of 4.27 compared to 3.33.  
  
 
Fig. 4.12.  The binding mode of compounds 4.27 (left) and 4.17 (right) with STS (Green dotted 
lines indicate H-bonding interactions; violet lines indicate hydrophobic interactions; some of H-
atoms were removed to increase clarity). 
 
 
Docking studies were also performed on the 4-fluoro sulfonamide derivative, 4.49 and 4-
F-E1, 4.30.  As seen in Fig. 4.13; the 3-OH group was interacting with FGly75 via a strong H-
bond interaction (distance 2.22 Å), one of the oxygen atoms of the –SO2NH- group was 
interacting with Phe178 residue, and finally, its 3´-CF3-benzene scaffold was interacting via a 
network of hydrophobic interactions with both Phe178 and Phe553 as seen in Fig. 4.13.  The 
fluorine at the 4-position does not seem to be involved in any significant interactions beyond a 
H-bond with a C-H of the Lys368 side chain. Such H-bonds are not considered to be very strong.  
On the other hand, 4.30 lacks the key interactions found with 4.49, and hence its lower potency.  
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Fig. 4.13. The binding mode of compounds 4.49 (left) and 4.30 (right) with STS (green dotted 
lines indicate H-bond interactions; violet lines indicate hydrophobic interactions; some of 
hydrogen atoms were removed to increase clarity). 
 
It is difficult to rationalize the increased potency of inhibitor 4.49 compared to inhibitor 
3.33 based upon the docking studies. Upon comparing the docking poses for both 4.49 and 3.33 
we found that even with the loss of the characteristic H-bond interactions of the CF3-group seen 
in 3.33 (Fig.3.14) compound 4.49 was more potent than 3.33.  Upon visualizing both of these 
two compounds in the context of almost the entire enzyme we noticed that the introduction of the 
fluorine atom at 4-position changed the orientation such that the arylsulfonamide moiety of 4.49 
was oriented almost in between the two alpha helices (Fig. 4.14).  This may somehow result in 
an increase in potency.  
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Fig. 4.14. The binding mode of compounds 4.49 (left) and 3.33 (right) with STS in its complete 
form.  
 
4.3.8 Anti-proliferative effect of the 17-arylsulfonamide E1 derivatives with the NCI-60 
panel 
To determine the anti-proliferative activity of our compounds, we submitted 29 of our 
sulfonamides to the Developmental Therapeutics Program (DTP) at the National Cancer Institute 
(NCI, USA) for in vitro primary screening in a diverse panel consisting of 60 human tumor cell 
lines (NCI-60 panel).  These 29 compounds were initially assessed by subjecting the cell lines to 
a one-dose screen at 10 M inhibitor. From these studies 17 of the 29 compounds exhibited 
sufficient antiproliferative activity in some or all of the cell lines to warrant further studies which 
consisted of a five-dose screen with each cell line. These compounds were: 3.22, 3.23, 3.27, 
3.28, 3.29, 3.30, 3.33, 3.34, 3.37, 3.38, 3.40, 3.45, 3.46, 3.48, 4.09, 4.10, and 4.53.  GI50‘s, TGI‘s 
and LC50‘s were obtained from these studies and are given in Appendix A and B .  The GI50 is 
the concentration of inhibitor that causes 50% growth inhibition.  The TGI is the concentration of 
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inhibitor that signifies a cytostatic effect. The LC50 is the concentration of drug that is lethal to 
50% of the cells.  Original reports of GI50‘s, TGIs and LC50‘s are in Appendix A and B.  
There was surprisingly little variation in GI50‘s, TGI‘s and LC50‘s for all 17 compounds,  
for example, almost all of the compounds exhibited GI50‘s in the 1-10 M range with all 60 cell 
lines which included two prostate cancer cell lines (PC-3 and DU-45) and six breast cancer cell 
lines (MCF7, MDA-MB-23, HS578T, BT-549, T-47D and MDA-MB-468).  Interestingly, there 
was no correlation between the STS inhibitory potency of the compounds (IC50‘s) and GI50‘s, 
TGIs and LC50‘s reported in the NCI60 panel.  Since all compounds moderately inhibited the 
growth of all of the cell lines it is possible that they are all affecting a common biological 
process/pathway that is necessary to the survival of all of the cell lines. 
4.4 Conclusions and Future work 
A series of 4-substituted 17-arylsulfonamide estrogen derivatives that were designed to 
act as potent inhibitors of STS were synthesized.  Inhibition studies revealed that the introduction 
of a NO2 group or F atom to the 4-position increased the potency of these compounds.  Some of 
these compounds are the most potent reversible STS inhibitors ever reported.  Introduction of a 
Br at this position resulted in a decrease in potency.  Modeling studies were performed on these 
compounds in an attempt to determine the origins of the effect of these C-4 substituents.  In 
general, 3-O-sulfation of these compounds did not affect potency.  It is not known if 3-O-
sulfated derivatives were acting as inhibitors or reversible suicide inhibitors (by acting as 
substrates).   
Future inhibitor design based upon the compounds presented in this thesis would benefit 
significantly from knowing where and how they interact with STS.  The modeling studies 
provided some guidance on this matter; however, in the absence of an X-ray crystal structure of 
164 
 
one of our inhibitors bound to STS the modeling studies must be interpreted with caution as we 
have assumed active site binding even though our kinetic studies indicate that these inhibitors 
bind at more than one site (i.e. perhaps at the active site and in the hydrophobic tunnel between 
the two -helices) or bind only to one site outside the active site (i.e. possibly just in the 
hydrophobic tunnel between the two -helices). Photoaffinity labels, such as compounds 4.55 
and 4.56 (Fig. 4.15), might be useful for determining where the aryl sulfonamide group is 
binding to STS.  These compounds should be readily accessible. Inhibitor 3.47, which contains a 
fluorescent dansyl group, may also be useful in shedding some light on this matter.  The 
fluorescence of the dansyl group is known to be very sensitive to the polarity of its environment 
in that its fluorescence increases and undergoes a blue shift when going from a polar 
environment to a hydrophobic environment.  Compounds containing this group and other similar 
environment-sensitive fluorophores have been used to examine protein-protein interactions,
195,196
  
protein conformation changes,
196
 and for structural characterization of ligand-binding 
domains.
197-200
  If our inhibitors are indeed binding in the hydrophobic tunnel then one would 
expect to see a large increase in fluorescence and a blue shift upon binding to STS.  However, it 
is also possible that such a change in fluorescence might also result from active site binding and 
so the results of such studies would have to be interpreted with caution. 
 
HN S
OO
O
S
O
O
O
N3
HN S
OO
HO
N3
HO
HN
CHO
S
O
O
N
4.55 (N3 is meta or para) 4.56 (N3 is meta or para) 4.57  
Fig. 4.15.  Structures of potential photoaffinity labels 4.55 and 4.56.   
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To determine if 4-formyl derivatives such as 4.50 are capable of forming Schiff bases 
with active site residues compound 4.57 (Fig. 4.15) will be examined as a time- and 
concentration-dependent inhibitor (Fig. 4.16).  Should this compounds exhibit time- and 
concentration-dependent inhibition then the imine adduct(s) will be reduced to a stable amine 
with sodium borohydride followed by proteolytic digestion of the inactivated enzyme and then 
sequencing of the modified peptides.  The advantage of using 4.57 instead of 4.50 for these 
studies is that any labelled peptide fragments will be fluorescent and therefore easy to detect and 
isolate using an HPLC equipped with a fluorescence detector.   
STS
CHO
NH2
STS
N
C
Compound 
4.57
H
STS
N
CH H
H
Compound 
4.57
Compound 
4.57
(A) (B) (C)
 
Fig. 4.16. Schematic presentation of the proposed fluorescence-tagging of STS by 4.57; (A) 
Nucleophilic attack of basic amino acids (lysine, or arginine) on CHO-group of 4.57, (B) Imine-
formation, (C) Borohydride reduction of unstable imine to corresponding stable amine. 
 
Selected inhibitors developed in Chapters 3 and 4 were sent to the NCI (USA) for in vitro 
screening with a panel of 60 human tumor cell lines (NCI-60 panel).  Almost all of the 
compounds exhibited GI50‘s in the 1-10 M range with all 60 cell lines and so were only 
moderately potent in terms of their ability to inhibit the growth.  None of the compounds stood 
out in terms of their ability to inhibit the growth of any breast cancer, prostate cancer or any 
other cancer cell line studied.  Many of the sulfamate-based inhibitors discussed in chapter 1 are 
highly active in cell assays.  It would be interesting to see if the introduction of a sulfamate 
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group or a non-hydrolyzable sulfate mimic at the 3-OH group in the inhibitors described here 
would result in more cell active compounds.   Our preliminary work on such compounds is 
described in Chapter 5. 
4.5 Experimental 
4.5.1 General 
 All starting materials and reagents were obtained from Aldrich Chemical Company.  
THF was distilled from sodium-benzophenone, Pyridine was distilled from KOH pellets, 1,2-
DCE and 1,1,2-TCE were dried by standing over activated type 4A molecular sieves, CH2Cl2 
was distilled from calcium hydride under nitrogen.  Both benzylamine and allylamine were dried 
by distillation from KOH pellets and stored in dark over type 4A molecular sieves. Tetrakis 
(triphenylphosphine)palladium (0), [Pd(Ph3)4] was prepared according to literature procedure 
from triphenylphosphine (PPh3) and palladium chloride (PdCl2). Dioxane was distilled from Na
o
 
and stored over type 4A molecular sieves. Both ethylene glycol and t-Butyl alcohol were dried 
by distillation and standing over type 3A molecular sieves. Silica gel chromatography was 
performed using silica gel (60Å, 230-400 mesh) obtained from Silicycle (Laval, Quebec, 
Canada). 
1
H, 
13
C, and 
19
F NMR spectra were recorded on a Bruker Avance 300 spectrometer.  
For NMR spectra obtained using CDCl3 as the solvent, chemical shifts () for 
1
H NMR spectra 
are reported relative to internal Me4Si ( 0.0 ppm), chemical shifts for 
13
C spectra are relative to 
the residual solvent peak (77.0 ppm, central peak), and chemical shifts for 19F NMR are 
relative to a CFCl3 ( 0.0 ppm) external standard.  Both Electron Impact-Low Resolution (EI-
LRMS) and Electro-Spray Ionization-Low Resolution (ESI) Mass Spectra were obtained on a 
JEOL HX110 double focusing mass spectrometer. Electro-Spray Ionization High Resolution 
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(ESI-HRMS) Mass Spectra were obtained with a Waters/Micromass QTOF Ultima Global mass 
spectrometer. Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected. Cellular studies were done using human tumor cell lines of the cancer screening 
panel (NCI60) at the U.S. NCI research centre. 
4.5.2 Syntheses 
HO
O
R2
4.3; R1= H, R2= NO2
4.4; R1= NO2, R2= H
R1
 
Nitroestrones, 4.3 and 4.4.
179
 To a stirred solution of E1 (1.73 g, 6.4 mmol) in glacial 
acetic acid (90 mL) at 70-75
o
C, was added a mixture of concentrated nitric acid (0.4 mL) and 
glacial acetic acid (10 mL), stirring was continued at room temperature for 18 h. The precipitate 
was filtered and washed with hot glacial acetic acid to afford (200 mg, 20%) of 4-NO2-E1, 4.3 as 
a pale yellow powder, while filtrate was concentrated, dissolved in benzene (30 mL), and stirred 
with NaHCO3 (2%, 20 mL) for 6 h, then aqueous layer was acidified with conc. HCl (10 mL), 
and the filtrate was concentrated and recrystallized from ethanol (95%, 10 mL) to afford 2-NO2-
E1, 4.4 as bright yellow crystals (250 mg, 23%). 4-NO2-E1, 4.3, Mp: 277-280
o
C;
179
 
1
H NMR 
(CDCl3, 300 MHz) δ 9.40 (brs, 1H, ArOH), 7.44 (d, J = 8.8 Hz, 1H, H-1), 6.94 (d, J = 8.8 Hz, 
1H, H-2), 3.20-3.14 (m, 1H), 3.02-2.94 (m, 1H), 2.55-2.46 (m, 1H), 2.35-1.94 (m, 6H), 1.67-1.23 
(m, 8H), 0.90 (s, 3H, H-18). 2-NO2-E1, 4.4, Mp: 181-183
o
C;
179
 
1
H NMR (CDCl3, 300         
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MHz) δ 10.32 (brs, 1H, ArOH), 7.90 (s, 1H, H-1), 6.80 (s, 1H, H-4), 2.95-2.92 (m, 2H, H-6), 
2.54-2.39 (m, 2H), 2.17-1.96 (m, 5H), 1.61-1.41 (m, 7H), 0.89 (s, 3H, H-18). 
General method for reductive amination of nitroestrones 4.3 and 4.4. To a stirred 
solution of nitroestrones, 4.3 or 4.4 (500 mg, 1.60 mmol) in THF (10 mL) was added allylamine 
(360 mg, 6.30 mmol), glacial acetic acid (375 µL, 6.30 mmol), and STABH (850 mg, 3.92 
mmol). The mixture was stirred for 2 d, after that the reaction was quenched with aq. saturated 
NaHCO3 and stirring was continued for additional 10 min. The reaction mixture was extracted 
with DCM, and the organic layer was washed with aq. saturated NaHCO3, water, brine, dried 
with Na2SO4, and finally concentrated under vacuum.  
HO
HN
NO2
4.5  
17-Allylamino-4-nitro-estratrien-1,3,5(10)-3-ol (4.5). Purification was done by flash 
chromatography (methanol/chloroform, 1:9) to afford 4.5 as a yellow solid (350 mg, 63%); Mp 
150-151
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.43 (d, J = 8.9 Hz, 1H, H-1), 6.94 (d, J = 8.2 Hz, 1H, 
H-2), 5.90 (m, 1H, NHCH2CHCH2), 5.15 (m, 2H, NHCH2CHCH2), 3.33 (m, 1H), 3.15 (m, 1H), 
2.95 (m, 1H), 2.77-2.70 (m, 1H), 2.22-1.90 (m, 6H), 1.70-1.20 (m, 6H), 0.76 (s, 3H, H-18); 
LRMS (ESI
+
) m/z (%) 357 (M+H, 100); HRMS (ESI
+
) calcd for C21H29N2O3 (M+H)
+
 357.2178; 
found 357.2186. 
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HO
HN
O2N
4.6  
17-Allylamino-2-nitro-estratrien-1,3,5(10)-3-ol (4.6). Purification was done by flash 
chromatography (ethyl acetate/hexane, 3:7) to afford 4.6 as a yellow solid (415 mg, 73%); Mp 
163-164
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.95 (s, 1H, H-1), 6.81 (s, 1H, H-4), 5.90 (dddd, J = 
6.0, 10.2, 11.9, 16.3 Hz, 1H, NHCH2CHCH2), 5.51 (brs, 1H, ArOH), 5.09 (ddd, J = 1.7, 17.2, 
18.8 Hz, 2H, NHCH2CHCH2), 3.27 (dd, J = 1.3 and 6.0 Hz, 2H, NHCH2CHCH2), 2.92-2.82 (m, 
2H, H-6), 2.67-2.61 (m, 1H), 2.30-2.26 (m, 1H), 2.15-1.98 (m, 3H), 1.89 (m, 1H), 1.71-1.20 (m, 
8H), 0.73 (s, 3H, H-18). 
13
C NMR (CDCl3, 75 MHz) δ 152.8 (C-3), 149.2, 137.4, 133.9 (C-5), 
131.7 (C-6), 121.4, 118.8, 115.5, 68.3 (C-17), 52.2 (NHCH2), , 51.1 (C-14), 43.5 (CH), 42.9 (C-
13), 38.1 (CH), 37.6 (CH2), 29.7 (2 CH2), 26.7 (CH2), 26.2 (CH2), 23.4 (CH2), 11.8 (CH3, C-18); 
LRMS (ESI
+
) m/z (%) 357 (M+H, 100); HRMS (ESI
+
) calcd for C21H29N2O3 (M+H)
+
 357.2178; 
found 357.2176. 
HO
NH2
R2
4.7; R1= H, R2= NO2
4.8; R1= NO2, R2= H
R1
 
General method for deallylation of 17β-Allyl-amino nitroestrones 4.5 and 4.6. To a 
stirred solution of compounds 4.5 or 4.6 (350 mg, 0.98 mmol) in dry DCM (20 mL) was added to 
a solution of N,N-dimethylbarbituric acid (NDMBA, 254 mg, 2.97 mmol) and Pd(Ph3)4 (23.5 
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mg, 0.02 mmol) in dry DCM (2 mL). The mixture was stirred for 3 h at 35
o
C under an Argon 
atmosphere, and then diluted with DCM (20 mL).  The mixture was washed with sat. NaHCO3, 
water, brine, and finally organic layer was dried with Na2SO4, and concentrated under vacuum.  
HO
NH2
NO2
4.7  
17-Amino-4-nitro-estratrien-1,3,5(10)-3-ol (4.7). Purification was done by flash 
chromatography (methanol/chloroform/NH4OH, 4.5:95:0.5) to afford 4.7 as a yellow solid (150 
mg, 47%). Mp 167-169
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.44 (d, J = 8.8 Hz, 1H, H-1), 6.92 (d, 
J = 9.0 Hz, 1H, H-2), 3.20 (m, 2H, H-6), 2.96-2.78 (m, 3H, NH2 and H-17), 2.23-2.15 (m, 4H), 
1.97-1.92 (m, 2H), 1.70 (m, 1H), 1.46-1.17 (m, 8H), 0.72 (s, 3H, H-18); LRMS (ESI
+
) m/z (%) 
317 (M+H, 10); HRMS (ESI
+
) calcd for C18H25N2O3 (M+H)
+
 317.18597; found 317.18601. 
HO
NH2
O2N
4.8  
17-Amino-2-nitro-estratrien-1,3,5(10)-3-ol (4.8). Purification was done by flash 
chromatography (methanol/chloroform/NH4OH, 4.5:95:0.5) to afford 4.8 as an orange solid (220 
mg, 71%). Mp 133-135
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.95 (s, 1H, H-1), 6.81 (s, 1H, H-4), 
3.77 (brs, 2H, NH2), 2.92-2.70 (m, 3H, H-6 and H-17), 2.33-2.28 (m, 1H), 2.14-2.00 (m, 2H), 
1.87 (m, 2H), 1.70-1.64 (m, 1H), 1.53-1.48 (m, 1H), 1.38-1.15 (m, 6H), 0.65 (s, 3H, H-18). 
13
C 
NMR (CDCl3, 75 MHz) δ 152.8 (C-3), 149.2, 133.8 (C-5), 131.7 (C-6), 121.4, 118.8, 62.7 (C-
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17), 51.9 (C-14), 43.4 (CH), 42.8 (C-13), 38.4 (CH), 36.3 (CH2), 30.9 (CH2), 29.8 (CH2), 26.7 
(CH2), 26.1 (CH2), 23.3 (CH2), 11.1 (CH3, C-18); LRMS (ESI
+
) m/z (%) 317 (M+H, 100); 
HRMS (ESI
+
) calcd for C18H25N2O3 (M+H)
+
 317.1865; found 317.1853. 
General procedure for synthesis of sulfonamides of 2-nitro or 4-nitro-17β-amino-
1,3,5(10)-estratrien-3-ol. To a stirred solution of 4.7 and/or 4.8 (50 mg, 0.16mmol) in dry 
pyridine (1 mL) at 0 
o
C was added a solution of the appropriate sulfonyl chloride (0.17 mmol) in 
dichloromethane (1 mL) drop-wise via a syringe pump over 10 min. The reaction was stirred for 
16 h at room temperature, and pyridine was azeotropically removed with toluene, and the residue 
was dissolved in chloroform, washed with water and brine, then dried with anhydrous Na2SO4, 
and finally concentrated under vacuum.  
HO
HN S
O O
Br
NO2
4.9  
4-Nitro-17β-(3'-bromobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.9). 
Purification was done by flash chromatography (ethyl acetate/hexane, 3:7) to afford 4.9 as a 
yellow solid (41 mg, 48%). Mp 230-231
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 9.40 (s, 1H, ArOH), 
8.02 (s, 1H, ArH), 7.80 (d, J = 6.9 Hz, 1H, ArH), 7.68 (d, J = 7.4 Hz, 1H, ArH), 7.44-7.35 (m, 
2H, ArH), 6.92 (d, J = 8.7 Hz, 1H, ArH), 4.55 (d, J = 9.2 Hz, 1H, NH), 3.21-3.09 (m, 2H, H-17 
and H-6), 2.94-2.88 (m, 1H), 2.23-2.15 (m, 2H), 1.89-1.65 (m, 4H), 1.44-1.19 (m, 8H), 0.72 (s, 
3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 152.1 (C-3), 143.1, 136.1, 135.6 (CHAr), 134.0 (C-5), 
133.6 (C-6), 132.8 (CHAr), 130.6 (CHAr), 130.0 (CHAr), 125.5 (CHAr), 122.9, 121.5, 116.5 
(CHAr), 63.3 (C-17), 50.8 (C-14), 44.2, 42.9 (C-13), 37.6 (CH), 36.3 (CH2), 29.5 (CH2), 27.8 
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(CH2), 26.5 (2 CH2), 22.9 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 537 (M+H+2, 90), 
535 (M+H, 80), 300 (100); HRMS (ESI
+
) calcd for C24H28N2O5SBr (M+H)
+
 535.0902; found 
535.0909. 
HO
HN S
O O
CF3
NO2
4.10  
4-Nitro-17β-(3'-trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.10). 
Purification was done by flash chromatography (ethyl acetate/hexane, 1:4) to afford 4.10 as a 
yellow solid (44 mg, 53%). Mp 263-264
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 9.42 (s, 1H, ArOH), 
8.15 (s, 1H, ArH), 8.07 (d, J = 7.7 Hz, 1H, ArH), 7.83 (d, J = 7.8 Hz, 1H, ArH), 7.66 (dd, J = 7.9 
and 8.0 Hz, 1H, ArH), 7.43 (d, J = 8.9 Hz, 1H, ArH), 6.94 (d, J = 8.9 Hz, 1H, ArH), 4.47 (d, J = 
9.5 Hz, 1H, NH), 3.25-3.08 (m, 2H), 2.96-2.89 (m, 1H), 2.18 (m, 2H), 1.94-1.87 (m, 4H), 1.36-
1.18 (m, 8H), 0.73 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 152.2 (C-3), 142.5, 136.1 (C-5), 
133.5 (q., J = 38.2 Hz, 1 C, C-CF3), 132.9 (CHAr), 132.0 (C-6), 130.2 (CHAr), 129.1 (apparent d, 
J = 3.6 Hz, 1 C, CHAr), 124.1 (apparent d, J = 3.7 Hz, 1 C, CHAr), 116.6 (CHAr), 63.4 (C-17), 
51.0 (C-14), 44.2 (CH), 42.8 (C-13), 37.5 (CH), 36.3 (CH2), 29.5 (CH2), 27.8 (CH2), 26.4 (2 
CH2), 22.9 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ  -63.1; LRMS (ESI
+
) m/z 
(%) 525 (M+H, 100); HRMS (ESI
+
) calcd for C25H28N2O5F3S (M+H)
+
 525.1671; found 
525.1667. 
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4.11  
4-Nitro-17β-(4'-t-butylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.11). 
Purification was done by flash chromatography (ethyl acetate/hexane, 2.5:7.5) to afford 4.11 as a 
yellow solid (32 mg, 40%). Mp 228-229
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 9.40 (s, 1H, ArOH), 
7.77 (d, J = 8.4 Hz, 1H, ArH), 7.48 (d, J = 8.4 Hz, 1H, ArH), 7.41 (d, J = 8.4 Hz, 1H, ArH), 6.92 
(d, J = 8.6 Hz, 1H, ArH), 4.35 (d, J = 9.3 Hz, 1H, NH), 3.22-3.06 (m, 2H, H-17 and H-6), 2.95-
2.87 (m, 1H, H-6), 2.20-2.11 (m, 2H), 1.90-1.77 (m, 3H), 1.67-1.59 (m, 1H), 1.43-1.12 (m, 17 
H), 0.71 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 156.4 (C-C(CH3)3, 152.2 (C-3), 138.0, 
136.1, 134.1 (C-5), 133.7 (C-6), 132.9 (CHAr), 126.9 (2 CHAr), 125.9 (2 CHAr), 116.5 (CHAr), 
63.1 (C-17), 50.9 (C-14), 44.3 (CH), 42.8 (C-13), 37.6 (CH), 36.2 (CH2), 35.1 (CH2), 31.1 (2 
CH), 29.5 (CH2), 27.8 (CH2), 26.5 (2 CH2), 22.9 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 
513 (M+H, 100); HRMS (ESI
+
) calcd for C28H37N2O5S (M+H)
+
 513.2423; found 513.2432.  
HO
HN S
O O
NO2
4.12  
4-Nitro-17β-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol (4.12). Purification was 
done by flash chromatography (methanol/chloroform, 1:8) to afford 4.12 as a yellow solid (23 
mg, 27%). Mp 270-271
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 9.40 (s, 1H, ArOH), 7.93 (d, J = 8.2 
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Hz, 2H, ArH), 7.70 (d, J = 8.3 Hz, 2H, ArH), 7.61 (d, J = 6.8 Hz, 2H, ArH), 7.49-7.38 (m, 4H), 
6.80 (d, J = 8.6 Hz, 1H, ArH), 4.51 (d, J = 8.9 Hz, 1H, NH), 3.47-3.17 (m, 2H, H-17 and H-6), 
3.12-3.06 (m, 1H), 2.22-2.15 (m, 3H), 1.91-1.80 (m, 3H), 1.66-1.60 (m, 2H), 1.44-1.15 (m, 8H), 
0.73 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 152.1 (C-3), 145.4, 139.7, 139.2, 136.1, 134.0 
(C-5), 133.7 (C-6), 132.7 (CHAr), 129.0 (2 CHAr), 128.5 (CHAr), 127.6 (4 CHAr), 127.3 (2 CHAr), 
116.5 (CHAr), 63.3 (C-17), 51.1 (C-14), 44.3 (CH), 42.8 (C-13), 37.6 (CH), 36.3 (CH2), 29.5 
(CH2), 27.8 (CH2), 26.5 (2 CH2), 23.0 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 533 
(M+H, 100); HRMS (ESI
+
) calcd for C30H33N2O5S (M+H)
+
 533.2110; found 533.2098. 
HO
HN
O2N
S
O O
Br
4.13  
2-Nitro-17β-(3'-bromobenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.13). 
Purification was done by flash chromatography (ethyl acetate/hexane, 3:7) to afford 4.13 as a 
yellow solid (56 mg, 66%). Mp 242-243
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 10.40 (s, 1H, ArOH), 
8.03 (s, 1H, ArH), 7.91 (s, 1H, ArH), 7.80 (d, J = 7.9 Hz, 1H, ArH), 7.68 (d, J = 7.9 Hz, 1H, 
ArH), 7.38 (dd, J = 7.9 and 7.9 Hz, 1H, ArH), 6.80 (s, 1H, ArH), 4.68 (d, J = 9.3 Hz, 1H, NH), 
3.19 (q, J = 8.7 Hz, 1H, H-17), 2.86-2.80 (m, 2H), 2.27-2.23 (m, 1H), 2.11 (m, 1H), 1.91-1.65 
(m, 4H), 1.46-1.14 (m, 7H), 0.70 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 152.8 (C-3), 
148.9, 143.0, 135.6 (CHAr), 133.3 (C-5), 131.7 (C-6), 130.6 (CHAr), 130.0 (CHAr), 125.5 (CHAr), 
122.9, 121.5, 118.8, 63.3 (C-17), 51.0 (C-14), 43.2 (CH), 42.8 (C-13), 38.2 (CH), 35.9 (CH2), 
29.5 (2 CH2), 26.5 (CH2), 25.8 (CH2), 23.1 (CH2), 11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 537 
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(M+H+2, 95), 535 (M+H, 90), 300 (100); HRMS (ESI
+
) calcd for C24H28N2O5SBr (M+H)
+
 
535.0902; found 535.0902. 
HO
HN
O2N
S
O O
CF3
4.14  
2-Nitro-17β-(3'-trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.14). 
Purification was done by flash chromatography (methanol/chloroform, 0.5:9.5) to afford 4.14 as 
a yellow solid (55 mg, 67%). Mp 278-279
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 10.40 (s, 1H, 
ArOH), 8.15 (s, 1H, ArH), 8.07 (d, J = 8.07 Hz, 1H, ArH), 7.91 (s, 1H, ArH), 7.83 (d, J = 7.8 
Hz, 1H, ArH), 7.66 (dd, J = 7.4 and 7.9 Hz, 1H, ArH), 6.80 (s, 1H, ArH), 4.59 (d, J = 9.6 Hz, 
1H, NH), 3.22 (q, J = 8.5 Hz, 1H, H-17), 2.89 (m, 2H, H-6), 2.26-2.22 (m, 1H), 2.11 (m, 1H), 
1.91-1.85 (m, 2H), 1.73-1.68 (m, 2H), 1.49-1.10 (m, 7H), 0.70 (s, 3H, H-18); 
13
C NMR (CDCl3, 
75 MHz) δ 152.8 (C-3), 148.9, 142.5, 133.3 (C-5), 131.8 (q., J = 33.3 Hz, 1 C, C-CF3), 131.7 (C-
6), 130.2 (d, J = 1.0 Hz, 1 C, CHAr), 129.8 (d, J = 2.5 Hz, 1 C, CHAr), 129.1 (q, J = 3.6 Hz, 1 C, 
CHAr), 124.1 (q, J = 3.8 Hz, 1 C, CHAr), 123.2, (q, J = 271.3 Hz, 1 C, C-CF3), 121.5 (CHAr), 
118.8 (CHAr), 63.4 (C-17), 51.0 (C-14), 43.2 (CH), 42.8 (C-13), 38.2 (CH), 35.9 (CH2), 29.5 (2 
CH2), 26.5 (CH2), 25.8 (CH2), 23.0 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ  -
63.1; LRMS (ESI
+
) m/z (%) 525 (M+H, 89), 300 (100%); HRMS (ESI
+
) calcd for 
C25H28N2O5F3S (M+H)
+
 525.1671; found 525.1656.  
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4.15  
2-Nitro-17β-(4'-t-butylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol (4.15). 
Purification was done by flash chromatography (ethyl acetate/hexane, 1:4) to afford 4.15 as a 
yellow solid (21 mg, 26%). Mp 212-213
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 10.37 (app. d, 1H, 
ArOH), 7.91 (s, 1H, ArH), 7.80-7.77 (2 overlapping d, J = 8.4 Hz, 2H, ArH), 7.50-7.47 (2 
overlapping d, J = 8.4 Hz, 2H, ArH), 6.80 (s, 1H, ArH), 4.57 (d, J = 9.2 Hz, 1H, NH), 3.15 
(apparent t., J = 8.6 Hz, 1H, H-17), 2.85 (m, 2H, H-6), 2.24-2.20 (m, 1H), 2.09-2.01 (m, 1H), 
1.84-1.75 (m, 3H), 1.65-1.62 (m, 1H), 1.49-1.14 (m, 17 H), 0.69 (s, 3H, H-18); 
13
C NMR 
(CDCl3, 75 MHz) δ 156.4 (C-C(CH3)3, 152.8 (C-3), 148.9, 137.9, 133.5 (C-5), 131.7 (C-6), 
126.9 (2 CHAr), 125.9 (2 CHAr), 121.5, 118.8, 63.1 (C-17), 51.1 (C-14), 43.2 (CH), 42.8 (C-13), 
38.2 (CH), 35.9 (CH2), 35.1 (CH2), 31.1 (CH), 29.5 (2 CH2), 26.5 (CH2), 25.8 (CH2), 23.1 (CH2), 
11.7 (CH3, C-18); LRMS (ESI
+
) m/z (%) 513 (M+H, 100); HRMS (ESI
+
) calcd for C28H37N2O5S 
(M+H)
+
 513.2423; found 513.2424. 
HO
HN
O2N
S
O O
4.16  
2-Nitro-17β-4'-biphenylsulfonamide-1,3,5(10)-estratrien-3-ol (4.16). Purification was 
done by flash chromatography (ethyl acetate/hexane, 1:9) to afford 4.16 as a yellow solid (36 
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mg, 43%). Mp 265-266
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 10.40 (s, 1H, ArOH), 7.96-7.91 (m, 
3H, ArH), 7.71 (d, J = 8.3 Hz, 2H, ArH), 7.61 (d, J = 7.7 Hz, 2H, ArH), 7.49-7.38 (m, 3H), 6.80 
(s, 1H, ArH), 4.67 (d, J = 9.2 Hz, 1H, NH), 3.21 (q, J = 8.7 Hz, 1H, H-17), 2.90-2.77 (m, 2H), 
2.26-2.21 (m, 2H), 1.90-1.63 (m, 4H), 1.40-1.12 (m, 8H), 0.71 (s, 3H, H-18); 
13
C NMR (CDCl3, 
75 MHz) δ 152.8 (C-3), 149.2, 145.5, 139.7, 139.2, 133.8 (C-5), 131.7 (C-6), 129.1 (2 CHAr), 
128.5 (CHAr), 127.6 (4 CHAr), 127.3 (2 CHAr), 121.5, 118.9, 63.3 (C-17), 51.1 (C-14), 43.3 (CH), 
42.8 (C-13), 38.1 (CH), 36.0 (CH2), 29.5 (2 CH2), 26.5 (CH2), 25.8 (CH2), 23.1 (CH2), 11.8 
(CH3, C-18); LRMS (ESI
+
) m/z (%) 533 (M+H, 100); HRMS (ESI
+
) calcd for C30H33N2O5S 
(M+H)
+
 533.2110; found 533.2103.  
N
H
CH3
O
Br
NBA  
N-Bromoacetamide (NBA).
184
 To a solution of acetamide (2.0 g, 34 mmol), and 
bromine (1.7 mL, 68 mmol) at 0-5
o
C, a 50% aqu. KOH solution (4 mL) was added drop-wise. 
After complete addition, the solution was left at 0-5
o
C for 2-3 h to complete precipitation, then 
NaCl (4 g) and CHCl3 (50 mL) were added, and the reaction was heated on a hot water bath to 
dissolve precipitate with vigorous stirring. The organic layer was dried with Na2SO4, then 
hexane (50 mL) was added and mixture was left in the fridge overnight. The formed needles of 
NBA were filtered, washed with cold hexane, and dried under vacuum (1.8 g, 39%). Mp: 103-
105
o
C. 
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4.17  
4-Bromo-estratrien-1,3,5(10)-3-ol (4.17). To a stirred solution of E1 (500 mg, 1.8 
mmol) in ethanol (50 mL), was added NBA (255 mg, 1.8 mmol), and stirring was continued for 
24 h. The precipitate formed was filtered and washed with cold ethanol. Purification was done by 
recrystallization from ethanol to afford 4.17 as white solid (575 mg, 89%). Mp: 264-265
o
C;
185
 
1
H 
NMR (DMSO-d6, 300 MHz) δ 9.80 (s, 1H, ArOH), 7.07 (d, J = 8.8 Hz, 1H, H-1), 6.72 (d, J = 
8.5 Hz, 1H, H-2), 2.87-2.79 (m, 1H), 2.63-2.51 (m, 1H), 2.42-1.92 (m, 6H), 1.72-1.65 (m, 1H), 
1.55-1.27 (m, 5H), 0.77 (s, 3H, H-18). 
AcO
O
4.18  
Estratrien-1,3,5(10)-3-acetate (4.18). To a stirred solution of estrone (1 g, 3.7 mmol) in 
pyridine (7 mL, 8.6 mmol), was added acetic anhydride (1.7 mL, 18 mmol). Stirring was 
continued under reflux for 2 h, and then pyridine was azeotropically removed with toluene. 
Residues was dissolved in ethyl acetate (10 mL), washed with water, brine, and dried with 
Na2SO4. Recrystallization from 95% ethanol afforded 4.18 as white plates (1.3 g, 89%). Mp: 
115-116
o
C;
185
 
1
H NMR (CDCl3, 300 MHz) δ 7.25 (d, J = 8.3 Hz, 1H, H-1), 6.83-6.78 (m, 2H, H-
2 and H-4), 2.01 (m, 2H, H-6), 2.51-2.34 (m, 2H), 2.24 (m, 4H), 2.16-1.90 (m, 4H), 1.61-1.33 
(m, 6H), 0.86 (s, 3H, H-18). 
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O
Br
4.19  
2-Bromo-estratrien-1,3,5(10)-3-acetate (4.19). To a stirred solution of 4.18 (1 g, 3.2 
mmol) in TFA (20 mL) at 0-5
o
C, was added TTFA (3.5 g, 6.4 mmol), and stirring was continued 
for 24 h. TFA was removed under vacuum, and then residue was washed with DCE (2x10 mL), 
dried under high vacuum for 6 h. The residue was then dissolve in 1,4-Dioxane (50 mL), and 
CuBr2 (1.14 g, 7.9 mmol) was added and mixture was refluxed for 3 h, after that, the solvent was 
removed, and residue was dissolved in DCM (25 mL), washed with water (2x20 mL), brine, 
dried by Na2SO4, and finally concentrated under vacuum. Purification was done by flash 
chromatography (ethyl acetate/hexane, 4:1) to afford 4.19 as white solid (0.9 g, 73%). Mp: 166-
167
o
C;
185
 
1
H NMR (CDCl3, 300 MHz) δ 7.46 (s, 1H, H-1), 6.82 (s, 1H, H-4), 2.85-2.82 (m, 2H, 
H-6), 2.53-2.44 (m, 1H), 2.31-1.93 (m, 9H), 1.59-1.39 (m, 6H), 0.88 (s, 3H, H-18). 
HO
O
Br
4.20  
2-Bromo-estratrien-1,3,5(10)-3-ol (4.20). To a stirred solution of 4.19 (0.5 g, 1.3 mmol) 
in methanol (20 mL), was added potassium carbonate (0.8 g, 6.3 mmol), and stirring was 
continued under reflux for 3 h. The solvent was then removed under vacuum, and then residue 
was dissolved in water (20 mL), extracted with DCM (20 mL), washed with brine, dried by 
Na2SO4, and finally concentrated under vacuum. Purification was done by flash chromatography 
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(ethyl acetate/hexane, 3:2) to afford 4.20 as white solid (0.45 g, 91%). Mp: 194-196
o
C;
185
 
1
H 
NMR (CDCl3, 300 MHz) δ 7.32 (s, 1H, H-1), 6.74 (s, 1H, H-4), 5.26 (s, 1H, ArOH), 2.83-2.80 
(m, 2H, H-6), 2.53-2.44 (m, 1H), 2.32-1.93 (m, 6H), 1.59-1.39 (m, 7H), 0.88 (s, 3H, H-18). 
HO
Br
HN
4.21  
4-Bromo-17-benzylamino-estratrien-1,3,5(10)-3-ol (4.21). To a stirred solution of 
4.17 (200 mg, 0.56 mmol) in DCE (10 mL), benzylamine (0.25 mL, 2.24 mmol), and glacial 
acetic acid (0.14 mL, 2.24 mmol) were added. After that, STABH (300 mg, 1.4 mmol) was 
added and stirring was continued for 48 h. The reaction was then quenched with sat. NaHCO3 
solution (10 mL), extracted with DCM (2x10 mL), washed with water, brine, dried with Na2SO4, 
and finally concentrated under vacuum. Purification was done by flash chromatography 
(methanol/chloroform, 1:9) to afford 4.21 as white solid (204 mg, 81%). Mp: 188-189
o
C; 
1
H 
NMR (CDCl3, 300 MHz) δ 7.34-7.23 (m, 5H, ArH), 7.13 (d, J = 8.5 Hz, 1H, H-1), 6.78 (d, J = 
8.4 Hz, 1H, H-4), 3.87 (brs, 4H, NH, ArOH, and C6H5CH2), 2.92-2.87 (m, 1H), 2.71-2.66 (m, 
2H), 2.27-1.92 (m, 5H), 1.73-1.70 (m, 1H), 1.49-1.17 (m, 7H), 0.78 (s, 3H, H-18); 
13
C NMR 
(CDCl3, 75 MHz) δ 150.4 (C-3), 140.7, 136.5 (C-5), 134.3 (C-6), 128.4 (2 CHAr), 128.1 (2 
CHAr), 126.9 (CHAr), 125.3 (CHAr), 113.9, 112.9 (CHAr), 68.2 (C-17), 52.7 (CH2), 52.1 (C-14), 
44.2 (CH), 43.1 (C-13), 38.0 (CH), 37.9 (CH2), 31.2 (CH2), 29.6 (CH2), 27.5 (CH2), 26.7 (CH2), 
23.5 (CH2), 11.9 (CH3, C-18); LRMS (ESI
+
) m/z (%) 442 (M+H+2, 99), 440 (M+H, 100); 
HRMS (ESI
+
) calcd for C25H31NOBr (M+H)
+
 440.1589; found 440.1591. 
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4.22  
2-Bromo-17-benzylamino-estratrien-1,3,5(10)-3-ol (4.22). Compound 4.20 (250 mg, 
0.7 mmol), DCE (10mL), benzylamine (0.3 mL, 2.8 mmol), Gl. AcOH (0.17 mL, 2.8 mmol), and 
STABH (375 mg, 1.4 mmol). Purification was done by flash chromatography 
(methanol/chloroform, 1:9) to afford 4.22 as white solid (277 mg, 88%). Mp: 156-157
o
C; 
1
H 
NMR (CDCl3, 300 MHz) δ 7.33-7.23 (m, 7H, ArH, ArOH, and H-1), 6.70 (s, 1H, H-4), 3.83 (AB 
system, J = 13.5 and 13.3 Hz, 2H, C6H5CH2), 3.40 (brs, 1H, NH), , 2.76-2.74 (m, 2H, H-6), 2.65 
(t, J = 8.2 Hz, 1H, H-17), 2.20-2.01 (m, 4H), 1.86-1.82 (m, 1H), 1.69-1.66 (m, 1H), 1.49-1.13 
(m, 7H), 0.77 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 149.8 (C-3), 138.2 (2 C), 134.6 (C-6), 
128.6 (2 CHAr), 128.3 (2 CHAr), 128.0 (2 CHAr), 126.8 (CHAr), 115.8 (CHAr), 107.3, 68.2 (C-17), 
52.7 (CH2), 52.1 (C-14), 43.8 (CH), 43.1 (C-13), 38.4 (CH), 37.8 (CH2), 29.1 (CH2), 27.2 (CH2), 
26.5 (CH2), 23.5 (CH2), 11.9 (CH3, C-18); LRMS (ESI
+
) m/z (%) 442 (M+H+2, 98), 440 (M+H, 
100); HRMS (ESI
+
) calcd for C25H31NOBr (M+H)
+
 440.1589; found 440.1600. 
HO
Br
HN
4.23  
4-Bromo-17-allylamino-estratrien-1,3,5(10)-3-ol (4.23). To a stirred solution of 4.17 
(200 mg, 0.5 mmol) in DCE (10 mL), allylamine (0.17 mL, 2.3 mmol), and glacial acetic acid 
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(0.13 mL, 2.3 mmol) were added. After that, STABH (280 mg, 1.3 mmol) was added and stirring 
was continued for 24 h. The reaction was then quenched with sat. NaHCO3 solution (15 mL), 
extracted with DCM (2x15 mL), washed with water, brine, dried with Na2SO4, and finally 
concentrated under vacuum. Purification was done by flash chromatography (ethyl 
acetate/hexane, 1:4) to afford 4.23 as white solid (160 mg, 71%). Mp: 145-147
o
C; 
1
H NMR 
(CDCl3, 300 MHz) δ 7.14 (d, J = 8.5 Hz, 1H, H-1), 6.81 (d, J = 8.5 Hz, 1H, H-2), 5.96-5.83 (m, 
1H, NHCH2CHCH2), 5.18-5.04 (m, 2H, NHCH2CHCH2), 3.46-3.27 (brs overlapped by an AB 
system, 3H, NHCH2CHCH2, and ArOH), 2.93-2.85 (m, 1H), 2.72-2.62 (m, 2H), 2.28-1.91 (m, 
5H), 1.72-1.70 (m, 1H), 1.47-1.23 (m, 7H), 0.72 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 
150.1 (C-3), 137.4 (NHCH2CHCH2), 136.5 (C-5), 134.4 (C-6), 125.4 (CHAr), 115.6 
(NHCH2CHCH2), 113.7 (C-Br), 112.6 (CHAr), 68.3 (C-17), 52.1 (CH2), 51.4 (C-14), 44.1 (CH), 
42.9 (C-13), 38.0 (CH), 37.9 (CH2), 31.1 (CH2), 29.7 (CH2), 27.5 (CH2), 26.7 (CH2), 23.4 (CH2), 
11.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 392 (M+H+2, 85), 390 (M+H, 90); HRMS (ESI
+
) calcd 
for C21H29NOBr (M+H)
+
 390.1433; found 390.1443. 
HO
HN
Br
4.24  
2-Bromo-17-allylamino-estratrien-1,3,5(10)-3-ol (4.24). Compound 4.20 (150 mg, 0.4 
mmol), DCE (8 mL), allylamine (0.13 mL, 1.7 mmol), glacial acetic acid (0.10 mL, 1.7 mmol), 
and STABH (210 mg, 1.0 mmol). Purification was done by flash chromatography (ethyl 
acetate/hexane, 1:4) to afford 4.24 as white solid (120 mg, 71%). Mp: 173-175
o
C; 
1
H NMR 
183 
 
(CDCl3, 300 MHz) δ 7.30 (s, 1H, H-1), 6.65 (s, 1H, H-4), 5.94-5.87 (m, 1H, NHCH2CHCH2), 
5.2-5.05 (m, 2H, NHCH2CHCH2), 4.10 (brs, 2H, NH and ArOH), 3.86 (t, J = 5.7 Hz, 1H, H-17), 
3.30-3.28 (m, 2H, NHCH2CHCH2), 2.75-2.63 (m, 3H), 2.20-1.97 (m, 5H), 1.84-1.81 (m, 1H), 
1.70-1.67 (m, 1H), 1.43-1.23 (m, 7H), 0.72 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 150.4 
(C-3), 137.7, 136.8 (CH, NHCH2CHCH2), 134.0 (C-6), 128.9 (CHAr), 116.1 (CHAr), 116.0 
(NHCH2CHCH2), 107.4, 68.2 (C-17), 52.1 (CH2), 51.2 (C-14), 43.7 (CH), 43.0 (C-13), 38.4 
(CH), 37.8 (CH2), 29.2 (2 CH2), 27.1 (CH2), 26.4 (CH2), 23.4 (CH2), 11.7 (CH3, C-18); LRMS 
(ESI
-
) m/z (%) 390 (M-H+2, 84), 388 (M-H, 100); HRMS (ESI
-
) calcd for C21H27NOBr (M-H)
-
 
388.1276; found 388.1272. 
HO
NH2
Br
4.25  
4-Bromo-17-amino-estratrien-1,3,5(10)-3-ol (4.25). To a stirred solution of 4.23 (150 
mg, 0.4 mmol) in DCM (8 mL), was added was added to a solution of dimethylbarbituric acid 
(177 mg, 1.14 mmol) and Pd(Ph3)4 (9 mg, 0.007 mmol) in dry DCM (1 mL). The mixture was 
stirred for 3 h at 35
o
C under argon atmosphere, and then diluted with DCM (10 mL), and the 
mixture was washed with sat. NaHCO3, water, brine, and finally organic layer was dried with 
Na2SO4, and concentrated under vacuum. Purification was done by flash chromatography 
(methanol/chloroform/NH4OH, 4.5:95:0.5) to afford 4.25 as white solid (58 mg, 63%). Mp: 163-
165
o
C; 
1
H NMR (CD3OD, 300 MHz) δ 7.28 (s, 1H, H-1), 6.57 (s, 1H, H-4), 2.73 (m, 3H), 2.26-
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1.73 (m, 7H), 1.35-1.28 (m, 9H), 0.73 (s, 3H, H-18); LRMS (ESI
+
) m/z (%) 352 (M+H+2, 100), 
350 (M+H, 98); HRMS (ESI
+
) calcd for C18H25NOBr (M+H)
+
 350.1120; found 350.1127. 
HO
NH2
Br
4.26  
2-Bromo-17-amino-estratrien-1,3,5(10)-3-ol (4.26). Compound 4.24 (100 mg, 0.25 
mmol), DCM (5 mL), NDMBA (118 mg, 0.76 mmol), Pd(Ph3)4 (6 mg, 0.005 mmol), DCM (1 
mL). Purification was done by flash chromatography (methanol/chloroform/NH4OH, 4.5:95:0.5) 
to afford 4.26 as a white solid (20 mg, 21%). Mp: 190-191
o
C; 
1
H NMR (CD3OD, 300 MHz) δ 
7.28 (s, 1H, H-1), 6.57 (s, 1H, H-4), 2.73 (m, 3H), 2.26-1.73 (m, 7H), 1.35-1.28 (m, 9H), 0.73 (s, 
3H, H-18); LRMS (ESI
+
) m/z (%) 352 (M+H+2, 98), 350 (M+H, 100); HRMS (ESI
+
) calcd for 
C18H25NOBr (M+H)
+
 350.1120; found 350.1111. 
HO
HN
Br
S
O
O
CF3
4.27  
4-Bromo-17β-(3'-trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol 
(4.27). To a stirred solution of 4.25 (50 mg, 0.12 mmol) in dry pyridine (2 mL) at 0 
o
C was 
added a solution of the 3'-CF3-benzenesulfonyl chloride (39 mg, 0.15 mmol) in DCM (1 mL) 
drop-wise via a syringe pump. The reaction was stirred for overnight at room temperature, then 
pyridine was removed under vacuum, and the residue was dissolved in ethyl acetate (5 mL), 
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washed with water (22.5 mL) and brine (5 mL), dried with Na2SO4, and concentrated under 
vacuum. Purification was done by flash chromatography (ethyl acetate/hexane, 1:9) to afford 
4.27 as a white solid (15 mg, 48%). Mp 215-217
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.15 (s, 1H, 
ArH), 8.07 (d, J = 7.9 Hz, 1H, ArH), 7.82 (d, J = 7.9 Hz, 1H, ArH), 7.65 (dd, J = 7.8 and 7.8 Hz, 
1H, ArH), 7.12 (d, J = 8.5 Hz, 1H, ArH), 6.81 (d, J = 8.5 Hz, 1H, ArH), 5.49 (brs, 1H, ArOH), 
4.72 (d, J = 9.4 Hz, 1H, NH), 3.20 (q , J = 8.6 Hz, 1H, H-17), 2.91-2.83 (m, 1H), 2.69-2.60 (m, 
1H), 2.24-2.15 (m, 2H), 1.92-1.83 (m, 2H), 1.72-1.62 (m, 3H), 1.37-1.08 (m, 8H), 0.69 (s, 3H, 
H-18); 
13
C NMR (CDCl3, 75 MHz) δ 150.1 (C-3), 142.5 (C-SO2NH), 136.2 (C-5), 133.9 (C-6), 
131.5 (q, J = 33.2 Hz, C-CF3), 130.2 (CHAr), 129.8 (CHAr), 129.1 (q, J = 3.4 Hz, CHAr), 125.5 
(CHAr), 124.1 (q, J = 3.7 Hz, CHAr), 123.4 (q, J = 306.7 Hz, CF3), 113.6 (C-Br), 112.7 (CHAr), 
63.5 (C-17), 50.9 (C-14), 43.8 (CH), 42.9 (C-13), 38.0 (CH), 36.3 (CH2), 30.9 (CH2), 29.5 
(CH2), 27.2 (CH2), 26.2 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ  -63.1; LRMS 
(ESI
-
) m/z (%) 558 (M-H+2, 100%), 556 (M-H, 98%); HRMS (ESI
-
) calcd for C25H26NO3F3SBr 
(M-H)
-
 556.0769; found 556.0756. 
HO
HN
Br
S
O
O
CF3
4.28  
2-Bromo-17β-(3'-trifluoromethylbenzene)sulfonamide-1,3,5(10)-estratrien-3-ol 
(4.28).  Compound 4.26 (20 mg, 0.05 mmol), dry pyridine (1 mL), 3'-CF3-benzenesulfonyl 
chloride (15.5 mg, 0.06 mmol), and DCM (0.5 mL). Purification was done by flash 
chromatography (ethyl acetate/hexane, 0.5:9.5) to afford 4.28 as a white solid (10 mg, 33%). Mp 
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233-234
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.14 (s, 1H, ArH), 8.06 (d, J = 7.7 Hz, 1H, ArH), 7.82 
(d, J = 8.0 Hz, 1H, ArH), 7.65 (dd, J = 7.7 and 8.0 Hz, 1H, ArH), 7.27 (s, 1H, ArH), 6.70 (s, 1H, 
ArH), 5.23 (brs, 1H, ArOH), 4.45 (d, J = 9.2 Hz, 1H, NH), 3.20 (app. t , J = 9.0 Hz, 1H, H-17), 
2.74 (m, 2H, H-6), 2.21-2.12 (m, 2H), 1.90-1.79 (m, 2H), 1.70-1.62 (m, 2H), 1.40-1.12 (m, 8H), 
0.69 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 149.9 (C-3), 142.5 (C-SO2NH), 138.0 (C-5), 
134.1 (C-6), 132.0 (C-CF3), 130.3 (CHAr), 129.9 (CHAr), 129.2 (CHAr), 128.7 (CHAr), 124.2, 
(CHAr), 107.4 (C-Br), 63.5 (C-17), 51.0 (C-14), 43.5 (CH), 42.9 (C-13), 38.5 (CH), 36.2 (CH2), 
26.9 (CH2), 26.0 (CH2), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz), δ  -63.1; LRMS (ESI
+
) 
m/z (%) 560 (M+H+2, 72), 558 (M+H, 70%), 335 (99%), 333 (100%); HRMS (ESI
+
) calcd for 
C25H28NO3F3SBr (M+H)
+
 558.0925; found 558.0927. 
O
HO
4.29  
2-t-Butyl-estra-1,3,5(10)-triene-17-one (4.29). To a suspension of E1 (0.7 g, 2.6 mmol) 
in DCM (30 mL), t-butyl alcohol (0.5 mL, 5 mmol) was added, after that BF3.OEt2 (1 mL, 7.4 
mmol) was added dropwise via a syringe pump, and stirring was continued for 2 h. The reaction 
mixture was then quenched by sat. NaHCO3 (15 mL) and organic layer was washed by water 
(210 mL), brine (15 mL), dried by Na2SO4, and finally concentrated under vacuum. Purification 
was done by flash chromatography (ethyl acetate/hexane, 1:4) to afford 4.29 as a white solid 
(0.78 g, 93%). Mp: 242-244
o
C;
192
 
1
H NMR (CDCl3, 300 MHz) δ 7.17 (s, 1H, H-1), 6.41 (s, 1H, 
H-4), 4.81 (brs, 1H, ArOH), 2.80-2.78 (m, 2H), 2.47-2.39 (m, 2H), 2.35-1.93 (m, 5H), 1.63-1.38 
(m, 16H), 0.89 (s, 3H, H-18). 
187 
 
O
HO
Br
4.31  
2-t-Butyl-4-bromoestra-1,3,5(10)-triene-17-one (4.31). A mixture of 4.29 (200 mg, 0.6 
mmol) and NBA (84.5 mg, 0.6 mmol) in EtOH (10 mL) was stirred at room temperature for 12 
h. The solvent was then removed, and residue was dissolved in DCM (20 mL), washed with 
water (25 mL), dried with Na2SO4, and concentrated under vacuum. Purification was done by 
flash chromatography (ethyl acetate/hexane, 1:9) to afford 4.31 as a white solid (203 mg, 81%). 
Mp: 171-172
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.19 (s, 1H, H-1), 5.86 (s, 1H, ArOH), 2.95-2.87 
(m, 1H), 2.71-2.68 (m, 1H), 2.54-2.38 (m, 1H), 2.26-1.94 (m, 5H), 1.67-1.35 (m, 16H), 0.89 (s, 
3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 220.7 (C=O), 148.3,  134.1, 133.6, 132.4, 122.9 
(CHAr), 115.8, 50.3, 47.9, 44.4, 37.7 (CH), 35.8, 35.3, 31.6 (CH2), 30.9, 29.5 (C(CH3)3, 26.2, 
26.7 (CH2), 21.5 (CH2), 13.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 407 (M+H+2, 100), 405 
(M+H, 98); HRMS (ESI
+
) calcd for C22H30O2Br (M+H)
+
 405.1429; found 405.1434. 
O
HO
Br
O
4.32  
2-t-Butyl-4-bromo-17,17-ethylenedioxyestra-1,3,5(10)-trien-3-ol (4.32). To A stirred 
solution of 4.31 (180 mg, 0.4 mmol) in toluene (2.5 mL) and ethylene glycol (0.15 mL, 1.0 
mmol), was added PTSA (11.2 mg, 0.04 mmol) and the reaction under a Dean-Stark conditions 
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for 6 h. After that, the reaction was poured into sat. NaHCO3 solution (5 mL), diluted with ethyl 
acetate (5 mL), then organic layer was washed with water, brine, dried with Na2SO4, and 
concentrated under vacuum. Purification was done by flash chromatography (ethyl 
acetate/hexane, 1:9) to afford 4.32 as a white solid (101 mg, 51%). Mp: 163-164
o
C; 
1
H NMR 
(CDCl3, 300 MHz) δ 7.19 (s, 1H, H-1), 5.82 (s, 1H, ArOH), 3.96-3.85 (m, 4H, OCH2CH2O), 
2.89-2.81 (m, 1H), 2.65-2.63 (m, 1H), 2.35-2.24 (m, 2H), 2.02-1.92 (m, 2H), 1.85-1.80 (m, 2H), 
1.79-1.75 (m, 3H), 1.74-1.71 (m, 3H), 1.54-1.27 (m, 13H), 0.86 (s, 3H, H-18); 
13
C NMR 
(CD3OD, 75 MHz) δ 149.1, 134.6, 133.5, 132.5, 122.3 (CHAr), 119.0, 115.5, 64.8, 64.2, 50.1, 
45.8, 44.1, 38.5, 34.8, 33.7, 30.8, 30.5, 28.7 (C(CH3)3, 27.1, 26.2, 21.8 (CH2), 13.4 (CH3, C-18); 
LRMS (ESI
+
) m/z (%) 449 (M+H+2, 40), 447 (M+H, 30), 415 (100); HRMS (ESI
+
) calcd for 
C24H32O3Br (M+H)
+
 447.1535; found 447.1534.
 
O
BnO
Br
O
4.33  
3-Benzyloxy-4-bromo-2-t-Butyl-17,17-ethylenedioxyestra-1,3,5(10)-triene (4.33). To 
a stirred solution of 4.32 (50 mg, 0.11 mmol) in acetone (5 mL), was added K2CO3 (17 mg, 0.12 
mmol), and the mixture was stirred for 30 min., after that, BnBr (16 uL, 0.13 mmol) was added 
and stirring was continued overnight. Solvent was then removed under vacuum, and residue was 
dissolved in water (10 mL), extracted by DCM (25 mL), washed with water, dried with 
Na2SO4, and concentrated under vacuum. Purification was done by flash chromatography 
(methanol/chloroform, 0.5:9.5) to afford 4.33 as a pale yellow solid (5 mg, 8%). 
1
H NMR 
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(CDCl3, 300 MHz) δ 7.46 (d, J = 7.5 Hz, 2H, ArH), 7.42-7.30 (m, 4H, ArH and H-1), 5.08 (s, 
1H, C6H5CH2O), 3.97-3.89 (m, 4H, OCH2CH2O), 2.93-2.92 (m, 1H), 2.67 (m, 1H), 2.32-2.28 
(m, 2H), 2.03-1.99 (m, 2H), 1.82-1.77 (m, 3H), 1.61-1.30 (m, 13H), 0.88 (s, 3H, H-18). 
O
MOMO
4.34  
Estra-1,3,5(10)-triene-3-(methoxymethyl)ether-17-one (4.34). To a stirred mixture of 
E1 (250 mg, 0.9 mmol) in THF (4 mL) at 0
o
C, was added DIPEA (0.25 mL, 1.4 mmol), and 
continue stirring at 0
o
C for 30 min., then MOMCl (0.1 mL, 1.4 mmol) was added. The reaction 
mixture was allowed to warm up to room temperature and stirring was continued for another 1 h, 
then refluxed for 24 h. The reaction was then cooled to room temperature, and quenched with 
NH4Cl, extracted with ether (215 mL), washed with brine, dried with Na2SO4, and finally 
concentrated under vacuum. Purification was done by flash chromatography (ethyl 
acetate/hexane, 1:4) to afford 4.34 as a white solid (195 mg, 67%). Mp: 97-99
o
C;
201
 
1
H NMR 
(CDCl3, 300 MHz) δ 7.18 (d, J = 8.6 Hz, 1H, H-1), 6.81 (dd, J = 2.4 and 8.8 Hz, 1H, H-2), 6.77 
(brs, 1H, H-4), 5.13 (s, 2H, CH3OCH2O), 3.45 (s, 3H, CH3OCH2O), 2.88-2.85 (m, 2H), 2.46-
2.36 (m, 2H), 2.15-1.95 (m, 5H), 1.60-1.41 (m, 7H), 0.88 (s, 3H, H-18). 
O
MOMO
Br
4.35  
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4-Bromo-estra-1,3,5(10)-triene-3-(methoxymethyl)ether-17-one (4.35). Method A To 
a stirred solution of 4.17 (100 mg, 0.25 mmol) in THF (5 mL), was added DIPEA (76 µL, 0.8 
mmol, Hungi‘s base) and stirring was continued at 0oC for 30 min. MOMCl (33 µL, 0.8 mmol) 
was then added and the reaction was allowed to warm up to room temperature for 1 h, then 
refluxed for 24 h. After that, reaction was cooled to room temperature, and quenched with 
NH4Cl, extracted with ether (210 mL), dried with Na2SO4. Purification was achieved by flash 
chromatography (ethyl acetate/hexane, 1:9) to afford 4.35 as a white solid (54 mg, 48%). Mp: 
171-173
o
C;
202
 
1
H NMR (CDCl3, 300 MHz) δ 7.18 (d, J = 8.6 Hz, 1H, H-1), 6.94 (d, J = 8.6 Hz, 
1H, H-2), 5.19 (s, 2H, CH3OCH2O), 3.48 (s, 3H, CH3OCH2O), 2.99-2.97 (m, 1H), 2.46-2.34 (m, 
2H), 2.15-1.91 (m, 7H), 1.60-1.40 (m, 6H), 0.86 (s, 3H, H-18). Method B To a stirred solution of 
4.17 (100 mg, 0.25 mmol) in DMF (5 mL), was added t-BuOK (40 mg, 0.37 mmol) and stirring 
was continued at 0
o
C for 10 min. MOMCl (26 µL, 0.37 mmol) was then added and the reaction 
was allowed to warm up to room temperature for 1 h, then refluxed for 24 h. After that, reaction 
was cooled to room temperature, and quenched with sat. NH4Cl solution, dilute with water (5 
mL), filter the formed precipitate, recrystallize from ethanol, and finally dried under high 
vacuum for overnight  to obtain 4.35 as a white solid (110 mg, 65%). 
OH
MOMO
Br
4.36  
4-Bromo-estra-1,3,5(10)-triene-3-(methoxymethyl)ether-17-ol (4.36). To a stirred 
solution of 4.35 (100 mg, 0.25 mmol) in methanol (5 mL) at 0
o
C, was added NaHB4 (54 mg, 
0.07 mmol), and stirring was continued for 1.5 h. at the same temperature. Quenched with sat. 
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NH4Cl solution, extracted with chloroform (27.5 mL), washed with water, dried with Na2SO4, 
and concentrated under vacuum to afford 4.36 as a white solid which used without further 
purification (100 mg, 99%). Mp: 155-157
o
C;
202
 
1
H NMR (CDCl3, 300 MHz) δ 7.19 (d, J = 8.5 
Hz, 1H, H-1), 6.94 (d, J = 8.6 Hz, 1H, H-2), 5.20 (s, 2H, CH3OCH2O), 3.70 (app. q, J = 8.7 Hz, 
1H, H-17), 3.50 (s, 3H, CH3OCH2O), 2.99-2.93 (m, 1H), 2.68 (m, 1H), 2.31-1.94 (m, 5H), 1.92-
1.91 (m, 1H), 1.49-1.27 (m, 7H), 0.75 (s, 3H, H-18). 
OMe
MOMO
Br
4.37  
4-Bromo-17-methoxy-estra-1,3,5(10)-triene-3-(methoxy methoxy)ether (4.37). To a 
stirred solution of 4.36 (100 mg, 0.25 mmol) in DMF (5 mL) at 0
o
C, was added t-BuOK (40 mg, 
0.37 mmol) and stirring was continued at 0
o
C for 5 min. A solution of MeI (21 µL, 0.32 mmol) 
in DMF (1 mL) was then added and the reaction was stirred at room temperature for 15 h, then 
the reaction was quenched with sat. NH4Cl solution, diluted with water (10 mL), and the formed 
precipitate was filtered, and recrystallized from ethanol obtain 4.37 as a white solid (80 mg, 
46%). Mp: 155-157
o
C;
202
 
1
H NMR (CDCl3, 300 MHz) δ 7.19 (d, J = 8.6 Hz, 1H, H-1), 6.95 (d, J 
= 8.6 Hz, 1H, H-2), 5.22 (s, 2H, CH3OCH2O), 3.51 (s, 3H, CH3OCH2O), 3.37 (s, 3H, OCH3), 
3.30 (t, J = 8.1 Hz, 1H, H-17), 3.01-2.93 (m, 1H), 2.75-2.68 (m, 1H), 2.29-1.92 (m, 5H), 1.71-
1.16 (m, 9H), 0.77 (s, 3H, H-18).  
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O
HO
O
4.39  
2-t-Butyl-17,17-ethylenedioxyestra-1,3,5(10)-trien-3-ol (4.39). To A stirred solution of 
4.29 (250 mg, 0.76 mmol) in toluene (5 mL) and ethylene glycol (0.20 mL, 1.9 mmol), was 
added PTSA (13 mg, 0.07 mmol) and the reaction under a Dean-Stark conditions for 6 h. After 
that, the reaction was quenched with sat. NaHCO3 solution (10 mL), diluted with ethyl acetate (5 
 2 mL), then organic layer was washed with water, brine, dried with Na2SO4, and concentrated 
under vacuum. Purification was done by flash chromatography (ethyl acetate/hexane, 0.5:99.5) 
to afford 4.39 as a white solid (133 mg, 47%). Mp: 144-146
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 
7.14 (s, 1H, H-1), 6.38 (s, 1H, H-4), 3.96-3.87 (m, 5H, 3-OH and OCH2CH2O), 2.73 (m, 2H), 
2.66-2.62 (m, 1H), 2.31 (m, 3H), 2.00-1.72 (m, 10H), 1.51-1.22 (m, 24H), 0.86 (s, 3H, H-18). 
OH
HO
4.41  
2-t-Butyl-estra-1,3,5(10)-triene-3,17-diol (4.41). To a stirred mixture solution of 4.29 
(500 mg, 1.53 mmol) in ethanol/THF (30 mL, 1:1) mixture, was added sodium borohydride (250 
mg, 6.1 mmol), and stirring was continued for 2 h, after that it was quenched with aqu. NH4Cl 
solution, extracted with ethyl acetate, washed with water, brine, dried with Na2SO4, and finally 
concentrated under vacuum to afford 4.41 as white solid (500 mg, 97%). The compound was 
used in the next step without further purification. Mp: 174-176
o
C;
193
 
1
H NMR (CDCl3, 300 
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MHz) δ 7.18 (s, 1H, H-1), 6.39 (s, 1H, H-4), 3.72 (t, J = 8.2 Hz, 1H, H-17), 2.78-2.73 (m, 2H), 
2.30 (m, 1H), 2.17-2.12 (m, 3H), 1.96-1.92 (m, 2H), 1.51-1.16 (m, 19H), 0.76 (s, 3H, H-18). 
O
HO
F
 
2- and 4-Fluoroestra-1,3,5(10)triene-17-one.
185
 A stirred mixture of E1 (250 mg, 0.9 
mmol), and NFPT (460 mg, 1.85 mmol) in 1,1,2-TCE (10 mL) was refluxed for 24 h, then 
solvent was removed under vacuum, and mixture was poured into water (20 mL), extracted with 
DCM (2x10 mL), dried with Na2SO4, and finally concentrated. Purification by different flash 
chromatography systems failed completely to separate two isomers a part, and gave a brown 
solid (360 mg). 
19
F NMR (CDCl3, 282 MHz) δ -145 and -146. 
O
AcO
F
 
2- and 4-Fluoro-3-acetyloxy-estra-1,3,5(10)triene-17-one.
185
 To a stirred solution of 
previous mixture (360 mg) in pyridine (2.5 mL), was added acetic anhydride (0.7 mL), and 
mixture was refluxed for 2 h. The solvent was then removed under vacuum, residue was poured 
into ice-water mixture (15 mL), and precipitate formed was filtered, washed with water, and 
finally dried under high vacuum for overnight. Purification by different flash chromatography 
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systems failed completely to separate two isomers a part, and gave a white solid (400 mg). 
19
F 
NMR (CDCl3, 282 MHz) δ -134 and -135. 
OH
HO
F
4.44  
4-Fluoro-2-t-butyl-estra-1,3,5(10)-triene-3,17-diol (4.44). To a stirred solution of 4.43 
(250 mg, 0.76 mmol) in 1,1,2-TCE (10 mL), was added NFPT (207 mg, 0.84 mmol), then the 
mixture was refluxed for 24 h. after that, it was cooled down, and solvent was azeotropically 
removed with toluene (10 mL), then residue was mixed with water (10 mL), extracted by DCM 
(2x10 mL). The organic layer was washed with water (2x5 mL), dried with Na2SO4, and finally 
concentrated under vacuum. Purification was achieved by flash chromatography (ethyl 
acetate/hexane, 1:9) to afford 4.44 as a pale brown solid (36 mg, 14%). Mp: 213-214
o
C; 
1
H 
NMR (CDCl3, 300 MHz) δ 6.96 (s, 1H, H-1), 5.28 (d, J = 7.6 Hz, 1H, ArOH), 3.73 (t, J = 8.0 
Hz, 1H, H-17), 2.86-2.84 (m, 1H), 2.62 (m, 1H), 2.30 (m, 1H), 2.16-2.04 (m, 2H), 1.97-1.93 (m, 
2H), 1.50-1.16 (m, 22H), 0.77 (s, 3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -147. 
HO
O
F
4.45  
2-t-Butyl-4-fluoroestra-1,3,5(10)-triene-17-one (4.45). A stirred mixture of 4.29 (1.9 g, 
6.0 mmol) and NFPT (2.9 g, 12.0 mmol) in DCE (50 mL) in a glass pump under Argon 
195 
 
atmosphere was heated at 135
o
C for 15 h. DCE was then removed under high vacuum and water 
(90 mL) was added and reaction mixture was extracted with DCM (230 mL). The combined 
organic extracts were washed with water, brine, dried with Na2SO4, and finally concentrated 
under vacuum. Purification was achieved by flash chromatography (ethyl acetate/hexane, 1:5) to 
afford 4.45 as a pale brown solid (330 mg, 16%). Mp: 181-183
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 
6.96 (s, 1H, H-1), 5.29 (d, J = 7.5 Hz, 1H, ArOH), 2.97 (m, 1H), 2.91-2.89 (m, 1H), 2.49-2.46 
(m, 2H), 2.21-1.95 (m, 5H), 1.62-1.34 (m, 16H), 0.90 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) 
δ 220.9 (C=O), 151.1, 148.0, 140 (d, J = 15.2 Hz, C-2), 134.9, 131 (d, J = 3.9 Hz), 121.3 (d, J = 
15.7 Hz, C-6), 117.9 (CHAr), 50.3, 47.9, 44.0 (d, J = 2.1Hz), 38.0 (CH), 35.8, 34.9, 31.5 (CH2), 
29.5, 25.7 (2 CH2), 22.0 (d, J = 3.9 Hz), 21.5 (CH2), 13.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 
MHz) δ -147; LRMS (ESI+) m/z (%) 345 (M+H, 100); HRMS (ESI+) calcd for C22H30O2F 
(M+H)
+
 345.22243; found 345.22235. 
HO
F
O
4.30  
4-Fluoroestra-1,3,5(10)-triene-17-one (4.30). To a stirred solution of 4.45 (325 mg, 0.9 
mmol) in DCM (40 mL), was added nitromethane (1.1 mL, 21.7 mmol), the mixture was then 
cooled to 0
o
C before addition of AlCl3 (1.26 g, 9.4 mmol). Stirring was continued at 0
o
C for 2 h, 
and then quenched by ice, acidified by HCl (1 M), extracted by ethyl acetate (210 mL), washed 
with water, brine, dried with Na2SO4, and finally concentrated under vacuum. Purification was 
done by flash chromatography (ethyl acetate/hexane, 3:7) to afford 4.30 as pink solid (108 mg, 
40%). Mp: 221-222
o
C;
185
 
1
H NMR (CDCl3, 300 MHz) δ 6.92 (d, J = 8.6 Hz, 1H, H-1), 6.78 (2 
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overlapping d, J = 8.8 Hz, 1H, H-2), 4.90 (d, J = 4.4 Hz, 1H, ArOH), 3.00-2.92 (m, 1H), 2.73-
2.69 (m, 1H), 2.54-2.45 (m, 1H), 2.36-2.33 (m, 1H), 2.22-1.91 (m, 5H), 1.61-1.24 (m, 7H), 0.89 
(s, 3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -146. 
HO
F
HN
4.46  
4-Fluoro-17-benzylamino-estra-1,3,5(10)-triene (4.46). To a stirred solution of 4.30 
(100 mg, 0.35 mmol) in DCE/THF (10 mL, 1:1) mixture, was added benzylamine (150 mg, 1.4 
mmol), glacial acetic acid (0.1 mL, 1.4 mmol), and STABH (185.4 mg, 0.9 mmol). Stirring was 
continued for 48 h, and then quenched with sat. NaHCO3 solution, extracted by DCM (20 mL), 
washed with water, brine, dried with Na2SO4, and concentrated. Purification by flash 
chromatography (methanol/chloroform, 1:9) to give 4.46 as a white solid (80 mg, 61%). Mp: 
211-213
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.32-7.25 (m, 5H, ArH), 6.91 (d, J = 8.6 Hz, 1H, H-
1), 6.75 (2 overlapped d, J = 8.6 Hz, 1H, H-2), 3.99-3.71 (m, 4H, ArCH2, NH, ArOH), 2.87-2.85 
(m, 1H), 2.70-2.64 (m, 2H), 2.22-2.02 (m, 5H), 1.90 (m, 1H), 1.72-1.69 (m, 1H), 1.49-1.21 (m, 
8H), 0.78 (s, 3H, H-18); 
13
C NMR (CDCl3, 75 MHz) δ 150.6, 147.5, 140.1 (d, J = 14.8 Hz, C-2), 
140.7, 133.6 (d, J = 3.1 Hz), 128.3 (2 CHAr), 128.0 (2 CHAr), 126.8 (CHAr), 124.1 (d, J = 14.1 
Hz, C-6), 120.7 (d, J = 3.8 Hz, CHAr), 113.8 (d, J = 2.2 Hz, CHAr), 68.1 (CH-17), 52.6 
(CH2C6H5), 52.1, 43.8 (d, J = 2.1 Hz), 43.1, 38.2 (CH), 37.9, 29.5, 26.4 (2 CH2), 23.5, 22.3 (d, J 
= 4.3 Hz), 11.8 (CH3, C-18); 
19
F NMR (CDCl3, 282 MHz) δ -144; LRMS (ESI
+
) m/z (%) 380 
(M+H, 100); HRMS (ESI
+
) calcd for C25H31NOF (M+H)
+
 380.2390; found 380.2380. 
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F
NH2
4.47  
4-Fluoro-17-amino-estra-1,3,5(10)-triene (4.47). To a stirred solution of 4.46 (80 mg, 
0.2 mmol) in methanol (10 mL), 10% Pd/C (13 wt%, 15 mg) was added, and the system was kept 
under H2 atmosphere for overnight. After that, the reaction mixture was filtered through Celite, 
and concentrated under vacuum. Purification was done by flash chromatography 
(methanol/chloroform/NH4OH, 4:95:1%) to afford 4.47 as a pale brown solid (42 mg), which 
turned out to be a mixture of two compounds, one of them is our target compound and this was 
clear from 
1
H NMR, 
19
F NMR, and LRMS, so it was used in the next step without further trials 
to separate it from the other compound. Here we are listing the 
1
H NMR (CD3OD, 300 MHz) δ 
6.84 (d, J = 8.3 Hz, 2H, ArH), 6.67 (2 overlapping d, J = 8.9 Hz, 2H, ArH),  2.90-2.62 (m, 6 H), 
2.47 (brs, 2H), 2.29-2.04 (m, 7H), 1.92-1.88 (m, 2H), 1.77-1.74 (m, 2H), 1.45-1.19 (m, 15H), 
0.76 (s, 3H), 0.71 (s, 3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -144; LRMS (ESI
+
) m/z (%) 304 
(100%), 290 (M+H, 78). 
O
F
HN
S CF3
O
O
S
F3C
O O
4.48  
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4-Fluoro-17-(3'-trifluoromethylbenzene)sulfonamide-estra-1,3,5(10)-trien-3-yl-(3'-
tirfluoromethyl)benzene sulfonate (4.48). To a solution of 4.47 (42 mg) in pyridine (1 mL), 
was added a solution of 3'-CF3-benzenesulfonyl chloride in DCM (0.5), and stirring was 
continued for overnight. Pyridine was azeotropically removed with toluene, residue was 
dissolved in ethyl acetate (5 mL), washed with water, brine, dried with Na2SO4, and concentrated 
under vacuum. Purification was achieved by flash chromatography (methanol/chloroform, 
0.5:9.5) to afford 4.48 as a white solid (31 mg). Mp: 221-222
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 
8.14-8.05 (m, 4H, ArH), 7.91 (d, J = 7.8 Hz, 1H, ArH), 7.81 (d, J = 7.8 Hz, 1H, ArH), 7.72-7.63 
(m, 2H, ArH), 7.00-6.90 (m, 2H, ArH), 4.58 (d, J = 9.6 Hz, 1H, NH), 3.20 (q, J = 8.5 Hz, 1H, H-
17), 2.79-2.71 (m, 1H), 2.53-2.50 (m, 1H), 2.22-2.15 (m, 2H), 1.88-1.82 (m, 3H), 1.74-1.53 (m, 
5H), 1.37-1.09 (m, 7H), 0.70 (s, 3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -133.0 (F-C-4), -63.0 
(-NHSO2C6H4CF3). 
HO
F
HN
S CF3
O
O
4.49  
4-Fluoro-17-(3'-trifluoromethylbenzene)sulfonamide-estra-1,3,5(10)-trien-3-ol 
(4.49). To a stirred solution of 4.48 (31 mg, 0.04 mmol) in methanol (2 mL), was added a 
solution of potassium carbonate (6 mg, 0.04 mmol) in water (0.1 mL), and stirring was continued 
for 2 h. after that the reaction mixture was diluted with water (2 mL), neutralized with dil. HCl, 
extracted with DCM, washed with brine, dried with Na2SO4, and finally concentrated. 
Purification was done by flash chromatography (ethyl acetate/hexane, 1:4) to afford 4.49 as a 
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white solid (13 mg, 62%). Mp: 253-255
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 8.14 (s, 1H, ArH), 
8.06 (d, J = 7.4 Hz, 1H, ArH), 7.81 (d, J = 7.5 Hz, 1H, ArH), 7.65 (2 overlapping d, J = 7.7 Hz, 
1H, ArH), 6.89 (d, J = 8.2 Hz, 1H, H-1), 6.76 (2 overlapping d, J = 8.5 Hz, 1H, H-2), 4.86 (brs, 
1H, ArOH), 4.46 (d, J = 9.3 Hz, 1H, NH), 3.21 (m, 1H, H-17), 2.91-2.85 (m, 1H), 2.62-2.58 (m, 
1H), 2.22-1.65 (m, 7H), 1.42-1.13 (m, 7H), 0.70 (s, 3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -
146 (F-C-4), -63 (2 C6H4CF3); LRMS (ESI
+
) m/z (%) 498 (M+H, 58), 273 (100); HRMS (ESI
+
) 
calcd for C25H28NO3F4S (M+H)
+
 498.1726; found 498.1723. 
4.5.3 Inhibition Studies 
4.5.3.1 General 
STS was purified as previously described in Chapter 2. All buffers and assay reagents 
were purchased form Sigma Aldrich (Milwaukee, WI, USA). All fluorescent measurements were 
carried out on a SpectraMax GeminiXS
®
 fluorimeter (Molecular Devices, Sunnyvale, CA, USA) 
at 24 
o
C in black microtiter plates from Corning (Corning, MA, USA). All determinations were 
carried out in triplicate and errors reported as  5% of obtained results. 
4.5.3.2 Determination of IC50 for compounds 4.9, 4.10, 4.13-4.16, 4.27, 4.28, 4.51-4.53 
20 µL of inhibitor stock solution in DMSO/0.1 M Tris-HCl, pH 7.0 (1:1), were added to 
the wells of a 96-well microtiter plate containing 140 µL of 0.1 M Tris, pH 7.0. After that, 20 µL 
of a 2 mM MUS stock solution in 0.1 M Tris–HCl, pH 7.0, was added. The assay was initiated 
by adding 20 µL STS (100 nM stock solution in 20 mM Tris–HCl, pH 7.4, 0.1% Triton X-100). 
The final concentration of inhibitor ranged from 5 nM to 5 µM. The final concentration of 4-
MUS was 200 µM, and 10 nM for STS. The reactions were followed as described before in § 
3.5.3.2. Each reaction was performed in quadruplicate. Additional controls were performed in an 
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identical manner but did not contain STS. Eleven concentrations of inhibitor bracketing the IC50 
value were used for each compound. The initial rates of enzyme activity in relative fluorescence 
units per second (RFU/s) were used to determine the IC50. The ratio of the initial rate in the 
presence of inhibitor (Vi) to that in the absence of inhibitor (Vo) was calculated and plotted as a 
semi-log curve in Grafit (Erithacus Software, Surrey, U.K.), from which the IC50 value was 
calculated based on the following equation: Vi = Vo/[1 + ([I]/IC50)S] + B, where: Vi is the initial 
rate of reaction at an inhibitor concentration of [I]; Vo is the velocity in the absence of inhibitor; 
B is background and s is the slope factor. 
4.5.3.3 Determination of IC50 for Tight-Binding Inhibitors, compounds 4.11, 4.12, 4.49, and 
4.54. 
The IC50 was be determined for each compound as described in § 4.5.3.2 at a number of 
different enzyme concentrations (stock solutions of 50, 100, 200, and 400 nM).  A plot of IC50 as 
a function of [E]T was constructed. The y-intercept provided the apparent Ki. The final 
concentration of STS in the plate will be 5, 10, 20, and 40 nM, (See Appendix B for IC50 plots 
used for construction of each compound apparent Ki plot). 
4.5.3.4 Determination of Ki and Ki of compound 4.2 
20 mL of MUS stock solution in 0.1 M Tris-HCl of pH 7.0 was added to the wells of a 
96-well microtiter plate containing 140 mL 0.1 M Tris-HCl buffer of the same pH such that the 
total volume was 160 µL. To the wells was added 20 µL of a stock solution of inhibitor in 50% 
DMSO, (for a control, 20 µL of 50% DMSO was added instead). The assay was initiated by the 
addition of 20 µL STS (100 nM stock solution in 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100). 
To detect non-enzymatic hydrolysis of the substrate 20 µL of 20 mM Tris-HCl, pH 7.4, 0.1% 
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Triton X-100 was added instead. The final volume of the assay was 200 µL. The final 
concentration of buffer was 184 mM Tris-HCl, 0.01% Triton X-100, and 5% DMSO. The final 
enzyme concentration was 10 nM.  
For studies with compound 4.2 at pH 7.0, the final concentration of MUS was 100–500 
µM, the final concentration of inhibitor was 1-3 times IC50. The reactions were followed by 
detection of fluorescent product, 4-methylumbelliferone (excitation 360 nm, emission, 460 nm), 
over 10 min at 24
o
C. Each reaction was performed in quadruplicate. Additional controls were 
performed in an identical manner but did not contain STS. Initial rates (v) were determined by 
taking the slopes of plots of the change in relative fluorescence units with time. These data were 
plotted as Lineweaver–Burk graphs and Ki and aKi values were calculated from re-plots of the 
slopes or intercepts of the Lineweaver–Burk graphs according to the equations for mixed and 
competitive inhibition. 
4.5.3.5 Examining Time- and/or Concentration-dependent Inhibition of STS with 
compound 4.50 
Compound 4.50 was screened for time- and/or conc.-dependent inhibition by incubating 
180 L solution of various concentrations of compound 4.50, in buffer containing 0.1 M tris, pH 
7.0, a 20 L solution of 400 nM STS in 20 mM tris, pH 7.4, 0.1% Triton X-100 was added. 
Controls which did not contain inhibitor were performed for all experiments. These mixtures 
were allowed to incubate at 24 
o
C and 4 L aliquots were removed at various time intervals and 
added to the wells of a 96-well microtiter plate containing 196 L of 4 mM of 4-MUS sulfate in 
assay buffer. The final concentrations of compound 4.50 were ranging from 50 nM to 1 M. The 
production of the fluorescent product, 4-methylumbelliferone (4-MU), was followed for 10 
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minutes (ex = 360 nm, em = 460 nm) at 24 
o
C. The percent activity of STS in the presence of 
inhibitor after each time interval was calculated as a percentage of activity in the absence of 
inhibitor. 
4.5.3.6 Dialysis Experiment 
STS (400 nM) was incubated with compound 4.50 (1 M) in assay buffer (200 L) for 1 
hour. A control was also performed in an identical manner except that it did not contain inhibitor. 
4 L aliquots were withdrawn and STS activity was determined as described in § 4.5.3.2. After 
no more than 15% of activity was remaining, the remaining incubation mixture was dialyzed in 
micro-dialysis units into 1 L of 0.1 M tris, pH 7, 0.1 % Triton at 1-4C. The dialysis proceeded 
for 24 hours with the dialysis buffer changed after 3, 6, 9, and 12 hours. After 24 h, aliquots (4 
L) were withdrawn from the incubation mixture and diluted into 196 L of 4 mM MUS in 0.1 
M tris, pH 7 and STS activity followed as described in § 4.5.3.2. More than 70% of STS activity 
was recovered with compound 4.50. 
4.5.4 Molecular Modeling (Docking) Experiments 
Docking experiments were performed on compounds 4.3, 4.10, 4.17, 4.27, 4.30, and 4.49 
using Discovery Studio Client v2.5.0.9164 (2005-09), Accelrys Software Inc. as described in § 
3.5.4. 
4.5.5 In Vitro Screening with the NCI-60 panel 
4.5.5.1 General Method   
The NCI screen is performed as follows.  Cell suspensions are added by pipet (100 µL) 
into 96-well microtiter plates. Inoculates were allowed a preincubation period of 24 h at 37 °C 
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for stabilization.  Dilutions at twice the intended inhibitor concentration were added at t = 0 in 
100 µL aliquots to the microtiter plate wells. Incubations lasted for 48 h in a 5% CO2 atmosphere 
and 100% humidity. The cells were assayed by using a sulforhodamine B assay. A plate reader 
was used to read the optical densities.  From this data GI50, TGI or LC50 values are calculated. 
The GI50 is the concentration of inhibitor that causes 50% growth inhibition or the 
concentration of inhibitor where 100 × (T - T0)/(C - T0) = 50.  The optical density of the test 
well after a 48-h period of exposure to test drug is T, the optical density at time zero is T0, and 
the control optical density is C.  The ``50'' is called the GI50PRCNT that can have values from 
+100 to -100.  The TGI is the concentration of test drug where 100 × (T - T0)/(C - T0) = 0. Thus, 
the TGI signifies a cytostatic effect. The LC50, which signifies a cytotoxic effect, is the 
concentration of drug where 100 × (T - T0)/T0 = -50. The control optical density is not used in 
the calculation of LC50.  It is the concentration of inhibitor that causes 50% cell death.   
4.5.5.2 The In-Vitro Testing Results Data Sheet 
This page of the data package presents the experimental data collected against each cell 
line. The first two columns describe the subpanel (e.g. leukemia) and cell line (e.g. CCRF-CEM) 
involved. The next two columns list the Mean ODtzero and Mean OCctrl: the next five columns list 
the Mean ODtest for each of five different concentrations. Each concentration is expressed as the 
log10 (molar or g/ml). The next five columns list the calculated PGs for each concentration. The 
response parameters GI50, TGI, and LC50 are interpolated values representing the concentrations 
at which the PG is +50.0, and -50, respectively. Sometimes these response parameters cannot be 
obtained by interpolation. If, for instance, all of the PGs in a given row exceed +50, then none of 
the three parameters can be obtained by interpolation. In such a case, the value given for each 
response parameter is the highest concentration tested and is preceded by a ―>‖ sign. This 
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practice is extended similarly to the other possible situations where a response parameter cannot 
be obtained by interpolation, as shown in Appendix A and B. 
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Chapter 5 - Towards the Synthesis of an E1S Analog Bearing a 
Thiadiazolidinedione Sulfate Mimic and a 3-O-Sulfamate of a 17-
Arylsulfonamide STS Inhibitor 
 
5.1. Introduction 
In Chapter 1 (§ 1.3.1.1, Table 1.2) we discussed E1S derivatives bearing non-
hydrolyzable sulfate mimics as inhibitors of STS.  With the exception of the sulfamate group 
(H2NO2SO) and a few other mimics, this was not a particularly effective approach for obtaining 
STS inhibitors.  The phosphate group proved to be one of the more effective mimics in that the 
monoanionic form of estrone-1-phosphate (E1P, 1.14, Fig. 5.1) was a reversible competitive 
inhibitor with a Ki = 2-4 M at pH 7 and exhibited an affinity for STS that was similar to that of 
the natural substrate, E1S.  However, the use of this group as a sulfate mimic is very limited in 
terms of drug development as it would be labile to phosphatases and might prevent movement of 
such inhibitors across cell membranes.   
1.14 (E1P)
O
O
P
O
O
OH
 
Fig. 5.1  Structure of E1P. 
It is possible that a good phosphate mimic that is less highly charged than a phosphate 
group may act as a good sulfate mimic for STS inhibition.  The question is how does one 
evaluate and chose a phosphate mimic for a sulfatase?  One approach is to look at inhibitors of 
phosphatases.  Perhaps it is not particularly surprising that the phosphate group is a good sulfate 
mimic for STS inhibition as it has been recently reported that arylsulfatases and phosphatases are 
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evolutionarily related and that arylsulfatases have evolved from phosphatases.
203
  There are 
multiple phosphate mimics that have been examined in the context of protein tyrosine 
phosphatase (PTP) inhibition.
204
  Among the most effective are specific five-membered ring 
heterocycles, such as the thiadiazolidinedione group (5.1, Fig. 5.2).  Compounds bearing this 
group exhibit higher affinity for PTP‘s and have better cell permeability than the analogous 
compounds bearing a phosphate group.
205
  Since the phosphate group is a good sulfate mimic in 
the context of STS inhibition then it is possible that the thiadiazolidinedione group may also be a 
good sulfate mimic. 
N
S
HN
O
O O
R
5.1  
Fig. 5.2.  Structure of a thiadiazolidinedione group, 5.1 
 As mentioned above, one of the few other effective sulfate mimics (in the context of STS 
inhibition), besides the phosphate group, is the sulfamate group.  Compounds bearing this group, 
such as EMATE, are usually irreversible inhibitors of STS.  However, whether the sulfamate 
group is a true sulfate mimic is debatable since the mechanism by which the sulfamates inhibit 
STS and other sulfatases is still not known.  Cleavage of the S-O bond in the sulfamates by 
sulfatases is necessary for irreversible inhibition and biphasic kinetics are always observed.  
Using Tritiated EMATE (labeled on the steroid portion), it has been shown that no association of 
the labeled inhibitor with inactivated STS was detected indicating that the estrone portion is 
released after cleavage of the ArO-S bond.
44
 The stoichiometry of the inactivation process was 
reported to be 3-6 as determined by quantifying the release of the parent phenol with the highest 
values being observed for the most potent inactivators.
206
 This result implies that multiple 
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sulfamoylation events occur during the inactivation process.  On the basis of these studies an 
inactivation mechanism has been proposed in which elimination of the phenolic portion occurs, 
assisted by active site acid and base residues, and the amino sulfene, NH2SO2, is formed (Fig. 
5.3).  The reactive amino sulfene then reacts non-specifically with active site residues.  Further 
support for the elimination mechanism shown in Fig. 5.3 is that N,N-dialkyl-substituted 
sulfamates are reversible inhibitors of STS.
57
 
ArO S
O
O
N
H
H
B -ArO-
B
H
B
S
O
O NH
BH
nu
SO O
NH2
nu
Enz Enz
Enz
Enz
Enz
 
Fig. 5.3.  Proposed mechanism for the inactivation of sulfatases by sulfamates.  
 
We wish to learn more about how our 17-arylsulfonamide inhibitors, described in 
Chapters 3 and 4, interact with STS in comparison to sulfamoylated inhibitors such as EMATE.  
Would 3-O-sulfamoylation of our 17-arylsulfonamide inhibitors yield irreversible inhibitors or 
would the sulfamoyl group have little or no effect on inhibition as was the case when we 
prepared the 3-O-sulfated 17-arylsulfonamide inhibitors (compounds 4.54-4.57, Table 4.2). 
Should 3-O-sulfamoylation have no little or no effect on our 17-arylsulfonamide inhibitors then 
it would suggest that these inhibitors are not occupying any or, only part of, the active site.   
5.2. Objectives 
The objectives of the work in this chapter were two-fold. One was to evaluate the 
thiadiazolidinedione group 5.1 as a sulfate mimic for STS inhibition. This was to be achieved by 
synthesizing compound 5.2 and evaluating it as an STS inhibitor (Fig. 5.4).  The other was to 
evaluate the sulfamate group as a sulfate mimic in the context of our 17-arylsulfonamide 
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inhibitors described in Chapters 3 and 4 (compounds of type 5.3).  Below we report our 
preliminary work towards attaining these objectives. 
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Fig. 5.4.  Compounds 5.2 and the general structure of sulfamates 5.3. 
5.3. Results and Discussion 
5.3.1 Towards the synthesis of 5.2 
Aryl thiadiazolidinediones are prepared by the route outlined in Scheme 5.1.  An aniline 
derivative is alkylated with the methyl ester of -bromoacetate to give compound 5.4.  Reaction 
of 5.4 with sulfamoyl chloride gives compound 5.5, Scheme 5.1. 
H2N
R BrCH2COOMe
N
H
MeOOC
R
5.4
S
NH2
OO
NMeOOC
5.5
N
HN S
O
O
O
5.6
R
R
H2NSO2Cl
Scheme 5.1.  General route to the synthesis of aryl thiadiazolidinediones 
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Treatment of 5.5 with base results in cyclization and formation of the desired aryl 
thiadiazolidinedione 5.6.  Consequently, to prepare compound 5.2 the first step was to prepare 3-
aminoestrone (5.7, Fig. 5.5). 
 
H2N
O
5.7  
Fig. 5.5.  Structure of 3-amino estrone 5.7. 
3-Aminoestrone is a non-natural C-18 steroid and has been used as a key intermediate for 
the synthesis of biologically active steroid derivatives.  Unfortunately it is not commercially 
available. After examining literature syntheses of 5.7 we concluded that both the classical and 
recently described synthetic methods had some serious drawbacks such as poor yields or 
requiring expensive catalysts and/or ligands.
53,207-212
  
We decided to prepare 5.7 by a new approach in which acid 5.10 would be converted to 
an acyl azide followed by a Curtius rearrangement (Scheme 5.2).  The resulting isocyanate 
would be trapped with an alcohol to give a carbamate (5.11) which would be converted into 5.7 
(Scheme 5.2).  The synthesis began with the construction of triflate 5.8 using a literature 
procedure.
49
 Thus, estrone was treated with triflic anhydride (Tf2O), 4-dimethylaminopyridine 
(DMAP), and 2,6-lutidine to give triflate 5.8 in a 87% yield. Palladium catalyzed carboxylation 
of 5.8 using Pd(OAc)2/DPPP and CO gave the corresponding methyl ester 5.9 in 91% yield.
49
 
Our first attempt to hydrolyze ester 5.9 using aqueous LiOH (2N) solution resulted in just a 31% 
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conversion to the corresponding acid, 5.10, however; using a stronger base, ethanolic NaOH 
(1N), we obtained a 91% yield of 5.10. 
HO
O
HOOC
O
TfO
O
H2N
O
N
H
O
O
RO
MeOOC
O
conversion to 
amine
LiOH/H2O, THF, 
stirring rt, 3h 
(31%)
EtOH / NaOH (1N.)
stirring 60oC, rt ON
(91%) 5.10 5.11
E1
Tf2O, DMAP, DCM,
2,6-Lutidine, 0oC, 1.5 h
5.8 (87%)
Pd(OAc)2, DPPP,
MeOH, DMF, TEA,
CO, 70 oC, O/N
5.9 (91%)
5.7
1. acyl azide formation
2. isocyanate formation
3. ROH
 
Scheme 5.2. Synthesis of acid 5.10 and its proposed conversion to 5.7. 
We anticipated that the conversion of the carboxylic acid 5.10 to the corresponding 3-
amino derivative 5.7 would be a straightforward. We first tried to prepare the Boc-protected 
amine, 5.12, from acid 5.10.  Acid 5.10 was reacted with diphenyl phosphoryl azide (DPPA) to 
give the acyl azide (Scheme 5.3).  However, we did not obtain compound 5.12, after heating of 
the acyl azide followed by trapping of the resulting isocyanate with t-BuOH in presence of 
toluene and TEA. 
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HOOC
O
BocHN
O
N3OC
O
N
O
C
O
N3 - P t-BuOH
XToluene, DPPA, TEAt-BuOH, 100oC, O/N
Heat
Acyl Azide Isocyanate
5.125.10
 
Scheme 5.3.  First attempt to prepare Boc-protected amine 5.12. 
We tried another approach to 5.12 by reacting 5.10 using NaN3 and di-t-butyldicarbonate 
(Boc2O) in 1,2-dimethoxy ethane (DME) but still none of the desired carbamate was formed 
(Scheme 5.4).
213
 
HOOC
O
BocHN
O
X
NaN3, DME, Boc2O
75
o
C, 20 h
5.125.10  
Scheme 5.4.  Second attempt to prepare 5.12. 
We also tried trapping the isocyanate with sodium trimethylsilanolate (NaOTMS, 
prepared from hexamethyldisiloxane)
214
 as this tactic has been used as a one-pot synthesis of free 
amines from carboxylic acids (Scheme 5.5),
215
 however; this also did not work. 
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HOOC
O
H2N
O
X
1. DPPA, TEA, toluene, 
    reflux 3 h
2. Cooling 0
o
C, NaOTMS 
     in THF, then rt5.10 5.7  
Scheme 5.5.  Attempted preparation of 5.7 by trapping the isocyanate with NaOTMS. 
 
Peet and coworkers reported the synthesis of the hydrochloride salt of 5.7 in an 
unspecified yield from E1 via Smiles rearrangement of ether 5.13 followed by hydrolysis of the 
resulting amide 5.14 (Scheme 5.6).
216
 We decided to attempt to prepare 5.7 using this approach.  
Although Peet and coworkers reported a one-pot synthesis of ether 5.14 in a 59% yield,
216
 we 
were unable to obtain any significant quantities of this compound. 
HO
O
O
O
H2N
O
N
H
O
HO
O
HCl.H2N
O
X
X
NaH, Dioxane, stirring 30  min.
then
NaOH, DMA, stirring at 20- 30
o
C 1h, 
then                  reflux
E1
5.13
5.14 5.7
O
NH2
Br
, reflux, O/N
O
NH2
Br
 
Scheme 5.6.   Attempted synthesis of 5.7 via a Smiles rearrangement. 
 
Our next approach to 5.7 was to use a Pd(0)-catalyzed amination reaction as this 
approach was reported by several groups as an efficient route to 5.7 (Scheme 5.7).
210,211
  One of 
these reports used triflate 5.8 as substrate.  In our hands this reaction resulted mainly in the 
formation of E1, generated by the hydrolysis of triflate 5.8 under the alkaline reaction 
213 
 
conditions, and only trace amounts of 5.7 were obtained. Another report claimed that nonaflate 
5.15 gave better yields due to its greater hydrolytic stability.
217
 However, as with the triflate 5.8, 
very little of the desired product was obtained. 
O
Nf or TfO
H2N
O
X
1.  BnNH2, Pd(OAc)2 (10 mol%)/X-Phos 
     (10 mol%),  Cs2CO3,  DMF, sealed tube
    at 70 
o
C for 10 min.
2.  160
o
C, 10 min.
1.  Pd(OAc)2 (10 mol%)/ BINAP 
     15 mol%), Cs2CO3, Schlenk Tube
2.  BnNH2, Toluene and/or Dioxane
     100
o
C, 20 h
5.8 and/or 5.15
5.7
X
 
Scheme 5.7.  Attempted synthesis of 5.6 via a Pd(0)-catalyzed amination reaction. 
We then turned our attention back to the acyl azide/Curtius rearrangement approach.  We 
found a procedure which reported the synthesis of Boc carbamates from carboxylic acids in high 
yields by forming the acyl azides and performing the Curtius rearrangements in t-BuOH without 
the use of other solvents.
218
 Using this procedure carbamate 5.12 was obtained in a 85% yield 
(Scheme 5.8).  Deprotection of 5.12 was achieved in a 73% yield using TFA in DCM.
219
 The 
overall yield of 5.7 from E1 was 53%. 
HOOC
O
BocHN
O
t-BuOH, DPPA,
TEA,reflux, 18 h
5.12 (85%)5.10
O
H2N
TFA/DCM (1:1)
rt, 30 min.
5.7 (73%)  
Scheme 5.8.  Synthesis of carbamate 5.12 and the target amine 5.7.   
With a good synthesis of 5.7 in hand we then proceeded to the alkylation step using the 
methyl ester of -bromoacetate.  Unfortunately, we have not been able to get this reaction to 
proceed in a significant yield under a variety of reaction conditions (Table 5.1).  We attempted 
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this reaction using aniline as a model substrate and the conditions outlined in entry 6 in Table 
5.1.  In this case we obtained a 62% yield of the alkylated product.  This suggests that steric 
hindrance might be affecting our ability to alkylate 5.7.  The synthesis of compound 5.16 is still 
in progress in the Taylor group 
 
Table5.1. Alkylation of 5.7 under different conditions. 
H2N
O
Br
O
OMe
N
H
O
MeO
O
5.7 5.16  
Entry Base Equiv 
Equiv. 
(BrCH2COOMe) 
Solvent 
Temp 
(
o
C) 
Time 
(h) 
% Yield 
1 NaH 1.5 1.2 DMF rt 48 - 
2 NaH 1.5 1.2 DMF reflux 6 11.5 
3 NaH 1.5 1.2 DMSO rt 96 - 
4 NaH 1.5 1.2 DMSO 50 48 - 
5 K2CO3 1.2 1.5 MeOH rt 20 11.0 
6 DIPEA 2.5 1.0 DMF 60 24 7.0 
 
5.3.2 Attempts to prepare a sulfamate derivative of a 17β-arylsulfonamide inhibitor. 
Sulfamoylation of phenolic hydroxyl groups is achieved using either sulfamoyl chloride 
(ClSO2NH2), with or without the aid of a base, or by reaction with chlorosulfonyl isocyanate 
(CSI, ClSO2NCO) followed by hydrolysis of the isocyanate group. Although sulfamoylation 
with sulfamoyl chloride is the more direct approach, sulfamoyl chloride is very expensive.  
Although it can be readily prepared it does not store well and so it is usually not isolated and is 
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used immediately after its preparation.  The CSI approach tends to be more widely used as CSI is 
commercially available and much less expensive and more stable than sulfamoyl chloride. 
We started with the sulfamoylation of one of our most potent sulfonamide inhibitors, the 
3-CF3-benzene sulfonamide 3.33 using CSI as shown in Scheme 5.9.  Unfortunately, the reaction 
gave a mixture of many products, which were difficult to separate and none of them were our 
desired sulfamate.  It appeared that some sulfamoylation was occurring at the 2-position of the 
A-ring and none of the desired product, 5.17, was obtained. 
HN
HO
S
O
O
CF3
HN
O
S
O
O
CF3
S
H2N
O OX
1.  ClSO2NCO, C6H5CH3, 
     reflux, O/N
2.  Cool 0
o
C, H2O
3.33 5.17  
Scheme 5.9.  First approach to the synthesis of the sulfamate derivative of compound 3.33. 
Our next approach was to use sulfamoyl chloride itself which we generated in situ from 
CSI and formic acid in DCM.
220
 A solution of sulfonamide 3.33 in DMF was added drop-wise to 
the sulfamoyl chloride solution in presence of TEA at 0 
o
C.  Since sulfamoylation of phenols is 
usually carried out with a considerable excess of sulfamoyl chloride, due to reaction of sulfamoyl 
chloride with DMF, we also used an excess of this reagent (5-fold excess over phenolic 
derivative).  Not surprisingly sulfamoylation occurred at two positions; the 3-OH and at the NH 
of the sulfonamide group, to give compound 5.18 (Scheme 5.10). 
216 
 
HN
HO
S
O
O
CF3
X
N
O
S
O
O
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H2N
O
O
S
H2N
O O
HN
O
S
O
O
CF3
S
H2N
O O
Instead
1.  ClSO2NH2 (5 eq.), 
    DMF, 24 h
2.  Cool 0
o
C, H2O
3.33 5.17
5.18  
Scheme 5.10.  Sulfamoylation of 3.33 with sulfamoyl chloride. 
Okada and coworkers reported that N,N-dimethylacetamide (DMA) is a better solvent 
than DMF for carrying out sulfamoylation reactions claiming that sulfamoyl chloride is more 
stable in DMA than DMF and so the amount of sulfamoyl chloride can be reduced.
221
  We used 
their procedure using 2 equivalents of sulfamoyl chloride.  This time we obtained a product with 
a sulfamoyl group at the 2-position of A-ring (Scheme 5.11). 
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Scheme 5.11.  Sulfamoylation of 3.33 by sulfamoyl chloride (2 equiv) in DMA. 
We reasoned that a sterically hindered form of sulfamoyl chloride; such as benzyl 
derivative 5.22, would be more selective for the less sterically hindered 3-OH group.  After 
sulfamoylation the benzyl group would then be removed by hydrogenolysis.  Compound 5.22 
was prepared by a literature route (Scheme 5.12).
222
 However, using E1 as a model substrate; we 
were unable to obtain any sulfamoylated product (no reaction occurred) using this reagent 
(Scheme 5.13).  The synthesis of compound 5.17 is still in progress in the Taylor group.  
NH2
H
N
SO3H
H
N
SO2Cl
ClSO3H, DCM,
0
o
C, 30 min.
PCl5, Toluene,
reflux 3 h
5.20 5.21 5.22  
Scheme 5.12.   Preparation of benzyl sulfamoyl chloride, compound 5.22. 
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O
HO O
S
BnHN
O O
O
X
1.  5.23 (2 eq.), DMA, 
    24 h
2.  Cool 0
o
C, H2O
E1 5.23  
Scheme 5.13.  Attempted sulfamoylation of E1 using 5.23 in DMA. 
5.3. Conclusions and Future Work 
The thiadiazolidinedione group was proposed as a sulfate mimic for obtaining STS 
inhibitors.  A new approach to the synthesis of 3-amino estrone (5.7) was achieved as part of an 
attempt to prepare the thiadiazolidinedione target, compound 5.2.  This new approach made use 
of a Curtius rearrangement of an acyl azide precursor followed by trapping of the resulting 
isocyanate with t-butyl alcohol to give a t-butyl carbamate which was then converted to 5.7 using 
TFA.  Unfortunately, conversion of compound 5.7 into compound 5.2 was not achieved.  This is 
due to difficulties in achieving reasonable yields for the alkylation of 5.7 with the methyl ester of 
-bromoacetate.  We believe that this reaction can accomplished in reasonable yield though it 
will require more screening of alternate reaction conditions such as using other bases, solvents, 
reaction temperatures etc.  These studies are in progress in the Taylor group.   
3-O-Sulfamoylation of sulfonamide 3.33 was attempted using a variety of reaction 
conditions.  Unfortunately, side reactions have prevented us from achieving the synthesis of the 
target compound 5.17.  Nevertheless, we believe that this reaction can be accomplished in 
reasonable yield although it will require more screening of alternate reaction conditions such as 
using other bases, solvents, reaction temperatures etc.  The use of  sterically hindered organic 
base such as 2,6-lutidine may be useful here as the N-H of the sulfonamide group is more 
sterically hindered than the 3-OH of 3.33.   These studies are in progress in the Taylor group. 
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5.4. Experimental 
5.4.1 General 
All starting materials and reagents were obtained from Aldrich Chemical Company.  THF 
was distilled from sodium-benzophenone, DCM was distilled from calcium hydride under 
nitrogen.  Benzylamine was dried by distillation from KOH pellets and stored in dark over type 
4A molecular sieves. Dioxane was distilled from Na
o
 and stored over type 4A molecular sieves. 
t-Butyl alcohol was dried by distillation and standing over type 3A molecular sieves. Silica gel 
chromatography was performed using silica gel (60Å, 230-400 mesh) obtained from Silicycle 
(Laval, Quebec, Canada). 
1
H, 
13
C, and 
19
F NMR spectra were recorded on a Bruker Avance 300 
spectrometer.  For NMR spectra obtained using CDCl3 as the solvent, chemical shifts () for 
1
H 
NMR spectra are reported relative to internal Me4Si ( 0.0 ppm), chemical shifts for 
13
C spectra 
are relative to the residual solvent peak (77.0 ppm, central peak), and chemical shifts for 19F 
NMR are relative to a CFCl3 ( 0.0 ppm) external standard.  Low-resolution (LRMS) and high-
resolution (HRMS) electron impact (EI) and electrospray ionization (ESI) mass spectra were 
obtained on a JEOL HX110 double focusing mass spectrometer. Electrospray (ESI) mass spectra 
were obtained with a Waters/Micromass QTOF Ultima Global mass spectrometer. Melting 
points were determined on a Fisher-Johns melting point apparatus and are uncorrected. 
5.4.2 Syntheses 
TfO
O
5.8  
220 
 
Estra-1,3,5(10)-trien-17-one-3-trifluoromethanesulfonate (5.8). To a solution of E1 
(5.0 g, 18.4 mmol), DMAP (0.6 g, 4.6 mmol, 0.25 equiv) and 2,6-lutidine (4.6 mL, 4.0 mmol, 2.1 
equiv) in DCM (140 mL) at 0 
o
C was added triflic anhydride (3.5 mL, 22.1 mmol, 1.2 equiv) 
slowly. After addition, the reaction mixture was stirred for 70 min at 0 
o
C before quenching with 
2 M HCl (30 mL) at 0 
o
C. The organic layer was separated and washed with 2N HCl, 7.5% 
NaHCO3, and brine, then dried with Na2SO4 and concentrated. Purification by flash 
chromatography (ethyl acetate/hexane, 1:9 to 1:5), afforded 5.8 as a white solid, which was 
recrystallized from hexane to give E1-3-triflate, 5.8 as white crystals (6.4 g, 87%). Mp 77-78
o
C 
(lit. 75-77
o
C);
49
 
1
H NMR (CDCl3, 300 MHz) δ 7.33 (d, J = 8.7 Hz, 1H, H-1), 7.01 (d, J = 8.7 Hz, 
1H, H-2), 6.99 (m, 1H, H-4), 2.95-2.91 (m, 2H), 2.55-1.95 (m, 7H), 1.69-1.57 (m, 7H), 0.91 (s, 
3H, CH3, H-18); 
19F NMR (CDCl3, 282 MHz) δ -73.2. 
MeOOC
O
5.9  
3-Methoxycarbonylestra-1,3,5(10)-trien-17-one (5.9). To a mixture of E1-3-triflate 5.8 
(1.0 g, 3.2 mol), Pd(OAc)2 (35.5 mg, 0.2 mmol) and 1,3-bis(diphenylphosphino) propane (DPPP, 
60 mg, 0.14 mmol) in a 250 mL round bottom flask under argon was added DMF (5 mL), MeOH 
(5 mL) and TEA (1 mL, 7.6 mmol, 2.4 equiv) successively. After purging with CO, the reaction 
mixture was heated at 70 
o
C under CO (balloon) overnight (16 h) and then cooled to rt. The 
mixture was diluted with water, extracted with ether (25ml), the combined extracts were 
washed with 2N HCl (10 mL), sat. NaHCO3 (10 mL), and brine, then dried with Na2SO4) and 
concentrated. Purification by recrystallization from MeOH afforded 5.9 as a white solid (91% 
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yield). Mp 134-136
o
C (lit. 134-135 
o
C);
49
 
1H NMR (CDCl3, 300 MHz) δ 7.70 (d, J = 9.3 Hz, 2H, 
H-2 and H-4), 7.25 (m, 1H, H-1), 3.80 (s, 3H, CO2CH3), 2.87-2.84 (m, 2H), 2.47-1.86 (m, 7H), 
1.60-1.38 (m, 6H), 0.87 (s, 3H, CH3, H-18). 
HOOC
O
5.10  
3-Carboxy-1,3,5(10)-estratrien-17-one (5.10). Method A To a stirred solution of 5.9 
(500 mg, 1.6 mmol) in THF (15 mL), was added a solution of LiOH (677 mg, 16 mmol) in water 
(10 mL), and stirring was continued at room temperature for 3 h. Then the reaction was 
neutralized by 1N HCl, the precipitate formed was filtered, washed twice with water to afford 
5.10 as a white solid (148 mg, 31%). Method B To a stirred solution of 5.9 (1 g, 3.2 mmol) in 
ethanol (150 mL), was added aqueous solution of 1N NaOH (42 mL), and stirring was continued 
at 60 
o
C for overnight. After that, the reaction was cooled to 0 
o
C, and neutralized by 1N HCl, 
and the precipitate formed was filtered, washed with water to afford 5.10 as a white solid (870 
mg, 91%). Mp: 318-320 
o
C;
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1
H NMR (CDCl3, 300 MHz) δ 7.87-7.83 (m, 2H, ArH), 7.38 (d, J 
= 7.2 Hz, 1H, ArH), 2.96 (m, 2H, H-6), 2.55-2.34 (m, 3H), 2.18-1.96 (m, 4H), 1.60-1.52 (m, 
6H), 0.91 (s, 3H, H-18). 
NaOTMS
Si
CH3
CH3
CH3ONa
 
Preparation of Sodium Trimethylsilanolate (NaOTMS).
214
 To a stirred solution of 
hexamethyldisiloxane (4 g, 0.02 mol) in 1,2-dimethoxyethane (25 mL), NaOH (2.0 g, 0.05 mol) 
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was added. The reaction mixture was vigorously stirred at reflux temperature for 72 h. After that, 
the mixture was filtered and the crude residue was washed with boiling DME (250 mL). The 
filtrate was evaporated to dryness. Crude product was azeotropically dried with toluene (2 x 100 
mL) affording NaOTMS as white crystals (2 g, 37% yield). Mp: > 300
o
C (lit. > 395
o
C). 
Br
NH2
O
2-Br-2-methyl propionamide
 
2-Bromo-2-methylpropionamide (5.12).
216
 To a stirred solution of bromoisobutyryl 
bromide,  5.11 (2.6 g, 40 mmol) in hexane (30 mL) at 0 
o
C, was added conc NH4OH solution 
portion-wise over 30 min, and stirring was continued for additional 30 min at the same 
temperature. The resulting white precipitate was filtered, washed with cold water, and dried 
under high vacuum to afford 5.12 as a white solid (1.8 g, 100%). Mp 146-147 
o
C (lit. 146-148 
o
C); 
1
HNMR (CDCl3, 300 MHz) δ 6.50 (brs, 1H, NH2), 5.65 (brs, 1H, NH2), 1.95 (s, 6H, 2 CH3). 
NfO
O
5.15  
Estra-1,3,5(10)-trien-17-one-3-nonafluorobutane-1-sulfonate (5.15).
217
 To a solution 
of E1 (2.1 g, 7.8 mmol) in DCM (100 mL), was added TEA (0.25 mL, 11.6 mmol), then 
nonafluorobutanesulfonyl fluoride (0.6 mL, 11.6 mmol) was added, and stirring was continued 
for 20h. After that, the reaction was washed twice NaOH (5%, 10 mL) and water, then, the 
organic layer was dried with Na2SO4, and finally concentrated under vacuum. Purification was 
done by flash chromatography (ethyl acetate/hexane, 1:4) to afford 5.15 as white plates (1.0 g, 
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23%). Mp: 177-178
o
C ; 
1
H NMR (CDCl3, 300 MHz) δ 7.31 (d, J = 8.6 Hz, 1H, H-1), 7.03-6.97 
(m, 2H, H-2 and H-4), 2.94-2.90 (m, 2H, H-6), 2.47-1.94 (m, 7H), 1.61-1.44 (m, 6H), 0.89 (s, 
3H, H-18); 
19
F NMR (CDCl3, 282 MHz) δ -80.5, -108.8, -120.8, -125.7. 
BocHN
O
5.12  
3-(t-Butyloxycarbonyl)-amino-1,3,5(10)-estratrien-17-one (5.12). To a stirred solution 
of 5.10 (750 mg, 2.5 mmol) in t-BuOH (60 mL), was added TEA (75 µL, 5.4 mmol), and stirring 
was continued for 30 min., after that, DPPA (60 µL, 2.7 mmol) was added, and the mixture was 
refluxed for 18-20 h. The solvent was then removed under vacuum, and the residue was 
dissolved in ethyl acetate, washed with water (50 mL), dried with Na2SO4, and finally 
concentrated under vacuum. Purification was done by flash chromatography (ethyl 
acetate/hexane, 1:4) to afford 5.12 as a white solid (790 mg, 85%). Mp: 199-201
o
C; 
1
H NMR 
(CDCl3, 300 MHz) δ 7.18-7.15 (m, 2H, ArH), 7.01 (d, J = 8.4 Hz, 1H, ArH), 6.45 (s, 1H, NH), 
2.87-2.85 (m, 2H, H-6), 2.46-2.34 (m, 2H), 2.14-1.91 (m, 5H), 1.59-1.25 (m, 6H), 0.88 (s, 3H, 
H-18); 
13
C NMR (CDCl3, 75 MHz) δ 220.9 (C-17), 152.8 (NHCO), 137.3 (C-5), 136.0 (C-3), 
134.6 (C-6), 125.8 (CHAr), 118.8 (CHAr), 116.2 (CHAr), 50.4, 47.9 (C(CH3)3), 44.1, 38.2, 35.8, 
31.5, 29.5, 28.3 (C(CH3)3), 26.5, 25.8, 22.1, 21.5, 13.8 (CH3, C-18); LRMS (ESI
+
) m/z (%) 370 
(M+H, 42), 369 (M, 94), 367 (100%); HRMS (ESI
+
) calcd for C23H32NO3 (M+H)
+
 370.23767; 
found 370.23757. 
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H2N
O
5.7  
3-Amino-1,3,5(10)-estratrien-17-one (5.7). Method A A stirred solution of 5.12 (100 
mg, 0.27 mmol) in ethanol/(6 M) HCl mixture (5 mL, 1:1) was heated under reflux for 6 h, then 
solvent was removed under vacuum, and residue was dissolved in water (5 mL), neutralized with 
2 M NaOH, and precipitate formed was filtered and washed twice with water giving 5.7 as a 
white solid (25 mg, 11%). Method B To a stirred solution of 5.12 (300 mg, 0.8 mmol) in DCM 
(5 mL), was added TFA (5 mL) and stirring was continued for 0.5 h, then solvent was removed, 
and residue was dissolved in ethyl acetate, washed with sat. NaHCO3 solution, water, and brine, 
dried by Na2SO4, and finally concentrated under vacuum. Purification was done by flash 
chromatography (methanol/chloroform, 3:7) to afford 5.7 as a white solid (160 mg, 73%). Mp: 
197-199
o
C (lit. 199-200);
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1
H NMR (CDCl3, 300 MHz) δ 7.06 (d, J = 8.2 Hz, 1H, H-1), 6.50 
(dd, J = 2.3 and 8.2 Hz, 1H, H-2), 6.44 (brs, 1H, H-4), 3.49 (brs, 2H, NH2), 2.84-2.79 (m, 2H, H-
6), 2.52-2.44 (m, 1H), 2.36-2.33 (m, 1H), 2.20-1.90 (m, 5H), 1.60-1.36 (m, 6H), 0.89 (s, 3H, H-
18).  
N
H
O
MeO
O
5.16  
(Estra-1,3,5(10)-trien-17-on-3-ylamino)acetic acid methyl ester (5.16). Method A To a 
stirred solution of 5.7 (100 mg, 0.37 mmol) in acetone (10 mL) was added K2CO3 (102.3 mg, 
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0.74 mmol), and stirring was continued for 30 min., after that methyl bromoacetate (53 µL, 0.55 
mmol) was added. Stirring was continued for another 30 min at room temperature, and under 
reflux for 2 h, and then left at room temperature for overnight. The solvent was then removed, 
water (10 mL) was added, and the mixture was extracted with DCM (2x5 mL), dried with 
Na2SO4, and finally concentrated. Method B To a stirred solution of 5.7 (250 mg, 0.9 mmol) in 
DMF (20 mL) was added NaH (33 mg, 1.4 mmol) at 0 
o
C, and stirring was continued for 30 
min., after that methyl bromoacetate (0.25 mL, 1.1 mmol) was added. Stirring was continued for 
another 30 min at room temperature, and under reflux for 6 h. after that the reaction mixture was 
cooled to room temperature and poured into ice-water mixture, extracted with ethyl acetate 
(210 mL), washed with brine, dried with Na2SO4, and finally concentrated under vacuum. 
Method C to a stirred solution of 5.7 (50 mg, 0.18 mmol) in DMF (5 mL), was added DIPEA (78 
µL, 0.45 mmol) at 0 
o
C, and stirring was continued at oC for an hour, after that it was heated at 
60 
o
C for 40 h. the reaction was then cooled to room temperature, and poured into an ice-water 
mixture, washed with sat. NH4Cl, brine, dried with Na2SO4, and concentrated under vacuum. 
Purification by flash chromatography (ethyl acetate/hexane, 3:7) afforded 5.16 as a white solid. 
Mp: 189-191
o
C; 
1
H NMR (CDCl3, 300 MHz) δ 7.11 (d, J = 8.5 Hz, 1H, H-1), 6.45 (dd, J = 2.3 
and 8.3 Hz, 1H, H-2), 6.37 (brs, 1H, H-4), 4.24 (s, 1H, NH), 3.89 (s, 2H, NHCH2COOCH3), 3.76 
(s, 3H, NHCH2COOCH3), 2.85-2.82 (m, 2H, H-6), 2.47-1.91 (m, 7H), 1.57-1.44 (m, 6H), 0.88 (s, 
3H, H-18). 
NH2SO2Cl
Sulfamoyl Chloride  
Sulfamoyl chloride.
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 To an ice-cooled solution of chlorosulfonyl isocyanate (1.2 mL, 
14.1 mmol) in DCM (7 mL), was added a solution of formic acid (97%, 0.54 mL, 5 eq.) in DCM 
226 
 
(3 mL) drop-wise under argon atmosphere for 10 min. after that, the reaction was warmed to 
room temperature with stirring for additional hour, before being used in the sulfamoylation 
reaction. 
H
N
SO3H
5.21  
N-Benzyl sulfonic acid (5.21).
222
 To an ice-cooled solution of benzylamine 5.20 (2.2 
mL, 0.02 mmol) in DCM (20 mL), was cautiously added chlorosulfonic acid (0.4 mL, 610-3 
mmol). After complete addition, the resultant suspension was stirred at room temperature for 30 
min., and then filtered. The solid was dried by leaving under vacuum overnight, and used in the 
next step without further purification (3.0 g, 90% yield). 
H
N
SO2Cl
5.22  
N-Benzyl sulfamoyl chloride (5.22).
222
 To a stirred solution of 5.21 (3.0 g, 0.02 mmol) 
in toluene (25 mL), was added phosphorous pentachloride (3.32 g, 0.02 mmol). Stirring was 
continued under reflux for 3 h, and then solvent was removed under vacuum, and dried under 
vacuum overnight to afford 5.22 as a syrupy liquid (2.8 g, 85% yield) which was used for the 
sulfamoylation without further purification. 
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Appendix A – Supplementary Figures and Tables for Chapter 3 
 
 
Figure A.1. (a) IC50 plot for 3.3 (left). (b) IC50 plot for 3.4 (right). 
 
 
 
 
Figure A.2. (a) IC50 plot for 3.5 (left). (b) IC50 plot for 3.6 (right). 
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Figure A.3. (a) IC50 plot for 3.18 (left). (b) IC50 plot for 3.19 (right). 
 
    
 
Figure A.4. (a) IC50 plot for 3.20 (left). (b) IC50 plot for 3.21 (right). 
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Figure A.5. (a) IC50 plot for 3.22 (left). (b) IC50 plot for 3.23 (right). 
 
    
 
Figure A.6. (a) IC50 plot for 3.24 (left). (b) IC50 plot for 3.25 (right). 
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Figure A.7. (a) IC50 plot for 3.26 (left). (b) IC50 plot for 3.27 (right). 
 
 
      
 
Figure A.8. (a) IC50 plot for 3.28 (left). (b) IC50 plot for 3.29 (right). 
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Figure A.9. (a) IC50 plot for 3.30 (left). (b) IC50 plot for 3.31 (right). 
 
    
 
Figure A.10. (a) IC50 plot for 3.32 (left). (b) IC50 plot for 3.33 (right). 
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Figure A.11. (a) IC50 plot for 3.34 (left). (b) IC50 plot for 3.35 (right). 
 
   
 
Figure A.12. (a) IC50 plot for 3.36 (left). (b) IC50 plot for 3.37 (right). 
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Figure A.13. (a) IC50 plot for 3.38 (left). (b) IC50 plot for 3.39 (right). 
 
  
 
Figure A.14. (a) IC50 plot for 3.40 (left). (b) IC50 plot for 3.42 (right). 
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Figure A.15. (a) IC50 plot for 3.43 (left). (b) IC50 plot for 3.44 (right). 
 
     
 
Figure A.16. (a) IC50 plot for 3.45 (left). (b) IC50 plot for 3.46 (right). 
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Figure A.17. (a) IC50 plot for 3.47 (left). (b) IC50 plot for 3.48 (right). 
 
 
 
Figure A.18. (a) IC50 plot for 3.49 (left). (b) IC50 plot for 3.50 (right). 
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Figure A.19. (a) IC50 plot for 3.51 (left). (b) IC50 plot for 3.56 (right). 
 
 
 
Figure A.20. (a) IC50 plot for 3.57 (left). (b) IC50 plot for 3.58 (right). 
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Figure A.21. Replot of the data from Fig. A.8 (a) to determine Ki of 3.28. 
 
 
 
Figure A.22. Replot of the data from Fig. A.8 (a) to determine αKi  of 3.28. 
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Table A.1. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.22. 
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Table A.2. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.23. 
 
253 
 
 
Table A.3. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.27. 
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Table A.4. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.28. 
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Table A.5. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.29. 
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Table A.6. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.30. 
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Table A.7. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.33. 
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Table A.8. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.34. 
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Table A.9. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.37. 
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Table A.10. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.38. 
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Table A.11. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.40. 
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Table A.12. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.45. 
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Table A.13. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.46. 
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Table A.14. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 3.48. 
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Appendix B – Supplementary Figures and Tables for Chapter 4 
 
 
Figure B.1. (a) IC50 plot for 4.09 (left). (b) IC50 plot for 4.10 (right). 
 
 
 
  
 
Figure B.2. (a) IC50 plot for 4.13 (left). (b) IC50 plot for 4.14 (right). 
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Figure B.3a. IC50 plot for 4.11 using 5 nM (left) and 10 nM (right) STS. 
 
 
 
  
 
Figure B.3b. IC50 plot for 4.11 using 20 nM (left) and 40 nM (right) STS. 
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Figure B.4a. IC50 plot for 4.12 using 5 nM (left) and 10 nM (right) STS. 
 
 
 
   
 
Figure B.4b. IC50 plot for 4.12 using 20 nM (left) and 40 nM (right) STS. 
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Figure B.5. (a) IC50 plot for 4.15 (left). (b) IC50 plot for 4.16 (right). 
 
 
 
 
 
Figure B.6. (a) IC50 plot for 4.27 (left). (b) IC50 plot for 4.28 (right). 
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Figure B.7a. IC50 plot for 4.49 using 5 nM (left) and 10 nM (right) STS. 
 
 
 
   
 
Figure B.7b. IC50 plot for 4.49 using 20 nM (left) and 40 nM (right) STS. 
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Figure B.8. (a) IC50 plot for 4.51 (left). (b) IC50 plot for 4.52 (right). 
 
 
 
 
 
Figure B.9. IC50 plot for 4.53. 
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Figure B.10a. IC50 plot for 4.54 using 5 nM (left) and 10 nM (right) STS. 
 
 
 
  
 
Figure B.10b. IC50 plot for 4.54 using 20 nM (left) and 40 nM (right) STS. 
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Figure B.11. IC50 plot for 4.2. 
 
 
 
 
Figure B.12. Replot of the data from Figure B.11 to determine Ki of 4.2. 
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Figure B.13. Replot of the data from Figure B.11 to determine αKi of 4.2. 
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Table B.1. In-Vitro Testing Results (GI50, TGI, and LC50) of 4.9. 
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Table B.2. In-Vitro Testing Results (GI50, TGI, and LC50) of 4.10. 
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Table B.3. In-Vitro Testing Results (GI50, TGI, and LC50) of Compound 4.53. 
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Appendix C – Supplementary X-ray Crystallographic Data for Compound 
3.33  
Crystal data 
C25H28F3NO3S F(000) = 1008 
Mr = 479.54 Density = 1.392 g cm
−3
 
Monoclinic, P21 Mo Kα radiation, λ = 0.71073 Å 
a = 9.611 (3) Å Cell parameters from 1582 reflections 
b = 13.461 (4) Å θ = 1.5–30° 
c = 17.786 (6) Å µ = 0.19 mm
−1
 
β = 96.239 (18)° T = 200 K 
V = 2287.5 (12) Å
3
 Plate, colourless 
Z = 4 0.25 × 0.08 × 0.02 mm 
Data collection 
Bruker Kappa APEX II  
diffractometer  
6503 reflections with I > 2σ(I) 
Radiation source: fine-focus sealed tube with 
graphite monochromator 
Rint = 0.067 
ω and phi scan  θmax = 26.0°, θmin = 3.0° 
Absorption correction: empirical (using 
intensity measurements)  
SADABS 
h = −11 11 
Tmin = 0.953, Tmax = 0.996 k = −16 16 
25349 measured reflections l = −21 21 
8534 independent reflections 
 
Refinement 
Refinement on F
2
 
Hydrogen site location: inferred from 
neighbouring sites 
Least-squares matrix: full H-atom parameters constrained  
R[F
2
 > 2σ(F2)] = 0.080 
w = 1/[σ2(Fo
2
) + (0.0019P)
2
 + 5.0121P]  
where P = (Fo
2
 + 2Fc
2
)/3 
278 
 
wR(F
2
) = 0.177 (Δ/σ)max < 0.001 
S = 1.20 Δρmax = 0.61 e Å
−3
 
8534 reflections Δρmin = −0.38 e Å
−3
 
609 parameters 
Extinction correction: ?, 
Fc
*
=kFc[1+0.001xFc
2λ3/sin(2θ)]-1/4 
19 restraints Extinction coefficient: ? 
0 constraints 
Absolute structure: Flack H D (1983), Acta 
Cryst. A39, 876-881 
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: −0.06 (14) 
 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å
2
) 
 
x y z Uiso*/Ueq Occ. (<1) 
S1A 0.06736 (17) −0.03120 (13) 0.69284 (9) 0.0363 (4) 
 
N1A 0.1541 (6) 0.0612 (4) 0.7280 (3) 0.0369 (13) 
 
H1AA 0.2311 0.0771 0.7082 0.044* 
 
O1A −0.0460 (5) −0.0493 (4) 0.7378 (3) 0.0449 (12) 
 
O2A 0.1602 (5) −0.1106 (4) 0.6805 (3) 0.0487 (13) 
 
O3A 0.0256 (7) 0.8482 (4) 0.8772 (3) 0.0648 (17) 
 
H3AA 0.0503 0.8799 0.8402 0.097* 
 
C1A 0.1154 (8) 0.1223 (5) 0.7912 (4) 0.0378 (17) 
 
H1AC 0.0135 0.1119 0.7952 0.045* 
 
C2A 0.1957 (11) 0.0950 (6) 0.8672 (4) 0.062 (2) 
 
H2AB 0.2905 0.0703 0.8603 0.075* 
 
H2AC 0.1454 0.0431 0.8929 0.075* 
 
C3A 0.2044 (10) 0.1937 (5) 0.9139 (4) 0.060 (2) 
 
H3AB 0.1646 0.1845 0.9624 0.072* 
 
H3AC 0.3027 0.2160 0.9245 0.072* 
 
C4A 0.1207 (8) 0.2671 (5) 0.8652 (4) 0.0392 (17) 
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H4AA 0.0209 0.2518 0.8716 0.047* 
 
C5A 0.1400 (7) 0.2346 (5) 0.7824 (4) 0.0362 (16) 
 
C6A 0.1357 (8) 0.3759 (5) 0.8782 (3) 0.0361 (16) 
 
H6AA 0.2330 0.3956 0.8694 0.043* 
 
C7A 0.0332 (7) 0.4320 (4) 0.8216 (3) 0.0316 (15) 
 
H7AA −0.0623 0.4101 0.8319 0.038* 
 
C8A 0.0476 (8) 0.4010 (5) 0.7390 (4) 0.0443 (18) 
 
H8AA −0.0271 0.4336 0.7050 0.053* 
 
H8AB 0.1388 0.4245 0.7249 0.053* 
 
C9A 0.0376 (8) 0.2886 (5) 0.7276 (4) 0.0421 (17) 
 
H9AA −0.0584 0.2662 0.7343 0.050* 
 
H9AB 0.0561 0.2722 0.6754 0.050* 
 
C10A 0.1111 (11) 0.4080 (5) 0.9584 (4) 0.057 (2) 
 
H10A 0.0127 0.3945 0.9668 0.068* 
 
H10B 0.1724 0.3690 0.9958 0.068* 
 
C11A 0.1418 (12) 0.5178 (6) 0.9699 (4) 0.064 (3) 
 
H11A 0.1059 0.5392 1.0174 0.076* 
 
H11B 0.2445 0.5273 0.9762 0.076* 
 
C12A 0.0804 (8) 0.5832 (5) 0.9074 (4) 0.0431 (18) 
 
C13A 0.0378 (7) 0.5434 (5) 0.8359 (4) 0.0351 (16) 
 
C14A 0.0761 (9) 0.6865 (5) 0.9194 (4) 0.050 (2) 
 
H14A 0.1079 0.7129 0.9677 0.060* 
 
C15A 0.0266 (8) 0.7494 (5) 0.8621 (4) 0.0435 (18) 
 
C16A −0.0162 (8) 0.7116 (5) 0.7910 (4) 0.0478 (19) 
 
H16A −0.0472 0.7555 0.7508 0.057* 
 
C17A −0.0140 (8) 0.6104 (5) 0.7783 (4) 0.0417 (17) 
 
H17A −0.0480 0.5853 0.7299 0.050* 
 
C18A 0.2879 (8) 0.2518 (6) 0.7636 (4) 0.0470 (19) 
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H18A 0.3046 0.3232 0.7591 0.071* 
 
H18B 0.3008 0.2190 0.7157 0.071* 
 
H18C 0.3543 0.2242 0.8040 0.071* 
 
C19A −0.0136 (7) 0.0040 (5) 0.6025 (4) 0.0333 (15) 
 
C20A −0.1121 (7) 0.0758 (5) 0.5972 (4) 0.0349 (15) 
 
H20A −0.1399 0.1061 0.6415 0.042* 
 
C21A −0.1725 (8) 0.1049 (6) 0.5256 (4) 0.0467 (18) 
 
C22A −0.1319 (10) 0.0602 (7) 0.4624 (5) 0.065 (2) 
 
H22A −0.1724 0.0804 0.4136 0.078* 
 
C23A −0.0315 (11) −0.0145 (8) 0.4692 (5) 0.079 (3) 
 
H23A −0.0058 −0.0463 0.4251 0.095* 
 
C24A 0.0307 (8) −0.0430 (6) 0.5387 (4) 0.0546 (19) 
 
H24A 0.1013 −0.0927 0.5437 0.066* 
 
C25A −0.2771 (10) 0.1876 (7) 0.5223 (6) 0.068 (3) 
 
F1AA −0.302 (2) 0.231 (2) 0.4529 (9) 0.111 (4) 0.449 (13) 
F1AB −0.3762 (18) 0.1735 (15) 0.4589 (8) 0.111 (4) 0.551 (13) 
F2AA −0.2279 (9) 0.2722 (6) 0.5519 (7) 0.095 (3) 0.686 (11) 
F2AB −0.234 (2) 0.2510 (13) 0.4784 (19) 0.095 (3) 0.314 (11) 
F3AA −0.3697 (8) 0.1777 (6) 0.5709 (5) 0.094 (3) 0.780 (10) 
F3AB −0.405 (3) 0.152 (2) 0.503 (2) 0.094 (3) 0.220 (10) 
S1B 0.47973 (16) 0.46528 (12) 0.32239 (9) 0.0346 (4) 
 
N1B 0.5455 (6) 0.3803 (4) 0.2771 (3) 0.0412 (14) 
 
H1BA 0.6354 0.3689 0.2886 0.049* 
 
O1B 0.3480 (5) 0.4922 (3) 0.2837 (3) 0.0417 (12) 
 
O2B 0.5842 (5) 0.5393 (3) 0.3412 (3) 0.0495 (13) 
 
O3B 0.3301 (7) −0.4081 (3) 0.1431 (3) 0.0649 (17) 
 
H3BA 0.3344 −0.4403 0.1838 0.097* 
 
C1B 0.4726 (7) 0.3178 (5) 0.2178 (4) 0.0358 (16) 
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H1BC 0.3701 0.3307 0.2175 0.043* 
 
C2B 0.5121 (10) 0.3438 (5) 0.1388 (4) 0.056 (2) 
 
H2BB 0.6088 0.3701 0.1421 0.067* 
 
H2BC 0.4473 0.3944 0.1144 0.067* 
 
C3B 0.5001 (10) 0.2452 (5) 0.0932 (4) 0.052 (2) 
 
H3BB 0.5933 0.2208 0.0828 0.062* 
 
H3BC 0.4400 0.2533 0.0447 0.062* 
 
C4B 0.4318 (7) 0.1740 (4) 0.1475 (4) 0.0336 (15) 
 
H4BA 0.3303 0.1919 0.1436 0.040* 
 
C5B 0.4946 (7) 0.2058 (5) 0.2262 (4) 0.0313 (15) 
 
C6B 0.4383 (8) 0.0631 (4) 0.1345 (3) 0.0316 (15) 
 
H6BA 0.5388 0.0424 0.1402 0.038* 
 
C7B 0.3648 (8) 0.0096 (4) 0.1936 (4) 0.0327 (15) 
 
H7BA 0.2650 0.0317 0.1847 0.039* 
 
C8B 0.4143 (8) 0.0412 (5) 0.2741 (3) 0.0373 (16) 
 
H8BA 0.5104 0.0160 0.2880 0.045* 
 
H8BB 0.3528 0.0108 0.3089 0.045* 
 
C9B 0.4136 (7) 0.1549 (5) 0.2842 (4) 0.0338 (15) 
 
H9BA 0.3158 0.1792 0.2785 0.041* 
 
H9BB 0.4562 0.1721 0.3357 0.041* 
 
C10B 0.3714 (10) 0.0304 (5) 0.0559 (4) 0.049 (2) 
 
H10C 0.2701 0.0459 0.0509 0.059* 
 
H10D 0.4142 0.0681 0.0165 0.059* 
 
C11B 0.3910 (10) −0.0786 (5) 0.0437 (4) 0.054 (2) 
 
H11C 0.4877 −0.0900 0.0313 0.065* 
 
H11D 0.3263 −0.0999 −0.0005 0.065* 
 
C12B 0.3661 (8) −0.1420 (5) 0.1104 (4) 0.0409 (17) 
 
C13B 0.3607 (7) −0.1022 (5) 0.1823 (4) 0.0316 (15) 
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C14B 0.3575 (9) −0.2449 (5) 0.0989 (4) 0.0471 (19) 
 
H14B 0.3648 −0.2721 0.0502 0.057* 
 
C15B 0.3384 (8) −0.3063 (5) 0.1591 (4) 0.0402 (17) 
 
C16B 0.3346 (7) −0.2693 (5) 0.2304 (4) 0.0374 (16) 
 
H16B 0.3254 −0.3126 0.2718 0.045* 
 
C17B 0.3442 (7) −0.1677 (5) 0.2412 (4) 0.0375 (16) 
 
H17B 0.3395 −0.1418 0.2905 0.045* 
 
C18B 0.6504 (7) 0.1833 (5) 0.2404 (4) 0.0414 (17) 
 
H18D 0.6642 0.1114 0.2460 0.062* 
 
H18E 0.6899 0.2168 0.2868 0.062* 
 
H18F 0.6973 0.2072 0.1977 0.062* 
 
C19B 0.4367 (7) 0.4156 (4) 0.4089 (3) 0.0293 (14) 
 
C20B 0.3302 (7) 0.3474 (4) 0.4075 (4) 0.0339 (15) 
 
H20B 0.2764 0.3314 0.3611 0.041* 
 
C21B 0.3011 (8) 0.3016 (5) 0.4748 (4) 0.0406 (17) 
 
C22B 0.3764 (10) 0.3293 (7) 0.5421 (5) 0.064 (3) 
 
H22B 0.3563 0.2995 0.5881 0.077* 
 
C23B 0.4812 (9) 0.4002 (7) 0.5430 (4) 0.059 (2) 
 
H23B 0.5308 0.4195 0.5898 0.070* 
 
C24B 0.5154 (9) 0.4445 (5) 0.4752 (4) 0.051 (2) 
 
H24B 0.5888 0.4917 0.4751 0.061* 
 
C25B 0.1927 (10) 0.2240 (6) 0.4725 (5) 0.056 (2) 
 
F1B 0.1313 (8) 0.2187 (6) 0.5344 (4) 0.138 (3) 
 
F2B 0.2460 (7) 0.1342 (4) 0.4644 (5) 0.120 (3) 
 
F3B 0.0921 (6) 0.2318 (4) 0.4170 (4) 0.098 (2) 
 
 
Geometric parameters (Å, °) 
S1A—O2A 1.425 (5) F1AB—F3AB 0.90 (3) 
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S1A—O1A 1.441 (5) F1AB—F2AB 1.72 (3) 
S1A—N1A 1.587 (6) S1B—O1B 1.421 (5) 
S1A—C19A 1.772 (7) S1B—O2B 1.428 (5) 
N1A—C1A 1.473 (8) S1B—N1B 1.571 (6) 
N1A—H1AA 0.8800 S1B—C19B 1.768 (6) 
O3A—C15A 1.358 (8) N1B—C1B 1.466 (8) 
O3A—H3AA 0.8400 N1B—H1BA 0.8800 
C1A—C2A 1.528 (10) O3B—C15B 1.400 (8) 
C1A—C5A 1.540 (9) O3B—H3BA 0.8400 
C1A—H1AC 1.0000 C1B—C5B 1.528 (9) 
C2A—C3A 1.564 (10) C1B—C2B 1.534 (9) 
C2A—H2AB 0.9900 C1B—H1BC 1.0000 
C2A—H2AC 0.9900 C2B—C3B 1.554 (9) 
C3A—C4A 1.489 (9) C2B—H2BB 0.9900 
C3A—H3AB 0.9900 C2B—H2BC 0.9900 
C3A—H3AC 0.9900 C3B—C4B 1.555 (9) 
C4A—C6A 1.488 (9) C3B—H3BB 0.9900 
C4A—C5A 1.567 (9) C3B—H3BC 0.9900 
C4A—H4AA 1.0000 C4B—C6B 1.513 (8) 
C5A—C9A 1.495 (9) C4B—C5B 1.524 (9) 
C5A—C18A 1.513 (10) C4B—H4BA 1.0000 
C6A—C7A 1.530 (8) C5B—C9B 1.521 (8) 
C6A—C10A 1.534 (9) C5B—C18B 1.521 (9) 
C6A—H6AA 1.0000 C6B—C7B 1.510 (9) 
C7A—C13A 1.520 (9) C6B—C10B 1.539 (9) 
C7A—C8A 1.548 (9) C6B—H6BA 1.0000 
C7A—H7AA 1.0000 C7B—C13B 1.518 (8) 
C8A—C9A 1.528 (10) C7B—C8B 1.520 (9) 
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C8A—H8AA 0.9900 C7B—H7BA 1.0000 
C8A—H8AB 0.9900 C8B—C9B 1.541 (9) 
C9A—H9AA 0.9900 C8B—H8BA 0.9900 
C9A—H9AB 0.9900 C8B—H8BB 0.9900 
C10A—C11A 1.516 (10) C9B—H9BA 0.9900 
C10A—H10A 0.9900 C9B—H9BB 0.9900 
C10A—H10B 0.9900 C10B—C11B 1.498 (9) 
C11A—C12A 1.488 (10) C10B—H10C 0.9900 
C11A—H11A 0.9900 C10B—H10D 0.9900 
C11A—H11B 0.9900 C11B—C12B 1.502 (10) 
C12A—C13A 1.400 (9) C11B—H11C 0.9900 
C12A—C14A 1.408 (10) C11B—H11D 0.9900 
C13A—C17A 1.414 (9) C12B—C13B 1.393 (9) 
C14A—C15A 1.369 (10) C12B—C14B 1.400 (9) 
C14A—H14A 0.9500 C13B—C17B 1.392 (8) 
C15A—C16A 1.383 (10) C14B—C15B 1.381 (9) 
C16A—C17A 1.382 (10) C14B—H14B 0.9500 
C16A—H16A 0.9500 C15B—C16B 1.366 (9) 
C17A—H17A 0.9500 C16B—C17B 1.383 (9) 
C18A—H18A 0.9800 C16B—H16B 0.9500 
C18A—H18B 0.9800 C17B—H17B 0.9500 
C18A—H18C 0.9800 C18B—H18D 0.9800 
C19A—C20A 1.349 (9) C18B—H18E 0.9800 
C19A—C24A 1.404 (9) C18B—H18F 0.9800 
C20A—C21A 1.397 (9) C19B—C20B 1.372 (9) 
C20A—H20A 0.9500 C19B—C24B 1.385 (9) 
C21A—C22A 1.370 (11) C20B—C21B 1.402 (9) 
C21A—C25A 1.496 (12) C20B—H20B 0.9500 
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C22A—C23A 1.391 (13) C21B—C22B 1.381 (11) 
C22A—H22A 0.9500 C21B—C25B 1.473 (11) 
C23A—C24A 1.368 (11) C22B—C23B 1.387 (12) 
C23A—H23A 0.9500 C22B—H22B 0.9500 
C24A—H24A 0.9500 C23B—C24B 1.415 (10) 
C25A—F2AB 1.26 (3) C23B—H23B 0.9500 
C25A—F3AA 1.313 (11) C24B—H24B 0.9500 
C25A—F2AA 1.322 (13) C25B—F1B 1.305 (9) 
C25A—F3AB 1.33 (4) C25B—F3B 1.310 (10) 
C25A—F1AA 1.364 (19) C25B—F2B 1.326 (10) 
C25A—F1AB 1.407 (16) 
  
O2A—S1A—O1A 118.9 (3) F3AA—C25A—C21A 113.5 (7) 
O2A—S1A—N1A 109.7 (3) F2AA—C25A—C21A 114.6 (8) 
O1A—S1A—N1A 108.1 (3) F3AB—C25A—C21A 109.8 (14) 
O2A—S1A—C19A 106.4 (3) F1AA—C25A—C21A 114.0 (11) 
O1A—S1A—C19A 105.4 (3) F1AB—C25A—C21A 109.0 (11) 
N1A—S1A—C19A 107.9 (3) F3AB—F1AB—C25A 66 (3) 
C1A—N1A—S1A 125.0 (5) F3AB—F1AB—F2AB 110 (4) 
C1A—N1A—H1AA 117.5 C25A—F1AB—F2AB 46.0 (11) 
S1A—N1A—H1AA 117.5 C25A—F2AB—F1AB 53.6 (10) 
C15A—O3A—H3AA 109.5 F1AB—F3AB—C25A 75 (3) 
N1A—C1A—C2A 113.3 (6) O1B—S1B—O2B 120.2 (3) 
N1A—C1A—C5A 114.6 (5) O1B—S1B—N1B 108.9 (3) 
C2A—C1A—C5A 104.9 (6) O2B—S1B—N1B 108.4 (3) 
N1A—C1A—H1AC 107.9 O1B—S1B—C19B 103.8 (3) 
C2A—C1A—H1AC 107.9 O2B—S1B—C19B 106.6 (3) 
C5A—C1A—H1AC 107.9 N1B—S1B—C19B 108.4 (3) 
C1A—C2A—C3A 104.9 (6) C1B—N1B—S1B 126.8 (5) 
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C1A—C2A—H2AB 110.8 C1B—N1B—H1BA 116.6 
C3A—C2A—H2AB 110.8 S1B—N1B—H1BA 116.6 
C1A—C2A—H2AC 110.8 C15B—O3B—H3BA 109.5 
C3A—C2A—H2AC 110.8 N1B—C1B—C5B 116.5 (6) 
H2AB—C2A—H2AC 108.8 N1B—C1B—C2B 112.5 (5) 
C4A—C3A—C2A 105.1 (6) C5B—C1B—C2B 105.6 (5) 
C4A—C3A—H3AB 110.7 N1B—C1B—H1BC 107.3 
C2A—C3A—H3AB 110.7 C5B—C1B—H1BC 107.3 
C4A—C3A—H3AC 110.7 C2B—C1B—H1BC 107.3 
C2A—C3A—H3AC 110.7 C1B—C2B—C3B 105.8 (5) 
H3AB—C3A—H3AC 108.8 C1B—C2B—H2BB 110.6 
C6A—C4A—C3A 121.7 (6) C3B—C2B—H2BB 110.6 
C6A—C4A—C5A 113.6 (5) C1B—C2B—H2BC 110.6 
C3A—C4A—C5A 104.5 (6) C3B—C2B—H2BC 110.6 
C6A—C4A—H4AA 105.2 H2BB—C2B—H2BC 108.7 
C3A—C4A—H4AA 105.2 C2B—C3B—C4B 102.4 (5) 
C5A—C4A—H4AA 105.2 C2B—C3B—H3BB 111.3 
C9A—C5A—C18A 110.5 (6) C4B—C3B—H3BB 111.3 
C9A—C5A—C1A 116.4 (6) C2B—C3B—H3BC 111.3 
C18A—C5A—C1A 109.3 (6) C4B—C3B—H3BC 111.3 
C9A—C5A—C4A 109.9 (5) H3BB—C3B—H3BC 109.2 
C18A—C5A—C4A 112.0 (6) C6B—C4B—C5B 113.5 (5) 
C1A—C5A—C4A 98.2 (5) C6B—C4B—C3B 119.1 (6) 
C4A—C6A—C7A 109.9 (6) C5B—C4B—C3B 104.2 (5) 
C4A—C6A—C10A 113.6 (6) C6B—C4B—H4BA 106.4 
C7A—C6A—C10A 108.6 (6) C5B—C4B—H4BA 106.4 
C4A—C6A—H6AA 108.2 C3B—C4B—H4BA 106.4 
C7A—C6A—H6AA 108.2 C9B—C5B—C18B 111.4 (6) 
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C10A—C6A—H6AA 108.2 C9B—C5B—C4B 108.4 (5) 
C13A—C7A—C6A 111.8 (6) C18B—C5B—C4B 112.4 (5) 
C13A—C7A—C8A 114.9 (5) C9B—C5B—C1B 115.8 (5) 
C6A—C7A—C8A 111.9 (5) C18B—C5B—C1B 109.6 (5) 
C13A—C7A—H7AA 105.8 C4B—C5B—C1B 98.7 (5) 
C6A—C7A—H7AA 105.8 C7B—C6B—C4B 109.5 (5) 
C8A—C7A—H7AA 105.8 C7B—C6B—C10B 108.4 (6) 
C9A—C8A—C7A 112.5 (6) C4B—C6B—C10B 113.6 (5) 
C9A—C8A—H8AA 109.1 C7B—C6B—H6BA 108.4 
C7A—C8A—H8AA 109.1 C4B—C6B—H6BA 108.4 
C9A—C8A—H8AB 109.1 C10B—C6B—H6BA 108.4 
C7A—C8A—H8AB 109.1 C6B—C7B—C13B 112.9 (6) 
H8AA—C8A—H8AB 107.8 C6B—C7B—C8B 113.6 (5) 
C5A—C9A—C8A 111.6 (6) C13B—C7B—C8B 113.8 (5) 
C5A—C9A—H9AA 109.3 C6B—C7B—H7BA 105.2 
C8A—C9A—H9AA 109.3 C13B—C7B—H7BA 105.2 
C5A—C9A—H9AB 109.3 C8B—C7B—H7BA 105.2 
C8A—C9A—H9AB 109.3 C7B—C8B—C9B 112.5 (5) 
H9AA—C9A—H9AB 108.0 C7B—C8B—H8BA 109.1 
C11A—C10A—C6A 110.6 (7) C9B—C8B—H8BA 109.1 
C11A—C10A—H10A 109.5 C7B—C8B—H8BB 109.1 
C6A—C10A—H10A 109.5 C9B—C8B—H8BB 109.1 
C11A—C10A—H10B 109.5 H8BA—C8B—H8BB 107.8 
C6A—C10A—H10B 109.5 C5B—C9B—C8B 111.0 (5) 
H10A—C10A—H10B 108.1 C5B—C9B—H9BA 109.4 
C12A—C11A—C10A 114.9 (7) C8B—C9B—H9BA 109.4 
C12A—C11A—H11A 108.5 C5B—C9B—H9BB 109.4 
C10A—C11A—H11A 108.5 C8B—C9B—H9BB 109.4 
288 
 
C12A—C11A—H11B 108.5 H9BA—C9B—H9BB 108.0 
C10A—C11A—H11B 108.5 C11B—C10B—C6B 111.4 (6) 
H11A—C11A—H11B 107.5 C11B—C10B—H10C 109.3 
C13A—C12A—C14A 120.3 (6) C6B—C10B—H10C 109.3 
C13A—C12A—C11A 120.4 (6) C11B—C10B—H10D 109.3 
C14A—C12A—C11A 119.2 (7) C6B—C10B—H10D 109.3 
C12A—C13A—C17A 117.4 (6) H10C—C10B—H10D 108.0 
C12A—C13A—C7A 121.9 (6) C10B—C11B—C12B 114.2 (7) 
C17A—C13A—C7A 120.4 (6) C10B—C11B—H11C 108.7 
C15A—C14A—C12A 120.8 (7) C12B—C11B—H11C 108.7 
C15A—C14A—H14A 119.6 C10B—C11B—H11D 108.7 
C12A—C14A—H14A 119.6 C12B—C11B—H11D 108.7 
O3A—C15A—C14A 117.9 (7) H11C—C11B—H11D 107.6 
O3A—C15A—C16A 122.2 (6) C13B—C12B—C14B 120.5 (6) 
C14A—C15A—C16A 119.8 (6) C13B—C12B—C11B 122.1 (6) 
C17A—C16A—C15A 120.2 (7) C14B—C12B—C11B 117.3 (6) 
C17A—C16A—H16A 119.9 C17B—C13B—C12B 117.7 (6) 
C15A—C16A—H16A 119.9 C17B—C13B—C7B 122.2 (6) 
C16A—C17A—C13A 121.4 (7) C12B—C13B—C7B 120.0 (6) 
C16A—C17A—H17A 119.3 C15B—C14B—C12B 119.4 (7) 
C13A—C17A—H17A 119.3 C15B—C14B—H14B 120.3 
C5A—C18A—H18A 109.5 C12B—C14B—H14B 120.3 
C5A—C18A—H18B 109.5 C16B—C15B—C14B 121.3 (6) 
H18A—C18A—H18B 109.5 C16B—C15B—O3B 122.6 (6) 
C5A—C18A—H18C 109.5 C14B—C15B—O3B 116.0 (6) 
H18A—C18A—H18C 109.5 C15B—C16B—C17B 118.8 (6) 
H18B—C18A—H18C 109.5 C15B—C16B—H16B 120.6 
C20A—C19A—C24A 122.6 (7) C17B—C16B—H16B 120.6 
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C20A—C19A—S1A 119.4 (5) C16B—C17B—C13B 122.3 (6) 
C24A—C19A—S1A 118.0 (6) C16B—C17B—H17B 118.9 
C19A—C20A—C21A 118.9 (6) C13B—C17B—H17B 118.9 
C19A—C20A—H20A 120.6 C5B—C18B—H18D 109.5 
C21A—C20A—H20A 120.6 C5B—C18B—H18E 109.5 
C22A—C21A—C20A 119.9 (7) H18D—C18B—H18E 109.5 
C22A—C21A—C25A 123.0 (8) C5B—C18B—H18F 109.5 
C20A—C21A—C25A 117.1 (7) H18D—C18B—H18F 109.5 
C21A—C22A—C23A 120.2 (8) H18E—C18B—H18F 109.5 
C21A—C22A—H22A 119.9 C20B—C19B—C24B 122.7 (6) 
C23A—C22A—H22A 119.9 C20B—C19B—S1B 118.8 (5) 
C24A—C23A—C22A 120.8 (8) C24B—C19B—S1B 118.4 (5) 
C24A—C23A—H23A 119.6 C19B—C20B—C21B 119.7 (6) 
C22A—C23A—H23A 119.6 C19B—C20B—H20B 120.1 
C23A—C24A—C19A 117.6 (8) C21B—C20B—H20B 120.1 
C23A—C24A—H24A 121.2 C22B—C21B—C20B 119.1 (7) 
C19A—C24A—H24A 121.2 C22B—C21B—C25B 121.2 (7) 
F2AB—C25A—F3AA 140.3 (13) C20B—C21B—C25B 119.6 (7) 
F2AB—C25A—F2AA 62.2 (13) C21B—C22B—C23B 120.5 (7) 
F3AA—C25A—F2AA 93.6 (10) C21B—C22B—H22B 119.8 
F2AB—C25A—F3AB 116.0 (19) C23B—C22B—H22B 119.8 
F3AA—C25A—F3AB 57.6 (16) C22B—C23B—C24B 121.1 (7) 
F2AA—C25A—F3AB 134.2 (16) C22B—C23B—H23B 119.5 
F2AB—C25A—F1AA 35.0 (12) C24B—C23B—H23B 119.5 
F3AA—C25A—F1AA 125.2 (11) C19B—C24B—C23B 116.8 (7) 
F2AA—C25A—F1AA 90.4 (14) C19B—C24B—H24B 121.6 
F3AB—C25A—F1AA 81.7 (17) C23B—C24B—H24B 121.6 
F2AB—C25A—F1AB 80.4 (14) F1B—C25B—F3B 106.0 (8) 
290 
 
F3AA—C25A—F1AB 93.8 (10) F1B—C25B—F2B 104.9 (8) 
F2AA—C25A—F1AB 128.1 (11) F3B—C25B—F2B 104.7 (8) 
F3AB—C25A—F1AB 38.3 (14) F1B—C25B—C21B 113.5 (7) 
F1AA—C25A—F1AB 45.5 (10) F3B—C25B—C21B 115.2 (7) 
F2AB—C25A—C21A 105.4 (12) F2B—C25B—C21B 111.6 (7) 
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Fig. B.14.  Two crystallographic-independent molecules A and B. 
 
 
